data_1zrp_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1zrp _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.52 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.444 ' N ' HG21 ' A' ' 4' ' ' VAL . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.51 ' N ' HD13 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.506 ' CD1' HD12 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.537 ' HA ' HD13 ' A' ' 32' ' ' LEU . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.537 HD13 ' HA ' ' A' ' 29' ' ' PHE . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.504 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.478 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.512 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.54 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.434 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.523 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.51 ' CD1' HD12 ' A' ' 40' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.434 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.509 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.512 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.509 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' HG22 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HA ' HD12 ' A' ' 32' ' ' LEU . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.478 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.526 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.511 ' NE1' HD13 ' A' ' 23' ' ' ILE . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.469 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.517 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.426 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.523 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.54 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.52 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.509 HD11 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CG ' HD11 ' A' ' 40' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.46 HD13 ' N ' ' A' ' 11' ' ' ILE . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.508 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.508 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.475 ' HA2' HG21 ' A' ' 23' ' ' ILE . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.534 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . 0.402 ' HB3' ' ND2' ' A' ' 21' ' ' ASN . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.402 ' ND2' ' HB3' ' A' ' 20' ' ' ASP . 0.4 OUTLIER -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.534 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.534 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.555 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HA ' HD11 ' A' ' 32' ' ' LEU . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.555 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.504 ' NE1' HD13 ' A' ' 23' ' ' ILE . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.527 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD11 ' CG ' ' A' ' 10' ' ' TYR . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.523 ' HB2' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.523 ' HG2' ' HB2' ' A' ' 43' ' ' ALA . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.539 HG22 HD13 ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD11 ' A' ' 40' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.539 HD13 HG22 ' A' ' 4' ' ' VAL . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.513 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.495 HG21 HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.598 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.506 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.598 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.421 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.539 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.52 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.532 HG22 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.461 ' CD1' ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD12 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG22 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.525 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.525 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.413 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.508 ' HE2' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.508 ' HG3' ' HE2' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 29' ' ' PHE . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.426 ' CD1' HD12 ' A' ' 23' ' ' ILE . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.508 HD12 ' CD1' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB3' ' CB ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.471 ' CB ' ' HB3' ' A' ' 43' ' ' ALA . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.468 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.485 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.508 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.508 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.461 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.404 ' ND2' ' N ' ' A' ' 21' ' ' ASN . 0.3 OUTLIER -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.519 HG23 HD21 ' A' ' 32' ' ' LEU . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.416 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.531 ' HB3' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HG2' ' HB3' ' A' ' 43' ' ' ALA . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.41 ' HE3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.467 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD11 ' A' ' 40' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.44 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.498 ' HB ' HG21 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.497 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.529 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.514 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HB2' ' CG ' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.466 ' CG ' ' HB2' ' A' ' 43' ' ' ALA . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.41 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 11' ' ' ILE . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.416 ' N ' HG21 ' A' ' 4' ' ' VAL . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.539 HD13 ' HB2' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CD1' HD12 ' A' ' 40' ' ' ILE . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.1 m-80 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.493 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.514 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.539 ' HB2' HD13 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.489 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.461 ' N ' HG21 ' A' ' 4' ' ' VAL . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.465 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.537 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.519 ' HB2' HD12 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.439 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.63 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.517 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.517 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.63 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HB2' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.428 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.537 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.465 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.539 HD13 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.492 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.586 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.476 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.586 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.539 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.416 ' HB3' HG11 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 24.3 tttt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.507 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.539 HG22 HD13 ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.52 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.405 ' CG1' ' HB3' ' A' ' 47' ' ' GLU . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CD1' HD11 ' A' ' 40' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.539 HD13 HG22 ' A' ' 4' ' ' VAL . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.463 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.463 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.491 HG22 ' N ' ' A' ' 28' ' ' LYS . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.518 ' HG2' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.507 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.518 ' HB2' ' HG2' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.523 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.523 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.506 ' CD1' HD11 ' A' ' 23' ' ' ILE . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.513 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.513 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.514 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.514 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.437 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CD1' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.477 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.505 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.505 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.459 ' CB ' HG22 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.486 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.496 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD13 ' CD1' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.538 ' HB3' HD12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.533 HG22 HG13 ' A' ' 11' ' ' ILE . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.458 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.419 ' CD1' ' HB2' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.507 ' CD1' HD11 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.533 HG13 HG22 ' A' ' 4' ' ' VAL . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.405 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.405 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.517 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.531 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.459 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.507 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.408 ' CB ' HD12 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.537 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.419 ' HB2' ' CD1' ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.466 ' HG3' HG12 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 6' ' ' LYS . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.53 HG12 ' HG3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.459 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.507 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.507 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.536 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.536 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.65 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.457 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.53 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.495 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.514 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.464 ' N ' HG21 ' A' ' 4' ' ' VAL . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.442 ' HG3' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.526 HD13 ' HG3' ' A' ' 47' ' ' GLU . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.536 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.6 m-80 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.536 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.458 HG21 ' CD2' ' A' ' 32' ' ' LEU . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.608 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.526 ' HG3' HD13 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.505 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.491 HG21 HD12 ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.528 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CD1' HD13 ' A' ' 40' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.491 HD12 HG21 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.515 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.51 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.515 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.652 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.505 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.467 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.652 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.517 HD13 ' CD1' ' A' ' 10' ' ' TYR . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.475 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.538 HG21 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.518 ' CD1' HD13 ' A' ' 40' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.538 HG13 HG21 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.446 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 0.4 OUTLIER -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.45 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.437 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 HD13 ' CD1' ' A' ' 10' ' ' TYR . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.518 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.484 HG11 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.482 HD12 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.491 ' HB2' HG13 ' A' ' 40' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 4' ' ' VAL . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.515 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.535 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.53 ' HG3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.53 ' HB2' ' HG3' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.526 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.526 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.491 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.469 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.482 ' HB3' HD12 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.484 ' HB3' HG11 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.417 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.52 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.533 HD12 ' HG3' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.513 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.52 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.519 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.519 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.467 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.539 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.539 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.515 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.513 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.417 ' HB3' ' HG3' ' A' ' 47' ' ' GLU . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.533 ' HG3' HD12 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.502 ' HE2' HG23 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.509 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.442 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.532 HG12 ' HG3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD13 ' A' ' 40' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.502 HG23 ' HE2' ' A' ' 2' ' ' LYS . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.53 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.53 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.509 HD11 ' HA ' ' A' ' 29' ' ' PHE . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.46 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.514 HD13 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.49 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.505 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 0 0 . 1 . 021 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.511 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.454 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.507 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.52 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD12 ' A' ' 40' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.454 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CE2' HD13 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.497 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.538 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.525 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.539 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.539 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.507 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.479 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 0 0 . 1 . 022 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD12 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.5 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.537 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.447 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.537 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.534 HG22 HD23 ' A' ' 32' ' ' LEU . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.622 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.517 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.469 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.523 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.516 ' CD1' HD12 ' A' ' 23' ' ' ILE . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' CD1' ' A' ' 10' ' ' TYR . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.406 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.7 pttm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 023 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.518 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.539 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.451 ' N ' HG22 ' A' ' 4' ' ' VAL . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.446 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.535 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . 0.49 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.534 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.534 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.524 HG23 HD21 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.535 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 HD11 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.535 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.539 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.517 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 024 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.482 ' HD3' HG22 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.521 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.507 HD13 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.501 ' CD1' HD12 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 4' ' ' VAL . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.459 ' CE2' HD12 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.461 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.517 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.465 HG23 HD22 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.663 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.521 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.469 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.511 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.4 ' CB ' ' CD1' ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.507 ' HB3' HD13 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 025 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.536 HG23 HG13 ' A' ' 11' ' ' ILE . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.506 ' N ' HG21 ' A' ' 4' ' ' VAL . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB2' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CG ' HD11 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.479 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.479 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.518 HG23 HD21 ' A' ' 32' ' ' LEU . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.61 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HA ' HD13 ' A' ' 32' ' ' LEU . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.532 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.61 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.512 HD11 ' CG ' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.411 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB2' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HD3' ' N ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 026 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 49' ' ' GLU . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.53 HD11 ' HB2' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.509 ' CD1' HD13 ' A' ' 40' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.538 HG23 HD22 ' A' ' 32' ' ' LEU . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.758 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.538 ' HA ' HD12 ' A' ' 32' ' ' LEU . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.485 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.758 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.53 ' HB2' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HB3' HG12 ' A' ' 4' ' ' VAL . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 027 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.516 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.535 HG22 HG13 ' A' ' 11' ' ' ILE . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.421 ' N ' HG21 ' A' ' 4' ' ' VAL . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD11 ' A' ' 40' ' ' ILE . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.535 HG13 HG22 ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.463 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 5.4 m-80 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.521 ' N ' HD11 ' A' ' 23' ' ' ILE . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.417 ' N ' HG21 ' A' ' 23' ' ' ILE . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.641 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.516 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' HB3' ' CB ' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.494 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB2' HD12 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 1 1 . 1 . 027 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 028 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.469 HD13 ' CB ' ' A' ' 47' ' ' GLU . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.475 ' CD1' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' HG21 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.519 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.519 ' HG2' ' HB2' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.51 HD11 ' HA ' ' A' ' 29' ' ' PHE . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HB2' HD11 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 HD11 ' HB2' ' A' ' 39' ' ' PRO . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.468 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.469 ' CB ' HD13 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 1 1 . 1 . 028 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.459 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 0 0 . 1 . 029 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.5 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 7' ' ' ILE . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CD1' HD11 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.493 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.519 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 32' ' ' LEU . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.485 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 29' ' ' PHE . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.513 ' HB3' HD12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 2 2 . 1 . 029 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.5 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 0 0 . 1 . 030 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.435 HG11 ' HB2' ' A' ' 49' ' ' GLU . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.522 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD12 ' A' ' 40' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.515 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.432 ' N ' ' ND2' ' A' ' 21' ' ' ASN . 0.2 OUTLIER -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.515 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.425 ' CG2' HD22 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.565 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.517 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.436 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' CD1' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.517 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.522 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.435 ' HB2' HG11 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 0 0 . 1 . 031 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.509 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.528 HD12 ' HG2' ' A' ' 47' ' ' GLU . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.518 ' CD1' HD11 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.516 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.504 ' N ' ' HA ' ' A' ' 25' ' ' PRO . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.469 ' N ' ' HB ' ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.453 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.469 ' HB ' ' N ' ' A' ' 18' ' ' ASP . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.509 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.51 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.467 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.482 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HG2' HD12 ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.476 ' HB3' HG13 ' A' ' 4' ' ' VAL . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 3 3 . 1 . 031 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.506 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 032 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.517 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.531 HD13 ' HB2' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.51 ' CD1' HD11 ' A' ' 40' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.448 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.52 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.459 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.538 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.538 HD12 ' HA ' ' A' ' 29' ' ' PHE . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.459 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.459 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.439 ' CG ' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB2' HD13 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 1 1 . 1 . 032 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.517 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 033 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.514 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.526 HD11 ' HB2' ' A' ' 47' ' ' GLU . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD11 ' A' ' 40' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 4' ' ' VAL . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.49 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.532 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.537 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.509 ' HB2' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.458 ' CD1' ' HA ' ' A' ' 29' ' ' PHE . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.535 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.535 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.469 HG11 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . 0.411 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.458 ' CB ' HD12 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.469 ' HA ' HG11 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.526 ' HB2' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.468 ' HB3' HG13 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 034 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.52 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 4' ' ' VAL . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.519 HD13 ' HG3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.537 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.502 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.533 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.524 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.509 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.517 HD11 ' CG ' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.519 ' HG3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.52 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 035 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.507 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.495 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD12 ' A' ' 40' ' ' ILE . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.501 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.501 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.535 HD11 ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.51 ' HB ' HG21 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.584 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.513 ' HA ' HD12 ' A' ' 32' ' ' LEU . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.584 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.492 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.426 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 0 0 . 1 . 036 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . 0.483 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.51 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.475 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.508 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.513 ' CD1' HD12 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.525 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.524 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.51 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.471 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB2' HD13 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.462 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.473 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HB3' HG12 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.7 tttt . . . . . 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 0 0 . 1 . 037 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.492 HG22 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.494 ' CD1' HD12 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.492 HG13 HG22 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.436 ' CE2' HD13 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.413 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.459 ' HB ' HG21 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.539 ' HA ' HD13 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CG ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.539 HD13 ' HA ' ' A' ' 29' ' ' PHE . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.505 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.505 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB2' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.497 ' HG2' ' HB2' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 038 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.512 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.459 ' CG1' ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD11 ' A' ' 40' ' ' ILE . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.514 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.518 ' CZ ' HD23 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . 0.52 ' N ' ' HA ' ' A' ' 25' ' ' PRO . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.51 ' N ' ' HB ' ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 24.5 m-80 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HB ' ' N ' ' A' ' 18' ' ' ASP . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 24' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . 0.52 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.537 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.512 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.518 HD23 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.514 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.459 ' HB3' ' CG1' ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.411 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 0 0 . 1 . 039 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.516 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . 0.514 ' N ' HG22 ' A' ' 4' ' ' VAL . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . 0.464 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 51.7 m-80 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.533 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.516 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . 0.513 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . 0.404 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 2 2 . 1 . 039 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.525 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.518 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 040 nuclear orig core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 4' ' ' VAL . . . . . 0.463 ' CG2' HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.485 HD12 ' HB2' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 10' ' ' TYR . . . . . 0.505 ' CD1' HD11 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 11' ' ' ILE . . . . . 0.482 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 12' ' ' TYR . . . . . 0.499 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . 0.499 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 27' ' ' THR . . . . . 0.466 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 28' ' ' LYS . . . . . 0.746 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HA ' HD13 ' A' ' 32' ' ' LEU . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.746 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 33' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 37' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 44' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.515 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear orig core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 47' ' ' GLU . . . . . 0.485 ' HB2' HD12 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear orig core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 1 1 . 1 . 040 nuclear orig core ' A' A ' 50' ' ' LYS . . . . . 0.462 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 2.1 ptpt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.52 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.444 ' N ' HG21 ' A' ' 4' ' ' VAL . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.475 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.51 ' N ' HD13 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.506 ' CD1' HD12 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.532 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.471 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.471 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.537 ' HA ' HD13 ' A' ' 32' ' ' LEU . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.537 HD13 ' HA ' ' A' ' 29' ' ' PHE . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.525 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.504 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.508 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.478 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.475 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt -98.17 161.09 13.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 11.6 tp -96.85 36.51 1.4 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.474 172.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 57.8 104.74 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.02 -171.652 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 C--O 1.24 0.605 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.346 168.954 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.512 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.54 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.44 HG13 HD12 ' A' ' 51' ' ' LEU . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.523 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.51 ' CD1' HD12 ' A' ' 40' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.434 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.509 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.512 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.509 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.52 ' HB ' HG22 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.528 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HA ' HD12 ' A' ' 32' ' ' LEU . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.478 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.528 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.526 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.511 ' NE1' HD13 ' A' ' 23' ' ' ILE . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.517 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.469 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.517 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.426 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.523 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.54 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt -125.18 124.9 42.76 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.44 HD12 HG13 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -115.61 66.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.322 170.734 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -39.89 29.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.371 170.45 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.375 170.252 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.52 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.509 HD11 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CG ' HD11 ' A' ' 40' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.46 HD13 ' N ' ' A' ' 11' ' ' ILE . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.508 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.508 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.475 ' HA2' HG21 ' A' ' 23' ' ' ILE . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.534 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . 0.402 ' HB3' ' ND2' ' A' ' 21' ' ' ASN . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.402 ' ND2' ' HB3' ' A' ' 20' ' ' ASP . 0.4 OUTLIER -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.534 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.534 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.555 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HA ' HD11 ' A' ' 32' ' ' LEU . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.465 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.555 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.504 ' NE1' HD13 ' A' ' 23' ' ' ILE . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.527 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD11 ' CG ' ' A' ' 10' ' ' TYR . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.523 ' HB2' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.527 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.523 ' HG2' ' HB2' ' A' ' 43' ' ' ALA . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -118.24 138.38 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -97.51 46.51 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.427 170.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -140.65 114.7 9.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.376 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.24 0.556 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.34 170.075 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.532 ' HG2' HD22 ' A' ' 51' ' ' LEU . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.539 HG22 HD13 ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD11 ' A' ' 40' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.539 HD13 HG22 ' A' ' 4' ' ' VAL . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.513 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.516 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.495 HG21 HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.598 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.506 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.465 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.598 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.539 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.421 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.539 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.52 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -113.89 159.16 20.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.532 HD22 ' HG2' ' A' ' 2' ' ' LYS . 1.7 pp -137.29 77.18 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.443 168.531 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -86.47 84.85 7.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.368 170.651 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.24 0.564 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.354 -170.423 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.46 ' HG3' ' CD1' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.532 HG22 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.461 ' CD1' ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD12 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG22 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.525 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.525 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.413 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.508 ' HE2' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.508 ' HG3' ' HE2' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 HD12 ' HA ' ' A' ' 29' ' ' PHE . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.426 ' CD1' HD12 ' A' ' 23' ' ' ILE . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.508 HD12 ' CD1' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.471 ' HB3' ' CB ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.403 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.471 ' CB ' ' HB3' ' A' ' 43' ' ' ALA . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.468 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.485 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt -85.61 132.72 34.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.46 ' CD1' ' HG3' ' A' ' 2' ' ' LYS . 0.3 OUTLIER -123.8 63.1 1.05 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.349 -0.842 . . . . 0.0 110.403 168.966 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -133.74 132.46 40.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.383 169.397 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 C--O 1.24 0.584 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.383 -170.259 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.529 HD12 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.485 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.508 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.508 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.461 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.404 ' ND2' ' N ' ' A' ' 21' ' ' ASN . 0.3 OUTLIER -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.519 HG23 HD21 ' A' ' 32' ' ' LEU . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.416 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.531 ' HB3' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HG2' ' HB3' ' A' ' 43' ' ' ALA . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -85.23 130.0 34.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 14.8 tp -138.2 80.32 1.79 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.359 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.449 ' HG2' ' N ' ' A' ' 53' ' ' ASP . 13.0 tt0 -129.84 -79.6 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.41 169.323 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.449 ' N ' ' HG2' ' A' ' 52' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--O 1.24 0.578 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.368 170.239 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.433 ' HB2' HD11 ' A' ' 51' ' ' LEU . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.44 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.473 ' HG2' ' HB2' ' A' ' 53' ' ' ASP . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.467 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD11 ' A' ' 40' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.44 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.445 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.498 ' HB ' HG21 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.497 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.494 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.529 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.514 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.466 ' HB2' ' CG ' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.466 ' CG ' ' HB2' ' A' ' 43' ' ' ALA . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.41 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.59 104.42 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.433 HD11 ' HB2' ' A' ' 2' ' ' LYS . 0.2 OUTLIER 60.06 31.3 20.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.587 168.87 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -171.38 179.03 3.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.389 170.072 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.473 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 2.8 p30 . . . . . 0 C--O 1.24 0.553 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.328 170.197 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.532 ' HG3' HD23 ' A' ' 51' ' ' LEU . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 11' ' ' ILE . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.416 ' N ' HG21 ' A' ' 4' ' ' VAL . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.539 HD13 ' HB2' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CD1' HD12 ' A' ' 40' ' ' ILE . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.1 m-80 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.493 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.493 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.514 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.539 ' HB2' HD13 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.492 ' HD2' ' HB3' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -74.11 167.96 20.51 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.532 HD23 ' HG3' ' A' ' 2' ' ' LYS . 1.9 pt? -76.7 -7.84 56.12 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.646 -177.024 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.492 ' HB3' ' HD2' ' A' ' 50' ' ' LYS . 3.9 tp10 -120.48 28.4 8.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.469 -169.386 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.365 169.444 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.461 ' N ' HG21 ' A' ' 4' ' ' VAL . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.465 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.537 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.519 ' HB2' HD12 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.528 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.523 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.523 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.439 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.63 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.517 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.517 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.63 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.532 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HB2' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.428 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.537 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.465 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -107.1 152.16 24.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.83 31.37 3.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.391 172.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -103.68 -41.13 6.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.443 -175.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 C--O 1.24 0.592 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.333 169.964 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.539 HD13 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.52 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.492 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.492 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.465 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 6.4 m-80 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.528 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.586 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.476 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.586 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.534 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.521 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.521 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.539 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.416 ' HB3' HG11 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.518 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 24.3 tttt -138.19 153.13 49.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.518 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.6 OUTLIER 60.0 90.82 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.544 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -79.43 -19.19 50.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.438 171.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.239 0.512 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.31 -169.786 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.507 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.539 HG22 HD13 ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.52 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.405 ' CG1' ' HB3' ' A' ' 47' ' ' GLU . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CD1' HD11 ' A' ' 40' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.539 HD13 HG22 ' A' ' 4' ' ' VAL . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.463 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.434 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.463 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.491 HG22 ' N ' ' A' ' 28' ' ' LYS . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.518 ' HG2' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.507 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.518 ' HB2' ' HG2' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.523 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.523 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.506 ' CD1' HD11 ' A' ' 23' ' ' ILE . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.516 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.513 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.52 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.514 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.514 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -108.54 154.89 21.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.67 44.48 1.08 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.496 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -121.16 40.02 3.68 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.395 176.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.542 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.357 170.204 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.437 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.538 HD12 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CD1' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.477 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.505 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.505 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.538 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.538 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.459 ' CB ' HG22 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.486 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.486 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.496 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD13 ' CD1' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.405 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.516 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.538 ' HB3' HD12 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.474 ' NZ ' ' HA ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -76.96 147.37 36.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.4 mt -97.63 40.46 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.413 -168.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.474 ' HA ' ' NZ ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER 57.89 14.21 2.47 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.976 169.271 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.876 174.971 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.533 HG22 HG13 ' A' ' 11' ' ' ILE . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.458 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.419 ' CD1' ' HB2' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.507 ' CD1' HD11 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.533 HG13 HG22 ' A' ' 4' ' ' VAL . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.405 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.405 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.517 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.531 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.531 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.459 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.507 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.408 ' CB ' HD12 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.537 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.419 ' HB2' ' CD1' ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.466 ' HG3' HG12 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.68 148.68 21.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.99 46.87 1.35 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.49 173.407 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -171.33 111.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.393 169.262 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.548 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.356 177.437 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 6' ' ' LYS . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.53 HG12 ' HG3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.459 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.507 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.507 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.536 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.536 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.65 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.65 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.492 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.457 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.471 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.53 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.495 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.514 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -130.3 154.12 47.96 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.9 tp -100.45 19.47 16.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.362 171.139 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.56 142.11 37.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.427 170.043 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 18.3 t70 . . . . . 0 C--O 1.241 0.608 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.355 -170.048 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.464 ' N ' HG21 ' A' ' 4' ' ' VAL . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.442 ' HG3' HD12 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.526 HD13 ' HG3' ' A' ' 47' ' ' GLU . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.536 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.6 m-80 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.536 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.458 HG21 ' CD2' ' A' ' 32' ' ' LEU . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.608 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.489 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.608 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' HG3' HD13 ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.26 152.42 36.71 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 24.2 tp -127.21 56.2 1.54 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.345 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -94.78 -52.43 4.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.434 169.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.307 170.012 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.505 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.491 HG21 HD12 ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.528 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CD1' HD13 ' A' ' 40' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.491 HD12 HG21 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.515 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.51 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.515 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.503 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.652 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.505 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.467 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.652 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.506 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.517 HD13 ' CD1' ' A' ' 10' ' ' TYR . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.475 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.73 136.16 53.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.02 85.24 0.11 Allowed 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.571 170.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.486 ' HB3' HG13 ' A' ' 4' ' ' VAL . 0.5 OUTLIER -152.3 -163.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.384 169.533 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 p30 . . . . . 0 C--O 1.241 0.625 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.365 -178.741 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.538 HG21 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.534 HG12 ' HG3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.518 ' CD1' HD13 ' A' ' 40' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.538 HG13 HG21 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.446 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 0.4 OUTLIER -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.45 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.504 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.538 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.535 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.437 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.529 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.446 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 HD13 ' CD1' ' A' ' 10' ' ' TYR . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.455 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.529 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.534 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.42 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.22 125.1 26.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.3 tp -128.55 63.34 1.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.333 -0.848 . . . . 0.0 110.362 -170.02 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -132.94 105.13 6.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.334 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 . . . . . 0 C--O 1.24 0.582 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.337 -169.617 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.518 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.484 HG11 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.482 HD12 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.491 ' HB2' HG13 ' A' ' 40' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 4' ' ' VAL . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.515 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.535 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.53 ' HG3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.53 ' HB2' ' HG3' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.526 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.526 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.53 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.491 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.469 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.53 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.482 ' HB3' HD12 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.484 ' HB3' HG11 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -105.26 118.58 36.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 52.09 0.78 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.418 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -62.81 -31.38 72.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.406 -170.251 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 . . . . . 0 C--O 1.24 0.574 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.358 -177.368 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.49 ' HA ' ' HB3' ' A' ' 53' ' ' ASP . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.417 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.52 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.533 HD12 ' HG3' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.513 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.52 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.519 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.519 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.3 m-80 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.467 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.505 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.505 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.539 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.539 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.515 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.513 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.417 ' HB3' ' HG3' ' A' ' 47' ' ' GLU . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.533 ' HG3' HD12 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -116.11 137.67 51.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.518 HD12 ' HG2' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -91.77 -104.54 0.11 Allowed 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.822 167.153 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.518 ' HG2' HD12 ' A' ' 51' ' ' LEU . 12.7 pt-20 -125.53 175.21 7.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.361 -172.174 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.49 ' HB3' ' HA ' ' A' ' 1' ' ' ALA . 1.4 p30 . . . . . 0 C--O 1.24 0.602 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.319 170.678 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.502 ' HE2' HG23 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.509 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.442 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.532 HG12 ' HG3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD13 ' A' ' 40' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.502 HG23 ' HE2' ' A' ' 2' ' ' LYS . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.511 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.511 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.53 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 9.5 m-80 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.53 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.514 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.509 HD11 ' HA ' ' A' ' 29' ' ' PHE . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.46 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.514 HD13 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.49 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HG3' HG12 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.514 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.505 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm -75.29 144.91 42.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.0 mt -155.01 85.6 1.09 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.405 169.93 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -61.54 121.43 12.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.394 169.48 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.9 t70 . . . . . 0 C--O 1.239 0.55 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.37 -169.974 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 0 0 . 1 . 021 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.511 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.454 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.507 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.52 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD12 ' A' ' 40' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.454 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CE2' HD13 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.538 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.497 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.538 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.525 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.539 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.539 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.405 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.405 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.483 ' HB3' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.52 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.507 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.479 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp -101.05 145.03 29.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 9.4 tt -110.03 4.63 21.5 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.15 -0.932 . . . . 0.0 111.885 177.356 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -128.67 112.44 14.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.334 -178.161 . . . . . . . . 2 2 . 1 . 021 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.349 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.44 ' CD1' ' HB2' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD12 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.522 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.5 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.5 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.537 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.447 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.537 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.534 HG22 HD23 ' A' ' 32' ' ' LEU . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.622 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.517 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.469 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.622 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.523 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.516 ' CD1' HD12 ' A' ' 23' ' ' ILE . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.532 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' CD1' ' A' ' 10' ' ' TYR . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.406 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.532 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.44 ' HB2' ' CD1' ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.7 pttm -133.64 128.5 35.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.4 mp -137.78 64.0 1.53 Allowed 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.375 -178.296 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -79.28 105.5 10.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.428 169.714 . . . . . . . . 1 1 . 1 . 022 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.359 179.662 . . . . . . . . 0 0 . 1 . 022 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.518 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.539 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.451 ' N ' HG22 ' A' ' 4' ' ' VAL . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.446 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.535 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CD1' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.53 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . 0.49 ' HB3' ' HB1' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.49 ' HB1' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.534 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.534 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.524 HG23 HD21 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.535 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.535 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.526 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 HD11 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.459 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.526 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.509 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.535 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.539 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.517 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER -91.84 142.76 27.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 3 3 . 1 . 023 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.443 HD11 ' HA ' ' A' ' 51' ' ' LEU . 3.3 mm? 60.03 86.57 0.09 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.552 168.682 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.05 116.67 32.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.376 169.066 . . . . . . . . 2 2 . 1 . 023 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.6 t70 . . . . . 0 C--O 1.24 0.594 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.32 -169.992 . . . . . . . . 0 0 . 1 . 023 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.482 ' HD3' HG22 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.521 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.536 HG22 HG13 ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.507 HD13 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.501 ' CD1' HD12 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG22 ' A' ' 4' ' ' VAL . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.459 ' CE2' HD12 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.517 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.461 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.517 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.465 HG23 HD22 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.663 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.521 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.469 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.663 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.538 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.511 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.4 ' CB ' ' CD1' ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.507 ' HB3' HD13 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -107.07 139.77 40.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 3 3 . 1 . 024 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.4 tp -99.98 16.75 22.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.523 173.602 . . . . . . . . 1 1 . 1 . 024 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.21 -83.61 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.032 -168.747 . . . . . . . . 2 2 . 1 . 024 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 . . . . . 0 C--O 1.24 0.554 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.33 169.664 . . . . . . . . 0 0 . 1 . 024 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.536 HG23 HG13 ' A' ' 11' ' ' ILE . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.506 ' N ' HG21 ' A' ' 4' ' ' VAL . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB2' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.512 ' CG ' HD11 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.536 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.479 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.479 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.7 m-80 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.518 HG23 HD21 ' A' ' 32' ' ' LEU . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.61 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HA ' HD13 ' A' ' 32' ' ' LEU . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.532 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.61 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.533 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.512 HD11 ' CG ' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.411 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.533 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB2' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HB3' ' HB2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.476 ' HD3' ' N ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -61.58 134.62 57.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 3 3 . 1 . 025 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 tp -109.38 51.35 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.467 -175.719 . . . . . . . . 1 1 . 1 . 025 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -129.92 149.02 51.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.371 170.053 . . . . . . . . 2 2 . 1 . 025 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.2 t70 . . . . . 0 C--O 1.24 0.561 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.31 -170.098 . . . . . . . . 0 0 . 1 . 025 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.478 ' HG2' ' HG ' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.463 HG12 ' HB3' ' A' ' 49' ' ' GLU . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.53 HD11 ' HB2' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.509 ' CD1' HD13 ' A' ' 40' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.521 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.538 HG23 HD22 ' A' ' 32' ' ' LEU . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.758 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.538 ' HA ' HD12 ' A' ' 32' ' ' LEU . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.485 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.758 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.418 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.53 ' HB2' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.468 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.463 ' HB3' HG12 ' A' ' 4' ' ' VAL . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -131.71 119.11 20.89 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.478 ' HG ' ' HG2' ' A' ' 2' ' ' LYS . 14.2 mt 60.01 57.72 2.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.616 168.128 . . . . . . . . 2 2 . 1 . 026 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 58.15 -84.49 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.129 173.73 . . . . . . . . 1 1 . 1 . 026 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.388 -170.043 . . . . . . . . 0 0 . 1 . 026 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 0 0 . 1 . 027 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.516 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.535 HG22 HG13 ' A' ' 11' ' ' ILE . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.421 ' N ' HG21 ' A' ' 4' ' ' VAL . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.528 HD12 ' HB2' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD11 ' A' ' 40' ' ' ILE . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.535 HG13 HG22 ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.516 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.463 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 5.4 m-80 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.521 ' N ' HD11 ' A' ' 23' ' ' ILE . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.417 ' N ' HG21 ' A' ' 23' ' ' ILE . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.641 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.516 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' HB3' ' CB ' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.641 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.494 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB2' HD12 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -104.15 143.49 32.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.7 tp -94.6 19.1 10.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.425 -176.164 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -76.72 -48.24 19.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.36 169.404 . . . . . . . . 2 2 . 1 . 027 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.539 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.327 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.469 HD13 ' CB ' ' A' ' 47' ' ' GLU . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.475 ' CD1' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.414 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.414 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' HG21 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.519 ' HB2' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.515 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.519 ' HG2' ' HB2' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.51 HD11 ' HA ' ' A' ' 29' ' ' PHE . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.476 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.518 ' HB2' HD11 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 HD11 ' HB2' ' A' ' 39' ' ' PRO . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.468 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.491 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.469 ' CB ' HD13 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 1 1 . 1 . 028 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.459 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -107.72 146.41 32.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 3 3 . 1 . 028 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -120.47 28.93 7.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.379 -170.444 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.82 -161.13 1.11 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.349 170.368 . . . . . . . . 2 2 . 1 . 028 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.36 170.145 . . . . . . . . 0 0 . 1 . 028 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.473 ' HA ' ' HB2' ' A' ' 53' ' ' ASP . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.5 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 7' ' ' ILE . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.515 ' CD1' HD11 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.493 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.519 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.519 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.485 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HA ' HD13 ' A' ' 32' ' ' LEU . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.485 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.524 HD13 ' HA ' ' A' ' 29' ' ' PHE . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.486 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD11 ' CD1' ' A' ' 10' ' ' TYR . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.513 ' HB3' HD12 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.5 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -65.17 124.63 22.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 3 3 . 1 . 029 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.23 44.42 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.36 -169.166 . . . . . . . . 2 2 . 1 . 029 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 57.78 172.86 0.05 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.045 168.839 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.473 ' HB2' ' HA ' ' A' ' 1' ' ' ALA . 5.3 t70 . . . . . 0 C--O 1.24 0.593 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.389 -171.621 . . . . . . . . 1 1 . 1 . 029 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.435 HG11 ' HB2' ' A' ' 49' ' ' GLU . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.522 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.52 ' CD1' HD12 ' A' ' 40' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.515 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.432 ' N ' ' ND2' ' A' ' 21' ' ' ASN . 0.2 OUTLIER -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.515 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.425 ' CG2' HD22 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.565 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.517 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.565 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.436 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.52 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' CD1' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.517 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.522 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 1 1 . 1 . 030 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.435 ' HB2' HG11 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.48 144.27 49.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.2 69.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.415 170.23 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.33 -24.02 37.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.428 -170.014 . . . . . . . . 2 2 . 1 . 030 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.57 175.774 . . . . . . . . 0 0 . 1 . 030 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.509 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.528 HD12 ' HG2' ' A' ' 47' ' ' GLU . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.518 ' CD1' HD11 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.516 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.503 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.504 ' N ' ' HA ' ' A' ' 25' ' ' PRO . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.469 ' N ' ' HB ' ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.453 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.469 ' HB ' ' N ' ' A' ' 18' ' ' ASP . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.427 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.504 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.477 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.509 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.477 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.51 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.467 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.482 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.52 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HG2' HD12 ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.476 ' HB3' HG13 ' A' ' 4' ' ' VAL . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.506 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER -110.42 124.6 52.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 3 3 . 1 . 031 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 tp -126.83 70.28 1.28 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.448 -177.045 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -103.61 -25.54 13.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.475 -172.303 . . . . . . . . 1 1 . 1 . 031 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 t0 . . . . . 0 C--O 1.24 0.603 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.403 177.128 . . . . . . . . 0 0 . 1 . 031 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 0 0 . 1 . 032 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.519 ' HD3' ' HB2' ' A' ' 53' ' ' ASP . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . . . . . . . . . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.517 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.531 HD13 ' HB2' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.51 ' CD1' HD11 ' A' ' 40' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . . . . . . . . . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.448 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.515 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.52 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.459 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.538 ' HA ' HD12 ' A' ' 32' ' ' LEU . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.538 HD12 ' HA ' ' A' ' 29' ' ' PHE . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.459 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.459 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.515 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.439 ' CG ' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB2' HD13 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.517 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.419 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -78.92 109.15 12.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 3 3 . 1 . 032 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.7 tt -115.35 65.21 0.69 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.426 -175.57 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -61.03 155.76 19.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.428 -169.303 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . 0.519 ' HB2' ' HD3' ' A' ' 2' ' ' LYS . 11.0 t0 . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.361 -169.707 . . . . . . . . 1 1 . 1 . 032 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 0 0 . 1 . 033 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.514 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.468 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.526 HD11 ' HB2' ' A' ' 47' ' ' GLU . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.511 ' CD1' HD11 ' A' ' 40' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.451 ' CD1' HG21 ' A' ' 4' ' ' VAL . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.49 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.532 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.532 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.537 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.509 ' HB2' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.458 ' CD1' ' HA ' ' A' ' 29' ' ' PHE . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.535 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.535 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.469 HG11 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . 0.411 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.411 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.458 ' CB ' HD12 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.469 ' HA ' HG11 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.512 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.526 ' HB2' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.468 ' HB3' HG13 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.87 129.68 38.71 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.3 tt 60.08 82.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.586 170.425 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -99.99 87.34 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.364 170.472 . . . . . . . . 2 2 . 1 . 033 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.24 0.585 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.338 -170.109 . . . . . . . . 1 1 . 1 . 033 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.52 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.482 ' N ' HG22 ' A' ' 4' ' ' VAL . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.519 HD13 ' HG3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.517 ' CG ' HD11 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.537 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.502 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.533 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.522 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.8 m-80 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.522 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.461 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.533 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.489 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.498 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.524 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.509 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.479 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.517 HD11 ' CG ' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.479 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.519 ' HG3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.52 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -126.27 146.25 50.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 3 3 . 1 . 034 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.2 tp 60.05 97.54 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.522 171.318 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -61.1 -176.26 0.06 Allowed 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.464 177.77 . . . . . . . . 1 1 . 1 . 034 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 19.5 t0 . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.354 171.089 . . . . . . . . 0 0 . 1 . 034 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.507 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.495 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.528 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.514 ' CD1' HD12 ' A' ' 40' ' ' ILE . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.501 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.501 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD11 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.535 HD11 ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.51 ' HB ' HG21 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.584 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.513 ' HA ' HD12 ' A' ' 32' ' ' LEU . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.584 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.492 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.523 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.426 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.523 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.528 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.426 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -117.96 126.28 52.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 27.3 mt 60.09 56.94 3.16 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.694 -177.775 . . . . . . . . 1 1 . 1 . 035 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.415 ' HB2' HG12 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -136.63 167.4 21.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.366 169.108 . . . . . . . . 3 3 . 1 . 035 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 p30 . . . . . 0 C--O 1.239 0.504 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.397 179.544 . . . . . . . . 0 0 . 1 . 035 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 0 0 . 1 . 036 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.483 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.51 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.525 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.475 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.508 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.513 ' CD1' HD12 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.525 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.54 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.1 m-80 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.54 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.524 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.573 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.51 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.484 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.529 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.471 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.522 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . 0.468 ' HB2' HD13 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.518 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.462 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.522 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.473 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.478 ' HB3' HG12 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.404 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 6.7 tttt -121.7 162.37 20.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.404 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER 60.0 80.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.589 169.597 . . . . . . . . 3 3 . 1 . 036 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -171.39 144.14 1.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.416 168.935 . . . . . . . . 2 2 . 1 . 036 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.241 0.623 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.362 -170.132 . . . . . . . . 1 1 . 1 . 036 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 0 0 . 1 . 037 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.492 HG22 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.494 ' CD1' HD12 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.492 HG13 HG22 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.436 ' CE2' HD13 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.413 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.459 ' HB ' HG21 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.464 ' HB2' ' CG ' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.539 ' HA ' HD13 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CG ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.539 HD13 ' HA ' ' A' ' 29' ' ' PHE . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.505 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.505 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.515 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB2' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.515 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.497 ' HG2' ' HB2' ' A' ' 43' ' ' ALA . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.93 149.86 26.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -119.25 68.38 0.8 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.389 169.704 . . . . . . . . 2 2 . 1 . 037 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -93.2 -158.56 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.363 170.716 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.239 0.534 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.381 170.411 . . . . . . . . 1 1 . 1 . 037 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.512 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.514 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.513 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.459 ' CG1' ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.508 ' CD1' HD11 ' A' ' 40' ' ' ILE . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.514 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.518 ' CZ ' HD23 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.537 ' HG2' ' HA ' ' A' ' 28' ' ' LYS . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . 0.52 ' N ' ' HA ' ' A' ' 25' ' ' PRO . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.51 ' N ' ' HB ' ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 24.5 m-80 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.51 ' HB ' ' N ' ' A' ' 18' ' ' ASP . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 24' ' ' SER . . . . . 0.421 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . 0.52 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.537 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.512 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.526 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.518 HD23 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.488 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.528 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.514 ' N ' HD13 ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.528 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.459 ' HB3' ' CG1' ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . 0.513 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.411 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -119.04 143.21 47.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 3 3 . 1 . 038 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.7 mp 60.05 39.82 19.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.534 169.876 . . . . . . . . 1 1 . 1 . 038 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.464 ' HA ' HG13 ' A' ' 4' ' ' VAL . 1.9 tt0 58.31 -86.75 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.208 169.665 . . . . . . . . 2 2 . 1 . 038 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 . . . . . 0 C--O 1.24 0.555 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.386 170.104 . . . . . . . . 0 0 . 1 . 038 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 0 0 . 1 . 039 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.516 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.535 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . 0.514 ' N ' HG22 ' A' ' 4' ' ' VAL . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.525 HD13 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.519 ' CD1' HD12 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.51 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.51 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . 0.464 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 51.7 m-80 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.533 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.499 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.516 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.499 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.521 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.521 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . 0.513 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . . . . . . . . . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.519 HD12 ' CD1' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . 0.404 ' CB ' HD11 ' A' ' 7' ' ' ILE . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 2 2 . 1 . 039 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.44 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.525 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.518 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.455 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -145.06 142.41 29.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 3 3 . 1 . 039 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.4 tp 59.9 86.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.523 168.739 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -107.92 114.95 29.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 169.454 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.62 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.345 -170.214 . . . . . . . . 1 1 . 1 . 039 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 0 0 . 1 . 040 nuclear orig full ' A' A ' 2' ' ' LYS . . . . . 0.538 ' HG3' ' HG2' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 4' ' ' VAL . . . . . 0.463 ' CG2' HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.485 HD12 ' HB2' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 10' ' ' TYR . . . . . 0.505 ' CD1' HD11 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 11' ' ' ILE . . . . . 0.482 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 12' ' ' TYR . . . . . 0.499 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . 0.499 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.529 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . 0.529 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 27' ' ' THR . . . . . 0.466 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 28' ' ' LYS . . . . . 0.746 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 29' ' ' PHE . . . . . 0.518 ' HA ' HD13 ' A' ' 32' ' ' LEU . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.746 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 33' ' ' PRO . . . . . 0.5 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 37' ' ' VAL . . . . . 0.443 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 40' ' ' ILE . . . . . 0.516 ' N ' HD13 ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 44' ' ' PRO . . . . . 0.443 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.515 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 47' ' ' GLU . . . . . 0.485 ' HB2' HD12 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 50' ' ' LYS . . . . . 0.462 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 2.1 ptpt -70.91 165.95 22.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 51' ' ' LEU . . . . . 0.404 ' HG ' ' O ' ' A' ' 51' ' ' LEU . 0.3 OUTLIER 60.18 60.21 2.14 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.702 170.574 . . . . . . . . 3 3 . 1 . 040 nuclear orig full ' A' A ' 52' ' ' GLU . . . . . 0.538 ' HG2' ' HG3' ' A' ' 2' ' ' LYS . 5.1 mm-40 57.7 -168.77 0.12 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.999 167.197 . . . . . . . . 2 2 . 1 . 040 nuclear orig full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.614 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.391 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear orig full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.499 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.522 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.548 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.666 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.646 ' CG ' HD13 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.499 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.448 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.419 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.438 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.646 HD13 ' CG ' ' A' ' 10' ' ' TYR . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.715 ' HA ' HG12 ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.548 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.796 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.485 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.828 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.861 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.711 ' C ' HD13 ' A' ' 11' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.828 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.562 ' H ' HG22 ' A' ' 11' ' ' ILE . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.485 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.796 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 25' ' ' PRO . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.763 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' ASP . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.763 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.642 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.694 HG12 ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.603 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.694 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.861 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.786 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.826 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.738 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.494 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.826 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.491 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.786 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' HE1' ' A' ' 12' ' ' TYR . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.51 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.789 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.789 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.59 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.542 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.573 HD22 HG12 ' A' ' 23' ' ' ILE . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.787 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.48 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.494 HD12 ' N ' ' A' ' 40' ' ' ILE . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.645 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.738 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.5 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.502 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.601 ' SG ' HD12 ' A' ' 7' ' ' ILE . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.915 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.732 ' O ' HD13 ' A' ' 11' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.559 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.569 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.523 ' CG2' HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.59 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.59 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.658 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.704 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.915 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.552 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.552 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.583 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.73 HG23 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.651 ' CB ' HD13 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.73 HG13 HG23 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.47 ' H ' HG22 ' A' ' 11' ' ' ILE . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.583 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.514 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.447 ' C ' HD12 ' A' ' 23' ' ' ILE . 4.5 m120 -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.469 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.45 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.515 ' HD3' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HG3' ' HD3' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.531 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.419 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.651 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.542 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.424 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.666 HG23 HG13 ' A' ' 11' ' ' ILE . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.858 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.525 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.666 HG13 HG23 ' A' ' 4' ' ' VAL . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.48 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.548 ' HB3' HD13 ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.534 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.626 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.569 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.459 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.805 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.468 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.805 HG13 ' O ' ' A' ' 35' ' ' ASP . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.43 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.64 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.408 ' HD2' ' OE1' ' A' ' 47' ' ' GLU . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.858 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.527 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.82 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.522 ' HE3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.82 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.68 ' H ' HG22 ' A' ' 11' ' ' ILE . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.465 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.665 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.53 ' HB ' HG23 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.493 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.527 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.546 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.546 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.612 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.679 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.557 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.612 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.598 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.525 HG12 ' O ' ' A' ' 49' ' ' GLU . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.81 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.482 ' O ' HG23 ' A' ' 4' ' ' VAL . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.496 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.598 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.42 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.5 m120 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.596 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.719 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.419 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.719 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.81 ' HB3' HD11 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.46 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.559 ' O ' HG23 ' A' ' 11' ' ' ILE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.516 HG23 HG13 ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.824 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.791 ' HB2' HD13 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.568 HD12 ' C ' ' A' ' 10' ' ' TYR . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.755 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.755 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.469 HG21 HD23 ' A' ' 32' ' ' LEU . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.62 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.773 ' O ' HG13 ' A' ' 37' ' ' VAL . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.439 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.773 HG13 ' O ' ' A' ' 35' ' ' ASP . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.467 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.791 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.824 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.427 ' H ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.59 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.531 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.773 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.613 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.512 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.59 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . 8.8 m120 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 21' ' ' ASN . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.504 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.58 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.531 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.58 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.461 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.699 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.476 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.613 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.476 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.699 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.435 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.773 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.47 ' HB3' HG13 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 24.3 tttt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.681 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.416 ' HG3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.714 ' C ' HD13 ' A' ' 11' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.714 HD13 ' C ' ' A' ' 10' ' ' TYR . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.445 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.513 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.583 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.554 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.681 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.424 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.423 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.529 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.546 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.546 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.83 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.638 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.698 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.809 ' HB2' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.638 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.83 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.804 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.486 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.804 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.4 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.502 ' CB ' HG23 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.508 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.585 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.677 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.809 HD13 ' HB2' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.429 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.677 ' HA ' HG12 ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.444 ' H ' ' HE3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.698 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.621 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' ILE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.547 HG13 ' HG3' ' A' ' 49' ' ' GLU . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.522 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.496 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.896 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CB ' HD13 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 10' ' ' TYR . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.451 ' OH ' HG21 ' A' ' 23' ' ' ILE . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.621 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.605 ' HB ' HG23 ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.672 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.733 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.616 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.799 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.733 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.896 ' CB ' HD11 ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' HG3' HG13 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.422 ' HE3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.846 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.821 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.875 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 11' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.821 HG13 HG23 ' A' ' 4' ' ' VAL . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.846 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.517 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.665 HG23 ' HB ' ' A' ' 27' ' ' THR . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.665 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 35' ' ' ASP . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.4 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.671 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.875 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.405 ' HB3' ' H ' ' A' ' 50' ' ' LYS . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.617 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 10' ' ' TYR . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.436 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.626 ' CG ' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.512 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.617 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.421 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.1 m120 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.738 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.738 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.666 ' O ' HG13 ' A' ' 37' ' ' VAL . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 35' ' ' ASP . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.437 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.579 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 6' ' ' LYS . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.838 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.909 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.671 ' C ' HD13 ' A' ' 11' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.838 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.565 ' H ' HG22 ' A' ' 11' ' ' ILE . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.554 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.554 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.541 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.667 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.555 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.643 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.508 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.643 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.547 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.838 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.675 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.745 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.909 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.636 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.716 HG23 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.896 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.479 ' CG ' ' N ' ' A' ' 11' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.716 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.636 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.74 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.74 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.566 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.499 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.544 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.527 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.672 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.544 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.417 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.896 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.523 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.67 HG13 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.828 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.546 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.462 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.63 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.63 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.429 HG22 ' O ' ' A' ' 28' ' ' LYS . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.525 ' CG ' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.689 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.498 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.716 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.828 ' HB3' HD11 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.67 ' HB3' HG13 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.497 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.408 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.408 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.566 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.891 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.785 HD11 ' CB ' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.891 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.496 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.496 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.402 ' C ' HD12 ' A' ' 23' ' ' ILE . 8.0 m120 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.704 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.431 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.431 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.704 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.573 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 37' ' ' VAL . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.571 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 35' ' ' ASP . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.551 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.611 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.551 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.408 ' HG3' ' HE3' ' A' ' 36' ' ' TRP . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.785 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.578 ' HE2' HG21 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.743 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.839 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.557 ' CE2' HD11 ' A' ' 32' ' ' LEU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.49 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.444 ' C ' HD12 ' A' ' 23' ' ' ILE . 7.4 m120 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.744 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.744 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.481 HG21 HD23 ' A' ' 32' ' ' LEU . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.557 HD11 ' CE2' ' A' ' 12' ' ' TYR . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.453 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.657 ' O ' HG13 ' A' ' 37' ' ' VAL . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.578 HD13 ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.533 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.743 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.432 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.522 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.627 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.535 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.619 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.828 ' O ' HD13 ' A' ' 11' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.828 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.54 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.542 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.542 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.785 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.578 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.578 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 44' ' ' PRO . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.653 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.619 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.481 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.847 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.466 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 3 3 . 1 . 022 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.596 ' O ' HG23 ' A' ' 11' ' ' ILE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.569 ' SG ' HD12 ' A' ' 7' ' ' ILE . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.918 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.593 ' CG ' HD13 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.596 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.475 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.847 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.633 ' OD2' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.423 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.633 HD13 ' OD2' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.606 ' O ' HG13 ' A' ' 37' ' ' VAL . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.427 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.722 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' C ' HD12 ' A' ' 40' ' ' ILE . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.781 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.722 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.918 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.7 pttm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 0 0 . 1 . 023 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.833 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.589 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.448 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.655 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 13' ' ' ASP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.833 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 16' ' ' ALA . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.783 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.783 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.452 HG21 HD23 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.527 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' THR . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.576 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.475 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.449 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.583 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.525 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.433 ' HD3' HG21 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.619 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.968 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.54 ' CG ' HD13 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.624 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.525 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.507 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.507 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.67 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.67 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.629 HG21 HD23 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.656 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.834 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.474 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.928 HG12 ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.506 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.67 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.506 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.513 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.928 ' HA ' HG12 ' A' ' 37' ' ' VAL . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.968 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' H ' ' A' ' 50' ' ' LYS . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 2 2 . 1 . 024 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.52 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.561 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.794 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.696 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.454 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.561 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.502 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.607 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.481 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.607 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.798 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.798 HG13 ' O ' ' A' ' 35' ' ' ASP . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.696 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.794 ' HB3' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.555 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.738 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.856 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.87 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.718 ' C ' HD13 ' A' ' 11' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.856 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.401 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.738 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.722 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.722 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.751 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.751 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.637 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 3 3 . 1 . 026 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.435 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.419 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.87 ' HB3' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' A' ' 50' ' ' LYS . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.498 ' H ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.764 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.508 ' O ' HG23 ' A' ' 4' ' ' VAL . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 25' ' ' PRO . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.559 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 9.9 m120 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.559 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 15' ' ' ASP . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.483 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.632 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.682 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HA ' HG12 ' A' ' 37' ' ' VAL . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.764 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.423 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 2 2 . 1 . 027 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.526 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.788 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.645 HD13 ' CB ' ' A' ' 43' ' ' ALA . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.788 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.697 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.563 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.563 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.662 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.662 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.55 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.483 ' H ' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.483 ' HG2' ' H ' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.503 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.686 ' O ' HG13 ' A' ' 37' ' ' VAL . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.707 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.414 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.645 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.707 ' HA ' HG12 ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.583 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.65 ' HB3' HG13 ' A' ' 4' ' ' VAL . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 2 2 . 1 . 028 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.452 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.781 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CE2' ' HB3' ' A' ' 50' ' ' LYS . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.677 HG23 HG13 ' A' ' 11' ' ' ILE . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.603 HD11 ' CB ' ' A' ' 47' ' ' GLU . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.555 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.677 HG13 HG23 ' A' ' 4' ' ' VAL . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.408 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.781 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.77 ' HB3' HD13 ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.77 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.491 HG21 HD23 ' A' ' 32' ' ' LEU . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.511 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.489 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 35' ' ' ASP . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.603 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.595 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 3 3 . 1 . 029 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.613 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.513 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.598 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.437 ' N ' HG22 ' A' ' 4' ' ' VAL . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.868 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.788 ' O ' HD13 ' A' ' 11' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.788 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.613 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.418 ' C ' HD12 ' A' ' 23' ' ' ILE . 1.7 m120 -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.43 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.976 HG21 HD23 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.54 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.976 HD23 HG21 ' A' ' 27' ' ' THR . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.697 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.671 ' HA ' HG12 ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.54 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.868 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 2 2 . 1 . 030 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HB2' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.602 ' O ' HG23 ' A' ' 11' ' ' ILE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.662 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.588 ' CG ' HD13 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.602 HG23 ' O ' ' A' ' 3' ' ' TRP . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.686 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.697 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.66 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.585 ' HB2' HD13 ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.413 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.567 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 23' ' ' ILE . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.557 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HB1' ' CD ' ' A' ' 47' ' ' GLU . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.582 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 2 2 . 1 . 031 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.831 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.809 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.553 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.776 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.719 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.809 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.46 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.831 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.5 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.543 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CG ' ' A' ' 3' ' ' TRP . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.543 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.451 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.571 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.672 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.776 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.449 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.43 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.602 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.618 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 4' ' ' VAL . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.515 HD13 ' CB ' ' A' ' 43' ' ' ALA . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.602 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.563 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.478 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.652 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.471 HG21 HD23 ' A' ' 32' ' ' LEU . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.534 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 HG21 ' A' ' 27' ' ' THR . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.49 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.59 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.49 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.515 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.507 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.515 ' CB ' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' HG12 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.538 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.582 ' SG ' HD12 ' A' ' 7' ' ' ILE . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.96 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.741 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.743 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.5 ' H ' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HB ' ' H ' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CE2' ' HD2' ' A' ' 45' ' ' LYS . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.674 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.564 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.588 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.73 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.483 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.748 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.73 ' HA ' HG12 ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.96 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.458 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 2 2 . 1 . 034 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.538 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.54 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.831 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.575 ' O ' HG23 ' A' ' 4' ' ' VAL . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.54 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.433 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.556 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.556 ' HB ' HG23 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.579 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.74 ' O ' HG13 ' A' ' 37' ' ' VAL . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.567 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.74 HG13 ' O ' ' A' ' 35' ' ' ASP . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.505 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.601 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.831 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.459 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.607 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.547 ' O ' HG23 ' A' ' 11' ' ' ILE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.577 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.468 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.704 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.625 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.547 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.607 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.434 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.6 m120 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.412 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.697 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.571 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.52 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.536 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.684 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HB2' HD12 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.659 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.455 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.684 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.407 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.704 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.577 ' HB3' HG13 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.7 tttt . . . . . 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 0 0 . 1 . 037 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.684 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.513 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.926 HG23 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.567 HD11 ' HG3' ' A' ' 47' ' ' GLU . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.583 ' CG ' HD13 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.926 HG13 HG23 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.696 ' CE2' HD11 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.684 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.427 ' C ' ' HD3' ' A' ' 19' ' ' PRO . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.519 ' C ' HD12 ' A' ' 23' ' ' ILE . 3.8 m120 -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' HG23 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.503 ' CB ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.579 ' O ' HD12 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.696 HD11 ' CE2' ' A' ' 12' ' ' TYR . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.589 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.589 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.44 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.65 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.567 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear build core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 10' ' ' TYR . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.493 ' O ' HG23 ' A' ' 4' ' ' VAL . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.545 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.798 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 17' ' ' GLY . . . . . 0.954 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.649 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.427 ' O ' HD12 ' A' ' 23' ' ' ILE . 14.5 m120 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.518 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.954 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 24' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 25' ' ' PRO . . . . . 0.575 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.545 HD21 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.528 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 3 3 . 1 . 038 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.449 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.428 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.663 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB3' HD11 ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 48' ' ' PHE . . . . . 0.488 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.413 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.52 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.557 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 6' ' ' LYS . . . . . 0.52 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.8 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.691 ' HB2' HD13 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.55 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.52 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.477 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 18.9 m120 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.528 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.577 ' HD2' ' CD1' ' A' ' 36' ' ' TRP . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.427 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.577 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.496 HG12 ' HA ' ' A' ' 44' ' ' PRO . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.691 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.496 ' HA ' HG12 ' A' ' 37' ' ' VAL . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 2 2 . 1 . 039 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.8 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.768 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 4' ' ' VAL . . . . . 0.953 HG23 HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 5' ' ' CYS . . . . . 0.571 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.837 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 10' ' ' TYR . . . . . 0.529 ' CG ' HD13 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 11' ' ' ILE . . . . . 0.953 HG13 HG23 ' A' ' 4' ' ' VAL . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 14' ' ' GLU . . . . . 0.768 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.506 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 19' ' ' PRO . . . . . 0.488 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 21' ' ' ASN . . . . . 0.442 ' C ' HD12 ' A' ' 23' ' ' ILE . 3.1 m120 -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 23' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 27' ' ' THR . . . . . 0.571 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 28' ' ' LYS . . . . . 0.731 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 29' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 31' ' ' GLU . . . . . 0.418 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.731 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 35' ' ' ASP . . . . . 0.77 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 36' ' ' TRP . . . . . 0.434 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 35' ' ' ASP . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 38' ' ' CYS . . . . . 0.5 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 40' ' ' ILE . . . . . 0.599 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 43' ' ' ALA . . . . . 0.738 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 44' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear build core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 47' ' ' GLU . . . . . 0.837 ' CB ' HD11 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 2 2 . 1 . 040 nuclear build core ' A' A ' 50' ' ' LYS . . . . . 0.467 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 2.1 ptpt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.499 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.522 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.548 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.666 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.646 ' CG ' HD13 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.499 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.448 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.419 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.438 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.646 HD13 ' CG ' ' A' ' 10' ' ' TYR . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.715 ' HA ' HG12 ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.548 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt -98.17 161.09 13.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 51' ' ' LEU . 11.6 tp -96.85 36.51 1.4 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.474 172.717 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 57.8 104.74 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.02 -171.652 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 C--O 1.24 0.605 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.346 168.954 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.796 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.485 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.828 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.861 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.711 ' C ' HD13 ' A' ' 11' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.828 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.562 ' H ' HG22 ' A' ' 11' ' ' ILE . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.485 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.796 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 25' ' ' PRO . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.9 m120 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.763 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' ASP . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.763 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.642 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.694 HG12 ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.603 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.694 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.861 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt -125.18 124.9 42.76 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.589 HD12 HG11 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -115.61 66.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.322 170.734 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -39.89 29.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.371 170.45 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.375 170.252 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.786 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.826 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.738 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.494 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.826 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.491 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.786 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' HE1' ' A' ' 12' ' ' TYR . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.51 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.9 m120 -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.789 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.789 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.59 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.542 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.573 HD22 HG12 ' A' ' 23' ' ' ILE . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.787 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.48 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.494 HD12 ' N ' ' A' ' 40' ' ' ILE . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.645 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.738 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -118.24 138.38 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -97.51 46.51 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.427 170.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -140.65 114.7 9.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.376 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.24 0.556 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.34 170.075 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.5 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.788 ' HG2' HD21 ' A' ' 51' ' ' LEU . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.502 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.601 ' SG ' HD12 ' A' ' 7' ' ' ILE . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.915 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.732 ' O ' HD13 ' A' ' 11' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.559 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.569 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.523 ' CG2' HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.59 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.59 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.658 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.704 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.915 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.552 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.552 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -113.89 159.16 20.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.788 HD21 ' HG2' ' A' ' 2' ' ' LYS . 1.7 pp -137.29 77.18 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.443 168.531 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -86.47 84.85 7.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.368 170.651 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.24 0.564 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.354 -170.423 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.583 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.491 ' HG3' ' CD1' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.73 HG23 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.651 ' CB ' HD13 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.73 HG13 HG23 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.47 ' H ' HG22 ' A' ' 11' ' ' ILE . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.583 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.514 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.447 ' C ' HD12 ' A' ' 23' ' ' ILE . 4.5 m120 -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.469 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.45 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.515 ' HD3' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HG3' ' HD3' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.531 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.419 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.651 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.542 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt -85.61 132.72 34.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.491 ' CD1' ' HG3' ' A' ' 2' ' ' LYS . 0.3 OUTLIER -123.8 63.1 1.05 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.349 -0.842 . . . . 0.0 110.403 168.966 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -133.74 132.46 40.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.383 169.397 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 C--O 1.24 0.584 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.383 -170.259 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.424 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.666 HG23 HG13 ' A' ' 11' ' ' ILE . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.858 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.525 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.666 HG13 HG23 ' A' ' 4' ' ' VAL . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.48 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.548 ' HB3' HD13 ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.5 m120 -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.534 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.626 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.569 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.459 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.805 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.468 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.805 HG13 ' O ' ' A' ' 35' ' ' ASP . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.43 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.64 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.408 ' HD2' ' OE1' ' A' ' 47' ' ' GLU . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.858 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -85.23 130.0 34.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 14.8 tp -138.2 80.32 1.79 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.359 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -129.84 -79.6 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.41 169.323 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.24 0.578 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.368 170.239 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.527 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.82 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.522 ' HE3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.82 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.68 ' H ' HG22 ' A' ' 11' ' ' ILE . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 24.2 m120 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.465 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.665 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.53 ' HB ' HG23 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.493 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.527 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.546 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.546 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.612 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.679 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.557 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.612 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.59 104.42 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 2' ' ' LYS . 0.2 OUTLIER 60.06 31.3 20.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.587 168.87 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -171.38 179.03 3.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.389 170.072 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.487 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 2.8 p30 . . . . . 0 C--O 1.24 0.553 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.328 170.197 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.598 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.919 ' CG ' HD13 ' A' ' 51' ' ' LEU . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.525 HG12 ' O ' ' A' ' 49' ' ' GLU . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.81 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.482 ' O ' HG23 ' A' ' 4' ' ' VAL . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.496 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.598 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.42 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.5 m120 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.596 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.719 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.419 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.719 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.81 ' HB3' HD11 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -74.11 167.96 20.51 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.919 HD13 ' CG ' ' A' ' 2' ' ' LYS . 1.9 pt? -76.7 -7.84 56.12 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.646 -177.024 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HB3' ' HD2' ' A' ' 50' ' ' LYS . 3.9 tp10 -120.48 28.4 8.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.469 -169.386 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.365 169.444 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.46 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.559 ' O ' HG23 ' A' ' 11' ' ' ILE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.516 HG23 HG13 ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.824 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.791 ' HB2' HD13 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.568 HD12 ' C ' ' A' ' 10' ' ' TYR . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m120 -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.755 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.755 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.469 HG21 HD23 ' A' ' 32' ' ' LEU . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.62 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.773 ' O ' HG13 ' A' ' 37' ' ' VAL . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.439 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.773 HG13 ' O ' ' A' ' 35' ' ' ASP . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.467 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.791 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.824 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.427 ' H ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER -107.1 152.16 24.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.83 31.37 3.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.391 172.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -103.68 -41.13 6.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.443 -175.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 C--O 1.24 0.592 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.333 169.964 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.59 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.531 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.773 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.613 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.512 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.59 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . 8.8 m120 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 21' ' ' ASN . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.504 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.58 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.531 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.58 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.461 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.699 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.476 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.613 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.476 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.699 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.435 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.773 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.47 ' HB3' HG13 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.503 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 24.3 tttt -138.19 153.13 49.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.503 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.6 OUTLIER 60.0 90.82 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.544 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -79.43 -19.19 50.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.438 171.12 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.239 0.512 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.31 -169.786 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.681 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' HG3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.714 ' C ' HD13 ' A' ' 11' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.714 HD13 ' C ' ' A' ' 10' ' ' TYR . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.445 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.513 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.583 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.554 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.681 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.424 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.423 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.529 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.546 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.546 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -108.54 154.89 21.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.67 44.48 1.08 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.496 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -121.16 40.02 3.68 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.395 176.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.542 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.357 170.204 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.83 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.638 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.698 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.809 ' HB2' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.638 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.83 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.804 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.486 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.804 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.4 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.502 ' CB ' HG23 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.508 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.585 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.677 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.809 HD13 ' HB2' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.429 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.677 ' HA ' HG12 ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.444 ' H ' ' HE3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.698 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.495 ' NZ ' ' HA ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -76.96 147.37 36.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.4 mt -97.63 40.46 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.413 -168.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' HA ' ' NZ ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER 57.89 14.21 2.47 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.976 169.271 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.876 174.971 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.621 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' ILE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.547 HG13 ' HG3' ' A' ' 49' ' ' GLU . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.522 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.496 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.896 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CB ' HD13 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 10' ' ' TYR . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.451 ' OH ' HG21 ' A' ' 23' ' ' ILE . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.621 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.3 m120 -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.605 ' HB ' HG23 ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.672 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.733 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.616 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.799 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.733 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.896 ' CB ' HD11 ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' HG3' HG13 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.422 ' HE3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER -92.68 148.68 21.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.99 46.87 1.35 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.49 173.407 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -171.33 111.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.393 169.262 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.548 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.356 177.437 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.846 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.821 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.875 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 11' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.821 HG13 HG23 ' A' ' 4' ' ' VAL . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.846 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.517 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.665 HG23 ' HB ' ' A' ' 27' ' ' THR . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.665 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 35' ' ' ASP . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.4 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.671 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.875 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.405 ' HB3' ' H ' ' A' ' 50' ' ' LYS . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -130.3 154.12 47.96 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.9 tp -100.45 19.47 16.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.362 171.139 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.56 142.11 37.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.427 170.043 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 18.3 t70 . . . . . 0 C--O 1.241 0.608 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.355 -170.048 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.617 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 10' ' ' TYR . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.436 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.626 ' CG ' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.512 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.617 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.421 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.1 m120 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.738 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.738 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.666 ' O ' HG13 ' A' ' 37' ' ' VAL . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 35' ' ' ASP . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.437 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.579 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 6' ' ' LYS . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.26 152.42 36.71 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 24.2 tp -127.21 56.2 1.54 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.345 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -94.78 -52.43 4.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.434 169.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.307 170.012 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.838 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.909 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.671 ' C ' HD13 ' A' ' 11' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.838 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.565 ' H ' HG22 ' A' ' 11' ' ' ILE . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.554 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.554 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.541 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.667 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.555 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.643 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.508 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.643 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.547 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.838 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.675 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.745 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.909 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.73 136.16 53.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.02 85.24 0.11 Allowed 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.571 170.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.529 ' HB3' HG11 ' A' ' 4' ' ' VAL . 0.5 OUTLIER -152.3 -163.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.384 169.533 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 p30 . . . . . 0 C--O 1.241 0.625 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.365 -178.741 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.636 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.716 HG23 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.896 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.479 ' CG ' ' N ' ' A' ' 11' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.716 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.636 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.74 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.74 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.566 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.499 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.544 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.527 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.414 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.672 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.544 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.417 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.896 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.22 125.1 26.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.3 tp -128.55 63.34 1.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.333 -0.848 . . . . 0.0 110.362 -170.02 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -132.94 105.13 6.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.334 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 . . . . . 0 C--O 1.24 0.582 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.337 -169.617 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.523 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.67 HG13 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.828 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.546 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.462 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.63 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.63 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.429 HG22 ' O ' ' A' ' 28' ' ' LYS . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.525 ' CG ' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.689 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.498 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.716 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.828 ' HB3' HD11 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.67 ' HB3' HG13 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.497 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -105.26 118.58 36.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 52.09 0.78 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.418 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -62.81 -31.38 72.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.406 -170.251 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 . . . . . 0 C--O 1.24 0.574 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.358 -177.368 . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.493 ' HA ' ' HB3' ' A' ' 53' ' ' ASP . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.408 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.566 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.891 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.785 HD11 ' CB ' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.891 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.496 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.496 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.402 ' C ' HD12 ' A' ' 23' ' ' ILE . 8.0 m120 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.704 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.431 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.431 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.704 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.573 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 37' ' ' VAL . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.571 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 35' ' ' ASP . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.551 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.413 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.611 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.551 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.408 ' HG3' ' HE3' ' A' ' 36' ' ' TRP . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.785 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -116.11 137.67 51.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.44 HD12 ' HG2' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -91.77 -104.54 0.11 Allowed 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.822 167.153 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.44 ' HG2' HD12 ' A' ' 51' ' ' LEU . 12.7 pt-20 -125.53 175.21 7.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.361 -172.174 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.493 ' HB3' ' HA ' ' A' ' 1' ' ' ALA . 1.4 p30 . . . . . 0 C--O 1.24 0.602 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.319 170.678 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.578 ' HE2' HG21 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.743 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.839 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.557 ' CE2' HD11 ' A' ' 32' ' ' LEU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.49 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.444 ' C ' HD12 ' A' ' 23' ' ' ILE . 7.4 m120 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.744 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.744 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.481 HG21 HD23 ' A' ' 32' ' ' LEU . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.557 HD11 ' CE2' ' A' ' 12' ' ' TYR . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.453 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.657 ' O ' HG13 ' A' ' 37' ' ' VAL . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.578 HD13 ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.533 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.743 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.432 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm -75.29 144.91 42.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.426 HD12 HG11 ' A' ' 4' ' ' VAL . 2.0 mt -155.01 85.6 1.09 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.405 169.93 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -61.54 121.43 12.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.394 169.48 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.9 t70 . . . . . 0 C--O 1.239 0.55 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.37 -169.974 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.522 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.627 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.535 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.619 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.828 ' O ' HD13 ' A' ' 11' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.828 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.54 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.542 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.542 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.7 m120 -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.785 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.578 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.578 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 44' ' ' PRO . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.653 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.619 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.481 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp -101.05 145.03 29.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 51' ' ' LEU . 9.4 tt -110.03 4.63 21.5 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.15 -0.932 . . . . 0.0 111.885 177.356 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -128.67 112.44 14.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.334 -178.161 . . . . . . . . 2 2 . 1 . 021 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.349 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.847 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.466 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 3 3 . 1 . 022 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.596 ' O ' HG23 ' A' ' 11' ' ' ILE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.706 HG11 HD13 ' A' ' 51' ' ' LEU . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.569 ' SG ' HD12 ' A' ' 7' ' ' ILE . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.918 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.593 ' CG ' HD13 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.596 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.475 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.847 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.633 ' OD2' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.423 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.633 HD13 ' OD2' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.606 ' O ' HG13 ' A' ' 37' ' ' VAL . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.427 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.722 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' C ' HD12 ' A' ' 40' ' ' ILE . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.781 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.722 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.918 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.642 ' O ' HD12 ' A' ' 51' ' ' LEU . 4.7 pttm -133.64 128.5 35.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.706 HD13 HG11 ' A' ' 4' ' ' VAL . 3.4 mp -137.78 64.0 1.53 Allowed 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.375 -178.296 . . . . . . . . 2 2 . 1 . 022 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -79.28 105.5 10.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.428 169.714 . . . . . . . . 1 1 . 1 . 022 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.359 179.662 . . . . . . . . 0 0 . 1 . 022 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.833 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.589 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.448 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.655 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 13' ' ' ASP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.833 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 16' ' ' ALA . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m120 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.783 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.783 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.452 HG21 HD23 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.527 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' THR . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.576 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.475 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.449 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.583 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER -91.84 142.76 27.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 3 3 . 1 . 023 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 51' ' ' LEU . 3.3 mm? 60.03 86.57 0.09 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.552 168.682 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.05 116.67 32.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.376 169.066 . . . . . . . . 2 2 . 1 . 023 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.6 t70 . . . . . 0 C--O 1.24 0.594 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.32 -169.992 . . . . . . . . 0 0 . 1 . 023 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.525 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.433 ' HD3' HG21 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.619 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.968 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.54 ' CG ' HD13 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.624 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.525 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.507 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.507 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.67 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.67 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.629 HG21 HD23 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.656 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.834 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.474 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.928 HG12 ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.506 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.67 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.506 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.513 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.928 ' HA ' HG12 ' A' ' 37' ' ' VAL . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.968 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' H ' ' A' ' 50' ' ' LYS . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.52 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -107.07 139.77 40.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 3 3 . 1 . 024 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.4 tp -99.98 16.75 22.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.523 173.602 . . . . . . . . 1 1 . 1 . 024 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.21 -83.61 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.032 -168.747 . . . . . . . . 2 2 . 1 . 024 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 . . . . . 0 C--O 1.24 0.554 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.33 169.664 . . . . . . . . 0 0 . 1 . 024 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.561 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.794 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.696 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.454 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.561 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.502 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.3 m120 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.607 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.481 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.607 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.798 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.798 HG13 ' O ' ' A' ' 35' ' ' ASP . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.696 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.794 ' HB3' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.555 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -61.58 134.62 57.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 3 3 . 1 . 025 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 tp -109.38 51.35 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.467 -175.719 . . . . . . . . 1 1 . 1 . 025 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -129.92 149.02 51.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.371 170.053 . . . . . . . . 2 2 . 1 . 025 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.2 t70 . . . . . 0 C--O 1.24 0.561 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.31 -170.098 . . . . . . . . 0 0 . 1 . 025 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.738 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.461 ' HG2' ' HG ' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.856 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.87 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.718 ' C ' HD13 ' A' ' 11' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.856 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.401 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.738 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 7.0 m120 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.722 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.722 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.751 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.751 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.637 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.435 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.419 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.87 ' HB3' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' A' ' 50' ' ' LYS . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.498 ' H ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -131.71 119.11 20.89 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 3 3 . 1 . 026 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.461 ' HG ' ' HG2' ' A' ' 2' ' ' LYS . 14.2 mt 60.01 57.72 2.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.616 168.128 . . . . . . . . 2 2 . 1 . 026 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 58.15 -84.49 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.129 173.73 . . . . . . . . 1 1 . 1 . 026 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.388 -170.043 . . . . . . . . 0 0 . 1 . 026 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.764 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.508 ' O ' HG23 ' A' ' 4' ' ' VAL . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 25' ' ' PRO . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.559 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 9.9 m120 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.559 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 15' ' ' ASP . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.483 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.632 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.682 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HA ' HG12 ' A' ' 37' ' ' VAL . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.764 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.423 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -104.15 143.49 32.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.7 tp -94.6 19.1 10.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.425 -176.164 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -76.72 -48.24 19.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.36 169.404 . . . . . . . . 2 2 . 1 . 027 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.539 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.327 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.526 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.788 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.645 HD13 ' CB ' ' A' ' 43' ' ' ALA . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.788 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.697 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.563 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.563 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.662 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.662 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.55 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.483 ' H ' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.483 ' HG2' ' H ' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.503 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.686 ' O ' HG13 ' A' ' 37' ' ' VAL . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.707 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.414 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.645 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.707 ' HA ' HG12 ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.583 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.65 ' HB3' HG13 ' A' ' 4' ' ' VAL . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.452 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -107.72 146.41 32.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 3 3 . 1 . 028 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -120.47 28.93 7.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.379 -170.444 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.82 -161.13 1.11 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.349 170.368 . . . . . . . . 2 2 . 1 . 028 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.36 170.145 . . . . . . . . 0 0 . 1 . 028 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.781 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CE2' ' HB3' ' A' ' 50' ' ' LYS . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.677 HG23 HG13 ' A' ' 11' ' ' ILE . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.603 HD11 ' CB ' ' A' ' 47' ' ' GLU . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.555 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.677 HG13 HG23 ' A' ' 4' ' ' VAL . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.408 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.781 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.77 ' HB3' HD13 ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.77 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.491 HG21 HD23 ' A' ' 32' ' ' LEU . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.511 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.489 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 35' ' ' ASP . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.603 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.595 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -65.17 124.63 22.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 3 3 . 1 . 029 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.23 44.42 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.36 -169.166 . . . . . . . . 2 2 . 1 . 029 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 57.78 172.86 0.05 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.045 168.839 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 1' ' ' ALA . 5.3 t70 . . . . . 0 C--O 1.24 0.593 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.389 -171.621 . . . . . . . . 1 1 . 1 . 029 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.613 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.513 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.598 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.437 ' N ' HG22 ' A' ' 4' ' ' VAL . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.868 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.788 ' O ' HD13 ' A' ' 11' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.788 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.613 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.418 ' C ' HD12 ' A' ' 23' ' ' ILE . 1.7 m120 -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.43 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.976 HG21 HD23 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.54 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.976 HD23 HG21 ' A' ' 27' ' ' THR . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.697 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.671 ' HA ' HG12 ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.54 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.868 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HB2' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.48 144.27 49.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.2 69.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.415 170.23 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.33 -24.02 37.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.428 -170.014 . . . . . . . . 2 2 . 1 . 030 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.57 175.774 . . . . . . . . 0 0 . 1 . 030 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.602 ' O ' HG23 ' A' ' 11' ' ' ILE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.662 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.588 ' CG ' HD13 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.602 HG23 ' O ' ' A' ' 3' ' ' TRP . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.686 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.697 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.66 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.585 ' HB2' HD13 ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.413 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.567 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 23' ' ' ILE . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.557 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HB1' ' CD ' ' A' ' 47' ' ' GLU . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.582 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 2 2 . 1 . 031 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER -110.42 124.6 52.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 3 3 . 1 . 031 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 tp -126.83 70.28 1.28 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.448 -177.045 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -103.61 -25.54 13.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.475 -172.303 . . . . . . . . 1 1 . 1 . 031 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 t0 . . . . . 0 C--O 1.24 0.603 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.403 177.128 . . . . . . . . 0 0 . 1 . 031 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 032 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.831 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.509 ' HD3' ' HB2' ' A' ' 53' ' ' ASP . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.809 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.553 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.776 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.719 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.809 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.46 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.831 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.5 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.543 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CG ' ' A' ' 3' ' ' TRP . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.543 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.451 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.571 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.672 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.776 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.449 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.43 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -78.92 109.15 12.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 3 3 . 1 . 032 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.639 HD23 ' O ' ' A' ' 51' ' ' LEU . 2.7 tt -115.35 65.21 0.69 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.426 -175.57 . . . . . . . . 2 2 . 1 . 032 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -61.03 155.76 19.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.428 -169.303 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 53' ' ' ASP . . . . . 0.509 ' HB2' ' HD3' ' A' ' 2' ' ' LYS . 11.0 t0 . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.361 -169.707 . . . . . . . . 1 1 . 1 . 032 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 033 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.602 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.618 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 4' ' ' VAL . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.515 HD13 ' CB ' ' A' ' 43' ' ' ALA . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.602 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.563 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.4 m120 -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.478 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.652 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.471 HG21 HD23 ' A' ' 32' ' ' LEU . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.534 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 HG21 ' A' ' 27' ' ' THR . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.49 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.59 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.49 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.515 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.507 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.515 ' CB ' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' HG12 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.87 129.68 38.71 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.459 HD23 ' O ' ' A' ' 51' ' ' LEU . 5.3 tt 60.08 82.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.586 170.425 . . . . . . . . 2 2 . 1 . 033 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.57 ' HB2' HG11 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -99.99 87.34 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.364 170.472 . . . . . . . . 3 3 . 1 . 033 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.24 0.585 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.338 -170.109 . . . . . . . . 1 1 . 1 . 033 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.538 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.582 ' SG ' HD12 ' A' ' 7' ' ' ILE . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.96 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.741 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.743 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.5 ' H ' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 4.6 m120 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HB ' ' H ' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CE2' ' HD2' ' A' ' 45' ' ' LYS . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.674 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.564 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.588 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.73 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.483 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.748 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.73 ' HA ' HG12 ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.96 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.458 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 2 2 . 1 . 034 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.538 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -126.27 146.25 50.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 3 3 . 1 . 034 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.2 tp 60.05 97.54 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.522 171.318 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -61.1 -176.26 0.06 Allowed 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.464 177.77 . . . . . . . . 1 1 . 1 . 034 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 19.5 t0 . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.354 171.089 . . . . . . . . 0 0 . 1 . 034 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.54 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.831 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.575 ' O ' HG23 ' A' ' 4' ' ' VAL . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.54 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.433 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.556 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.556 ' HB ' HG23 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.579 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.74 ' O ' HG13 ' A' ' 37' ' ' VAL . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.567 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.74 HG13 ' O ' ' A' ' 35' ' ' ASP . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.505 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.601 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.831 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.459 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -117.96 126.28 52.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 3 3 . 1 . 035 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 27.3 mt 60.09 56.94 3.16 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.694 -177.775 . . . . . . . . 1 1 . 1 . 035 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.63 167.4 21.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.366 169.108 . . . . . . . . 2 2 . 1 . 035 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 p30 . . . . . 0 C--O 1.239 0.504 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.397 179.544 . . . . . . . . 0 0 . 1 . 035 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 036 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.607 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.547 ' O ' HG23 ' A' ' 11' ' ' ILE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.468 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.704 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.625 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.547 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.607 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.434 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.6 m120 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.412 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.697 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.571 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.52 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.536 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.684 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HB2' HD12 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.659 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.455 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.684 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.407 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.704 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.577 ' HB3' HG13 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 6.7 tttt -121.7 162.37 20.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.415 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER 60.0 80.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.589 169.597 . . . . . . . . 3 3 . 1 . 036 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -171.39 144.14 1.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.416 168.935 . . . . . . . . 2 2 . 1 . 036 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.241 0.623 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.362 -170.132 . . . . . . . . 1 1 . 1 . 036 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 037 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.684 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.513 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.926 HG23 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.567 HD11 ' HG3' ' A' ' 47' ' ' GLU . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.583 ' CG ' HD13 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.926 HG13 HG23 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.696 ' CE2' HD11 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.684 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.427 ' C ' ' HD3' ' A' ' 19' ' ' PRO . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.519 ' C ' HD12 ' A' ' 23' ' ' ILE . 3.8 m120 -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' HG23 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.503 ' CB ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.579 ' O ' HD12 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.696 HD11 ' CE2' ' A' ' 12' ' ' TYR . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.589 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.589 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.44 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.65 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.567 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.93 149.86 26.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 2 2 . 1 . 037 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.73 HD23 HG11 ' A' ' 4' ' ' VAL . 0.2 OUTLIER -119.25 68.38 0.8 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.389 169.704 . . . . . . . . 3 3 . 1 . 037 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -93.2 -158.56 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.363 170.716 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.239 0.534 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.381 170.411 . . . . . . . . 1 1 . 1 . 037 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 10' ' ' TYR . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.493 ' O ' HG23 ' A' ' 4' ' ' VAL . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.545 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.798 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 17' ' ' GLY . . . . . 0.954 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.649 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.427 ' O ' HD12 ' A' ' 23' ' ' ILE . 14.5 m120 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.518 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.954 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 24' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 25' ' ' PRO . . . . . 0.575 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.545 HD21 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.528 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.449 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.428 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.663 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB3' HD11 ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 48' ' ' PHE . . . . . 0.488 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.413 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -119.04 143.21 47.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 3 3 . 1 . 038 nuclear build full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.7 mp 60.05 39.82 19.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.534 169.876 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 58.31 -86.75 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.208 169.665 . . . . . . . . 1 1 . 1 . 038 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 . . . . . 0 C--O 1.24 0.555 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.386 170.104 . . . . . . . . 0 0 . 1 . 038 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 039 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.52 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.557 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 6' ' ' LYS . . . . . 0.52 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.8 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.691 ' HB2' HD13 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.55 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.52 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.477 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 18.9 m120 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.528 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.577 ' HD2' ' CD1' ' A' ' 36' ' ' TRP . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.427 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.577 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.496 HG12 ' HA ' ' A' ' 44' ' ' PRO . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.691 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.496 ' HA ' HG12 ' A' ' 37' ' ' VAL . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.8 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -145.06 142.41 29.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 3 3 . 1 . 039 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HA ' ' A' ' 51' ' ' LEU . 6.4 tp 59.9 86.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.523 168.739 . . . . . . . . 2 2 . 1 . 039 nuclear build full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -107.92 114.95 29.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 169.454 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.62 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.345 -170.214 . . . . . . . . 1 1 . 1 . 039 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 040 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.768 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 2' ' ' LYS . . . . . 0.509 ' HG3' ' HG2' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 4' ' ' VAL . . . . . 0.953 HG23 HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 5' ' ' CYS . . . . . 0.571 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.837 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 10' ' ' TYR . . . . . 0.529 ' CG ' HD13 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 11' ' ' ILE . . . . . 0.953 HG13 HG23 ' A' ' 4' ' ' VAL . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 14' ' ' GLU . . . . . 0.768 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.506 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 19' ' ' PRO . . . . . 0.488 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 21' ' ' ASN . . . . . 0.442 ' C ' HD12 ' A' ' 23' ' ' ILE . 3.1 m120 -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 23' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 27' ' ' THR . . . . . 0.571 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 28' ' ' LYS . . . . . 0.731 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 29' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 31' ' ' GLU . . . . . 0.418 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.731 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 35' ' ' ASP . . . . . 0.77 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 36' ' ' TRP . . . . . 0.434 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 35' ' ' ASP . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 38' ' ' CYS . . . . . 0.5 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 40' ' ' ILE . . . . . 0.599 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 43' ' ' ALA . . . . . 0.738 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 44' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 47' ' ' GLU . . . . . 0.837 ' CB ' HD11 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 50' ' ' LYS . . . . . 0.571 ' HG3' HD23 ' A' ' 51' ' ' LEU . 2.1 ptpt -70.91 165.95 22.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 51' ' ' LEU . . . . . 0.571 HD23 ' HG3' ' A' ' 50' ' ' LYS . 0.3 OUTLIER 60.18 60.21 2.14 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.702 170.574 . . . . . . . . 3 3 . 1 . 040 nuclear build full ' A' A ' 52' ' ' GLU . . . . . 0.509 ' HG2' ' HG3' ' A' ' 2' ' ' LYS . 5.1 mm-40 57.7 -168.77 0.12 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.999 167.197 . . . . . . . . 2 2 . 1 . 040 nuclear build full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.614 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.391 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear build full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.499 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.522 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.548 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.666 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.646 ' CG ' HD13 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.499 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.448 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.419 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.438 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.646 HD13 ' CG ' ' A' ' 10' ' ' TYR . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.715 ' HA ' HG12 ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.548 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt . . . . . 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.796 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.485 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.828 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.861 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.711 ' C ' HD13 ' A' ' 11' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.828 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.562 ' H ' HG22 ' A' ' 11' ' ' ILE . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.485 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.796 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 25' ' ' PRO . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.446 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.763 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' ASP . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.763 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.642 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.694 HG12 ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.603 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.694 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.861 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt . . . . . 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.786 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.826 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.738 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.494 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.826 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.491 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.786 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' HE1' ' A' ' 12' ' ' TYR . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.51 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . 0.41 ' HB3' ' ND2' ' A' ' 21' ' ' ASN . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.41 ' ND2' ' HB3' ' A' ' 20' ' ' ASP . 0.4 OUTLIER -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.789 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.789 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.59 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.542 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.573 HD22 HG12 ' A' ' 23' ' ' ILE . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.787 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.48 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.494 HD12 ' N ' ' A' ' 40' ' ' ILE . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.645 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.738 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.5 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.502 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.601 ' SG ' HD12 ' A' ' 7' ' ' ILE . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.915 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.732 ' O ' HD13 ' A' ' 11' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.559 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.569 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.523 ' CG2' HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.59 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.59 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.658 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.704 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.915 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.552 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.552 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.583 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.73 HG23 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.651 ' CB ' HD13 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.73 HG13 HG23 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.47 ' H ' HG22 ' A' ' 11' ' ' ILE . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.583 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.514 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.447 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.7 OUTLIER -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.469 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.45 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.515 ' HD3' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HG3' ' HD3' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.531 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.419 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.651 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.542 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt . . . . . 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.424 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.666 HG23 HG13 ' A' ' 11' ' ' ILE . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.858 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.525 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.666 HG13 HG23 ' A' ' 4' ' ' VAL . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.48 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.548 ' HB3' HD13 ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.434 HD21 ' HB3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.534 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.626 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.569 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.459 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.805 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.468 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.805 HG13 ' O ' ' A' ' 35' ' ' ASP . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.43 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HB3' HD21 ' A' ' 21' ' ' ASN . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.64 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.408 ' HD2' ' OE1' ' A' ' 47' ' ' GLU . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.858 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? . . . . . 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.527 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.82 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.522 ' HE3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.82 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.68 ' H ' HG22 ' A' ' 11' ' ' ILE . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.465 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.665 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.53 ' HB ' HG23 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.493 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.527 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.546 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.546 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.612 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.679 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.557 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.612 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.598 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.525 HG12 ' O ' ' A' ' 49' ' ' GLU . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.81 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.482 ' O ' HG23 ' A' ' 4' ' ' VAL . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.496 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.598 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.463 HD21 ' HB3' ' A' ' 39' ' ' PRO . 20.1 m-80 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.417 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.596 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.719 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.419 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.463 ' HB3' HD21 ' A' ' 21' ' ' ASN . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.719 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.81 ' HB3' HD11 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.46 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.559 ' O ' HG23 ' A' ' 11' ' ' ILE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.516 HG23 HG13 ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.824 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.791 ' HB2' HD13 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.568 HD12 ' C ' ' A' ' 10' ' ' TYR . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.755 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.755 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.469 HG21 HD23 ' A' ' 32' ' ' LEU . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.62 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.773 ' O ' HG13 ' A' ' 37' ' ' VAL . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.439 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.773 HG13 ' O ' ' A' ' 35' ' ' ASP . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.467 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.791 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.824 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.427 ' H ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER . . . . . 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.59 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.531 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.773 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.613 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.512 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.59 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.4 m-80 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 21' ' ' ASN . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.504 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.58 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.531 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.58 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.461 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.699 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.476 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.613 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.476 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.699 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.435 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.773 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.47 ' HB3' HG13 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 24.3 tttt . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.681 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.416 ' HG3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.714 ' C ' HD13 ' A' ' 11' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.714 HD13 ' C ' ' A' ' 10' ' ' TYR . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.445 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.513 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.583 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.554 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.681 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.424 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.423 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.529 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.546 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.546 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.83 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.638 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.698 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.809 ' HB2' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.638 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.83 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.804 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.486 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.804 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.4 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.502 ' CB ' HG23 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.508 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.585 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.677 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.809 HD13 ' HB2' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.429 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.677 ' HA ' HG12 ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.444 ' H ' ' HE3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.698 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.621 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' ILE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.547 HG13 ' HG3' ' A' ' 49' ' ' GLU . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.522 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.496 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.896 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CB ' HD13 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 10' ' ' TYR . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.451 ' OH ' HG21 ' A' ' 23' ' ' ILE . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.621 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.605 ' HB ' HG23 ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.672 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.733 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.616 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.799 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.733 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.896 ' CB ' HD11 ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' HG3' HG13 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.422 ' HE3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.846 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.821 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.875 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 11' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.821 HG13 HG23 ' A' ' 4' ' ' VAL . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.846 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.517 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.665 HG23 ' HB ' ' A' ' 27' ' ' THR . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.665 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 35' ' ' ASP . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.4 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.671 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.875 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.405 ' HB3' ' H ' ' A' ' 50' ' ' LYS . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.617 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 10' ' ' TYR . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.436 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.626 ' CG ' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.512 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.617 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.421 ' C ' HD12 ' A' ' 23' ' ' ILE . 7.6 m-80 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.738 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.738 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.666 ' O ' HG13 ' A' ' 37' ' ' VAL . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 35' ' ' ASP . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.437 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.579 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 6' ' ' LYS . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.838 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.909 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.671 ' C ' HD13 ' A' ' 11' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.838 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.565 ' H ' HG22 ' A' ' 11' ' ' ILE . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.554 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.554 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.541 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.667 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.555 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.643 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.508 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.643 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.547 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.838 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.675 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.745 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.909 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.636 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.716 HG23 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.896 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.479 ' CG ' ' N ' ' A' ' 11' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.716 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.636 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.528 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 0.4 OUTLIER -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.74 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.74 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.566 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.499 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.544 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.527 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.528 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.672 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.544 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.417 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.896 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.523 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.67 HG13 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.828 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.546 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.462 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.63 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.63 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.429 HG22 ' O ' ' A' ' 28' ' ' LYS . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.525 ' CG ' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.689 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.498 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.404 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.716 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.828 ' HB3' HD11 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.67 ' HB3' HG13 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.497 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.408 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.408 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.566 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.891 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.785 HD11 ' CB ' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.891 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.496 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.496 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.458 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 2.3 m-80 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.704 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.431 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.431 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.704 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.573 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 37' ' ' VAL . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.571 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 35' ' ' ASP . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.551 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.458 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.611 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.551 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.408 ' HG3' ' HE3' ' A' ' 36' ' ' TRP . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.785 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.578 ' HE2' HG21 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.743 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.839 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.557 ' CE2' HD11 ' A' ' 32' ' ' LEU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.49 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.444 ' C ' HD12 ' A' ' 23' ' ' ILE . 9.5 m-80 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.744 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.744 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.481 HG21 HD23 ' A' ' 32' ' ' LEU . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.482 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.557 HD11 ' CE2' ' A' ' 12' ' ' TYR . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.453 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.657 ' O ' HG13 ' A' ' 37' ' ' VAL . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.578 HD13 ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.533 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.743 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.432 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.522 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.627 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.535 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.619 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.828 ' O ' HD13 ' A' ' 11' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.828 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.54 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.542 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.542 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.785 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.578 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.578 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 44' ' ' PRO . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.653 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.619 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.481 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp . . . . . 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.847 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.466 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.596 ' O ' HG23 ' A' ' 11' ' ' ILE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.569 ' SG ' HD12 ' A' ' 7' ' ' ILE . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.918 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.593 ' CG ' HD13 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.596 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.475 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.847 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.633 ' OD2' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.423 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.633 HD13 ' OD2' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.606 ' O ' HG13 ' A' ' 37' ' ' VAL . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.427 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.722 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.417 ' C ' HD12 ' A' ' 40' ' ' ILE . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.781 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.722 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.918 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 4.7 pttm . . . . . 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.833 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.589 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.448 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.655 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.833 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.783 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.783 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.452 HG21 HD23 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.527 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' THR . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.576 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.475 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.449 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.583 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.525 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.433 ' HD3' HG21 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.619 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.968 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.54 ' CG ' HD13 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.624 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.525 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.507 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.507 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.67 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.67 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.629 HG21 HD23 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.656 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.834 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.474 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.928 HG12 ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.506 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.67 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.506 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.513 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.928 ' HA ' HG12 ' A' ' 37' ' ' VAL . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.968 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' H ' ' A' ' 50' ' ' LYS . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.52 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.561 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.794 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.696 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.454 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.561 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.502 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.472 HD21 ' HB3' ' A' ' 39' ' ' PRO . 10.7 m-80 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.607 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.481 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.607 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.798 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.798 HG13 ' O ' ' A' ' 35' ' ' ASP . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HB3' HD21 ' A' ' 21' ' ' ASN . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.696 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.794 ' HB3' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.555 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.738 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.856 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.87 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.718 ' C ' HD13 ' A' ' 11' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.856 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.401 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.738 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.722 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.722 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.751 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.751 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.637 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.435 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.419 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.87 ' HB3' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' A' ' 50' ' ' LYS . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.498 ' H ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.764 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.508 ' O ' HG23 ' A' ' 4' ' ' VAL . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 25' ' ' PRO . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.559 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 5.4 m-80 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.559 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 15' ' ' ASP . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.483 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.632 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.682 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HA ' HG12 ' A' ' 37' ' ' VAL . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.764 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.423 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.526 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.788 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.645 HD13 ' CB ' ' A' ' 43' ' ' ALA . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.788 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.697 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.563 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.563 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.662 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.662 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.55 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.483 ' H ' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.483 ' HG2' ' H ' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.503 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.686 ' O ' HG13 ' A' ' 37' ' ' VAL . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.707 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.414 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.645 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.707 ' HA ' HG12 ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.583 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.65 ' HB3' HG13 ' A' ' 4' ' ' VAL . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.452 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.781 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CE2' ' HB3' ' A' ' 50' ' ' LYS . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.677 HG23 HG13 ' A' ' 11' ' ' ILE . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.603 HD11 ' CB ' ' A' ' 47' ' ' GLU . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.555 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.677 HG13 HG23 ' A' ' 4' ' ' VAL . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.408 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.781 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.77 ' HB3' HD13 ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.77 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.491 HG21 HD23 ' A' ' 32' ' ' LEU . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.511 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.489 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 35' ' ' ASP . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.603 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.595 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER . . . . . 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.613 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.513 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.598 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.437 ' N ' HG22 ' A' ' 4' ' ' VAL . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.868 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.788 ' O ' HD13 ' A' ' 11' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.788 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.613 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.471 HD21 ' HB3' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.43 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.976 HG21 HD23 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.54 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.976 HD23 HG21 ' A' ' 27' ' ' THR . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB3' HD21 ' A' ' 21' ' ' ASN . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.697 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.671 ' HA ' HG12 ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.54 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.868 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HB2' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.602 ' O ' HG23 ' A' ' 11' ' ' ILE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.662 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.588 ' CG ' HD13 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.602 HG23 ' O ' ' A' ' 3' ' ' TRP . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.686 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.697 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.66 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.585 ' HB2' HD13 ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.413 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.567 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 23' ' ' ILE . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.557 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HB1' ' CD ' ' A' ' 47' ' ' GLU . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.582 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER . . . . . 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.831 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.809 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.553 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.776 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.719 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.809 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.46 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.831 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.5 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.543 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CG ' ' A' ' 3' ' ' TRP . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.543 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.451 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.571 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.672 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.776 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.449 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.43 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.602 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.618 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 4' ' ' VAL . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.515 HD13 ' CB ' ' A' ' 43' ' ' ALA . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.602 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.563 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.478 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.652 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.471 HG21 HD23 ' A' ' 32' ' ' LEU . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.534 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 HG21 ' A' ' 27' ' ' THR . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.49 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.59 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.49 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.515 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.507 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.515 ' CB ' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' HG12 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.538 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.582 ' SG ' HD12 ' A' ' 7' ' ' ILE . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.96 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.741 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.743 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.5 ' H ' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.425 HD21 ' HB3' ' A' ' 39' ' ' PRO . 3.8 m-80 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HB ' ' H ' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CE2' ' HD2' ' A' ' 45' ' ' LYS . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.674 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.564 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.588 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.73 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.483 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.425 ' HB3' HD21 ' A' ' 21' ' ' ASN . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.748 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.73 ' HA ' HG12 ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.96 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.458 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.538 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.54 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.831 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.575 ' O ' HG23 ' A' ' 4' ' ' VAL . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.54 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.433 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.556 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.556 ' HB ' HG23 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.579 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.74 ' O ' HG13 ' A' ' 37' ' ' VAL . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.567 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.74 HG13 ' O ' ' A' ' 35' ' ' ASP . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.505 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.601 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.831 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.459 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.607 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.547 ' O ' HG23 ' A' ' 11' ' ' ILE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.577 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.468 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.704 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.625 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.547 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.607 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.434 ' C ' HD12 ' A' ' 23' ' ' ILE . 4.1 m-80 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.412 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.697 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.571 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.52 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.536 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.684 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.455 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HB2' HD12 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.659 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.455 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.684 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.407 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.704 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.577 ' HB3' HG13 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.7 tttt . . . . . 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 0 0 . 1 . 037 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.684 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.513 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.926 HG23 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.567 HD11 ' HG3' ' A' ' 47' ' ' GLU . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.583 ' CG ' HD13 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.926 HG13 HG23 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.696 ' CE2' HD11 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.684 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.427 ' C ' ' HD3' ' A' ' 19' ' ' PRO . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.519 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.9 OUTLIER -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' HG23 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.503 ' CB ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.579 ' O ' HD12 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.696 HD11 ' CE2' ' A' ' 12' ' ' TYR . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.589 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.589 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.44 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.65 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.567 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 10' ' ' TYR . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.493 ' O ' HG23 ' A' ' 4' ' ' VAL . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.545 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.798 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . 0.954 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.649 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.427 ' O ' HD12 ' A' ' 23' ' ' ILE . 24.5 m-80 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.518 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.954 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . 0.575 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.545 HD21 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.528 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.449 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.428 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.663 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB3' HD11 ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . 0.488 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.413 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.52 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.557 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . 0.52 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.8 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.691 ' HB2' HD13 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.55 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.52 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.477 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 51.7 m-80 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.528 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.577 ' HD2' ' CD1' ' A' ' 36' ' ' TRP . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.427 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.577 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.496 HG12 ' HA ' ' A' ' 44' ' ' PRO . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.691 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.496 ' HA ' HG12 ' A' ' 37' ' ' VAL . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.8 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER . . . . . 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.768 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 4' ' ' VAL . . . . . 0.953 HG23 HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 5' ' ' CYS . . . . . 0.571 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.837 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 10' ' ' TYR . . . . . 0.529 ' CG ' HD13 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 11' ' ' ILE . . . . . 0.953 HG13 HG23 ' A' ' 4' ' ' VAL . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . 0.768 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.506 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 19' ' ' PRO . . . . . 0.488 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 21' ' ' ASN . . . . . 0.442 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.5 OUTLIER -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 22' ' ' GLY . . . . . 0.441 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . 0.571 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 28' ' ' LYS . . . . . 0.731 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 29' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 31' ' ' GLU . . . . . 0.418 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.731 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 35' ' ' ASP . . . . . 0.77 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 36' ' ' TRP . . . . . 0.434 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 37' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 35' ' ' ASP . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 38' ' ' CYS . . . . . 0.5 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 40' ' ' ILE . . . . . 0.599 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 43' ' ' ALA . . . . . 0.738 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 44' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild core ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 47' ' ' GLU . . . . . 0.837 ' CB ' HD11 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild core ' A' A ' 50' ' ' LYS . . . . . 0.467 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 2.1 ptpt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.499 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.098 0.475 . . . . 0.0 109.784 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mppt? -104.0 137.95 41.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.372 171.928 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.522 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 26.3 m95 -118.1 166.74 12.19 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.386 171.466 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.505 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.8 p -137.72 155.61 30.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.316 177.738 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.9 t -84.15 118.14 23.93 Favored 'General case' 0 C--O 1.236 0.38 0 CA-C-N 115.729 -0.668 . . . . 0.0 110.006 163.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.548 ' HG2' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.78 17.05 5.92 Favored 'General case' 0 N--CA 1.452 -0.337 0 CA-C-N 114.342 -1.299 . . . . 0.0 110.919 176.075 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.666 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.1 mp -101.33 -79.64 0.33 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.48 158.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -80.38 -30.3 37.88 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.974 -0.557 . . . . 0.0 110.497 -162.553 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.55 20.81 16.15 Favored Glycine 0 CA--C 1.525 0.709 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.572 -177.776 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.646 ' CG ' HD13 ' A' ' 40' ' ' ILE . 67.7 t80 -73.39 170.31 15.35 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-O 120.952 0.406 . . . . 0.0 110.21 165.529 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.522 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.1 mp -142.33 139.71 29.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.515 -174.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.441 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 12.5 t80 -103.99 141.2 36.59 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.168 165.101 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -125.04 107.6 10.97 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.427 172.174 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.499 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 30.1 mt-10 -62.11 -17.78 58.77 Favored 'General case' 0 C--O 1.234 0.253 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.781 -174.138 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 17.3 t0 -61.02 -77.67 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.68 163.348 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.37 -14.9 21.27 Favored 'General case' 0 N--CA 1.454 -0.274 0 CA-C-N 113.798 -1.547 . . . . 0.0 110.478 -171.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.3 -151.57 42.48 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 178.627 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.509 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -161.09 56.72 0.76 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.668 0.747 . . . . 0.0 109.811 -174.187 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_endo -52.51 -19.09 9.38 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.486 2.124 . . . . 0.0 113.533 173.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.31 -32.97 72.84 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.447 178.309 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 8.7 m-80 -128.82 23.49 5.75 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.096 -0.956 . . . . 0.0 110.335 -177.175 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 85.58 44.28 6.19 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.415 -1.074 . . . . 0.0 110.415 168.544 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.535 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -120.7 136.32 58.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 115.327 -0.436 . . . . 0.0 110.432 170.687 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.07 143.94 27.58 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.061 -0.972 . . . . 0.0 109.803 177.052 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -54.96 89.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.572 2.181 . . . . 0.0 113.599 172.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.66 19.14 1.07 Allowed Glycine 0 CA--C 1.526 0.762 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 178.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.448 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.0 m -87.08 150.08 24.25 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.308 168.19 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.5 OUTLIER -94.54 166.14 12.19 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.467 -175.311 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 68.9 t80 -61.73 -66.03 0.6 Allowed 'General case' 0 C--O 1.232 0.133 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.262 -175.148 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 16.3 mt-10 -78.96 7.05 7.86 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.431 -1.259 . . . . 0.0 111.699 177.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.419 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.0 OUTLIER -102.17 20.51 16.59 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.821 -0.627 . . . . 0.0 110.392 165.25 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.5 mt -90.16 168.91 13.36 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-N 115.404 -0.816 . . . . 0.0 109.654 168.745 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.7 Cg_endo -54.27 151.83 27.68 Favored 'Trans proline' 0 N--CA 1.484 0.939 0 C-N-CA 122.684 2.256 . . . . 0.0 113.561 170.942 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -60.96 -41.99 97.39 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.441 171.926 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -94.05 20.07 8.35 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.227 -0.897 . . . . 0.0 110.353 -174.342 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 23.5 t90 -72.72 108.92 5.97 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.426 169.184 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.715 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -117.27 -176.94 1.02 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.389 171.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.438 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -63.89 126.0 89.04 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.117 -0.947 . . . . 0.0 109.401 179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.1 Cg_endo -61.35 -12.73 25.13 Favored 'Trans proline' 0 N--CA 1.485 0.997 0 C-N-CA 122.603 2.202 . . . . 0.0 113.652 171.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.646 HD13 ' CG ' ' A' ' 10' ' ' TYR . 2.9 mp -103.62 -81.19 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.476 176.719 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.33 -20.87 43.26 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.026 -162.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.443 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.96 25.18 41.9 Favored Glycine 0 CA--C 1.525 0.711 0 N-CA-C 110.488 -1.045 . . . . 0.0 110.488 -177.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.401 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -85.79 111.76 40.0 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.351 0.596 . . . . 0.0 109.656 170.696 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.715 ' HA ' HG12 ' A' ' 37' ' ' VAL . 14.1 Cg_exo -46.41 158.35 0.36 Allowed 'Trans proline' 0 N--CA 1.485 1.018 0 C-N-CA 122.806 2.337 . . . . 0.0 113.709 173.266 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.5 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 4.8 pttp -60.94 -11.11 6.94 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.479 -167.559 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.1 p -60.85 -20.52 61.92 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.443 174.039 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.601 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.0 OUTLIER -106.13 18.17 22.44 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.509 -170.538 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -112.3 112.7 24.48 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.404 -175.937 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.548 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 1.7 tp10 -77.83 162.94 26.51 Favored 'General case' 0 C--O 1.228 -0.035 0 CA-C-N 114.696 -1.138 . . . . 0.0 110.35 177.199 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.507 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 16.1 mtmt -98.17 161.09 13.89 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.359 174.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.417 HD12 ' HA ' ' A' ' 51' ' ' LEU . 11.6 tp -96.85 36.51 1.4 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.474 172.717 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.9 mm-40 57.8 104.74 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.385 0 CA-C-N 115.232 -0.894 . . . . 0.0 111.02 -171.652 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 11.0 t70 . . . . . 0 C--O 1.24 0.605 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.346 168.954 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.796 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.759 0 N-CA-C 109.654 -0.499 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.485 ' HG2' ' HB2' ' A' ' 13' ' ' ASP . 8.3 mtpt -126.73 135.71 51.46 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.432 177.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.557 ' HB3' ' HB3' ' A' ' 48' ' ' PHE . 61.4 m95 -122.5 123.0 40.25 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.22 -0.9 . . . . 0.0 110.296 -176.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.828 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.8 p -100.85 134.1 41.95 Favored 'Isoleucine or valine' 0 C--O 1.239 0.548 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.178 173.255 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.2 t -73.25 105.89 4.85 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.623 162.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -62.17 -20.94 64.66 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.524 -179.452 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.861 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -78.96 -55.25 10.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.358 -166.415 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -98.51 -42.53 7.26 Favored 'General case' 0 C--O 1.232 0.138 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.529 -173.467 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.53 20.79 5.33 Favored Glycine 0 CA--C 1.527 0.809 0 N-CA-C 110.509 -1.036 . . . . 0.0 110.509 -179.399 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.711 ' C ' HD13 ' A' ' 11' ' ' ILE . 87.4 t80 -84.78 160.25 20.29 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.239 169.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.828 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.2 mm -127.53 177.53 5.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.243 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.003 -174.48 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.562 ' H ' HG22 ' A' ' 11' ' ' ILE . 10.7 t80 -155.13 137.9 15.29 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-N 114.638 -1.164 . . . . 0.0 110.207 168.886 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.485 ' HB2' ' HG2' ' A' ' 2' ' ' LYS . 38.0 t0 -121.47 133.24 55.05 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.175 161.877 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.796 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.4 mt-10 -61.35 -18.95 61.08 Favored 'General case' 0 C--O 1.233 0.206 0 CA-C-N 115.166 -0.924 . . . . 0.0 110.704 -174.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.423 ' O ' ' HA ' ' A' ' 25' ' ' PRO . 7.1 t0 -60.82 -73.41 0.09 Allowed 'General case' 0 CA--C 1.538 0.501 0 CA-C-N 115.617 -0.72 . . . . 0.0 109.546 164.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -64.51 -28.1 69.42 Favored 'General case' 0 N--CA 1.456 -0.133 0 CA-C-N 113.954 -1.475 . . . . 0.0 110.501 -160.025 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.08 -179.72 5.32 Favored Glycine 0 CA--C 1.525 0.678 0 N-CA-C 110.087 -1.205 . . . . 0.0 110.087 163.403 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.498 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.2 t0 -144.52 66.32 13.61 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-O 121.459 0.647 . . . . 0.0 109.725 -165.416 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.5 Cg_exo -51.69 -22.16 12.68 Favored 'Trans proline' 0 N--CA 1.485 1.01 0 C-N-CA 122.465 2.11 . . . . 0.0 113.454 172.132 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 5.4 m-20 -61.14 -16.04 40.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.459 176.772 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.1 m-80 -149.48 19.68 0.93 Allowed 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.344 -0.844 . . . . 0.0 110.302 -172.459 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.446 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.68 32.11 28.12 Favored Glycine 0 CA--C 1.527 0.794 0 N-CA-C 110.36 -1.096 . . . . 0.0 110.36 167.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.763 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.3 mp -104.05 112.56 38.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.361 0 CA-C-N 115.395 -0.403 . . . . 0.0 110.277 169.224 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -81.86 140.15 46.85 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-N 114.991 -1.004 . . . . 0.0 109.737 -178.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' ASP . 4.6 Cg_exo -50.33 84.71 0.02 OUTLIER 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.208 1.939 . . . . 0.0 113.502 179.464 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.11 18.71 1.48 Allowed Glycine 0 CA--C 1.526 0.743 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.573 -175.665 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.763 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.5 m -79.48 143.64 34.74 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.387 -0.406 . . . . 0.0 110.302 167.825 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 4.6 mmtt -88.38 161.06 17.3 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.441 179.004 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.8 t80 -61.86 -64.68 0.86 Allowed 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 114.926 -1.034 . . . . 0.0 110.285 -175.354 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.93 6.64 8.76 Favored 'General case' 0 C--O 1.234 0.27 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.664 179.359 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.3 tt0 -109.85 21.04 17.36 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.903 -0.59 . . . . 0.0 110.406 164.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 29.3 mt -80.36 169.19 20.72 Favored Pre-proline 0 CA--C 1.545 0.773 0 CA-C-N 115.359 -0.837 . . . . 0.0 109.561 167.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.0 OUTLIER -46.06 149.94 2.12 Favored 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.763 2.308 . . . . 0.0 113.621 169.477 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.48 -50.29 73.33 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.577 -0.738 . . . . 0.0 110.419 -167.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.642 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.6 OUTLIER -106.7 35.69 2.9 Favored 'General case' 0 N--CA 1.455 -0.21 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.43 -176.987 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.2 t90 -61.42 120.84 11.27 Favored 'General case' 0 C--N 1.332 -0.194 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.382 179.213 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.694 HG12 ' HA ' ' A' ' 44' ' ' PRO . 34.0 m -119.19 170.84 8.03 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.84 -1.073 . . . . 0.0 110.422 -177.106 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.0 t -63.68 122.18 75.01 Favored Pre-proline 0 C--O 1.25 1.082 0 CA-C-N 115.049 -0.978 . . . . 0.0 109.586 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -61.27 -17.83 55.14 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.421 2.081 . . . . 0.0 113.663 172.369 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.603 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -93.46 -81.01 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.153 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.406 177.406 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.1 -23.51 35.68 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.756 -0.656 . . . . 0.0 110.662 -161.08 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.98 26.29 26.9 Favored Glycine 0 CA--C 1.527 0.803 0 N-CA-C 110.45 -1.06 . . . . 0.0 110.45 -175.887 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.51 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -88.9 115.82 64.61 Favored Pre-proline 0 C--O 1.243 0.733 0 CA-C-O 121.228 0.537 . . . . 0.0 109.601 168.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.694 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -44.92 167.47 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.041 0 C-N-CA 122.907 2.405 . . . . 0.0 113.619 167.377 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.421 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.23 -9.99 5.97 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.529 -167.113 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 87.9 p -61.47 -32.86 72.87 Favored 'General case' 0 C--N 1.333 -0.119 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.395 -179.325 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.861 ' HB3' HD13 ' A' ' 7' ' ' ILE . 3.3 mp0 -92.77 14.69 16.53 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.817 . . . . 0.0 110.785 -168.462 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.557 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -105.24 106.27 16.69 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.393 175.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.2 -171.08 0.7 Allowed 'General case' 0 N--CA 1.458 -0.054 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.192 175.57 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 17.4 mtmt -125.18 124.9 42.76 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.957 -1.019 . . . . 0.0 110.462 178.27 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.589 HD12 HG11 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -115.61 66.06 0.7 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.322 170.734 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.93 -39.89 29.31 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.371 170.45 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.375 170.252 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.786 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.73 0 N-CA-C 109.688 -0.486 . . . . 0.0 109.688 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.95 133.86 55.51 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.481 178.721 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 45.0 m95 -118.82 130.13 55.6 Favored 'General case' 0 C--N 1.332 -0.176 0 CA-C-N 114.864 -1.062 . . . . 0.0 110.222 178.952 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.826 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -110.25 133.9 54.15 Favored 'Isoleucine or valine' 0 C--O 1.24 0.582 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.378 178.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.89 105.95 3.44 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.09 -0.959 . . . . 0.0 109.68 162.432 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER -61.91 -20.5 63.83 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.823 -1.081 . . . . 0.0 110.555 -179.466 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.738 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -79.81 -54.56 10.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.158 -166.34 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.8 p -99.24 -47.47 5.18 Favored 'General case' 0 C--O 1.231 0.102 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.539 -174.421 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 115.1 36.63 1.2 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.611 -1.177 . . . . 0.0 110.565 -174.655 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.494 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.1 t80 -94.21 163.02 13.62 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.466 -0.367 . . . . 0.0 110.166 165.383 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.826 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -146.19 120.56 2.68 Favored 'Isoleucine or valine' 0 C--O 1.231 0.113 0 CA-C-N 114.7 -1.137 . . . . 0.0 110.363 -177.739 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.491 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 10.8 t80 -81.44 134.15 35.5 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.525 -0.761 . . . . 0.0 109.94 163.871 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -117.84 126.63 52.76 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.203 165.171 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.786 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 18.6 mt-10 -63.36 -10.86 18.51 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.497 -169.023 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.9 t70 -89.07 -20.1 24.76 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 114.863 -1.062 . . . . 0.0 110.402 175.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -99.75 -36.11 9.57 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.448 -0.797 . . . . 0.0 110.355 -165.458 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.413 ' HA2' ' HE1' ' A' ' 12' ' ' TYR . . . 62.32 174.43 2.06 Favored Glycine 0 CA--C 1.527 0.785 0 N-CA-C 110.288 -1.125 . . . . 0.0 110.288 173.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.51 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -138.62 76.32 36.0 Favored Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.643 0.735 . . . . 0.0 109.713 -164.729 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.5 Cg_exo -49.72 -31.92 27.11 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.404 2.069 . . . . 0.0 113.534 174.281 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . 0.41 ' HB3' ' ND2' ' A' ' 21' ' ' ASN . 0.7 OUTLIER -61.78 -29.86 70.42 Favored 'General case' 0 C--N 1.331 -0.21 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.455 -176.996 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.41 ' ND2' ' HB3' ' A' ' 20' ' ' ASP . 0.4 OUTLIER -131.7 19.34 4.67 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.34 -173.801 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.789 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 72.57 54.98 7.01 Favored Glycine 0 CA--C 1.525 0.713 0 N-CA-C 110.471 -1.052 . . . . 0.0 110.471 169.143 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.789 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -123.2 124.2 69.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.378 -0.411 . . . . 0.0 110.308 168.845 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 57.8 m -84.88 140.79 37.61 Favored Pre-proline 0 CA--C 1.543 0.686 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.831 -179.146 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_exo -52.47 87.64 0.03 OUTLIER 'Trans proline' 0 N--CA 1.486 1.039 0 C-N-CA 122.311 2.007 . . . . 0.0 113.534 177.95 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.92 19.62 1.12 Allowed Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 179.097 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.59 ' HB ' HG23 ' A' ' 23' ' ' ILE . 98.9 m -82.86 163.31 21.23 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.414 169.183 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.542 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 4.7 mttt -103.54 159.95 15.15 Favored 'General case' 0 C--O 1.235 0.295 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.417 -175.564 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.3 t80 -61.72 -65.37 0.7 Allowed 'General case' 0 C--O 1.232 0.134 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.306 -175.638 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.03 7.0 8.06 Favored 'General case' 0 N--CA 1.453 -0.305 0 CA-C-N 114.552 -1.204 . . . . 0.0 111.691 177.938 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.476 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -108.65 21.49 17.2 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.769 -0.65 . . . . 0.0 110.421 164.874 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.573 HD22 HG12 ' A' ' 23' ' ' ILE . 61.0 mt -83.01 173.26 7.8 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.683 169.209 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.551 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -50.8 155.89 5.17 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.405 2.07 . . . . 0.0 113.788 174.932 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.74 -48.42 80.79 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.348 -169.082 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.787 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.8 m-20 -113.53 35.56 3.98 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.467 -178.931 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.447 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 90.5 t90 -61.44 123.26 17.33 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.912 -1.04 . . . . 0.0 110.334 178.579 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.787 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.7 m -122.96 168.93 14.88 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 CA-C-N 114.928 -1.033 . . . . 0.0 110.383 -173.194 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.48 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.2 t -63.88 119.28 53.46 Favored Pre-proline 0 C--O 1.249 1.066 0 CA-C-N 114.944 -1.026 . . . . 0.0 109.538 175.705 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.2 Cg_endo -60.62 -18.34 54.36 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.366 2.044 . . . . 0.0 113.622 173.437 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.494 HD12 ' N ' ' A' ' 40' ' ' ILE . 4.2 mp -91.21 -80.66 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.211 0 CA-C-N 115.172 -0.922 . . . . 0.0 110.398 177.038 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.6 -23.84 34.18 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.773 -0.649 . . . . 0.0 110.588 -159.244 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.06 28.11 12.48 Favored Glycine 0 CA--C 1.526 0.749 0 N-CA-C 110.556 -1.018 . . . . 0.0 110.556 -176.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.645 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -94.91 111.48 54.66 Favored Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.367 0.604 . . . . 0.0 109.723 174.061 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 3.1 Cg_exo -45.71 165.87 0.06 OUTLIER 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.884 2.39 . . . . 0.0 113.485 167.441 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -60.76 -11.3 7.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.653 -0.703 . . . . 0.0 110.533 -164.079 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.7 t -63.56 -19.11 64.54 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.474 -177.697 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.738 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -105.39 14.84 28.18 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.614 -168.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -106.68 100.81 10.3 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.346 176.444 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -62.89 179.3 0.38 Allowed 'General case' 0 N--CA 1.46 0.03 0 CA-C-N 114.88 -1.055 . . . . 0.0 110.229 173.264 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.437 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -118.24 138.38 52.38 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.452 170.319 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.6 mt -97.51 46.51 1.03 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.427 170.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 7.5 tp10 -140.65 114.7 9.11 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.376 -170.452 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.8 p30 . . . . . 0 C--O 1.24 0.556 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.34 170.075 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.5 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.786 0 CA-C-O 121.155 0.502 . . . . 0.0 109.769 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.788 ' HG2' HD21 ' A' ' 51' ' ' LEU . 9.8 tttm -123.99 121.73 36.04 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.372 -172.722 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.502 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 40.6 m95 -113.53 174.53 5.87 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.439 -177.135 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.6 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.0 p -148.77 151.74 12.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.231 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.141 -178.43 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.601 ' SG ' HD12 ' A' ' 7' ' ' ILE . 20.3 t -85.05 116.73 23.59 Favored 'General case' 0 C--O 1.237 0.447 0 CA-C-N 115.748 -0.66 . . . . 0.0 109.704 162.827 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.2 17.62 5.82 Favored 'General case' 0 N--CA 1.453 -0.3 0 CA-C-N 114.591 -1.186 . . . . 0.0 110.901 176.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.915 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -98.87 -76.7 0.41 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.626 -0.715 . . . . 0.0 110.562 161.457 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.9 p -83.68 -30.67 26.62 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.927 -0.578 . . . . 0.0 110.508 -164.605 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.48 17.72 23.29 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.631 -178.588 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.732 ' O ' HD13 ' A' ' 11' ' ' ILE . 57.5 t80 -69.87 164.85 22.84 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.029 0.442 . . . . 0.0 110.006 164.545 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.732 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.2 mm -126.7 153.78 35.87 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 CA-C-N 114.784 -1.098 . . . . 0.0 110.274 178.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 16.4 t80 -119.54 126.91 52.39 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.182 165.531 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.6 t0 -114.51 113.93 25.1 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.337 171.696 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.5 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.4 mt-10 -70.74 -23.79 62.5 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.443 -171.166 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -34.03 74.22 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.39 169.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.52 -17.21 16.51 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.31 -171.751 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 61.65 -149.48 46.29 Favored Glycine 0 CA--C 1.527 0.805 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.529 177.484 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.559 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.4 t0 -152.49 48.99 0.49 Allowed Pre-proline 0 CA--C 1.544 0.715 0 CA-C-O 121.438 0.637 . . . . 0.0 109.726 -172.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.559 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 8.4 Cg_exo -51.16 -19.74 6.61 Favored 'Trans proline' 0 N--CA 1.484 0.926 0 C-N-CA 122.548 2.166 . . . . 0.0 113.582 -175.823 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.9 -27.94 69.17 Favored 'General case' 0 N--CA 1.454 -0.266 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.421 175.743 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 33.3 m-80 -127.26 19.57 6.91 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.426 -178.055 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 81.0 43.08 9.03 Favored Glycine 0 CA--C 1.525 0.716 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 169.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.569 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -109.16 122.17 63.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.407 170.198 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.3 m -72.1 145.89 89.22 Favored Pre-proline 0 CA--C 1.542 0.661 0 CA-C-N 115.178 -0.919 . . . . 0.0 109.833 177.488 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.2 Cg_exo -54.26 91.27 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.019 0 C-N-CA 122.446 2.098 . . . . 0.0 113.53 172.762 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 127.03 19.01 2.02 Favored Glycine 0 CA--C 1.525 0.709 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 169.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.523 ' CG2' HD23 ' A' ' 32' ' ' LEU . 95.0 m -66.83 135.47 53.95 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.417 -0.392 . . . . 0.0 110.378 169.226 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.59 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.9 tptt -79.69 154.01 28.92 Favored 'General case' 0 C--O 1.235 0.296 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.493 -178.015 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.504 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.3 t80 -61.8 -65.51 0.68 Allowed 'General case' 0 C--O 1.231 0.126 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.366 -174.615 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.09 7.07 8.04 Favored 'General case' 0 N--CA 1.454 -0.25 0 CA-C-N 114.615 -1.175 . . . . 0.0 111.726 179.548 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 tm-20 -116.65 21.23 13.58 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.845 -0.616 . . . . 0.0 110.352 166.242 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.59 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.3 mt -71.97 171.96 8.25 Favored Pre-proline 0 CA--C 1.545 0.771 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.668 168.461 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.0 Cg_exo -48.23 156.74 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.958 0 C-N-CA 122.551 2.167 . . . . 0.0 113.753 171.39 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.0 m-20 -61.72 -46.28 90.34 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.358 -170.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 6.9 m-20 -110.2 26.56 10.54 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.417 -172.479 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.45 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 72.5 t90 -61.8 116.08 4.53 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.009 -0.996 . . . . 0.0 110.38 -177.734 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -121.25 -178.25 1.52 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 114.91 -1.041 . . . . 0.0 110.442 -177.221 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.1 t -70.45 124.35 90.67 Favored Pre-proline 0 C--O 1.25 1.09 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.534 -176.12 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.5 Cg_exo -52.41 -24.11 20.71 Favored 'Trans proline' 0 N--CA 1.485 0.981 0 C-N-CA 122.869 2.379 . . . . 0.0 113.699 168.955 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.658 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -97.21 -81.39 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.271 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.489 -179.897 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -80.82 -13.51 58.89 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.715 -0.675 . . . . 0.0 111.261 -162.333 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.32 24.78 46.11 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.515 -1.034 . . . . 0.0 110.515 178.501 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.704 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.44 116.97 65.95 Favored Pre-proline 0 C--O 1.242 0.669 0 CA-C-O 121.483 0.659 . . . . 0.0 109.523 -177.081 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.9 Cg_exo -47.53 161.77 0.27 Allowed 'Trans proline' 0 N--CA 1.484 0.921 0 C-N-CA 122.796 2.33 . . . . 0.0 113.705 174.103 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 2.2 ptmm? -60.85 -11.46 7.86 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.668 -0.696 . . . . 0.0 110.495 -165.353 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 51.5 p -61.47 -30.81 70.83 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.587 -174.026 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.915 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.8 OUTLIER -103.9 21.1 16.93 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.346 -175.341 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -98.75 116.35 30.79 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.388 169.012 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.552 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 8.4 tp10 -92.92 179.7 5.38 Favored 'General case' 0 C--N 1.334 -0.087 0 CA-C-N 114.87 -1.059 . . . . 0.0 110.301 176.868 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.552 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -113.89 159.16 20.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.382 -0.826 . . . . 0.0 110.357 -169.313 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.788 HD21 ' HG2' ' A' ' 2' ' ' LYS . 1.7 pp -137.29 77.18 1.62 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.359 -0.837 . . . . 0.0 110.443 168.531 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 8.8 mm-40 -86.47 84.85 7.34 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.425 -0.807 . . . . 0.0 110.368 170.651 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.24 0.564 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.354 -170.423 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.583 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.777 0 N-CA-C 109.779 -0.452 . . . . 0.0 109.779 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.491 ' HG3' ' CD1' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -118.88 122.28 41.94 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.419 -0.81 . . . . 0.0 110.392 175.555 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.497 ' CD2' ' CD1' ' A' ' 29' ' ' PHE . 41.3 m95 -109.28 127.98 54.71 Favored 'General case' 0 C--O 1.234 0.249 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.337 178.704 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.73 HG23 HG13 ' A' ' 11' ' ' ILE . 10.7 p -108.32 133.66 52.6 Favored 'Isoleucine or valine' 0 C--O 1.24 0.579 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.261 176.11 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -66.92 106.39 1.89 Allowed 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.827 -1.079 . . . . 0.0 109.715 163.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.71 -22.43 65.34 Favored 'General case' 0 N--CA 1.454 -0.24 0 CA-C-N 114.645 -1.162 . . . . 0.0 110.485 -179.493 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -77.38 -59.88 2.75 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.315 -168.244 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -95.43 -41.92 8.74 Favored 'General case' 0 C--O 1.231 0.087 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.491 -170.965 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.65 34.15 2.5 Favored Glycine 0 CA--C 1.527 0.787 0 CA-C-N 114.653 -1.158 . . . . 0.0 110.537 -174.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.651 ' CB ' HD13 ' A' ' 40' ' ' ILE . 72.7 t80 -94.33 168.05 11.14 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-O 120.904 0.383 . . . . 0.0 110.146 164.893 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.73 HG13 HG23 ' A' ' 4' ' ' VAL . 3.1 mp -141.96 170.57 12.28 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.089 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.519 -173.962 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.47 ' H ' HG22 ' A' ' 11' ' ' ILE . 21.9 t80 -150.42 109.7 3.96 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.025 -0.988 . . . . 0.0 110.215 -177.475 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -94.13 110.85 22.54 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.282 168.202 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.583 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 15.7 mt-10 -60.93 -18.34 56.26 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.417 -0.81 . . . . 0.0 110.374 -169.7 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.9 t70 -93.63 -18.22 22.41 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.367 -172.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.02 -22.95 17.59 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.285 169.596 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 76.39 -155.22 45.22 Favored Glycine 0 CA--C 1.526 0.755 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 170.068 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.514 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.8 t0 -156.95 66.85 4.06 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.444 0.64 . . . . 0.0 109.786 -173.786 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_exo -52.86 -25.83 28.85 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.484 2.122 . . . . 0.0 113.604 178.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -73.21 -29.47 62.82 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.407 -170.77 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.447 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.7 OUTLIER -111.28 21.19 16.57 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.366 169.77 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.469 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.05 47.32 11.47 Favored Glycine 0 CA--C 1.525 0.666 0 N-CA-C 110.434 -1.066 . . . . 0.0 110.434 170.502 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.7 mp -117.09 141.38 35.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.363 -0.418 . . . . 0.0 110.398 170.641 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -91.87 147.92 35.96 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.174 -0.921 . . . . 0.0 109.776 179.488 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.3 89.39 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.57 2.18 . . . . 0.0 113.632 173.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.99 18.91 1.17 Allowed Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.484 -1.046 . . . . 0.0 110.484 177.92 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.45 ' CB ' HG23 ' A' ' 23' ' ' ILE . 93.3 m -76.04 148.17 38.2 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.374 168.92 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.515 ' HD3' ' HG3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.25 160.1 15.7 Favored 'General case' 0 C--O 1.235 0.291 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.452 177.856 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.497 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 80.8 t80 -61.87 -65.24 0.72 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.3 -173.177 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.02 8.16 6.12 Favored 'General case' 0 C--O 1.233 0.237 0 CA-C-N 114.595 -1.184 . . . . 0.0 111.635 179.946 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.515 ' HG3' ' HD3' ' A' ' 28' ' ' LYS . 2.5 tm-20 -111.12 20.22 17.63 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.601 -0.727 . . . . 0.0 110.408 166.337 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.531 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.3 mt -78.33 172.29 10.23 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.485 -0.78 . . . . 0.0 109.586 165.768 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.531 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 20.1 Cg_exo -51.71 164.98 0.83 Allowed 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.282 1.988 . . . . 0.0 113.678 178.68 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.7 m-20 -61.56 -51.78 67.14 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.472 -0.785 . . . . 0.0 110.468 -169.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.845 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.7 m-20 -113.31 43.84 1.67 Allowed 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.025 -0.989 . . . . 0.0 110.312 178.689 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.419 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 82.5 t90 -61.01 117.25 5.25 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 114.748 -1.115 . . . . 0.0 110.366 175.654 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.845 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.0 m -125.84 171.88 13.97 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.32 -172.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.512 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.7 t -66.16 118.49 53.27 Favored Pre-proline 0 C--O 1.249 1.069 0 CA-C-N 114.995 -1.002 . . . . 0.0 109.542 177.527 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -58.39 -21.3 52.7 Favored 'Trans proline' 0 N--CA 1.484 0.954 0 C-N-CA 122.533 2.155 . . . . 0.0 113.676 172.969 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.651 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.9 mp -89.42 -80.62 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.138 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.414 178.604 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -82.55 -26.23 32.63 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.765 -0.652 . . . . 0.0 110.449 -159.902 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 96.6 27.41 9.79 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.734 -1.121 . . . . 0.0 110.504 -176.939 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.542 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -95.66 110.76 52.88 Favored Pre-proline 0 C--O 1.241 0.648 0 CA-C-N 114.884 -0.658 . . . . 0.0 109.741 175.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.734 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.3 Cg_endo -45.64 167.04 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.836 2.357 . . . . 0.0 113.544 169.295 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.407 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.91 -12.84 12.45 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.524 -165.703 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 41.0 p -63.85 -18.6 64.31 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.488 -177.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.2 mt-10 -108.0 15.53 24.26 Favored 'General case' 0 C--O 1.235 0.302 0 CA-C-N 115.449 -0.796 . . . . 0.0 110.615 -167.19 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.493 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -105.44 107.65 18.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.219 -0.901 . . . . 0.0 110.273 174.019 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -86.22 141.59 29.2 Favored 'General case' 0 N--CA 1.457 -0.125 0 CA-C-N 114.437 -1.256 . . . . 0.0 110.347 -179.97 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.473 ' HD3' ' CZ2' ' A' ' 3' ' ' TRP . 8.5 mttt -85.61 132.72 34.12 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.46 -175.124 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.491 ' CD1' ' HG3' ' A' ' 2' ' ' LYS . 0.3 OUTLIER -123.8 63.1 1.05 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.349 -0.842 . . . . 0.0 110.403 168.966 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.1 tm-20 -133.74 132.46 40.59 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.383 169.397 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 p30 . . . . . 0 C--O 1.24 0.584 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.383 -170.259 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.424 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.772 0 CA-C-O 121.149 0.5 . . . . 0.0 109.755 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.0 mttt -117.16 134.73 54.42 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.495 172.794 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.498 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 41.1 m95 -119.09 122.74 42.78 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.337 178.501 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.666 HG23 HG13 ' A' ' 11' ' ' ILE . 8.0 p -101.43 132.57 46.99 Favored 'Isoleucine or valine' 0 C--O 1.238 0.496 0 CA-C-N 115.267 -0.879 . . . . 0.0 110.366 -179.787 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 21.8 t -72.27 105.64 4.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.002 -0.999 . . . . 0.0 109.654 164.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 6.9 mmmt -62.38 -19.79 63.77 Favored 'General case' 0 N--CA 1.454 -0.258 0 CA-C-N 114.886 -1.052 . . . . 0.0 110.576 -179.438 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.858 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.73 -53.56 12.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.168 -165.278 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.9 p -98.93 -46.94 5.44 Favored 'General case' 0 C--O 1.232 0.135 0 CA-C-N 114.907 -1.042 . . . . 0.0 110.538 -175.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.59 41.97 0.99 Allowed Glycine 0 CA--C 1.527 0.819 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.611 -171.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.525 ' C ' HD12 ' A' ' 11' ' ' ILE . 77.6 t80 -104.38 169.63 8.37 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.355 -0.422 . . . . 0.0 110.112 166.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.666 HG13 HG23 ' A' ' 4' ' ' VAL . 4.1 mp -146.49 123.78 3.8 Favored 'Isoleucine or valine' 0 C--O 1.231 0.13 0 CA-C-N 114.828 -1.078 . . . . 0.0 110.441 -177.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -79.99 137.83 36.92 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.09 163.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 37.9 t0 -121.06 113.03 19.47 Favored 'General case' 0 C--O 1.236 0.36 0 CA-C-N 115.277 -0.874 . . . . 0.0 110.362 168.074 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.48 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 20.6 mt-10 -62.78 -17.19 60.67 Favored 'General case' 0 C--O 1.233 0.234 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.847 -173.088 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.2 t70 -60.74 -76.0 0.06 Allowed 'General case' 0 C--N 1.325 -0.459 0 CA-C-N 115.859 -0.61 . . . . 0.0 109.681 163.763 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.84 -31.6 69.9 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.018 -1.446 . . . . 0.0 110.49 -167.902 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 80.94 -152.12 32.73 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -174.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.548 ' HB3' HD13 ' A' ' 23' ' ' ILE . 19.5 t0 -149.54 54.21 1.54 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.575 0.703 . . . . 0.0 109.82 -173.32 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.505 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.0 Cg_exo -52.13 -19.85 9.72 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.411 2.074 . . . . 0.0 113.542 -177.328 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.4 t70 -60.81 -49.87 75.73 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.431 173.496 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.434 HD21 ' HB3' ' A' ' 39' ' ' PRO . 0.3 OUTLIER -102.74 19.73 18.64 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.07 -0.968 . . . . 0.0 110.354 178.136 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.534 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.41 51.68 8.23 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 169.077 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.626 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -113.62 138.49 43.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.307 168.799 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 m -80.56 139.77 51.38 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-N 115.155 -0.929 . . . . 0.0 109.86 177.843 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.3 Cg_exo -55.17 89.84 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.029 0 C-N-CA 122.491 2.127 . . . . 0.0 113.568 173.006 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.2 18.98 1.14 Allowed Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.504 -1.038 . . . . 0.0 110.504 178.044 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.463 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 96.9 m -81.7 151.8 27.36 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 115.406 -0.397 . . . . 0.0 110.4 168.25 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.569 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.2 mttp -94.35 159.08 15.28 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.441 -176.648 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 78.8 t80 -61.72 -65.16 0.73 Allowed 'General case' 0 C--O 1.231 0.12 0 CA-C-N 114.884 -1.053 . . . . 0.0 110.311 -176.034 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -78.85 7.88 6.4 Favored 'General case' 0 C--O 1.234 0.282 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.652 177.523 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.459 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.86 21.19 17.18 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.381 164.974 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.569 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -83.31 168.27 23.6 Favored Pre-proline 0 CA--C 1.543 0.706 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.678 168.441 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -50.32 153.84 6.66 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.631 2.221 . . . . 0.0 113.599 171.195 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -61.94 -47.96 82.54 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.283 -0.871 . . . . 0.0 110.383 -172.702 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.805 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -98.57 26.46 5.54 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.508 -171.945 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.468 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 83.9 t90 -61.89 124.91 22.05 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.357 -172.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.805 HG13 ' O ' ' A' ' 35' ' ' ASP . 27.5 m -121.53 160.47 22.88 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.331 -169.644 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.43 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.9 t -65.13 122.45 79.81 Favored Pre-proline 0 C--O 1.249 1.046 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.507 174.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.434 ' HB3' HD21 ' A' ' 21' ' ' ASN . 2.4 Cg_endo -59.69 -19.63 54.28 Favored 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.482 2.121 . . . . 0.0 113.629 172.156 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.5 mp -93.55 -80.16 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.497 179.403 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -82.12 -23.9 35.43 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.787 -0.642 . . . . 0.0 110.583 -162.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.94 36.5 13.19 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.524 -174.399 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.64 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -91.76 140.6 25.07 Favored Pre-proline 0 CA--C 1.547 0.833 0 CA-C-N 115.012 -0.594 . . . . 0.0 109.562 172.038 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.408 ' HD2' ' OE1' ' A' ' 47' ' ' GLU . 5.0 Cg_exo -49.88 160.38 1.28 Allowed 'Trans proline' 0 N--CA 1.488 1.179 0 C-N-CA 122.396 2.064 . . . . 0.0 113.27 167.083 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -10.27 5.28 Favored 'General case' 0 C--O 1.234 0.266 0 CA-C-N 114.697 -1.138 . . . . 0.0 110.605 179.687 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.1 t -93.42 20.36 7.29 Favored 'General case' 0 C--O 1.231 0.128 0 CA-C-N 114.612 -1.176 . . . . 0.0 110.393 -178.656 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.858 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.0 OUTLIER -120.21 14.93 12.25 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.767 166.134 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.401 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.1 m-85 -106.49 106.47 17.0 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.227 173.188 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tp10 -90.01 154.63 19.67 Favored 'General case' 0 N--CA 1.458 -0.071 0 CA-C-N 114.563 -1.198 . . . . 0.0 110.426 178.751 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 6.1 mtpm? -85.23 130.0 34.69 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.395 -175.152 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 14.8 tp -138.2 80.32 1.79 Allowed 'General case' 0 N--CA 1.455 -0.224 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.359 -179.642 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -129.84 -79.6 0.55 Allowed 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.263 -0.881 . . . . 0.0 110.41 169.323 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.24 0.578 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.368 170.239 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.473 0.697 0 CA-C-O 121.075 0.464 . . . . 0.0 109.811 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.601 ' HB2' HD12 ' A' ' 51' ' ' LEU . 6.8 mtpp -129.36 112.79 14.2 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.407 -170.859 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.527 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 42.3 m95 -104.91 122.13 45.16 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.416 -173.468 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.82 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -104.57 133.71 47.93 Favored 'Isoleucine or valine' 0 C--O 1.242 0.677 0 CA-C-N 115.164 -0.926 . . . . 0.0 110.198 178.693 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.1 t -68.59 106.58 2.64 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.885 -1.052 . . . . 0.0 109.618 162.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.522 ' HE3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.67 -20.11 63.07 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.639 -1.164 . . . . 0.0 110.468 -179.496 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.701 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -80.84 -58.16 4.09 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.298 -168.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.4 p -98.33 -39.15 8.95 Favored 'General case' 0 C--O 1.232 0.168 0 CA-C-N 115.428 -0.806 . . . . 0.0 110.596 -169.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.57 19.16 7.57 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.9 -1.045 . . . . 0.0 110.492 -179.437 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.0 t80 -83.5 159.35 21.73 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-O 120.98 0.419 . . . . 0.0 110.256 168.302 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.82 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -127.64 179.21 3.86 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 115.314 -0.857 . . . . 0.0 109.943 -171.214 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.68 ' H ' HG22 ' A' ' 11' ' ' ILE . 23.3 t80 -157.96 108.95 2.21 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 114.374 -1.285 . . . . 0.0 110.23 174.023 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -96.48 112.46 24.2 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.323 168.819 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 24.7 mt-10 -61.93 -18.06 58.98 Favored 'General case' 0 C--O 1.234 0.261 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.757 -173.749 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 13.8 t0 -60.88 -77.45 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 115.732 -0.667 . . . . 0.0 109.703 163.473 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.51 -16.09 33.65 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 113.823 -1.535 . . . . 0.0 110.486 -173.454 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.88 -145.13 49.59 Favored Glycine 0 CA--C 1.527 0.801 0 N-CA-C 110.412 -1.075 . . . . 0.0 110.412 168.93 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -165.05 51.86 0.26 Allowed Pre-proline 0 CA--C 1.541 0.634 0 CA-C-O 121.565 0.698 . . . . 0.0 109.842 -170.292 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.494 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 3.2 Cg_exo -51.64 -15.23 2.62 Favored 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.371 2.047 . . . . 0.0 113.487 177.712 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.98 -38.35 85.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 114.933 -1.031 . . . . 0.0 110.474 174.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 54.1 m-80 -114.4 17.15 17.62 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.222 -0.899 . . . . 0.0 110.41 -175.178 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.465 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.36 34.49 22.96 Favored Glycine 0 CA--C 1.525 0.677 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 176.169 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.665 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -105.05 122.36 58.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.4 -0.4 . . . . 0.0 110.298 170.572 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 8.7 m -77.01 147.08 76.49 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-N 115.149 -0.932 . . . . 0.0 109.82 175.747 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_exo -53.07 90.45 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.46 2.106 . . . . 0.0 113.523 171.835 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 129.65 19.1 1.52 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.963 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.53 ' HB ' HG23 ' A' ' 23' ' ' ILE . 86.8 m -72.14 143.0 49.12 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.445 -0.377 . . . . 0.0 110.337 167.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.493 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 52.4 mttp -87.7 160.56 18.05 Favored 'General case' 0 C--O 1.234 0.245 0 CA-C-N 115.132 -0.94 . . . . 0.0 110.483 179.434 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.527 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.6 t80 -61.9 -64.56 0.9 Allowed 'General case' 0 C--O 1.232 0.139 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.373 -173.406 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.81 8.1 6.0 Favored 'General case' 0 C--O 1.234 0.262 0 CA-C-N 114.646 -1.161 . . . . 0.0 111.624 179.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.45 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -111.0 19.71 18.2 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.488 165.611 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.546 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 16.2 mt -79.84 168.51 25.6 Favored Pre-proline 0 CA--C 1.544 0.712 0 CA-C-N 115.482 -0.781 . . . . 0.0 109.655 167.345 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.546 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.6 Cg_endo -51.85 147.89 24.05 Favored 'Trans proline' 0 N--CA 1.485 0.977 0 C-N-CA 122.533 2.156 . . . . 0.0 113.604 171.934 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -61.01 -44.44 97.42 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.465 -173.27 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 28.3 t70 -100.97 29.56 4.55 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 115.059 -0.973 . . . . 0.0 110.285 -177.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 34.1 t90 -62.98 106.45 0.83 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.478 171.25 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.612 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 28.6 m -111.3 170.26 3.67 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.129 -0.942 . . . . 0.0 110.288 175.053 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -62.06 119.73 51.37 Favored Pre-proline 0 C--O 1.249 1.059 0 CA-C-N 115.075 -0.966 . . . . 0.0 109.677 173.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -58.62 -20.43 50.27 Favored 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.531 2.154 . . . . 0.0 113.663 172.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.679 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -91.76 -78.39 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.175 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.544 -179.232 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -84.15 -25.71 29.41 Favored 'General case' 0 C--N 1.332 -0.158 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.579 -162.448 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 93.11 26.89 14.79 Favored Glycine 0 CA--C 1.527 0.833 0 CA-C-N 114.754 -1.112 . . . . 0.0 110.551 -176.054 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.557 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.86 114.37 61.2 Favored Pre-proline 0 C--O 1.242 0.698 0 CA-C-O 121.341 0.591 . . . . 0.0 109.665 171.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.612 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 18.9 Cg_exo -45.81 163.62 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.793 2.329 . . . . 0.0 113.608 168.347 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.81 -11.68 8.46 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.691 -0.686 . . . . 0.0 110.527 -165.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.1 p -63.74 -18.45 64.06 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.475 -178.442 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.701 ' HB3' HD13 ' A' ' 7' ' ' ILE . 1.1 mm-40 -106.38 16.37 24.84 Favored 'General case' 0 C--O 1.235 0.325 0 CA-C-N 115.499 -0.773 . . . . 0.0 110.568 -167.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.41 ' HB3' ' HB3' ' A' ' 3' ' ' TRP . 1.3 m-85 -106.04 104.23 13.89 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.276 175.034 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.522 ' HB2' ' HE3' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -83.71 145.04 28.97 Favored 'General case' 0 N--CA 1.456 -0.15 0 CA-C-N 114.338 -1.301 . . . . 0.0 110.398 -179.662 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.59 104.42 16.49 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.396 -169.456 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.601 HD12 ' HB2' ' A' ' 2' ' ' LYS . 0.2 OUTLIER 60.06 31.3 20.55 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.587 168.87 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -171.38 179.03 3.05 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.389 170.072 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.487 ' HB2' ' HG2' ' A' ' 6' ' ' LYS . 2.8 p30 . . . . . 0 C--O 1.24 0.553 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.328 170.197 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.598 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.746 0 CA-C-O 121.129 0.49 . . . . 0.0 109.734 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.919 ' CG ' HD13 ' A' ' 51' ' ' LEU . 0.1 OUTLIER -122.86 131.8 53.91 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.348 169.292 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 10.4 m95 -104.92 152.44 22.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.47 -0.786 . . . . 0.0 110.447 171.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.525 HG12 ' O ' ' A' ' 49' ' ' GLU . 7.2 p -121.8 157.31 25.88 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.431 -0.804 . . . . 0.0 109.863 170.596 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -83.02 113.6 20.69 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.14 162.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.46 -23.89 67.15 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.591 178.006 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.81 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.7 mp -80.05 -71.5 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.273 0 CA-C-N 114.944 -1.025 . . . . 0.0 110.821 -173.631 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -87.83 -32.92 18.79 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.84 -0.618 . . . . 0.0 110.572 -166.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 21.84 10.46 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 -179.464 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.482 ' O ' HG23 ' A' ' 4' ' ' VAL . 91.6 t80 -78.28 168.44 19.83 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 121.07 0.462 . . . . 0.0 110.211 165.548 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.496 HG13 HG23 ' A' ' 4' ' ' VAL . 3.6 mp -140.36 145.74 25.53 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.193 0 CA-C-N 115.276 -0.875 . . . . 0.0 110.352 -173.241 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 19.0 t80 -119.87 109.72 15.9 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.393 -0.821 . . . . 0.0 110.115 165.707 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 51.0 t0 -98.86 120.31 39.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.347 168.614 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.598 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 36.4 mt-10 -61.04 -18.57 58.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.849 . . . . 0.0 110.423 -169.541 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 22.2 t0 -61.08 -50.21 74.19 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.386 170.74 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -68.46 -42.11 79.26 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.34 -170.058 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.97 -162.7 34.16 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.451 -1.059 . . . . 0.0 110.451 -169.769 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.527 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.0 t0 -152.97 62.11 4.09 Favored Pre-proline 0 CA--C 1.542 0.651 0 CA-C-O 121.446 0.641 . . . . 0.0 109.838 174.361 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.0 Cg_endo -50.97 -22.48 10.39 Favored 'Trans proline' 0 N--CA 1.483 0.904 0 C-N-CA 122.549 2.166 . . . . 0.0 113.605 174.65 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.61 -19.62 62.43 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.409 -179.785 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.463 HD21 ' HB3' ' A' ' 39' ' ' PRO . 20.1 m-80 -145.04 21.13 1.59 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.367 -171.048 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.417 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.03 45.14 7.26 Favored Glycine 0 CA--C 1.525 0.676 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 170.116 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' HB ' ' HB3' ' A' ' 18' ' ' ASP . 4.2 mp -120.39 138.19 51.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 115.302 -0.449 . . . . 0.0 110.425 172.48 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 69.4 m -94.68 149.67 36.82 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.093 -0.958 . . . . 0.0 109.755 177.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.7 Cg_endo -57.43 89.15 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.022 0 C-N-CA 122.509 2.139 . . . . 0.0 113.635 173.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.71 18.91 1.21 Allowed Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 175.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.478 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.8 m -78.82 144.03 35.46 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.419 -0.39 . . . . 0.0 110.366 169.499 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.481 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -85.26 162.2 19.24 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.0 -1.0 . . . . 0.0 110.469 -179.336 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 76.4 t80 -61.77 -66.03 0.6 Allowed 'General case' 0 C--O 1.233 0.203 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.302 -173.863 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -79.16 8.43 5.87 Favored 'General case' 0 C--O 1.235 0.308 0 CA-C-N 114.534 -1.212 . . . . 0.0 111.636 178.189 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -95.72 -13.48 24.15 Favored 'General case' 0 C--N 1.328 -0.368 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.438 168.276 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.559 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 13.0 mt -61.03 171.64 1.09 Allowed Pre-proline 0 CA--C 1.544 0.717 0 CA-C-N 115.114 -0.948 . . . . 0.0 109.786 171.326 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_exo -57.4 161.91 10.88 Favored 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.142 1.895 . . . . 0.0 113.545 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.2 m-20 -61.85 -50.54 71.85 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.472 -169.269 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.596 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -109.1 38.08 2.39 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 -177.298 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.46 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 68.0 t90 -60.95 112.75 2.19 Favored 'General case' 0 C--N 1.331 -0.233 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.412 173.701 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.719 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -116.18 179.49 1.57 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.163 0 CA-C-N 114.857 -1.065 . . . . 0.0 110.413 179.513 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.419 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.7 t -66.79 124.09 87.65 Favored Pre-proline 0 C--O 1.252 1.218 0 CA-C-N 115.238 -0.892 . . . . 0.0 109.463 -177.177 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.463 ' HB3' HD21 ' A' ' 21' ' ' ASN . 2.2 Cg_endo -60.13 -10.04 11.77 Favored 'Trans proline' 0 N--CA 1.483 0.894 0 C-N-CA 122.594 2.196 . . . . 0.0 113.721 171.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.594 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.6 mp -107.7 -78.68 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.558 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -82.52 -21.56 35.38 Favored 'General case' 0 N--CA 1.455 -0.175 0 CA-C-N 115.639 -0.71 . . . . 0.0 110.949 -164.847 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.432 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 83.13 27.78 39.39 Favored Glycine 0 CA--C 1.527 0.835 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -176.56 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -88.73 111.55 44.92 Favored Pre-proline 0 CA--C 1.543 0.677 0 CA-C-O 121.456 0.646 . . . . 0.0 109.562 169.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.719 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.1 Cg_exo -48.3 164.59 0.19 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.698 2.265 . . . . 0.0 113.703 174.11 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.519 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.88 -12.21 10.31 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.599 -165.493 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.8 p -61.61 -26.59 68.08 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.41 -174.223 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.81 ' HB3' HD11 ' A' ' 7' ' ' ILE . 7.6 mt-10 -113.52 20.9 15.62 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.457 -0.792 . . . . 0.0 110.304 -172.51 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -94.03 101.12 13.15 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.252 166.876 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.1 OUTLIER -81.7 125.64 30.85 Favored 'General case' 0 N--CA 1.457 -0.094 0 CA-C-N 114.297 -1.32 . . . . 0.0 110.393 -179.249 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.471 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -74.11 167.96 20.51 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.5 177.228 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.919 HD13 ' CG ' ' A' ' 2' ' ' LYS . 1.9 pt? -76.7 -7.84 56.12 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.31 -0.859 . . . . 0.0 111.646 -177.024 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.406 ' HB3' ' HD2' ' A' ' 50' ' ' LYS . 3.9 tp10 -120.48 28.4 8.02 Favored 'General case' 0 C--N 1.327 -0.4 0 CA-C-N 115.632 -0.713 . . . . 0.0 110.469 -169.386 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 26.3 t70 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.365 169.444 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.46 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.751 0 CA-C-O 121.134 0.492 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -120.23 130.38 54.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.401 171.887 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.559 ' O ' HG23 ' A' ' 11' ' ' ILE . 41.4 m95 -112.9 154.06 26.96 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.363 178.179 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.516 HG23 HG13 ' A' ' 11' ' ' ILE . 7.1 p -122.58 151.75 26.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.029 -0.987 . . . . 0.0 110.228 178.681 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -84.33 113.16 20.94 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.782 -0.645 . . . . 0.0 109.952 161.634 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.467 ' HG3' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -87.14 17.18 4.42 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 114.577 -1.192 . . . . 0.0 111.023 178.552 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.824 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.9 mp -99.63 -74.2 0.49 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.44 163.537 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.3 p -84.13 -34.75 24.02 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.416 -165.543 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.78 33.26 4.46 Favored Glycine 0 CA--C 1.527 0.828 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.553 -175.144 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.791 ' HB2' HD13 ' A' ' 40' ' ' ILE . 61.4 t80 -87.54 170.14 11.58 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-O 121.189 0.518 . . . . 0.0 110.211 165.794 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.568 HD12 ' C ' ' A' ' 10' ' ' TYR . 4.3 mp -141.76 134.14 28.28 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 115.053 -0.976 . . . . 0.0 110.466 178.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.7 t80 -93.1 134.23 35.47 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.17 165.1 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -121.01 112.86 19.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.451 171.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.46 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.1 mt-10 -68.57 -28.05 66.61 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.45 -172.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -64.52 -28.85 69.93 Favored 'General case' 0 C--N 1.33 -0.255 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.336 173.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.38 -42.54 7.7 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.289 -0.869 . . . . 0.0 110.304 -170.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 105.98 -161.16 14.45 Favored Glycine 0 CA--C 1.526 0.767 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 177.135 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.504 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.3 t0 -152.86 51.56 0.74 Allowed Pre-proline 0 CA--C 1.543 0.702 0 CA-C-O 121.54 0.686 . . . . 0.0 109.795 173.371 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.437 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 1.4 Cg_endo -55.82 -18.33 21.25 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.472 2.114 . . . . 0.0 113.488 -171.288 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.74 -49.37 77.76 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.099 -0.955 . . . . 0.0 110.514 171.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -100.91 19.5 17.17 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.399 177.977 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.755 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.42 54.2 6.27 Favored Glycine 0 CA--C 1.526 0.761 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 168.287 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.755 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.2 mp -120.71 141.47 40.99 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.337 168.866 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -94.13 144.72 28.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.271 -0.877 . . . . 0.0 109.812 -179.313 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_exo -54.23 90.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.457 2.105 . . . . 0.0 113.511 172.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.48 19.12 1.09 Allowed Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.466 -1.054 . . . . 0.0 110.466 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.469 HG21 HD23 ' A' ' 32' ' ' LEU . 94.8 m -82.45 153.53 25.61 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.342 168.022 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.62 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -100.24 159.82 14.82 Favored 'General case' 0 C--O 1.235 0.307 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.413 -179.031 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.8 t80 -61.69 -65.76 0.64 Allowed 'General case' 0 C--O 1.232 0.153 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.309 -176.118 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.01 6.93 8.19 Favored 'General case' 0 N--CA 1.452 -0.344 0 CA-C-N 114.477 -1.238 . . . . 0.0 111.703 177.8 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.541 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -108.66 21.02 17.82 Favored 'General case' 0 C--N 1.327 -0.392 0 CA-C-N 115.786 -0.643 . . . . 0.0 110.392 165.118 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.62 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 56.2 mt -84.0 171.96 10.17 Favored Pre-proline 0 CA--C 1.543 0.68 0 CA-C-N 115.331 -0.85 . . . . 0.0 109.672 169.293 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.9 Cg_exo -49.28 156.57 2.45 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.569 2.18 . . . . 0.0 113.763 174.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 -61.72 -49.97 74.31 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.392 -169.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.773 ' O ' HG13 ' A' ' 37' ' ' VAL . 8.7 m-20 -109.75 36.73 2.87 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 114.979 -1.009 . . . . 0.0 110.41 -178.013 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.439 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 88.7 t90 -61.54 124.73 21.47 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 114.867 -1.06 . . . . 0.0 110.378 -179.674 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.773 HG13 ' O ' ' A' ' 35' ' ' ASP . 20.7 m -122.93 172.36 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 115.246 -0.888 . . . . 0.0 110.362 -169.657 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.467 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 17.5 t -68.64 130.05 92.17 Favored Pre-proline 0 C--O 1.253 1.273 0 CA-C-N 114.898 -1.046 . . . . 0.0 109.21 -177.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 4.6 Cg_endo -62.19 -17.05 54.68 Favored 'Trans proline' 0 N--CA 1.485 1.007 0 C-N-CA 122.558 2.172 . . . . 0.0 113.648 171.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.791 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.3 mp -101.16 -83.8 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.173 0 CA-C-N 115.134 -0.939 . . . . 0.0 110.191 174.007 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.8 p -75.43 -18.3 59.94 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.633 -0.712 . . . . 0.0 111.151 -162.034 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.467 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.3 30.24 50.74 Favored Glycine 0 CA--C 1.526 0.763 0 N-CA-C 110.441 -1.064 . . . . 0.0 110.441 -178.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.509 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.57 138.53 26.67 Favored Pre-proline 0 CA--C 1.544 0.733 0 CA-C-N 115.173 -0.513 . . . . 0.0 109.654 173.52 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -51.8 163.14 1.41 Allowed 'Trans proline' 0 N--CA 1.485 1.009 0 C-N-CA 122.365 2.043 . . . . 0.0 113.513 174.661 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.03 -12.67 12.49 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.422 175.433 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 15.5 t -71.69 -23.59 61.67 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.462 176.915 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.824 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -92.3 12.01 23.93 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.701 179.034 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -109.06 115.68 30.53 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.412 178.822 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.467 ' HG3' ' HG3' ' A' ' 6' ' ' LYS . 3.2 mt-10 -83.37 169.42 15.63 Favored 'General case' 0 N--CA 1.461 0.087 0 CA-C-N 115.044 -0.98 . . . . 0.0 110.192 172.974 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.427 ' H ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER -107.1 152.16 24.4 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.373 177.165 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -99.83 31.37 3.28 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.298 -0.865 . . . . 0.0 110.391 172.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -103.68 -41.13 6.03 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.443 -175.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 6.4 p-10 . . . . . 0 C--O 1.24 0.592 0 CA-C-N 115.309 -0.859 . . . . 0.0 110.333 169.964 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.59 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.13 0.491 . . . . 0.0 109.726 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -117.89 133.6 55.76 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.534 -0.757 . . . . 0.0 110.42 171.663 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.531 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 44.3 m95 -119.74 163.79 16.92 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.11 -0.95 . . . . 0.0 110.449 179.209 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 5.5 p -140.02 154.02 23.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.354 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.378 -173.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 15.8 t -87.89 118.45 27.44 Favored 'General case' 0 C--O 1.236 0.389 0 CA-C-N 115.666 -0.697 . . . . 0.0 110.02 165.286 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -89.15 17.3 6.07 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.401 -1.272 . . . . 0.0 110.928 175.734 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.773 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mp -101.03 -79.14 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.239 0 CA-C-N 115.784 -0.644 . . . . 0.0 110.532 158.77 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -80.96 -31.53 34.81 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 116.014 -0.539 . . . . 0.0 110.526 -163.502 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.87 19.72 16.5 Favored Glycine 0 CA--C 1.526 0.768 0 CA-C-N 114.751 -1.113 . . . . 0.0 110.483 -179.051 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.613 ' CG ' HD13 ' A' ' 40' ' ' ILE . 89.9 t80 -71.93 169.57 15.59 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.031 0.443 . . . . 0.0 110.211 165.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.512 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.8 mp -142.38 144.38 24.91 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-N 115.239 -0.892 . . . . 0.0 110.346 -175.203 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.464 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.0 t80 -107.27 134.99 49.54 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.194 166.878 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -118.95 114.46 22.59 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.342 169.172 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.59 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 14.9 mt-10 -66.2 -28.21 68.58 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.501 -170.22 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -67.09 -30.34 70.35 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.34 176.83 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.96 -51.55 5.15 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.284 -170.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 114.74 -142.25 17.49 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.462 -1.055 . . . . 0.0 110.462 169.382 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.535 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.4 t0 -172.98 55.06 0.19 Allowed Pre-proline 0 CA--C 1.542 0.669 0 CA-C-O 121.543 0.687 . . . . 0.0 109.772 179.74 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.512 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 12.6 Cg_exo -54.91 -15.93 10.83 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.506 2.138 . . . . 0.0 113.572 -173.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.04 -49.74 76.16 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.393 170.238 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . 6.4 m-80 -99.08 19.31 15.43 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 114.972 -1.013 . . . . 0.0 110.474 176.192 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 66.95 45.24 85.08 Favored Glycine 0 CA--C 1.525 0.704 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 169.677 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 21' ' ' ASN . 3.9 mp -102.88 126.3 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.334 -0.433 . . . . 0.0 110.331 169.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -82.08 143.46 49.3 Favored Pre-proline 0 CA--C 1.541 0.619 0 CA-C-N 115.067 -0.969 . . . . 0.0 109.891 175.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -59.67 72.84 0.06 OUTLIER 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 122.512 2.141 . . . . 0.0 113.572 177.033 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.24 0.08 OUTLIER Glycine 0 CA--C 1.526 0.736 0 N-CA-C 109.867 -1.293 . . . . 0.0 109.867 -162.419 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.504 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.9 m -60.63 147.62 41.24 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 114.684 -0.758 . . . . 0.0 110.61 178.598 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.58 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -98.39 170.41 8.87 Favored 'General case' 0 C--O 1.235 0.303 0 CA-C-N 115.307 -0.861 . . . . 0.0 110.369 175.103 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.531 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.5 t80 -61.72 -65.67 0.65 Allowed 'General case' 0 C--O 1.232 0.171 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.265 -175.546 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.07 7.12 7.93 Favored 'General case' 0 C--O 1.234 0.284 0 CA-C-N 114.54 -1.209 . . . . 0.0 111.681 178.153 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.488 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.9 mm-40 -108.52 20.69 18.26 Favored 'General case' 0 C--N 1.326 -0.42 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.462 166.196 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.58 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 35.7 mt -83.38 167.53 28.25 Favored Pre-proline 0 CA--C 1.543 0.682 0 CA-C-N 115.36 -0.837 . . . . 0.0 109.704 169.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -47.8 151.2 3.8 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.7 2.267 . . . . 0.0 113.579 172.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 9.6 m-20 -61.77 -46.76 88.17 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.446 -170.227 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -98.23 25.12 6.46 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.381 -171.625 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.461 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 58.5 t90 -66.59 108.66 2.52 Favored 'General case' 0 C--N 1.33 -0.239 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.407 -177.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.699 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -112.4 -179.99 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.223 0 CA-C-N 115.197 -0.91 . . . . 0.0 110.402 174.815 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.476 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.2 t -62.63 123.71 80.28 Favored Pre-proline 0 C--O 1.252 1.221 0 CA-C-N 115.337 -0.847 . . . . 0.0 109.433 -177.444 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 22.6 Cg_exo -52.81 -19.27 10.59 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.821 2.347 . . . . 0.0 113.823 169.283 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.613 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.8 mp -104.3 -78.61 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.39 -0.823 . . . . 0.0 110.589 -176.793 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -81.73 -21.56 37.84 Favored 'General case' 0 N--CA 1.456 -0.153 0 CA-C-N 115.62 -0.718 . . . . 0.0 110.977 -164.886 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.476 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.35 24.86 49.9 Favored Glycine 0 CA--C 1.527 0.8 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 -177.649 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.04 113.39 51.54 Favored Pre-proline 0 C--O 1.242 0.69 0 CA-C-O 121.425 0.631 . . . . 0.0 109.681 169.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.699 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.9 Cg_exo -49.48 159.21 1.4 Allowed 'Trans proline' 0 N--CA 1.486 1.053 0 C-N-CA 122.549 2.166 . . . . 0.0 113.688 176.844 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.435 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.1 OUTLIER -60.79 -11.12 6.68 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.535 -0.757 . . . . 0.0 110.46 -165.983 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 21.9 t -61.17 -33.61 73.72 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.379 178.595 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.773 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.3 mm-40 -97.21 19.95 12.21 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.155 -0.93 . . . . 0.0 110.43 -174.575 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.67 119.37 38.66 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.394 174.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.47 ' HB3' HG13 ' A' ' 4' ' ' VAL . 1.7 tm-20 -84.09 177.81 8.09 Favored 'General case' 0 C--N 1.334 -0.094 0 CA-C-N 114.913 -1.039 . . . . 0.0 110.358 176.373 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.503 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 24.3 tttt -138.19 153.13 49.18 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.427 -0.806 . . . . 0.0 110.348 -170.063 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.503 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.6 OUTLIER 60.0 90.82 0.05 Allowed 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.107 -0.951 . . . . 0.0 110.544 172.416 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 pt-20 -79.43 -19.19 50.54 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.219 -0.9 . . . . 0.0 110.438 171.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 C--O 1.239 0.512 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.31 -169.786 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.467 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 20.7 mtmm -111.11 131.17 55.3 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.542 -0.754 . . . . 0.0 110.388 170.253 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.514 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 31.4 m95 -108.37 -179.79 3.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.434 173.601 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.681 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.9 p -152.93 146.48 14.88 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.133 0 CA-C-N 114.841 -1.072 . . . . 0.0 110.103 -176.21 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.494 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.8 t -79.64 112.37 16.83 Favored 'General case' 0 N--CA 1.468 0.437 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 160.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.416 ' HG3' ' HB2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -65.91 -22.89 66.53 Favored 'General case' 0 N--CA 1.453 -0.319 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.905 178.114 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 12.5 mm -71.66 -70.69 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.143 0 CA-C-N 114.641 -1.163 . . . . 0.0 110.215 -175.659 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.62 -39.44 13.23 Favored 'General case' 0 C--O 1.231 0.114 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.575 -167.418 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.5 17.33 8.75 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.759 -1.11 . . . . 0.0 110.704 -179.81 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.714 ' C ' HD13 ' A' ' 11' ' ' ILE . 90.4 t80 -72.53 161.36 30.9 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-O 120.913 0.387 . . . . 0.0 109.977 164.392 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.714 HD13 ' C ' ' A' ' 10' ' ' TYR . 7.4 mm -127.23 158.15 38.47 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.147 0 CA-C-N 114.976 -1.011 . . . . 0.0 110.257 -177.325 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.445 ' CE1' ' HA2' ' A' ' 17' ' ' GLY . 26.4 t80 -126.49 107.73 10.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.071 164.044 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.2 t0 -91.14 107.56 19.29 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.343 168.041 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.467 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.3 mt-10 -65.54 -28.02 68.87 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.42 -169.836 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.4 t70 -72.78 -18.1 61.52 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 115.007 -0.997 . . . . 0.0 110.401 -178.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -100.73 -27.18 13.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.265 -0.879 . . . . 0.0 110.31 169.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.445 ' HA2' ' CE1' ' A' ' 12' ' ' TYR . . . 61.7 -172.6 8.06 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.683 -1.144 . . . . 0.0 110.474 176.741 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.513 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.1 t0 -133.57 58.88 36.31 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.542 0.687 . . . . 0.0 109.786 -168.909 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.6 Cg_endo -52.48 -18.42 8.2 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.471 2.114 . . . . 0.0 113.528 173.437 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -41.62 96.88 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.443 176.092 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 10.1 m-80 -117.65 24.53 11.02 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.325 -179.954 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.448 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 80.74 43.38 9.12 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.411 -1.076 . . . . 0.0 110.411 169.056 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.583 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.5 mp -114.05 118.81 59.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 115.386 -0.407 . . . . 0.0 110.36 169.641 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 7.5 t -81.7 142.98 49.87 Favored Pre-proline 0 CA--C 1.543 0.704 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.788 -177.068 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_exo -53.46 90.35 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.006 0 C-N-CA 122.475 2.117 . . . . 0.0 113.428 171.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.93 18.37 1.09 Allowed Glycine 0 CA--C 1.526 0.772 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.517 -178.483 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.3 m -90.83 158.83 16.59 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.482 -0.359 . . . . 0.0 110.256 166.146 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.533 ' CG ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -116.56 171.93 7.54 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.618 -177.734 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.514 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 80.1 t80 -61.26 -63.45 1.28 Allowed 'General case' 0 C--O 1.233 0.221 0 CA-C-N 115.683 -0.689 . . . . 0.0 110.47 -164.602 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.7 mp0 -90.85 19.86 5.23 Favored 'General case' 0 C--O 1.234 0.252 0 CA-C-N 114.766 -1.106 . . . . 0.0 110.739 -175.752 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.533 ' HB2' ' CG ' ' A' ' 28' ' ' LYS . 20.9 mm-40 -118.12 20.18 13.3 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.626 -0.716 . . . . 0.0 110.369 162.694 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.554 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 25.3 mt -72.15 172.86 6.39 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.707 167.565 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.554 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 18.4 Cg_exo -49.9 161.74 0.88 Allowed 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.464 2.109 . . . . 0.0 113.767 176.433 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -61.7 -47.99 82.81 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.462 -169.892 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.681 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -106.84 25.4 11.33 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.43 -171.807 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.424 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.2 t90 -61.81 108.48 1.02 Allowed 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.317 -172.24 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -116.36 176.1 2.66 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.199 0 CA-C-N 114.882 -1.054 . . . . 0.0 110.285 179.312 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 16.4 t -63.16 122.09 73.26 Favored Pre-proline 0 C--O 1.252 1.204 0 CA-C-N 114.93 -1.032 . . . . 0.0 109.414 175.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -60.91 -19.09 60.78 Favored 'Trans proline' 0 N--CA 1.484 0.924 0 C-N-CA 122.5 2.134 . . . . 0.0 113.693 172.13 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -93.97 -81.14 0.21 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 114.957 -1.02 . . . . 0.0 110.514 178.893 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.97 -22.72 42.24 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.718 -162.554 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.423 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 88.39 23.92 35.53 Favored Glycine 0 CA--C 1.526 0.771 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -177.016 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.529 ' HB1' ' HB2' ' A' ' 47' ' ' GLU . . . -86.65 112.61 47.94 Favored Pre-proline 0 C--O 1.242 0.686 0 CA-C-O 121.194 0.521 . . . . 0.0 109.627 169.458 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.3 Cg_exo -45.16 167.19 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.076 0 C-N-CA 122.821 2.347 . . . . 0.0 113.682 169.061 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.3 -9.41 5.13 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.586 -170.16 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 10.7 t -93.9 20.99 7.05 Favored 'General case' 0 N--CA 1.457 -0.09 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.415 -176.941 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.529 ' HB2' ' HB1' ' A' ' 43' ' ' ALA . 3.8 mm-40 -126.86 22.93 6.71 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.428 165.41 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.494 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 3.7 m-85 -108.42 127.09 53.59 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.549 178.716 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.546 ' HG3' ' N ' ' A' ' 50' ' ' LYS . 7.0 tp10 -88.8 -179.09 5.91 Favored 'General case' 0 N--CA 1.461 0.101 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.138 172.135 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.546 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -108.54 154.89 21.3 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.434 172.191 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -95.67 44.48 1.08 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.496 170.553 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -121.16 40.02 3.68 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.395 176.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.542 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.357 170.204 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.83 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.765 0 CA-C-O 121.053 0.454 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.6 mtpm? -132.35 141.03 48.76 Favored 'General case' 0 C--N 1.33 -0.244 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.321 -176.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.494 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 51.7 m95 -138.31 124.18 19.98 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.199 -0.91 . . . . 0.0 110.288 -172.081 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.638 HG23 HG13 ' A' ' 11' ' ' ILE . 8.4 p -107.17 132.03 55.65 Favored 'Isoleucine or valine' 0 C--O 1.241 0.633 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.586 -176.981 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -69.25 106.85 3.02 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 114.811 -1.086 . . . . 0.0 109.985 166.843 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.3 tppt? -63.53 -23.19 67.29 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.743 -178.978 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.698 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.4 mp -70.08 -69.44 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.334 -0.084 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.315 -178.033 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -91.94 -43.67 9.33 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.561 -164.455 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 137.54 -15.01 3.65 Favored Glycine 0 CA--C 1.523 0.533 0 CA-C-N 114.773 -1.103 . . . . 0.0 110.823 179.299 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.809 ' HB2' HD13 ' A' ' 40' ' ' ILE . 87.1 t80 -61.15 168.74 2.39 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.571 -0.315 . . . . 0.0 110.265 -171.469 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.638 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -145.59 126.24 7.22 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.132 0 CA-C-N 114.575 -1.193 . . . . 0.0 110.484 179.882 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.48 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 30.4 t80 -79.79 138.56 37.28 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.5 -0.773 . . . . 0.0 109.957 163.776 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -122.82 110.4 15.4 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.236 -0.893 . . . . 0.0 110.355 167.604 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.83 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 39.0 mt-10 -64.02 -22.1 66.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.49 -169.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -67.88 -32.99 73.87 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.197 -0.911 . . . . 0.0 110.342 175.182 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.67 -30.54 10.38 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.256 -169.0 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 86.6 -135.81 13.58 Favored Glycine 0 CA--C 1.526 0.732 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 170.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.804 ' HB3' HD13 ' A' ' 23' ' ' ILE . 30.5 t0 -162.11 71.12 2.3 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-O 121.399 0.619 . . . . 0.0 109.7 -171.462 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -50.27 -47.08 25.66 Favored 'Trans proline' 0 N--CA 1.486 1.058 0 C-N-CA 122.605 2.203 . . . . 0.0 113.589 -169.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -73.23 -17.62 61.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.35 -172.751 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.486 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.0 m-80 -102.4 1.18 35.07 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 115.183 -0.917 . . . . 0.0 111.608 172.692 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 74.18 36.95 49.8 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.551 -1.02 . . . . 0.0 110.551 171.764 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.804 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -102.08 128.23 54.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.26 -0.47 . . . . 0.0 110.368 169.472 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.4 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 7.6 t -84.51 144.73 43.52 Favored Pre-proline 0 CA--C 1.543 0.691 0 CA-C-N 115.231 -0.895 . . . . 0.0 109.822 -176.395 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.4 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 1.0 OUTLIER -56.77 73.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.015 0 C-N-CA 122.264 1.976 . . . . 0.0 113.514 174.572 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.74 -34.22 0.08 OUTLIER Glycine 0 CA--C 1.527 0.791 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 -162.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.502 ' CB ' HG23 ' A' ' 23' ' ' ILE . 20.4 m -60.38 145.83 46.52 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 114.679 -0.761 . . . . 0.0 110.642 177.681 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.5 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 34.2 mttm -99.8 164.54 11.99 Favored 'General case' 0 C--O 1.235 0.339 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.422 176.12 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.494 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 77.1 t80 -61.84 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.141 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.315 -175.451 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.6 tt0 -78.96 7.72 6.79 Favored 'General case' 0 C--O 1.235 0.326 0 CA-C-N 114.523 -1.217 . . . . 0.0 111.666 178.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.5 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 10.0 tt0 -117.64 22.75 12.17 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 115.633 -0.712 . . . . 0.0 110.377 166.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.508 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 30.0 mt -70.38 172.73 5.48 Favored Pre-proline 0 CA--C 1.545 0.782 0 CA-C-N 115.191 -0.913 . . . . 0.0 109.682 172.358 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.508 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.6 Cg_exo -47.7 157.04 1.03 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.629 2.219 . . . . 0.0 113.682 171.113 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 8.2 m-20 -61.73 -45.9 91.95 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.477 -170.868 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.585 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -110.27 23.14 14.68 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.45 -171.174 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.467 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 75.4 t90 -61.97 113.76 2.99 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.377 -173.009 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.677 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -118.37 176.24 3.16 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.162 -0.927 . . . . 0.0 110.256 176.808 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.2 t -61.88 119.22 46.15 Favored Pre-proline 0 C--O 1.25 1.085 0 CA-C-N 115.098 -0.955 . . . . 0.0 109.501 178.474 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.422 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -53.69 -25.54 34.28 Favored 'Trans proline' 0 N--CA 1.486 1.063 0 C-N-CA 122.558 2.172 . . . . 0.0 113.671 170.948 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.809 HD13 ' HB2' ' A' ' 10' ' ' TYR . 3.5 mp -90.94 -81.86 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.253 -179.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -80.48 -23.54 40.09 Favored 'General case' 0 C--N 1.332 -0.18 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.688 -159.777 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.85 26.42 24.55 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.477 -1.049 . . . . 0.0 110.477 -176.175 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.429 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -91.45 114.09 60.63 Favored Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.331 0.586 . . . . 0.0 109.646 170.285 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.677 ' HA ' HG12 ' A' ' 37' ' ' VAL . 12.5 Cg_exo -48.33 167.07 0.12 Allowed 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.769 2.313 . . . . 0.0 113.744 173.502 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.444 ' H ' ' HE3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.89 -11.85 9.19 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.588 -167.985 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 28.2 p -61.76 -34.01 75.08 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.221 -0.9 . . . . 0.0 110.377 -175.718 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.698 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -102.79 18.73 20.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.507 -167.375 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.414 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 m-85 -94.3 104.87 16.86 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.459 -0.791 . . . . 0.0 110.064 166.015 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.84 129.99 34.94 Favored 'General case' 0 C--O 1.231 0.119 0 CA-C-N 114.21 -1.359 . . . . 0.0 110.359 -179.184 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.495 ' NZ ' ' HA ' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -76.96 147.37 36.94 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.173 -0.922 . . . . 0.0 110.357 -174.565 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 5.4 mt -97.63 40.46 1.16 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.237 -0.892 . . . . 0.0 110.413 -168.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.495 ' HA ' ' NZ ' ' A' ' 50' ' ' LYS . 0.9 OUTLIER 57.89 14.21 2.47 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.976 169.271 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 4.3 p-10 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.096 -0.957 . . . . 0.0 110.876 174.971 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.621 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.781 0 N-CA-C 109.743 -0.466 . . . . 0.0 109.743 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -123.11 121.48 36.09 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.431 -177.03 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.54 ' O ' HG23 ' A' ' 11' ' ' ILE . 38.5 m95 -108.18 148.74 29.48 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 114.989 -1.005 . . . . 0.0 110.387 -179.853 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.547 HG13 ' HG3' ' A' ' 49' ' ' GLU . 6.2 p -123.43 152.5 28.52 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.198 178.97 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.522 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.1 t -83.73 115.44 22.2 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.661 -0.699 . . . . 0.0 109.771 162.291 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.496 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -88.98 17.3 5.87 Favored 'General case' 0 N--CA 1.453 -0.315 0 CA-C-N 114.648 -1.16 . . . . 0.0 110.929 176.768 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.896 HD11 ' CB ' ' A' ' 47' ' ' GLU . 1.9 mt -96.81 -76.53 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.683 -0.69 . . . . 0.0 110.466 160.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -83.76 -37.49 22.56 Favored 'General case' 0 C--N 1.331 -0.219 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.368 -164.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.85 37.4 2.97 Favored Glycine 0 CA--C 1.527 0.83 0 CA-C-N 114.615 -1.175 . . . . 0.0 110.473 -174.418 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CB ' HD13 ' A' ' 40' ' ' ILE . 63.4 t80 -90.99 170.21 10.24 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-O 121.076 0.465 . . . . 0.0 110.141 163.845 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.556 HD12 ' C ' ' A' ' 10' ' ' TYR . 3.9 mp -141.67 136.73 31.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.25 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.486 -178.545 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.451 ' OH ' HG21 ' A' ' 23' ' ' ILE . 12.7 t80 -99.05 137.85 36.98 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.109 164.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -123.4 110.72 15.49 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.276 -0.874 . . . . 0.0 110.497 171.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.621 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.2 mt-10 -61.05 -20.82 63.01 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.435 -171.498 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.49 -32.03 54.02 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.179 -0.919 . . . . 0.0 110.421 -174.781 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -103.0 -19.85 14.42 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.297 -171.069 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -159.38 22.68 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.409 -1.076 . . . . 0.0 110.409 169.291 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.497 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.4 t0 -159.27 57.62 1.08 Allowed Pre-proline 0 CA--C 1.542 0.646 0 CA-C-O 121.681 0.753 . . . . 0.0 109.898 175.083 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 2.9 Cg_endo -52.74 -16.34 5.59 Favored 'Trans proline' 0 N--CA 1.484 0.912 0 C-N-CA 122.553 2.168 . . . . 0.0 113.56 179.212 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 32.7 t70 -74.66 -22.79 58.69 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 114.922 -1.035 . . . . 0.0 110.361 178.737 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -125.98 19.4 7.75 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.401 170.801 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.47 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 73.23 48.05 20.9 Favored Glycine 0 CA--C 1.525 0.692 0 N-CA-C 110.457 -1.057 . . . . 0.0 110.457 168.077 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.637 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -106.76 136.35 41.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-N 115.441 -0.38 . . . . 0.0 110.343 169.035 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 54.3 m -83.93 148.65 54.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 CA-C-N 115.194 -0.912 . . . . 0.0 109.869 177.26 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -58.24 87.5 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.573 2.182 . . . . 0.0 113.689 173.217 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.97 19.29 1.27 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 175.188 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.605 ' HB ' HG23 ' A' ' 23' ' ' ILE . 96.3 m -82.63 165.37 20.1 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.332 -0.434 . . . . 0.0 110.346 170.023 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.562 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.3 OUTLIER -112.41 161.4 16.73 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.332 -169.459 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.2 t80 -61.76 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.164 0 CA-C-N 114.83 -1.077 . . . . 0.0 110.231 -176.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.18 6.99 8.37 Favored 'General case' 0 N--CA 1.453 -0.299 0 CA-C-N 114.498 -1.228 . . . . 0.0 111.693 177.557 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -109.71 21.21 17.22 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.405 165.816 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.516 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 85.4 mt -80.57 171.03 13.36 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.695 169.964 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.496 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.5 Cg_exo -49.08 158.15 1.48 Allowed 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.579 2.186 . . . . 0.0 113.791 172.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -61.78 -50.15 73.5 Favored 'General case' 0 C--N 1.331 -0.231 0 CA-C-N 115.473 -0.785 . . . . 0.0 110.326 -169.926 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.672 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -108.92 34.83 3.49 Favored 'General case' 0 N--CA 1.454 -0.227 0 CA-C-N 114.993 -1.003 . . . . 0.0 110.417 -176.648 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 69.8 t90 -61.67 112.66 2.34 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.418 176.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.733 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.4 m -118.19 179.89 1.7 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.22 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.423 -179.342 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 15.2 t -68.72 127.18 93.23 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.132 -0.94 . . . . 0.0 109.402 -176.41 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -62.39 -14.52 39.45 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.505 2.137 . . . . 0.0 113.695 171.746 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.616 HD13 ' CB ' ' A' ' 10' ' ' TYR . 4.8 mp -100.28 -83.89 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.259 0 CA-C-N 115.409 -0.814 . . . . 0.0 110.281 172.9 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.6 p -77.85 -15.58 58.94 Favored 'General case' 0 CA--C 1.519 -0.215 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.275 -160.118 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.14 23.49 54.8 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 179.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.799 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.11 117.52 67.93 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.423 0.63 . . . . 0.0 109.588 176.348 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.733 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.4 Cg_exo -47.53 165.74 0.11 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.765 2.31 . . . . 0.0 113.824 172.613 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 2.7 ptmt -61.29 -11.54 10.09 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.624 -0.716 . . . . 0.0 110.643 -168.23 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 80.2 p -61.49 -32.88 72.91 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.399 -0.819 . . . . 0.0 110.516 -172.396 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.896 ' CB ' HD11 ' A' ' 7' ' ' ILE . 6.1 mm-40 -105.89 21.58 17.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.348 -174.59 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.7 m-85 -95.31 108.64 20.82 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.322 -0.854 . . . . 0.0 110.261 166.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' HG3' HG13 ' A' ' 4' ' ' VAL . 1.1 pp20? -96.07 156.78 16.19 Favored 'General case' 0 N--CA 1.457 -0.079 0 CA-C-N 114.516 -1.22 . . . . 0.0 110.301 -179.127 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.422 ' HE3' ' HB1' ' A' ' 1' ' ' ALA . 0.0 OUTLIER -92.68 148.68 21.86 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.4 -170.421 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -90.99 46.87 1.35 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.49 173.407 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -171.33 111.52 0.34 Allowed 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.393 169.262 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 . . . . . 0 C--O 1.239 0.548 0 CA-C-N 115.086 -0.961 . . . . 0.0 110.356 177.437 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.846 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 34.0 mttt -138.74 130.94 28.36 Favored 'General case' 0 N--CA 1.454 -0.249 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.388 -178.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CH2' ' HG2' ' A' ' 50' ' ' LYS . 42.3 m95 -120.37 140.44 51.31 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.358 -176.016 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.821 HG23 HG13 ' A' ' 11' ' ' ILE . 15.0 p -119.81 134.72 62.44 Favored 'Isoleucine or valine' 0 C--O 1.238 0.498 0 CA-C-N 114.881 -1.054 . . . . 0.0 110.317 -178.046 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.7 t -74.23 106.34 5.83 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.066 -0.97 . . . . 0.0 109.862 163.761 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.8 tptp -62.37 -21.93 65.72 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.837 -1.074 . . . . 0.0 110.543 -179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.875 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mp -77.06 -59.14 3.38 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-N 115.14 -0.936 . . . . 0.0 110.435 -167.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.7 p -95.69 -41.41 8.9 Favored 'General case' 0 C--O 1.231 0.094 0 CA-C-N 115.327 -0.851 . . . . 0.0 110.479 -171.356 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 108.63 37.94 1.98 Allowed Glycine 0 CA--C 1.527 0.807 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.485 -172.843 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.535 ' C ' HD12 ' A' ' 11' ' ' ILE . 70.2 t80 -99.62 167.59 10.48 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.393 -0.403 . . . . 0.0 110.14 167.057 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.821 HG13 HG23 ' A' ' 4' ' ' VAL . 4.2 mp -146.26 129.56 9.66 Favored 'Isoleucine or valine' 0 C--N 1.333 -0.117 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.348 -177.842 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.477 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.5 t80 -86.15 132.92 33.91 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.435 -0.802 . . . . 0.0 110.16 164.995 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.5 t0 -116.3 116.73 28.28 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.402 168.94 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.846 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.3 mt-10 -70.38 -24.62 62.99 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.428 -169.134 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -69.8 -28.22 65.54 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.333 174.542 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -105.19 -18.25 14.2 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.218 -169.881 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 69.98 -175.96 34.19 Favored Glycine 0 CA--C 1.526 0.773 0 N-CA-C 110.41 -1.076 . . . . 0.0 110.41 170.334 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.521 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.2 t70 -137.15 56.46 12.44 Favored Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.606 0.717 . . . . 0.0 109.881 -176.874 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.44 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 7.8 Cg_exo -50.82 -19.65 5.69 Favored 'Trans proline' 0 N--CA 1.484 0.966 0 C-N-CA 122.466 2.111 . . . . 0.0 113.521 174.589 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -30.44 70.46 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.469 177.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -132.04 24.0 4.56 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.368 -176.659 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.517 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.54 42.47 7.82 Favored Glycine 0 CA--C 1.525 0.696 0 N-CA-C 110.443 -1.063 . . . . 0.0 110.443 168.265 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.665 HG23 ' HB ' ' A' ' 27' ' ' THR . 3.4 mp -116.49 130.47 71.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.39 -0.405 . . . . 0.0 110.331 170.321 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -90.58 149.18 40.27 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-N 115.139 -0.937 . . . . 0.0 109.766 -179.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.1 Cg_exo -53.73 89.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.532 2.155 . . . . 0.0 113.582 172.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.11 19.2 1.01 Allowed Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.665 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.0 m -89.81 151.13 21.95 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.449 -0.375 . . . . 0.0 110.399 168.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.635 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 6.1 tttp -105.22 159.57 15.77 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.388 -170.337 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.511 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.3 t80 -61.76 -65.49 0.68 Allowed 'General case' 0 CA--C 1.528 0.1 0 CA-C-N 114.969 -1.014 . . . . 0.0 110.271 -173.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.92 6.42 9.25 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.657 -1.156 . . . . 0.0 111.72 179.788 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.562 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 0.8 OUTLIER -114.66 22.17 13.8 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 115.897 -0.592 . . . . 0.0 110.304 165.848 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.635 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 60.8 mt -77.58 171.6 12.0 Favored Pre-proline 0 CA--C 1.545 0.764 0 CA-C-N 115.21 -0.905 . . . . 0.0 109.724 169.174 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.513 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.2 Cg_exo -50.36 155.22 5.13 Favored 'Trans proline' 0 N--CA 1.483 0.886 0 C-N-CA 122.635 2.223 . . . . 0.0 113.604 172.236 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.07 -49.01 77.66 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.336 -172.644 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.653 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.9 OUTLIER -102.93 28.17 6.44 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.21 -0.905 . . . . 0.0 110.427 -172.344 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 73.3 t90 -61.9 126.96 29.18 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.193 -0.912 . . . . 0.0 110.338 -174.975 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.653 HG13 ' O ' ' A' ' 35' ' ' ASP . 10.1 m -130.13 166.26 28.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.381 -169.116 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.4 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.4 t -71.44 123.42 89.35 Favored Pre-proline 0 C--O 1.25 1.097 0 CA-C-N 114.993 -1.003 . . . . 0.0 109.399 -178.099 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -60.66 -18.24 54.02 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.525 2.15 . . . . 0.0 113.686 172.008 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.671 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.6 mp -94.22 -81.95 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.429 177.441 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.57 -24.39 39.25 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.559 -0.746 . . . . 0.0 110.526 -162.052 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.19 36.1 15.9 Favored Glycine 0 CA--C 1.527 0.84 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.496 -173.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.554 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -90.7 140.59 26.52 Favored Pre-proline 0 CA--C 1.546 0.79 0 CA-C-N 115.165 -0.517 . . . . 0.0 109.628 170.277 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.52 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.7 Cg_exo -51.72 167.58 0.41 Allowed 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.512 2.142 . . . . 0.0 113.377 170.831 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' HE3' ' A' ' 45' ' ' LYS . 17.2 ttpp -60.73 -12.13 9.6 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 114.545 -1.207 . . . . 0.0 110.523 176.18 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 35.5 t -93.34 21.29 6.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.433 -177.621 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.875 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.1 OUTLIER -123.97 12.9 9.08 Favored 'General case' 0 C--O 1.236 0.362 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.979 168.471 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.511 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -106.93 100.68 10.17 Favored 'General case' 0 C--N 1.327 -0.372 0 CA-C-N 115.453 -0.794 . . . . 0.0 110.407 174.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.405 ' HB3' ' H ' ' A' ' 50' ' ' LYS . 4.7 mm-40 -69.13 -164.38 0.06 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 115.052 -0.977 . . . . 0.0 110.3 172.805 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HG2' ' CH2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -130.3 154.12 47.96 Favored 'General case' 0 C--N 1.331 -0.202 0 CA-C-N 115.168 -0.924 . . . . 0.0 110.376 -176.194 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.9 tp -100.45 19.47 16.71 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.362 171.139 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -139.56 142.11 37.19 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.427 170.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 18.3 t70 . . . . . 0 C--O 1.241 0.608 0 CA-C-N 115.395 -0.82 . . . . 0.0 110.355 -170.048 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.617 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.738 0 CA-C-O 121.125 0.488 . . . . 0.0 109.759 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -129.15 122.49 29.93 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.494 -0.775 . . . . 0.0 110.428 171.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.506 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 31.7 m95 -99.28 163.85 12.37 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 115.05 -0.977 . . . . 0.0 110.298 177.25 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.534 HG23 ' O ' ' A' ' 10' ' ' TYR . 9.2 p -131.1 156.2 42.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.144 171.424 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 16.2 t -80.73 116.79 20.91 Favored 'General case' 0 C--O 1.236 0.375 0 CA-C-N 115.786 -0.643 . . . . 0.0 109.989 162.981 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.436 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 0.1 OUTLIER -87.07 15.54 5.97 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.148 176.788 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.663 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.0 mp -100.06 -78.39 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-N 115.833 -0.621 . . . . 0.0 110.574 160.051 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -81.99 -31.31 31.15 Favored 'General case' 0 C--N 1.332 -0.188 0 CA-C-N 115.995 -0.548 . . . . 0.0 110.524 -162.427 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.2 18.63 16.55 Favored Glycine 0 CA--C 1.526 0.738 0 CA-C-N 114.719 -1.128 . . . . 0.0 110.582 -178.27 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.626 ' CG ' HD13 ' A' ' 40' ' ' ILE . 66.9 t80 -73.02 170.26 15.24 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-O 120.898 0.38 . . . . 0.0 110.212 166.328 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.512 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.6 mp -139.68 146.31 25.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.411 -174.427 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 11.3 t80 -114.41 129.27 56.64 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.223 165.856 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.5 t0 -112.46 119.85 39.64 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.415 -0.811 . . . . 0.0 110.394 169.941 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.617 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -68.48 -27.95 66.6 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 115.116 -0.947 . . . . 0.0 110.398 -178.386 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 t0 -61.04 -41.98 97.61 Favored 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.428 170.385 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.61 -26.89 21.68 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.347 -0.842 . . . . 0.0 110.267 -170.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 73.58 -153.28 47.38 Favored Glycine 0 CA--C 1.527 0.786 0 N-CA-C 110.491 -1.044 . . . . 0.0 110.491 -176.527 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.533 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 20.0 t70 -161.87 50.88 0.31 Allowed Pre-proline 0 CA--C 1.541 0.609 0 CA-C-O 121.641 0.734 . . . . 0.0 109.872 -172.105 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.439 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.26 -17.43 1.51 Allowed 'Trans proline' 0 N--CA 1.484 0.927 0 C-N-CA 122.403 2.069 . . . . 0.0 113.576 176.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.5 -28.61 69.43 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 114.819 -1.082 . . . . 0.0 110.516 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.421 ' C ' HD12 ' A' ' 23' ' ' ILE . 7.6 m-80 -134.44 22.07 3.69 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.407 -174.312 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.738 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 88.42 49.6 3.64 Favored Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.408 -1.077 . . . . 0.0 110.408 169.9 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.738 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -131.36 133.42 62.16 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.977 -0.611 . . . . 0.0 110.405 178.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -89.38 147.52 38.34 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-N 115.154 -0.93 . . . . 0.0 109.854 178.093 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -55.96 88.77 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.096 0 C-N-CA 122.423 2.082 . . . . 0.0 113.556 172.585 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.15 18.77 1.16 Allowed Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.453 -1.059 . . . . 0.0 110.453 175.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.474 ' HB ' HG23 ' A' ' 23' ' ' ILE . 92.9 m -78.68 138.41 38.27 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.404 -0.398 . . . . 0.0 110.397 168.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.601 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -83.5 154.06 24.08 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.456 -173.532 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.506 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.92 -65.68 0.65 Allowed 'General case' 0 C--O 1.232 0.158 0 CA-C-N 115.133 -0.939 . . . . 0.0 110.262 -172.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.5 mm-40 -79.06 7.18 7.81 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.588 -1.187 . . . . 0.0 111.63 178.671 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.564 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -112.76 21.05 15.93 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.421 166.161 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.601 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 22.0 mt -78.09 168.42 27.69 Favored Pre-proline 0 CA--C 1.543 0.707 0 CA-C-N 115.285 -0.871 . . . . 0.0 109.68 168.84 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.559 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 3.0 Cg_endo -48.35 152.95 3.4 Favored 'Trans proline' 0 N--CA 1.486 1.035 0 C-N-CA 122.645 2.23 . . . . 0.0 113.571 169.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.9 m-20 -61.78 -47.09 86.73 Favored 'General case' 0 C--N 1.331 -0.228 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.439 -171.148 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.666 ' O ' HG13 ' A' ' 37' ' ' VAL . 5.9 t70 -98.54 21.3 11.41 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.46 -0.791 . . . . 0.0 110.416 -169.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.477 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 71.0 t90 -61.79 115.17 3.78 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.293 -172.412 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.666 HG13 ' O ' ' A' ' 35' ' ' ASP . 35.2 m -117.19 173.96 4.0 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 CA-C-N 114.885 -1.052 . . . . 0.0 110.445 -176.529 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.437 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.4 t -65.05 125.04 88.4 Favored Pre-proline 0 C--O 1.251 1.166 0 CA-C-N 114.907 -1.042 . . . . 0.0 109.424 176.991 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.418 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.0 Cg_endo -54.97 -23.66 35.94 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.886 2.391 . . . . 0.0 113.581 169.87 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.16 -81.74 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.176 0 CA-C-N 114.856 -1.065 . . . . 0.0 110.31 -179.604 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.75 -20.63 45.9 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.659 -0.7 . . . . 0.0 110.893 -163.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.437 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 79.88 33.23 34.13 Favored Glycine 0 CA--C 1.526 0.735 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 -177.817 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.37 136.8 32.97 Favored Pre-proline 0 CA--C 1.543 0.703 0 N-CA-C 109.671 -0.492 . . . . 0.0 109.671 170.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.44 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -53.37 155.41 12.7 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.391 2.061 . . . . 0.0 113.443 172.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.37 -11.96 12.24 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 114.946 -1.025 . . . . 0.0 110.501 -178.345 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 25.7 p -63.7 -19.15 64.69 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.49 175.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.579 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 0.2 OUTLIER -109.75 16.45 22.07 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.406 -170.232 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -103.92 106.04 16.42 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.368 175.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' HB2' ' HB3' ' A' ' 6' ' ' LYS . 2.3 tt0 -72.21 -163.41 0.11 Allowed 'General case' 0 N--CA 1.458 -0.063 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.327 178.581 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -119.26 152.42 36.71 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.453 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 24.2 tp -127.21 56.2 1.54 Allowed 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.149 -0.932 . . . . 0.0 110.345 177.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -94.78 -52.43 4.27 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.434 169.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.307 170.012 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.689 ' HB3' ' OE1' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.723 0 CA-C-O 121.114 0.483 . . . . 0.0 109.719 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.1 ptmt -124.64 127.14 46.87 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.494 -0.776 . . . . 0.0 110.309 173.162 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.508 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 18.5 m95 -104.57 166.23 10.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.439 174.145 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.838 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.5 p -141.22 135.65 32.29 Favored 'Isoleucine or valine' 0 C--O 1.24 0.553 0 CA-C-N 115.12 -0.946 . . . . 0.0 110.106 176.122 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.6 t -75.93 104.68 6.58 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.003 -0.999 . . . . 0.0 109.689 162.596 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -63.11 -20.03 64.99 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 114.82 -1.082 . . . . 0.0 110.649 -178.933 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.909 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -77.77 -57.45 5.64 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.219 -167.664 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -96.64 -36.3 10.76 Favored 'General case' 0 C--O 1.231 0.103 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.585 -171.241 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.35 20.31 7.91 Favored Glycine 0 CA--C 1.527 0.784 0 N-CA-C 110.489 -1.044 . . . . 0.0 110.489 -178.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.671 ' C ' HD13 ' A' ' 11' ' ' ILE . 76.7 t80 -87.2 157.95 19.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.259 -0.471 . . . . 0.0 110.339 170.513 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.838 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.5 mm -125.06 176.78 5.49 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.227 0 CA-C-N 115.041 -0.981 . . . . 0.0 110.031 -175.544 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.565 ' H ' HG22 ' A' ' 11' ' ' ILE . 19.1 t80 -149.98 123.36 9.02 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.554 -1.203 . . . . 0.0 110.388 170.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -111.65 122.59 48.23 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.396 168.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.689 ' OE1' ' HB3' ' A' ' 1' ' ' ALA . 64.6 mt-10 -74.7 -20.58 59.79 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.405 -168.882 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 5.3 t70 -68.45 -34.49 76.05 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.44 -0.8 . . . . 0.0 110.482 172.307 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -77.33 -65.06 1.0 Allowed 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.303 175.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.98 -155.24 16.45 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.475 -1.05 . . . . 0.0 110.475 179.012 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.554 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.6 t0 -158.14 51.06 0.44 Allowed Pre-proline 0 CA--C 1.543 0.681 0 CA-C-O 121.572 0.701 . . . . 0.0 109.723 -172.424 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.554 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -53.36 -18.78 11.57 Favored 'Trans proline' 0 N--CA 1.485 1.008 0 C-N-CA 122.433 2.089 . . . . 0.0 113.628 -172.373 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 11.9 m-20 -65.74 -33.9 76.94 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.392 176.941 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 14.8 m-80 -113.7 19.42 16.75 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.414 179.122 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.541 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 77.85 41.84 18.06 Favored Glycine 0 CA--C 1.525 0.683 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 169.385 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.667 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.3 mp -109.58 129.2 64.83 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 115.412 -0.394 . . . . 0.0 110.38 170.129 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 9.1 m -88.25 147.64 40.75 Favored Pre-proline 0 CA--C 1.544 0.728 0 CA-C-N 115.128 -0.942 . . . . 0.0 109.762 176.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.3 Cg_endo -56.53 90.17 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.968 0 C-N-CA 122.546 2.164 . . . . 0.0 113.54 173.103 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.32 18.82 1.27 Allowed Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.508 -1.037 . . . . 0.0 110.508 179.953 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.555 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.6 m -82.1 144.38 30.82 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.373 -0.414 . . . . 0.0 110.416 168.74 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.643 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 7.7 mmtp -93.55 160.94 14.56 Favored 'General case' 0 C--O 1.234 0.265 0 CA-C-N 114.979 -1.01 . . . . 0.0 110.364 -178.134 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.508 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.7 t80 -61.81 -65.89 0.62 Allowed 'General case' 0 C--O 1.231 0.105 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.321 -174.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -79.08 6.31 9.8 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.679 -1.146 . . . . 0.0 111.695 178.476 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 5.4 tp10 -112.0 20.3 17.05 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 115.916 -0.584 . . . . 0.0 110.37 165.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.643 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 31.1 mt -77.1 170.58 15.63 Favored Pre-proline 0 CA--C 1.543 0.7 0 CA-C-N 115.453 -0.794 . . . . 0.0 109.682 167.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.547 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 14.4 Cg_exo -47.25 155.73 1.05 Allowed 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.558 2.172 . . . . 0.0 113.688 171.054 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.0 m-20 -61.55 -50.35 73.03 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.379 -169.842 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.838 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -107.34 33.7 3.88 Favored 'General case' 0 N--CA 1.455 -0.219 0 CA-C-N 114.827 -1.079 . . . . 0.0 110.416 -174.894 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.432 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.4 t90 -61.61 120.84 11.36 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 114.915 -1.039 . . . . 0.0 110.366 179.838 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.838 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.9 m -130.16 170.6 18.93 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 115.09 -0.959 . . . . 0.0 110.414 -173.777 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.408 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.0 t -68.8 122.03 83.46 Favored Pre-proline 0 C--O 1.248 1.02 0 CA-C-N 115.286 -0.87 . . . . 0.0 109.553 -174.839 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.408 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.5 Cg_endo -60.39 -18.76 55.07 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.511 2.141 . . . . 0.0 113.755 172.151 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.675 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -92.99 -79.85 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.135 0 CA-C-N 114.966 -1.016 . . . . 0.0 110.437 178.316 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.9 p -83.35 -25.08 31.76 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.798 -0.637 . . . . 0.0 110.494 -161.945 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 90.7 26.27 23.04 Favored Glycine 0 CA--C 1.527 0.816 0 CA-C-N 114.777 -1.101 . . . . 0.0 110.448 -176.048 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.525 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -89.28 116.79 67.25 Favored Pre-proline 0 C--O 1.243 0.753 0 CA-C-O 121.354 0.597 . . . . 0.0 109.623 169.456 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.745 ' HA ' HG12 ' A' ' 37' ' ' VAL . 17.5 Cg_exo -45.8 172.43 0.02 OUTLIER 'Trans proline' 0 N--CA 1.487 1.093 0 C-N-CA 122.753 2.302 . . . . 0.0 113.514 166.801 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.9 -11.06 6.71 Favored 'General case' 0 C--O 1.233 0.204 0 CA-C-N 115.664 -0.698 . . . . 0.0 110.581 -167.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 46.7 p -61.76 -29.68 70.29 Favored 'General case' 0 C--N 1.334 -0.102 0 CA-C-N 115.054 -0.976 . . . . 0.0 110.394 -176.548 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.909 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -98.68 15.11 26.25 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.566 -0.743 . . . . 0.0 110.66 -167.181 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 0.8 OUTLIER -107.03 97.48 7.25 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.248 -0.887 . . . . 0.0 110.32 175.031 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 mm-40 -72.18 175.3 6.16 Favored 'General case' 0 N--CA 1.461 0.108 0 CA-C-N 114.848 -1.069 . . . . 0.0 110.166 173.786 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -113.73 136.16 53.15 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.372 -174.154 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 60.02 85.24 0.11 Allowed 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.571 170.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.529 ' HB3' HG11 ' A' ' 4' ' ' VAL . 0.5 OUTLIER -152.3 -163.36 1.71 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.273 -0.876 . . . . 0.0 110.384 169.533 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 3.8 p30 . . . . . 0 C--O 1.241 0.625 0 CA-C-N 115.031 -0.986 . . . . 0.0 110.365 -178.741 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.636 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.726 0 N-CA-C 109.736 -0.468 . . . . 0.0 109.736 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 10.2 mttm -120.12 134.57 55.22 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.411 171.369 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.499 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 40.4 m95 -119.12 123.7 45.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.049 -0.978 . . . . 0.0 110.326 178.757 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.716 HG23 HG13 ' A' ' 11' ' ' ILE . 8.1 p -103.17 132.71 48.82 Favored 'Isoleucine or valine' 0 C--O 1.238 0.489 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.39 -178.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 22.4 t -71.65 105.01 3.52 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 114.87 -1.059 . . . . 0.0 109.635 164.831 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.2 mmtt -62.29 -21.74 65.47 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.55 -179.152 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.896 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -75.55 -57.63 5.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.342 -168.911 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.0 p -97.22 -46.08 6.27 Favored 'General case' 0 C--O 1.231 0.101 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.454 -172.25 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.65 38.31 1.2 Allowed Glycine 0 CA--C 1.527 0.789 0 CA-C-N 114.669 -1.151 . . . . 0.0 110.568 -173.213 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.479 ' CG ' ' N ' ' A' ' 11' ' ' ILE . 81.2 t80 -100.94 169.04 9.24 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.367 -0.417 . . . . 0.0 110.173 167.246 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.716 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -147.49 123.29 2.65 Favored 'Isoleucine or valine' 0 C--O 1.231 0.121 0 CA-C-N 114.899 -1.046 . . . . 0.0 110.418 -177.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.487 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.9 t80 -76.25 135.84 39.67 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.059 163.5 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -117.63 113.55 22.09 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.295 167.82 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.636 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.2 mt-10 -68.13 -22.64 64.87 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.373 -168.644 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -76.46 -30.31 57.28 Favored 'General case' 0 C--N 1.331 -0.198 0 CA-C-N 115.203 -0.908 . . . . 0.0 110.416 175.844 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -83.54 -35.52 24.72 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.309 179.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.71 -153.98 44.76 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.378 -1.089 . . . . 0.0 110.378 -169.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 19.3 t0 -153.79 57.53 1.91 Allowed Pre-proline 0 CA--C 1.542 0.668 0 CA-C-O 121.522 0.677 . . . . 0.0 109.836 -172.803 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.2 Cg_endo -49.31 -18.02 1.92 Allowed 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.538 2.158 . . . . 0.0 113.538 177.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -71.59 -36.31 70.8 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.416 179.81 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.528 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 0.4 OUTLIER -114.43 20.08 15.7 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 171.137 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.74 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.99 60.12 4.7 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.425 -1.07 . . . . 0.0 110.425 169.182 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.74 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -120.45 144.27 29.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 115.321 -0.439 . . . . 0.0 110.318 169.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -85.14 142.49 38.41 Favored Pre-proline 0 CA--C 1.543 0.69 0 CA-C-N 115.243 -0.89 . . . . 0.0 109.802 -178.745 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.6 Cg_endo -56.46 85.33 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.098 0 C-N-CA 122.371 2.047 . . . . 0.0 113.502 172.105 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.26 23.31 0.93 Allowed Glycine 0 CA--C 1.526 0.724 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.46 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 95.5 m -81.25 155.46 26.08 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.371 -0.414 . . . . 0.0 110.462 169.339 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.566 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 7.3 mmtp -99.69 150.8 21.92 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.412 -172.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.499 ' CE2' ' CZ3' ' A' ' 3' ' ' TRP . 80.0 t80 -61.84 -65.43 0.69 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 115.046 -0.979 . . . . 0.0 110.315 -172.11 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 47.8 tt0 -78.98 6.62 8.87 Favored 'General case' 0 C--O 1.234 0.273 0 CA-C-N 114.655 -1.157 . . . . 0.0 111.679 179.837 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.566 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -115.88 21.42 13.83 Favored 'General case' 0 C--N 1.327 -0.399 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.359 165.946 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.544 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 40.6 mt -71.37 169.21 16.17 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.747 169.236 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.544 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.7 Cg_endo -46.55 151.56 1.86 Allowed 'Trans proline' 0 N--CA 1.485 1.028 0 C-N-CA 122.602 2.202 . . . . 0.0 113.605 169.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.43 -49.59 76.23 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.597 -0.729 . . . . 0.0 110.441 -167.473 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.824 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.8 OUTLIER -107.83 35.05 3.25 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.443 -176.526 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.527 ' CD1' ' HG2' ' A' ' 33' ' ' PRO . 81.0 t90 -61.43 122.12 14.38 Favored 'General case' 0 C--N 1.331 -0.2 0 CA-C-N 114.743 -1.117 . . . . 0.0 110.456 178.165 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.824 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.4 m -123.55 162.71 23.88 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.385 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.326 -172.858 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.3 t -62.54 121.28 66.31 Favored Pre-proline 0 C--O 1.249 1.074 0 CA-C-N 115.036 -0.984 . . . . 0.0 109.465 174.851 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.528 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 21.7 Cg_exo -58.43 -21.24 52.68 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.437 2.091 . . . . 0.0 113.786 171.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.672 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -91.85 -80.0 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.151 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.497 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.3 p -82.46 -25.62 33.4 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 115.785 -0.643 . . . . 0.0 110.518 -162.135 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 115.24 -18.52 15.81 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 114.715 -1.129 . . . . 0.0 110.53 -177.476 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.544 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.94 118.03 34.96 Favored Pre-proline 0 C--O 1.244 0.809 0 N-CA-C 109.435 -0.58 . . . . 0.0 109.435 -167.833 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.59 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.1 Cg_endo -45.0 169.95 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 123.008 2.472 . . . . 0.0 113.602 166.029 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.417 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.1 -12.38 12.02 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.564 -167.677 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 43.4 t -63.41 -23.56 67.46 Favored 'General case' 0 C--N 1.331 -0.206 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.362 -175.27 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.896 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -101.35 14.55 31.61 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.634 -167.283 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.433 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.2 m-85 -107.53 105.19 14.97 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.28 176.895 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -87.81 130.36 34.89 Favored 'General case' 0 N--CA 1.455 -0.183 0 CA-C-N 114.549 -1.205 . . . . 0.0 110.427 -179.359 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -71.22 125.1 26.05 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.444 -175.562 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 6.3 tp -128.55 63.34 1.45 Allowed 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.333 -0.848 . . . . 0.0 110.362 -170.02 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 tt0 -132.94 105.13 6.92 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.334 169.364 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 35.7 m-20 . . . . . 0 C--O 1.24 0.582 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.337 -169.617 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.459 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.725 0 CA-C-O 121.106 0.479 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.4 ptpp? -121.0 125.23 46.83 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.546 -0.752 . . . . 0.0 110.449 170.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.523 ' CE2' ' HB2' ' A' ' 29' ' ' PHE . 23.6 m95 -100.1 171.33 7.88 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.385 175.014 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.67 HG13 ' HB3' ' A' ' 49' ' ' GLU . 6.0 p -137.54 157.15 33.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.281 -177.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.8 t -87.84 119.45 28.2 Favored 'General case' 0 C--O 1.238 0.494 0 CA-C-N 115.564 -0.744 . . . . 0.0 109.836 163.56 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 9.6 tptm -87.64 15.57 6.66 Favored 'General case' 0 N--CA 1.452 -0.361 0 CA-C-N 114.327 -1.306 . . . . 0.0 111.106 175.361 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.828 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.6 mp -101.31 -79.45 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-N 115.815 -0.63 . . . . 0.0 110.518 159.018 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.2 p -82.63 -30.59 29.3 Favored 'General case' 0 C--N 1.333 -0.152 0 CA-C-N 115.986 -0.552 . . . . 0.0 110.601 -161.728 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.56 17.88 27.36 Favored Glycine 0 CA--C 1.526 0.754 0 CA-C-N 114.835 -1.075 . . . . 0.0 110.541 -178.981 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 77.7 t80 -69.6 163.29 25.83 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-O 121.061 0.458 . . . . 0.0 110.093 163.868 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.0 mm -126.87 146.73 32.26 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.254 -178.338 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.546 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 15.1 t80 -108.74 112.99 25.57 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.18 -0.918 . . . . 0.0 110.102 164.47 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.6 t0 -97.0 109.86 22.53 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.483 171.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.459 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 19.0 mt-10 -67.41 -30.6 70.4 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.356 -171.942 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.6 t70 -75.1 -19.3 60.01 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.043 -0.98 . . . . 0.0 110.365 -179.768 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.05 -19.82 29.71 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.24 169.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 64.59 -137.46 39.59 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -169.36 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -169.79 61.0 0.4 Allowed Pre-proline 0 CA--C 1.543 0.708 0 CA-C-O 121.435 0.636 . . . . 0.0 109.763 176.019 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 7.0 Cg_endo -50.17 -26.08 14.4 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.374 2.05 . . . . 0.0 113.586 -179.041 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.7 -37.75 85.32 Favored 'General case' 0 C--N 1.331 -0.225 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.38 -177.917 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.462 ' C ' HD12 ' A' ' 23' ' ' ILE . 11.2 m-80 -120.17 19.89 12.13 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.365 -173.236 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.63 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 84.03 56.17 2.64 Favored Glycine 0 CA--C 1.526 0.779 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 169.002 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.63 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.4 mp -135.91 137.48 48.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-N 115.04 -0.58 . . . . 0.0 110.554 175.518 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 19.8 m -90.35 142.74 28.57 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-N 115.401 -0.818 . . . . 0.0 109.774 -174.603 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.3 Cg_endo -56.46 87.78 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.145 0 C-N-CA 122.304 2.003 . . . . 0.0 113.462 171.278 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 134.08 18.94 0.92 Allowed Glycine 0 CA--C 1.526 0.764 0 N-CA-C 110.414 -1.074 . . . . 0.0 110.414 176.584 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.429 HG22 ' O ' ' A' ' 28' ' ' LYS . 93.4 m -75.2 160.92 29.83 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-O 120.919 0.39 . . . . 0.0 110.365 166.203 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.525 ' CG ' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -111.18 172.81 6.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.401 -0.818 . . . . 0.0 110.451 170.998 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.523 ' HB2' ' CE2' ' A' ' 3' ' ' TRP . 81.7 t80 -61.6 -64.26 1.0 Allowed 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.382 -0.827 . . . . 0.0 110.38 -168.603 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.84 8.35 5.63 Favored 'General case' 0 C--O 1.235 0.306 0 CA-C-N 114.673 -1.148 . . . . 0.0 111.62 -177.099 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.525 ' HB3' ' CG ' ' A' ' 28' ' ' LYS . 4.0 tp10 -107.75 21.94 16.7 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.644 -0.707 . . . . 0.0 110.461 166.641 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.56 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 37.6 mt -82.7 166.73 34.36 Favored Pre-proline 0 CA--C 1.542 0.667 0 CA-C-N 115.214 -0.903 . . . . 0.0 109.738 170.07 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.56 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.9 Cg_endo -49.96 156.08 3.75 Favored 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.573 2.182 . . . . 0.0 113.541 172.649 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.4 m-20 -61.83 -49.7 75.23 Favored 'General case' 0 C--N 1.332 -0.166 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.484 -174.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -103.7 33.2 3.49 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.15 -0.932 . . . . 0.0 110.356 -175.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.464 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 24.7 t90 -65.03 110.98 2.67 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.378 169.261 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.689 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.0 m -113.65 -176.32 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.363 170.881 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.0 t -63.84 123.45 81.74 Favored Pre-proline 0 C--O 1.25 1.102 0 CA-C-N 115.016 -0.993 . . . . 0.0 109.509 176.663 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.9 Cg_endo -62.14 -6.19 7.69 Favored 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 122.662 2.241 . . . . 0.0 113.716 171.312 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.498 HG13 ' HB2' ' A' ' 10' ' ' TYR . 14.0 mm -109.0 -76.94 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.452 -179.819 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -85.75 -20.94 28.52 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.554 -0.748 . . . . 0.0 110.997 -165.657 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.404 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 86.15 19.68 56.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -178.502 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.716 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -80.84 116.34 61.7 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.358 0.599 . . . . 0.0 109.536 168.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.689 ' HA ' HG12 ' A' ' 37' ' ' VAL . 15.7 Cg_exo -50.03 163.71 0.53 Allowed 'Trans proline' 0 N--CA 1.486 1.075 0 C-N-CA 122.598 2.199 . . . . 0.0 113.769 175.77 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.506 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -62.87 -7.81 5.84 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.552 -0.749 . . . . 0.0 110.759 -169.255 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 26.4 p -92.46 19.94 6.73 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.208 -0.905 . . . . 0.0 110.54 -175.356 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.828 ' HB3' HD11 ' A' ' 7' ' ' ILE . 4.3 mp0 -135.7 27.62 3.32 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.571 -0.74 . . . . 0.0 110.286 162.733 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -101.26 116.84 33.73 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.201 -0.909 . . . . 0.0 110.386 173.024 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.67 ' HB3' HG13 ' A' ' 4' ' ' VAL . 11.8 tp10 -80.4 156.61 26.58 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.321 177.324 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.497 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -105.26 118.58 36.92 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.14 -0.937 . . . . 0.0 110.483 -175.057 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -112.31 52.09 0.78 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.418 177.63 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.0 pm0 -62.81 -31.38 72.36 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.406 -170.251 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 22.7 m-20 . . . . . 0 C--O 1.24 0.574 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.358 -177.368 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.493 ' HA ' ' HB3' ' A' ' 53' ' ' ASP . . . . . . . . 0 N--CA 1.473 0.7 0 CA-C-O 121.112 0.482 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.408 ' HE2' ' N ' ' A' ' 2' ' ' LYS . 1.3 mppt? -116.54 119.42 35.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.528 -0.76 . . . . 0.0 110.432 170.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.566 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.7 m95 -108.99 145.04 36.16 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.356 -179.55 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.891 HG23 HG13 ' A' ' 11' ' ' ILE . 14.5 p -126.26 134.76 65.68 Favored 'Isoleucine or valine' 0 C--O 1.239 0.525 0 CA-C-N 115.188 -0.914 . . . . 0.0 110.375 -179.845 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 20.8 t -70.82 107.14 3.86 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 114.861 -1.063 . . . . 0.0 109.768 164.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.0 ttmm -63.03 -24.18 67.8 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 114.728 -1.124 . . . . 0.0 110.655 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.785 HD11 ' CB ' ' A' ' 47' ' ' GLU . 6.2 mt -69.55 -68.76 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 CA-C-N 114.699 -1.137 . . . . 0.0 110.4 -175.182 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -92.5 -36.17 13.21 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.661 -0.7 . . . . 0.0 110.419 -163.675 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.12 32.88 3.61 Favored Glycine 0 CA--C 1.528 0.848 0 CA-C-N 114.836 -1.075 . . . . 0.0 110.547 -173.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 76.0 t80 -94.27 169.65 10.08 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.331 -0.434 . . . . 0.0 110.261 167.721 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.891 HG13 HG23 ' A' ' 4' ' ' VAL . 4.4 mp -148.0 133.77 11.73 Favored 'Isoleucine or valine' 0 C--N 1.334 -0.108 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.359 -177.065 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.496 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.7 t80 -95.45 129.48 42.59 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.172 166.253 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 60.0 t0 -113.1 112.67 24.22 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.343 169.304 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.496 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 15.2 mt-10 -61.0 -15.14 28.4 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.315 -0.857 . . . . 0.0 110.441 -169.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 15.1 t70 -90.54 -19.0 24.27 Favored 'General case' 0 C--N 1.331 -0.224 0 CA-C-N 115.119 -0.946 . . . . 0.0 110.461 -177.555 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -91.61 -30.18 16.5 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.278 -169.592 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.88 -172.64 29.87 Favored Glycine 0 CA--C 1.525 0.688 0 N-CA-C 110.509 -1.037 . . . . 0.0 110.509 -179.624 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.505 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 18.3 t0 -167.92 50.46 0.19 Allowed Pre-proline 0 CA--C 1.543 0.685 0 CA-C-O 121.58 0.705 . . . . 0.0 109.809 174.724 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.45 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 5.2 Cg_endo -56.49 -10.78 5.44 Favored 'Trans proline' 0 N--CA 1.485 1.002 0 C-N-CA 122.476 2.117 . . . . 0.0 113.595 -173.164 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 6.3 t70 -78.63 -26.03 45.18 Favored 'General case' 0 N--CA 1.455 -0.204 0 CA-C-N 114.902 -1.044 . . . . 0.0 110.439 179.379 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.458 ' ND2' ' HG3' ' A' ' 39' ' ' PRO . 2.3 m-80 -113.46 19.12 17.19 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.425 170.922 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.62 46.21 12.03 Favored Glycine 0 CA--C 1.525 0.656 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 170.28 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.704 HG23 ' HB ' ' A' ' 27' ' ' THR . 2.2 mp -116.45 137.03 51.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 115.322 -0.439 . . . . 0.0 110.257 172.283 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.431 ' OG ' ' HD2' ' A' ' 25' ' ' PRO . 0.5 OUTLIER -87.54 152.93 52.72 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.825 172.696 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.431 ' HD2' ' OG ' ' A' ' 24' ' ' SER . 2.7 Cg_endo -55.78 90.83 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.0 0 C-N-CA 122.51 2.14 . . . . 0.0 113.484 171.529 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 126.37 18.67 2.23 Favored Glycine 0 CA--C 1.526 0.743 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 169.846 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.704 ' HB ' HG23 ' A' ' 23' ' ' ILE . 94.1 m -72.18 152.98 41.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.414 -0.393 . . . . 0.0 110.466 169.149 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.461 ' HB3' ' CB ' ' A' ' 31' ' ' GLU . 7.2 ttpt -93.86 166.36 12.22 Favored 'General case' 0 C--O 1.233 0.231 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.326 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CD2' ' A' ' 3' ' ' TRP . 77.5 t80 -61.71 -65.32 0.71 Allowed 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.805 -1.089 . . . . 0.0 110.286 -175.88 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 -79.02 6.12 10.13 Favored 'General case' 0 N--CA 1.453 -0.304 0 CA-C-N 114.598 -1.183 . . . . 0.0 111.68 179.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 7.2 tp10 -101.73 20.94 15.32 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.947 -0.569 . . . . 0.0 110.423 163.882 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.573 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 70.8 mt -87.6 173.7 6.17 Favored Pre-proline 0 CA--C 1.544 0.714 0 CA-C-N 115.44 -0.8 . . . . 0.0 109.566 166.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.573 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 23.0 Cg_exo -49.07 153.56 4.01 Favored 'Trans proline' 0 N--CA 1.483 0.876 0 C-N-CA 122.753 2.302 . . . . 0.0 113.71 172.998 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -65.38 -34.59 78.67 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.127 -0.942 . . . . 0.0 109.948 168.659 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.797 ' O ' HG13 ' A' ' 37' ' ' VAL . 72.2 m-20 -111.05 25.79 11.39 Favored 'General case' 0 N--CA 1.455 -0.177 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.357 179.903 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.571 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 68.8 t90 -60.21 119.3 7.62 Favored 'General case' 0 N--CA 1.453 -0.28 0 CA-C-N 114.543 -1.208 . . . . 0.0 110.396 170.437 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.797 HG13 ' O ' ' A' ' 35' ' ' ASP . 31.1 m -128.99 158.89 41.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 115.03 -0.986 . . . . 0.0 110.308 -169.594 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.551 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.5 t -61.56 120.52 56.79 Favored Pre-proline 0 C--O 1.248 1.008 0 CA-C-N 115.041 -0.982 . . . . 0.0 109.685 176.336 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.458 ' HG3' ' ND2' ' A' ' 21' ' ' ASN . 17.3 Cg_exo -62.23 -10.48 18.5 Favored 'Trans proline' 0 N--CA 1.486 1.04 0 C-N-CA 122.259 1.973 . . . . 0.0 113.818 173.713 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.611 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.9 mp -99.65 -77.56 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.426 -0.806 . . . . 0.0 110.582 177.353 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.6 p -85.53 -26.25 26.32 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.857 -0.61 . . . . 0.0 110.584 -161.848 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 98.68 27.29 8.55 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.764 -1.107 . . . . 0.0 110.561 -178.698 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.551 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . -100.3 121.88 51.98 Favored Pre-proline 0 C--O 1.243 0.74 0 CA-C-N 114.835 -0.682 . . . . 0.0 109.536 -179.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.598 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 15.1 Cg_exo -50.25 -176.68 0.01 OUTLIER 'Trans proline' 0 N--CA 1.485 1.011 0 C-N-CA 122.569 2.179 . . . . 0.0 113.652 175.832 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.408 ' HG3' ' HE3' ' A' ' 36' ' ' TRP . 1.9 mtpt -60.31 -20.24 58.4 Favored 'General case' 0 N--CA 1.456 -0.146 0 CA-C-N 114.533 -1.212 . . . . 0.0 110.739 179.738 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.5 p -61.23 -24.2 66.19 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.333 -166.931 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.785 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -117.98 16.8 14.23 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.543 -0.753 . . . . 0.0 110.56 -166.473 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.8 m-85 -95.83 99.12 10.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.592 -0.731 . . . . 0.0 110.207 167.525 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.0 tt0 -63.85 178.93 0.56 Allowed 'General case' 0 C--O 1.23 0.066 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.205 174.442 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -116.11 137.67 51.92 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.411 -0.813 . . . . 0.0 110.484 169.081 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.44 HD12 ' HG2' ' A' ' 52' ' ' GLU . 0.4 OUTLIER -91.77 -104.54 0.11 Allowed 'General case' 0 C--O 1.239 0.529 0 CA-C-N 115.209 -0.905 . . . . 0.0 108.822 167.153 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.44 ' HG2' HD12 ' A' ' 51' ' ' LEU . 12.7 pt-20 -125.53 175.21 7.69 Favored 'General case' 0 C--N 1.325 -0.495 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.361 -172.174 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.493 ' HB3' ' HA ' ' A' ' 1' ' ' ALA . 1.4 p30 . . . . . 0 C--O 1.24 0.602 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.319 170.678 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.684 0 N-CA-C 109.689 -0.486 . . . . 0.0 109.689 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.578 ' HE2' HG21 ' A' ' 11' ' ' ILE . 0.0 OUTLIER -118.95 122.04 41.33 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 115.55 -0.75 . . . . 0.0 110.434 169.32 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.517 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.2 m95 -92.66 156.38 17.11 Favored 'General case' 0 C--N 1.332 -0.17 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.261 175.072 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.839 HG23 ' CD1' ' A' ' 11' ' ' ILE . 7.7 p -126.88 136.42 60.85 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 CA-C-N 115.368 -0.833 . . . . 0.0 110.055 175.398 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.5 t -73.78 104.97 4.87 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.232 -0.895 . . . . 0.0 109.631 159.839 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.83 -20.48 63.69 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.804 -1.089 . . . . 0.0 110.528 -179.16 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.743 HD13 ' HB3' ' A' ' 47' ' ' GLU . 1.8 mp -79.04 -55.43 9.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.245 -0.889 . . . . 0.0 110.19 -167.017 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.2 p -99.5 -43.41 6.54 Favored 'General case' 0 C--O 1.231 0.104 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.525 -171.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 111.8 32.64 2.41 Favored Glycine 0 CA--C 1.527 0.838 0 CA-C-N 114.735 -1.12 . . . . 0.0 110.538 -175.698 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.716 ' C ' HD13 ' A' ' 11' ' ' ILE . 60.5 t80 -95.2 160.06 14.72 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.344 -0.428 . . . . 0.0 110.124 166.965 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.839 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.77 139.11 52.81 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.235 0 CA-C-N 114.609 -1.178 . . . . 0.0 110.078 -179.329 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.557 ' CE2' HD11 ' A' ' 32' ' ' LEU . 20.5 t80 -102.46 111.56 23.92 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.002 163.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 52.4 t0 -94.68 112.23 23.98 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.364 167.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.49 ' HA ' ' CZ ' ' A' ' 12' ' ' TYR . 21.9 mt-10 -62.73 -28.07 69.71 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.243 -0.889 . . . . 0.0 110.447 -170.131 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 31.7 t70 -66.76 -29.58 69.58 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.403 177.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -92.05 -23.79 19.38 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.28 -0.873 . . . . 0.0 110.27 -170.203 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.77 -142.01 32.82 Favored Glycine 0 CA--C 1.525 0.691 0 N-CA-C 110.486 -1.045 . . . . 0.0 110.486 -176.397 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.6 t0 -175.35 54.87 0.13 Allowed Pre-proline 0 CA--C 1.542 0.655 0 CA-C-O 121.645 0.736 . . . . 0.0 109.784 -171.267 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -50.14 -20.14 5.05 Favored 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.48 2.12 . . . . 0.0 113.554 178.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.61 -34.04 74.95 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 114.953 -1.021 . . . . 0.0 110.449 -178.871 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.444 ' C ' HD12 ' A' ' 23' ' ' ILE . 9.5 m-80 -126.33 24.43 6.79 Favored 'General case' 0 C--N 1.331 -0.217 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.334 -174.555 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.744 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.64 49.87 4.95 Favored Glycine 0 CA--C 1.526 0.731 0 N-CA-C 110.427 -1.069 . . . . 0.0 110.427 170.029 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.744 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.6 mp -130.73 133.66 63.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.072 -0.564 . . . . 0.0 110.434 175.897 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -91.65 159.09 39.29 Favored Pre-proline 0 C--O 1.245 0.828 0 CA-C-N 115.292 -0.867 . . . . 0.0 109.738 176.407 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.0 Cg_exo -80.54 53.3 4.7 Favored 'Trans proline' 0 C--N 1.364 1.36 0 C-N-CA 122.618 2.212 . . . . 0.0 114.214 175.723 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -137.95 -8.55 1.21 Allowed Glycine 0 CA--C 1.522 0.493 0 CA-C-N 114.791 -1.095 . . . . 0.0 111.58 163.575 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.481 HG21 HD23 ' A' ' 32' ' ' LEU . 89.0 m -73.52 147.56 43.9 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-O 120.814 0.34 . . . . 0.0 110.444 -168.192 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.482 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.4 OUTLIER -97.29 167.52 10.97 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.447 171.781 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.528 ' CZ ' ' HB2' ' A' ' 48' ' ' PHE . 80.9 t80 -61.66 -64.79 0.83 Allowed 'General case' 0 C--N 1.334 -0.071 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.379 -175.679 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.99 6.75 8.58 Favored 'General case' 0 C--O 1.235 0.328 0 CA-C-N 114.712 -1.131 . . . . 0.0 111.624 -179.939 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.424 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.1 OUTLIER -105.84 22.63 15.27 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.446 163.532 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.557 HD11 ' CE2' ' A' ' 12' ' ' TYR . 20.6 mt -88.88 168.03 16.73 Favored Pre-proline 0 CA--C 1.546 0.826 0 CA-C-N 115.177 -0.92 . . . . 0.0 109.626 169.163 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.453 ' CG ' ' HB2' ' A' ' 36' ' ' TRP . 6.7 Cg_exo -55.84 149.9 48.56 Favored 'Trans proline' 0 N--CA 1.484 0.935 0 C-N-CA 122.693 2.262 . . . . 0.0 113.465 168.566 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -77.36 -28.84 53.11 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 115.116 -0.947 . . . . 0.0 109.915 166.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.657 ' O ' HG13 ' A' ' 37' ' ' VAL . 32.1 t70 -62.79 -25.19 68.11 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.061 -0.972 . . . . 0.0 110.389 167.436 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.453 ' HB2' ' CG ' ' A' ' 33' ' ' PRO . 64.1 t90 -61.61 110.82 1.6 Allowed 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.465 -0.789 . . . . 0.0 110.281 -167.355 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.657 HG13 ' O ' ' A' ' 35' ' ' ASP . 23.8 m -120.71 168.54 13.0 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 114.85 -1.068 . . . . 0.0 110.379 -177.38 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.6 t -63.08 122.16 73.52 Favored Pre-proline 0 C--O 1.25 1.107 0 CA-C-N 115.165 -0.925 . . . . 0.0 109.528 178.15 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.404 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 1.0 OUTLIER -61.57 -17.91 56.84 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.56 2.173 . . . . 0.0 113.719 172.673 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.578 HD13 ' CG ' ' A' ' 10' ' ' TYR . 4.1 mp -93.13 -80.62 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.129 0 CA-C-N 115.021 -0.99 . . . . 0.0 110.493 176.785 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -82.35 -24.12 34.71 Favored 'General case' 0 C--N 1.332 -0.175 0 CA-C-N 115.83 -0.623 . . . . 0.0 110.628 -160.996 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 112.73 -17.91 22.66 Favored Glycine 0 CA--C 1.524 0.635 0 CA-C-N 114.898 -1.047 . . . . 0.0 110.605 -177.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.533 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.63 116.38 20.29 Favored Pre-proline 0 C--O 1.245 0.835 0 CA-C-O 121.182 0.515 . . . . 0.0 109.63 -169.854 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.609 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.7 Cg_endo -45.04 168.99 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.978 2.452 . . . . 0.0 113.619 167.605 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.0 -10.97 6.66 Favored 'General case' 0 C--N 1.33 -0.241 0 CA-C-N 115.659 -0.701 . . . . 0.0 110.599 -167.484 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 23.0 t -61.94 -28.39 69.5 Favored 'General case' 0 C--N 1.332 -0.165 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.391 -177.88 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.743 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -97.77 15.96 22.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.516 -166.939 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.528 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.1 m-85 -108.17 97.58 7.25 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.313 176.438 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.432 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.8 mm-40 -85.94 146.6 26.62 Favored 'General case' 0 C--O 1.23 0.067 0 CA-C-N 114.457 -1.247 . . . . 0.0 110.35 177.506 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HG3' ' CZ3' ' A' ' 3' ' ' TRP . 5.0 mttm -75.29 144.91 42.24 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.374 -173.646 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.426 HD12 HG11 ' A' ' 4' ' ' VAL . 2.0 mt -155.01 85.6 1.09 Allowed 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.357 -0.838 . . . . 0.0 110.405 169.93 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -61.54 121.43 12.71 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.394 169.48 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 30.9 t70 . . . . . 0 C--O 1.239 0.55 0 CA-C-N 115.301 -0.863 . . . . 0.0 110.37 -169.974 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 021 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.701 0 CA-C-O 121.12 0.486 . . . . 0.0 109.77 . . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 2.7 mtmt -119.08 128.11 54.02 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.452 -0.795 . . . . 0.0 110.451 175.027 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.522 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 29.4 m95 -111.73 153.24 26.77 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.139 -0.937 . . . . 0.0 110.49 176.388 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.627 HG23 ' CD1' ' A' ' 11' ' ' ILE . 5.2 p -124.31 155.9 31.91 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.147 -0.933 . . . . 0.0 110.193 177.44 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -84.5 117.24 23.56 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.682 -0.69 . . . . 0.0 109.84 160.967 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.535 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 23.7 tptt -88.19 16.39 6.27 Favored 'General case' 0 N--CA 1.451 -0.381 0 CA-C-N 114.326 -1.306 . . . . 0.0 110.974 176.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.619 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -98.67 -80.14 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 CA-C-N 115.978 -0.555 . . . . 0.0 110.407 157.301 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.2 p -80.66 -34.4 34.88 Favored 'General case' 0 C--N 1.333 -0.146 0 CA-C-N 115.877 -0.601 . . . . 0.0 110.6 -161.589 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 103.43 19.23 12.66 Favored Glycine 0 CA--C 1.525 0.701 0 CA-C-N 114.803 -1.089 . . . . 0.0 110.554 -179.06 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.828 ' O ' HD13 ' A' ' 11' ' ' ILE . 75.7 t80 -73.12 163.21 28.48 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.06 0.457 . . . . 0.0 110.108 164.633 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.828 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.04 151.11 33.52 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 CA-C-N 115.087 -0.96 . . . . 0.0 110.097 -177.108 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.54 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.9 t80 -117.63 114.71 23.79 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.151 -0.931 . . . . 0.0 110.047 164.196 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.6 t0 -98.62 118.43 35.32 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 115.257 -0.883 . . . . 0.0 110.389 169.25 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 22.3 mt-10 -69.33 -23.47 63.78 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.386 -0.825 . . . . 0.0 110.417 -170.957 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -69.47 -34.55 74.53 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.339 171.947 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -93.38 -22.34 18.99 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 115.361 -0.836 . . . . 0.0 110.26 -169.112 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.5 -151.9 36.84 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.458 -1.057 . . . . 0.0 110.458 170.92 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.542 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 22.4 t0 -155.93 51.69 0.59 Allowed Pre-proline 0 CA--C 1.542 0.649 0 CA-C-O 121.648 0.737 . . . . 0.0 109.856 175.25 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.542 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 14.8 Cg_exo -51.29 -16.83 3.41 Favored 'Trans proline' 0 N--CA 1.484 0.913 0 C-N-CA 122.424 2.083 . . . . 0.0 113.668 -177.15 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 13.7 t70 -71.38 -41.6 69.46 Favored 'General case' 0 N--CA 1.454 -0.239 0 CA-C-N 114.854 -1.066 . . . . 0.0 110.406 178.783 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -104.79 19.55 20.29 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.278 -0.874 . . . . 0.0 110.371 172.434 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.785 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 76.76 55.98 4.32 Favored Glycine 0 CA--C 1.525 0.71 0 N-CA-C 110.476 -1.05 . . . . 0.0 110.476 168.698 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.785 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -122.56 136.79 58.22 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.337 -0.431 . . . . 0.0 110.38 169.15 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 m -80.6 141.49 52.33 Favored Pre-proline 0 CA--C 1.542 0.672 0 CA-C-N 115.262 -0.881 . . . . 0.0 109.778 -178.651 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.6 Cg_endo -57.83 88.83 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.494 2.129 . . . . 0.0 113.603 172.949 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.63 18.86 1.09 Allowed Glycine 0 CA--C 1.526 0.753 0 N-CA-C 110.463 -1.055 . . . . 0.0 110.463 177.637 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 92.5 m -82.12 144.82 30.5 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.421 -0.389 . . . . 0.0 110.418 168.448 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.578 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.1 mtmm -87.79 167.93 13.39 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 115.081 -0.963 . . . . 0.0 110.552 179.443 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.522 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 80.7 t80 -61.83 -65.08 0.75 Allowed 'General case' 0 C--O 1.232 0.15 0 CA-C-N 115.1 -0.954 . . . . 0.0 110.318 -173.929 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 20.6 mt-10 -78.89 6.64 8.69 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.576 -1.193 . . . . 0.0 111.754 178.854 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.578 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.2 mm-40 -104.4 20.66 18.07 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.873 -0.603 . . . . 0.0 110.494 165.268 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 27.1 mt -87.29 167.18 22.2 Favored Pre-proline 0 CA--C 1.543 0.689 0 CA-C-N 115.288 -0.869 . . . . 0.0 109.671 168.151 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.4 Cg_endo -46.79 151.89 1.91 Allowed 'Trans proline' 0 N--CA 1.484 0.957 0 C-N-CA 122.773 2.315 . . . . 0.0 113.612 171.333 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -61.51 -48.41 81.16 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.487 -0.779 . . . . 0.0 110.472 -168.682 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -103.85 30.15 5.32 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.2 -0.909 . . . . 0.0 110.436 -173.669 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.481 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.9 t90 -61.7 118.79 7.57 Favored 'General case' 0 N--CA 1.455 -0.216 0 CA-C-N 114.99 -1.004 . . . . 0.0 110.431 -178.588 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.56 HG12 ' HA ' ' A' ' 44' ' ' PRO . 16.2 m -113.29 174.33 2.55 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.219 0 CA-C-N 114.952 -1.022 . . . . 0.0 110.391 -179.496 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.6 t -64.39 124.99 87.49 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.899 -1.046 . . . . 0.0 109.432 177.836 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -54.58 -23.96 34.53 Favored 'Trans proline' 0 N--CA 1.484 0.949 0 C-N-CA 122.847 2.365 . . . . 0.0 113.658 169.745 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.653 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.41 -81.94 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.248 0 CA-C-N 114.908 -1.042 . . . . 0.0 110.385 -179.2 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.5 p -79.17 -20.64 47.95 Favored 'General case' 0 N--CA 1.455 -0.193 0 CA-C-N 115.652 -0.703 . . . . 0.0 110.999 -163.342 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 78.89 33.91 35.7 Favored Glycine 0 CA--C 1.526 0.77 0 N-CA-C 110.47 -1.052 . . . . 0.0 110.47 -175.49 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.5 ' HB1' ' HG3' ' A' ' 47' ' ' GLU . . . -90.57 137.01 27.48 Favored Pre-proline 0 C--O 1.242 0.696 0 CA-C-O 121.189 0.519 . . . . 0.0 109.657 170.637 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.56 ' HA ' HG12 ' A' ' 37' ' ' VAL . 2.7 Cg_exo -53.95 157.14 11.09 Favored 'Trans proline' 0 N--CA 1.486 1.043 0 C-N-CA 122.441 2.094 . . . . 0.0 113.482 176.696 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.21 -9.16 4.41 Favored 'General case' 0 C--N 1.331 -0.207 0 CA-C-N 114.717 -1.129 . . . . 0.0 110.461 177.37 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 40.9 t -92.71 18.75 8.34 Favored 'General case' 0 N--CA 1.455 -0.197 0 CA-C-N 114.768 -1.106 . . . . 0.0 110.545 178.514 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.619 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -132.26 18.55 4.45 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.25 165.073 . . . . . . . . 3 3 . 1 . 021 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -98.17 110.55 23.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.323 171.436 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.535 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.3 mt-10 -88.37 167.82 13.19 Favored 'General case' 0 N--CA 1.457 -0.075 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.302 179.823 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.481 ' HD2' ' CZ2' ' A' ' 3' ' ' TRP . 7.6 mtpp -101.05 145.03 29.26 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.42 -176.142 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.633 HD23 ' O ' ' A' ' 51' ' ' LEU . 9.4 tt -110.03 4.63 21.5 Favored 'General case' 0 N--CA 1.45 -0.433 0 CA-C-N 115.15 -0.932 . . . . 0.0 111.885 177.356 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -128.67 112.44 14.24 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 115.677 -0.692 . . . . 0.0 110.334 -178.161 . . . . . . . . 2 2 . 1 . 021 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.349 169.553 . . . . . . . . 1 1 . 1 . 021 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.847 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.743 0 CA-C-O 121.08 0.467 . . . . 0.0 109.747 . . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.466 ' H ' ' HG2' ' A' ' 2' ' ' LYS . 0.1 OUTLIER -119.36 129.55 54.89 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.415 171.134 . . . . . . . . 3 3 . 1 . 022 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.596 ' O ' HG23 ' A' ' 11' ' ' ILE . 25.4 m95 -109.73 161.72 15.14 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.402 173.144 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.706 HG11 HD13 ' A' ' 51' ' ' LEU . 5.4 p -130.89 152.11 37.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.135 -0.939 . . . . 0.0 110.409 -176.626 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.569 ' SG ' HD12 ' A' ' 7' ' ' ILE . 17.2 t -86.21 115.16 23.59 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.019 166.647 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 2.5 tptt -61.5 -23.75 66.12 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 114.589 -1.187 . . . . 0.0 110.485 176.589 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.918 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.2 mt -83.78 -68.06 0.61 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.224 0 CA-C-N 114.991 -1.004 . . . . 0.0 110.718 -168.985 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.6 p -90.53 -29.15 18.06 Favored 'General case' 0 C--N 1.334 -0.093 0 CA-C-N 115.641 -0.709 . . . . 0.0 110.542 -169.141 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 98.95 19.6 21.3 Favored Glycine 0 CA--C 1.526 0.736 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.487 -177.87 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.593 ' CG ' HD13 ' A' ' 40' ' ' ILE . 68.2 t80 -75.69 170.06 16.9 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-O 121.103 0.478 . . . . 0.0 110.328 167.566 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.596 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.7 mp -142.32 139.42 29.54 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.254 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.448 -177.761 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.475 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 18.5 t80 -97.98 127.01 43.66 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.297 167.603 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 59.0 t0 -110.74 112.1 23.74 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.331 -0.85 . . . . 0.0 110.341 168.855 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.847 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 21.2 mt-10 -61.27 -30.93 70.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.436 -169.034 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.0 t70 -78.29 -21.15 50.17 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.352 179.024 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -86.96 -36.27 18.4 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.278 -169.839 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.12 -177.52 50.72 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.025 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.633 ' OD2' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -161.07 48.62 0.25 Allowed Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.458 0.647 . . . . 0.0 109.762 -172.327 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.448 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.3 Cg_endo -58.23 -20.43 47.03 Favored 'Trans proline' 0 N--CA 1.484 0.931 0 C-N-CA 122.546 2.164 . . . . 0.0 113.611 -176.788 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.29 -32.33 72.17 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.902 -1.045 . . . . 0.0 110.448 178.186 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 65.4 m-80 -120.11 19.18 12.3 Favored 'General case' 0 C--N 1.331 -0.211 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.35 -174.973 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.423 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 90.13 43.4 5.02 Favored Glycine 0 CA--C 1.526 0.73 0 N-CA-C 110.416 -1.074 . . . . 0.0 110.416 168.825 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.633 HD13 ' OD2' ' A' ' 18' ' ' ASP . 5.0 mp -131.7 129.38 61.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.449 179.644 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -87.19 139.43 32.27 Favored Pre-proline 0 CA--C 1.542 0.666 0 CA-C-N 115.167 -0.924 . . . . 0.0 109.77 -178.958 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_exo -54.02 89.87 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.521 2.147 . . . . 0.0 113.514 171.985 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.06 19.38 1.0 Allowed Glycine 0 CA--C 1.526 0.779 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.49 179.735 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 98.8 m -84.33 141.74 30.69 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 115.389 -0.405 . . . . 0.0 110.389 167.795 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.617 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.7 mttm -86.32 171.1 11.46 Favored 'General case' 0 C--O 1.234 0.268 0 CA-C-N 115.125 -0.943 . . . . 0.0 110.44 179.4 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.528 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 75.6 t80 -61.78 -64.78 0.83 Allowed 'General case' 0 C--O 1.233 0.206 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.285 -176.196 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.4 mt-10 -87.94 15.73 6.84 Favored 'General case' 0 C--O 1.233 0.228 0 CA-C-N 114.371 -1.286 . . . . 0.0 111.175 178.594 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 2.1 tp10 -111.68 20.4 17.14 Favored 'General case' 0 C--N 1.327 -0.379 0 CA-C-N 115.706 -0.679 . . . . 0.0 110.366 163.023 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.617 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 25.1 mt -79.75 168.06 29.1 Favored Pre-proline 0 CA--C 1.544 0.729 0 CA-C-N 115.362 -0.836 . . . . 0.0 109.636 169.668 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 2.6 Cg_endo -46.51 157.23 0.49 Allowed 'Trans proline' 0 N--CA 1.486 1.052 0 C-N-CA 122.575 2.183 . . . . 0.0 113.576 169.216 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -61.71 -46.0 91.57 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.417 -0.811 . . . . 0.0 110.457 -169.463 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.606 ' O ' HG13 ' A' ' 37' ' ' VAL . 3.8 m-20 -112.2 33.82 4.64 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.38 -176.234 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.427 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 77.8 t90 -60.91 117.28 5.25 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 114.925 -1.034 . . . . 0.0 110.425 174.122 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.722 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.1 m -116.67 -176.15 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.236 0 CA-C-N 114.919 -1.037 . . . . 0.0 110.442 -179.45 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 14.5 t -67.29 124.85 90.04 Favored Pre-proline 0 C--O 1.252 1.193 0 CA-C-N 115.111 -0.949 . . . . 0.0 109.461 179.755 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.417 ' C ' HD12 ' A' ' 40' ' ' ILE . 2.5 Cg_endo -56.9 -16.99 22.16 Favored 'Trans proline' 0 N--CA 1.485 1.005 0 C-N-CA 122.793 2.328 . . . . 0.0 113.669 170.386 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -102.88 -80.39 0.31 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.332 0 CA-C-N 115.349 -0.841 . . . . 0.0 110.575 179.815 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.49 -16.31 54.63 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.621 -0.718 . . . . 0.0 111.278 -163.682 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 99.43 -14.24 60.95 Favored Glycine 0 CA--C 1.524 0.603 0 N-CA-C 110.782 -0.927 . . . . 0.0 110.782 179.826 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.781 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -61.72 118.21 35.91 Favored Pre-proline 0 C--O 1.243 0.759 0 CA-C-O 121.336 0.588 . . . . 0.0 109.621 -173.345 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.722 ' HA ' HG12 ' A' ' 37' ' ' VAL . 18.7 Cg_exo -48.23 160.15 0.59 Allowed 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.81 2.34 . . . . 0.0 113.686 171.618 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.79 -12.09 9.67 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.587 -0.733 . . . . 0.0 110.617 -166.404 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 24.8 t -61.62 -35.92 79.27 Favored 'General case' 0 C--N 1.332 -0.161 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.42 -173.971 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.918 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.3 mm-40 -96.13 24.44 5.63 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 115.101 -0.954 . . . . 0.0 110.408 -177.487 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -100.25 115.29 29.55 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.254 -0.884 . . . . 0.0 110.442 170.284 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -81.17 -178.26 6.83 Favored 'General case' 0 C--N 1.335 -0.06 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.269 174.779 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.642 ' O ' HD12 ' A' ' 51' ' ' LEU . 4.7 pttm -133.64 128.5 35.22 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.371 -170.938 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.706 HD13 HG11 ' A' ' 4' ' ' VAL . 3.4 mp -137.78 64.0 1.53 Allowed 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.974 -1.012 . . . . 0.0 110.375 -178.296 . . . . . . . . 2 2 . 1 . 022 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 43.0 tt0 -79.28 105.5 10.65 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.428 169.714 . . . . . . . . 1 1 . 1 . 022 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.2 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.028 -0.987 . . . . 0.0 110.359 179.662 . . . . . . . . 0 0 . 1 . 022 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.833 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.785 0 CA-C-O 121.146 0.498 . . . . 0.0 109.693 . . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -115.38 125.95 53.81 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.537 -0.756 . . . . 0.0 110.391 170.339 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.525 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 19.5 m95 -101.25 156.29 17.52 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.426 171.15 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.589 HG13 ' HG3' ' A' ' 49' ' ' GLU . 7.3 p -123.09 156.03 28.86 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.214 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.105 175.058 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.2 t -82.43 113.92 20.51 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.701 -0.681 . . . . 0.0 110.179 164.941 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.448 ' CG ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -61.45 -24.2 66.38 Favored 'General case' 0 N--CA 1.454 -0.273 0 CA-C-N 114.493 -1.23 . . . . 0.0 110.47 177.721 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.655 ' N ' HD12 ' A' ' 7' ' ' ILE . 1.9 mp -82.4 -72.21 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 114.994 -1.003 . . . . 0.0 110.732 -172.765 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -86.76 -30.55 21.5 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.572 -166.389 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 100.91 19.61 16.72 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.777 -1.102 . . . . 0.0 110.527 -177.945 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.616 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.7 t80 -74.7 169.94 16.83 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-O 121.014 0.435 . . . . 0.0 110.366 167.089 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 3.9 mp -140.77 147.88 22.4 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.346 -176.285 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.3 t80 -112.13 124.51 52.6 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.367 -0.833 . . . . 0.0 110.283 165.978 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . 0.402 ' HB3' ' HB3' ' A' ' 16' ' ' ALA . 56.3 t0 -107.1 114.25 28.2 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.379 170.463 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.833 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 17.5 mt-10 -67.31 -30.3 70.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.373 -0.831 . . . . 0.0 110.438 -170.064 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -68.15 -25.08 65.09 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.25 -0.886 . . . . 0.0 110.33 175.149 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . 0.402 ' HB3' ' HB3' ' A' ' 13' ' ' ASP . . . -105.37 -17.73 14.35 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.279 -170.154 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 67.62 -170.36 35.88 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 171.043 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.528 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.0 t0 -137.52 48.14 2.04 Favored Pre-proline 0 CA--C 1.543 0.687 0 CA-C-O 121.468 0.652 . . . . 0.0 109.747 -179.149 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.6 Cg_endo -49.59 -19.6 3.47 Favored 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.413 2.075 . . . . 0.0 113.56 -178.218 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.29 -29.96 70.19 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 114.823 -1.08 . . . . 0.0 110.483 178.299 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 12.2 m-80 -131.97 28.22 4.51 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.36 -174.6 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.783 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.29 45.44 6.55 Favored Glycine 0 CA--C 1.527 0.841 0 N-CA-C 110.328 -1.109 . . . . 0.0 110.328 168.461 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.783 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.6 mp -124.92 125.68 70.06 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 115.089 -0.556 . . . . 0.0 110.394 172.783 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 30.8 t -80.46 140.71 52.19 Favored Pre-proline 0 CA--C 1.542 0.648 0 CA-C-N 114.971 -1.013 . . . . 0.0 109.835 176.595 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_endo -58.52 73.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.045 0 C-N-CA 122.452 2.101 . . . . 0.0 113.495 171.632 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.3 -34.59 0.09 OUTLIER Glycine 0 CA--C 1.526 0.723 0 N-CA-C 109.856 -1.298 . . . . 0.0 109.856 -162.562 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.452 HG21 HD23 ' A' ' 32' ' ' LEU . 23.5 m -60.84 141.93 56.64 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 114.83 -0.685 . . . . 0.0 110.577 -178.633 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.527 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.5 tttp -87.8 170.75 10.93 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.438 -0.801 . . . . 0.0 110.478 171.706 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.525 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.58 -65.93 0.61 Allowed 'General case' 0 C--O 1.233 0.219 0 CA-C-N 114.859 -1.064 . . . . 0.0 110.285 -176.667 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 23.8 mt-10 -79.13 7.02 8.21 Favored 'General case' 0 N--CA 1.453 -0.317 0 CA-C-N 114.529 -1.214 . . . . 0.0 111.668 176.681 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.404 ' O ' HG23 ' A' ' 27' ' ' THR . 4.1 tp10 -107.74 20.27 19.03 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.794 -0.639 . . . . 0.0 110.479 166.133 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.558 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 34.3 mt -81.25 166.97 35.15 Favored Pre-proline 0 CA--C 1.543 0.679 0 CA-C-N 115.365 -0.834 . . . . 0.0 109.67 168.246 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.558 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 5.6 Cg_endo -48.16 153.61 2.8 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 122.47 2.114 . . . . 0.0 113.65 169.829 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.48 -50.33 73.19 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.547 -0.751 . . . . 0.0 110.431 -167.648 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.576 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -104.3 39.02 1.73 Allowed 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 115.173 -0.921 . . . . 0.0 110.386 -178.51 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.475 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 79.5 t90 -66.13 116.4 7.18 Favored 'General case' 0 N--CA 1.455 -0.222 0 CA-C-N 114.657 -1.156 . . . . 0.0 110.489 175.268 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.583 ' HA ' ' HA ' ' A' ' 44' ' ' PRO . 18.8 m -117.78 174.21 4.13 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 CA-C-N 114.943 -1.026 . . . . 0.0 110.435 -177.84 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.449 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -62.05 124.01 80.23 Favored Pre-proline 0 C--O 1.251 1.138 0 CA-C-N 115.008 -0.996 . . . . 0.0 109.444 178.143 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.445 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 4.6 Cg_exo -51.58 -25.78 20.64 Favored 'Trans proline' 0 N--CA 1.484 0.96 0 C-N-CA 123.026 2.484 . . . . 0.0 113.651 168.792 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.657 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.3 mp -96.6 -80.83 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.448 -177.834 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -80.3 -21.04 43.04 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 115.65 -0.705 . . . . 0.0 110.974 -163.513 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.449 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.31 23.51 40.16 Favored Glycine 0 CA--C 1.527 0.792 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 -178.604 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.463 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -84.28 111.6 35.05 Favored Pre-proline 0 C--O 1.242 0.674 0 CA-C-O 121.404 0.621 . . . . 0.0 109.66 173.165 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.583 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 5.9 Cg_exo -44.86 161.7 0.09 OUTLIER 'Trans proline' 0 N--CA 1.485 1.027 0 C-N-CA 123.006 2.47 . . . . 0.0 113.598 169.034 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.546 ' HD2' ' N ' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -60.72 -16.83 43.82 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.694 -0.684 . . . . 0.0 110.67 -164.745 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 32.4 t -61.46 -19.52 62.11 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.439 -0.801 . . . . 0.0 110.429 -172.106 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.531 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.7 OUTLIER -115.19 19.42 15.65 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.363 -173.496 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.0 m-85 -97.24 106.04 18.29 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.27 -0.877 . . . . 0.0 110.277 169.205 . . . . . . . . 1 1 . 1 . 023 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.589 ' HG3' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -85.25 137.15 33.17 Favored 'General case' 0 N--CA 1.457 -0.1 0 CA-C-N 114.365 -1.288 . . . . 0.0 110.311 -179.088 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.501 ' HB3' ' CE3' ' A' ' 3' ' ' TRP . 0.4 OUTLIER -91.84 142.76 27.22 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.356 -167.561 . . . . . . . . 3 3 . 1 . 023 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.405 HD13 ' HA ' ' A' ' 51' ' ' LEU . 3.3 mm? 60.03 86.57 0.09 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.294 -0.866 . . . . 0.0 110.552 168.682 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -107.05 116.67 32.33 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.376 169.066 . . . . . . . . 2 2 . 1 . 023 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 38.6 t70 . . . . . 0 C--O 1.24 0.594 0 CA-C-N 115.316 -0.856 . . . . 0.0 110.32 -169.992 . . . . . . . . 0 0 . 1 . 023 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.525 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.693 0 N-CA-C 109.782 -0.451 . . . . 0.0 109.782 . . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.433 ' HD3' HG21 ' A' ' 11' ' ' ILE . 0.7 OUTLIER -114.02 130.35 56.55 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.58 -0.736 . . . . 0.0 110.313 171.57 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 17.8 m95 -108.66 155.68 20.43 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.35 -0.841 . . . . 0.0 110.326 169.993 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 11.0 p -124.44 149.87 28.93 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.184 0 CA-C-N 114.967 -1.015 . . . . 0.0 109.981 175.06 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.619 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.7 t -83.5 112.62 20.14 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.554 -0.748 . . . . 0.0 109.879 163.861 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.6 ttpp -64.52 -23.29 67.22 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.73 -1.123 . . . . 0.0 110.844 177.924 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.968 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.3 mt -74.65 -70.52 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.68 -1.146 . . . . 0.0 110.496 -173.447 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.4 p -89.46 -29.84 18.72 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.466 -166.736 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.34 23.87 9.29 Favored Glycine 0 CA--C 1.527 0.806 0 N-CA-C 110.487 -1.045 . . . . 0.0 110.487 -176.363 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.54 ' CG ' HD13 ' A' ' 40' ' ' ILE . 59.0 t80 -81.01 169.51 17.4 Favored 'General case' 0 C--N 1.327 -0.371 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.31 169.569 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.523 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.4 mp -135.2 145.77 31.41 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.23 0 CA-C-N 114.801 -1.09 . . . . 0.0 110.361 176.588 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.624 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.0 t80 -108.86 129.66 55.41 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.307 166.65 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.8 t0 -114.03 112.51 23.38 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 115.34 -0.846 . . . . 0.0 110.414 169.877 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.525 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 23.4 mt-10 -66.77 -31.02 71.39 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.434 -171.788 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.6 t0 -69.82 -26.38 64.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.386 177.752 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -98.1 -28.63 13.66 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 115.252 -0.885 . . . . 0.0 110.274 -172.173 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 95.14 -170.26 28.71 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.389 -1.084 . . . . 0.0 110.389 169.096 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.507 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.2 t0 -141.94 54.98 4.32 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-O 121.341 0.591 . . . . 0.0 109.725 171.668 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.507 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 13.3 Cg_exo -54.62 -17.82 13.99 Favored 'Trans proline' 0 N--CA 1.484 0.959 0 C-N-CA 122.46 2.107 . . . . 0.0 113.584 -172.351 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -74.95 -17.08 60.61 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.975 -1.011 . . . . 0.0 110.375 178.711 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -127.06 19.17 7.07 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.465 172.166 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.67 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 75.66 47.62 11.79 Favored Glycine 0 CA--C 1.524 0.633 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 168.724 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.67 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.3 mp -116.89 125.47 73.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 115.387 -0.407 . . . . 0.0 110.276 170.595 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 4.8 t -81.98 141.8 47.57 Favored Pre-proline 0 CA--C 1.543 0.705 0 CA-C-N 115.278 -0.874 . . . . 0.0 109.769 -172.876 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.75 89.25 0.03 OUTLIER 'Trans proline' 0 N--CA 1.485 0.975 0 C-N-CA 122.493 2.128 . . . . 0.0 113.527 173.834 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.64 18.86 0.97 Allowed Glycine 0 CA--C 1.526 0.727 0 CA-C-N 114.909 -1.041 . . . . 0.0 110.506 178.113 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.629 HG21 HD23 ' A' ' 32' ' ' LEU . 99.3 m -77.47 163.6 26.19 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-O 120.981 0.42 . . . . 0.0 110.369 167.311 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.656 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 16.6 mmtp -108.76 162.42 14.2 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.447 174.693 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.4 t80 -61.9 -65.44 0.69 Allowed 'General case' 0 C--O 1.231 0.1 0 CA-C-N 114.934 -1.03 . . . . 0.0 110.358 -174.54 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -78.96 6.57 8.98 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-N 114.512 -1.222 . . . . 0.0 111.742 177.826 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.453 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -108.76 20.03 18.98 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 115.839 -0.619 . . . . 0.0 110.392 165.01 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.656 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 30.4 mt -83.1 167.18 30.96 Favored Pre-proline 0 CA--C 1.542 0.657 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.627 168.0 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.553 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.8 Cg_endo -46.89 151.12 2.31 Favored 'Trans proline' 0 N--CA 1.485 0.995 0 C-N-CA 122.704 2.269 . . . . 0.0 113.618 171.01 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 16.2 m-20 -61.56 -46.05 91.54 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.498 -0.773 . . . . 0.0 110.429 -169.04 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.834 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.4 OUTLIER -103.04 24.79 10.25 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.383 -172.346 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.474 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 81.2 t90 -62.05 132.66 53.63 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.206 -0.906 . . . . 0.0 110.406 -175.611 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.928 HG12 ' HA ' ' A' ' 44' ' ' PRO . 23.4 m -140.4 175.17 6.82 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 115.387 -0.824 . . . . 0.0 110.38 -171.007 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.506 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 15.5 t -71.04 124.51 91.14 Favored Pre-proline 0 C--O 1.249 1.054 0 CA-C-N 115.369 -0.832 . . . . 0.0 109.363 -169.538 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.6 Cg_exo -55.18 -21.78 29.54 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.637 2.225 . . . . 0.0 113.834 169.718 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.67 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.5 mp -96.55 -81.34 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.245 0 CA-C-N 115.187 -0.915 . . . . 0.0 110.486 178.419 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.9 p -81.57 -21.1 38.64 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.905 -161.724 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.506 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 87.38 38.2 7.83 Favored Glycine 0 CA--C 1.525 0.695 0 N-CA-C 110.471 -1.051 . . . . 0.0 110.471 177.791 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.513 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -102.44 140.31 21.0 Favored Pre-proline 0 C--O 1.245 0.825 0 CA-C-N 115.0 -0.6 . . . . 0.0 109.56 179.865 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.928 ' HA ' HG12 ' A' ' 37' ' ' VAL . 7.5 Cg_exo -50.47 158.06 2.92 Favored 'Trans proline' 0 N--CA 1.486 1.06 0 C-N-CA 122.559 2.173 . . . . 0.0 113.352 169.063 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.47 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.24 -11.12 8.29 Favored 'General case' 0 C--O 1.232 0.15 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.643 -176.816 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 37.3 p -61.74 -40.94 96.86 Favored 'General case' 0 C--N 1.333 -0.15 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.516 -175.009 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.968 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.7 tp10 -93.1 17.93 10.12 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.597 -175.097 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -94.19 99.65 11.87 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.166 165.405 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' H ' ' A' ' 50' ' ' LYS . 1.6 tp10 -73.72 176.17 6.52 Favored 'General case' 0 C--N 1.338 0.081 0 CA-C-N 114.525 -1.216 . . . . 0.0 110.177 176.659 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.52 ' H ' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -107.07 139.77 40.96 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 115.036 -0.983 . . . . 0.0 110.533 179.191 . . . . . . . . 3 3 . 1 . 024 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 31.4 tp -99.98 16.75 22.91 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.432 -0.804 . . . . 0.0 110.523 173.602 . . . . . . . . 1 1 . 1 . 024 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER 58.21 -83.61 0.02 OUTLIER 'General case' 0 N--CA 1.451 -0.377 0 CA-C-N 115.584 -0.734 . . . . 0.0 111.032 -168.747 . . . . . . . . 2 2 . 1 . 024 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 7.3 m-20 . . . . . 0 C--O 1.24 0.554 0 CA-C-N 115.614 -0.721 . . . . 0.0 110.33 169.664 . . . . . . . . 0 0 . 1 . 024 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.561 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.71 0 CA-C-O 121.089 0.471 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 3.2 mtmp? -113.95 135.29 54.15 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.61 -0.723 . . . . 0.0 110.294 171.197 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.481 ' CE2' ' CG ' ' A' ' 29' ' ' PHE . 17.4 m95 -116.45 152.11 34.68 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 115.392 -0.822 . . . . 0.0 110.353 166.698 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.3 p -118.68 152.8 20.89 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.27 -0.877 . . . . 0.0 109.761 171.388 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.9 t -77.83 114.49 16.74 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.85 -0.614 . . . . 0.0 109.793 161.328 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.518 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 0.9 OUTLIER -88.84 17.34 5.73 Favored 'General case' 0 N--CA 1.453 -0.312 0 CA-C-N 114.573 -1.194 . . . . 0.0 110.812 177.6 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.794 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.5 mp -95.94 -77.75 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.234 0 CA-C-N 115.776 -0.647 . . . . 0.0 110.501 158.474 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.4 p -82.42 -36.9 26.22 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.919 -0.582 . . . . 0.0 110.43 -163.309 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 106.06 26.82 5.88 Favored Glycine 0 CA--C 1.526 0.758 0 CA-C-N 114.649 -1.16 . . . . 0.0 110.523 -176.991 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.696 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.7 t80 -78.18 170.08 17.21 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 120.881 0.372 . . . . 0.0 110.115 164.342 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.532 HG13 HG23 ' A' ' 4' ' ' VAL . 3.9 mp -139.09 141.81 35.32 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.205 0 CA-C-N 115.015 -0.993 . . . . 0.0 110.447 178.61 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.454 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 14.6 t80 -104.08 135.73 45.03 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.429 -0.805 . . . . 0.0 110.233 165.955 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -119.88 113.11 20.09 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.366 169.599 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.561 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.9 mt-10 -66.38 -18.02 65.11 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.365 -0.834 . . . . 0.0 110.433 -169.935 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 33.4 t0 -81.38 -20.95 39.42 Favored 'General case' 0 N--CA 1.454 -0.236 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.473 177.82 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -111.71 -18.89 12.65 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.242 -170.381 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 75.35 -162.73 53.6 Favored Glycine 0 CA--C 1.525 0.693 0 N-CA-C 110.496 -1.042 . . . . 0.0 110.496 169.916 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.502 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -142.98 59.4 7.91 Favored Pre-proline 0 CA--C 1.544 0.739 0 CA-C-O 121.395 0.617 . . . . 0.0 109.777 -176.033 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -53.81 -29.41 52.49 Favored 'Trans proline' 0 N--CA 1.485 1.026 0 C-N-CA 122.491 2.128 . . . . 0.0 113.575 -171.458 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 8.3 m-20 -61.7 -19.84 62.81 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.073 -0.967 . . . . 0.0 110.417 -177.393 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.472 HD21 ' HB3' ' A' ' 39' ' ' PRO . 10.7 m-80 -133.84 19.61 3.83 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.394 -174.079 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 77.63 47.65 8.61 Favored Glycine 0 CA--C 1.526 0.734 0 N-CA-C 110.474 -1.051 . . . . 0.0 110.474 169.169 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.527 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.9 mp -113.89 123.97 70.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.307 -0.447 . . . . 0.0 110.434 170.028 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 68.5 m -69.61 138.22 88.44 Favored Pre-proline 0 CA--C 1.542 0.66 0 CA-C-N 115.18 -0.918 . . . . 0.0 109.816 178.052 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -56.1 88.46 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.082 0 C-N-CA 122.419 2.079 . . . . 0.0 113.46 171.973 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.92 19.06 1.04 Allowed Glycine 0 CA--C 1.526 0.769 0 N-CA-C 110.424 -1.07 . . . . 0.0 110.424 175.931 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 95.6 m -78.71 137.31 37.73 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.364 -0.418 . . . . 0.0 110.324 168.791 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.607 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 1.4 mtmm -82.33 160.26 22.9 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.525 -178.161 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.481 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.7 t80 -61.98 -65.52 0.68 Allowed 'General case' 0 C--O 1.232 0.174 0 CA-C-N 115.012 -0.994 . . . . 0.0 110.223 -173.585 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 4.6 tt0 -79.05 6.97 8.16 Favored 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.675 -1.148 . . . . 0.0 111.684 179.118 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.575 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 2.8 mm-40 -110.62 20.89 17.19 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 115.801 -0.636 . . . . 0.0 110.374 165.883 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.607 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -81.52 166.42 38.15 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.35 -0.841 . . . . 0.0 109.718 168.599 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.418 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 11.8 Cg_exo -49.98 154.58 5.11 Favored 'Trans proline' 0 N--CA 1.486 1.051 0 C-N-CA 122.578 2.186 . . . . 0.0 113.575 171.065 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 7.8 m-20 -61.95 -46.39 89.51 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.368 -171.815 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.798 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 m-20 -103.7 23.84 12.11 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.334 -171.445 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 79.7 t90 -64.39 122.85 17.7 Favored 'General case' 0 N--CA 1.455 -0.22 0 CA-C-N 115.011 -0.995 . . . . 0.0 110.369 179.218 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.798 HG13 ' O ' ' A' ' 35' ' ' ASP . 18.1 m -129.27 -177.42 1.98 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 115.175 -0.92 . . . . 0.0 110.475 -173.205 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.404 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.7 t -69.64 122.08 84.59 Favored Pre-proline 0 C--O 1.252 1.225 0 CA-C-N 115.037 -0.983 . . . . 0.0 109.483 178.987 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.472 ' HB3' HD21 ' A' ' 21' ' ' ASN . 3.9 Cg_exo -55.19 -23.11 35.07 Favored 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.725 2.284 . . . . 0.0 113.597 170.52 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.696 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -94.42 -82.78 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.235 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.345 178.967 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.9 p -79.45 -21.77 45.03 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.865 -160.4 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 83.41 30.5 30.23 Favored Glycine 0 CA--C 1.526 0.74 0 N-CA-C 110.49 -1.044 . . . . 0.0 110.49 -175.116 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.412 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -90.83 110.75 43.91 Favored Pre-proline 0 CA--C 1.543 0.693 0 CA-C-O 121.531 0.682 . . . . 0.0 109.6 168.264 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.0 Cg_exo -48.93 166.7 0.15 Allowed 'Trans proline' 0 N--CA 1.485 0.998 0 C-N-CA 122.762 2.308 . . . . 0.0 113.626 173.741 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.87 -12.34 10.7 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.569 -0.741 . . . . 0.0 110.539 -166.287 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 22.8 t -61.68 -34.33 75.56 Favored 'General case' 0 C--N 1.331 -0.196 0 CA-C-N 115.338 -0.846 . . . . 0.0 110.421 -174.275 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.794 ' HB3' HD11 ' A' ' 7' ' ' ILE . 8.2 mp0 -107.66 23.01 15.11 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.334 -171.788 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -92.38 103.91 16.3 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 115.375 -0.829 . . . . 0.0 110.089 164.324 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.555 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -79.71 121.51 25.41 Favored 'General case' 0 C--N 1.339 0.136 0 CA-C-N 114.105 -1.407 . . . . 0.0 110.299 -179.773 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.597 ' HD3' ' H ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -61.58 134.62 57.05 Favored 'General case' 0 C--N 1.331 -0.208 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.442 -178.227 . . . . . . . . 3 3 . 1 . 025 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 7.3 tp -109.38 51.35 0.75 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.288 -0.869 . . . . 0.0 110.467 -175.719 . . . . . . . . 1 1 . 1 . 025 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -129.92 149.02 51.83 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.371 170.053 . . . . . . . . 2 2 . 1 . 025 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 12.2 t70 . . . . . 0 C--O 1.24 0.561 0 CA-C-N 115.371 -0.831 . . . . 0.0 110.31 -170.098 . . . . . . . . 0 0 . 1 . 025 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.738 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.763 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 . . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.461 ' HG2' ' HG ' ' A' ' 51' ' ' LEU . 0.0 OUTLIER -127.28 127.78 44.9 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.413 -175.807 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 55.9 m95 -118.8 136.45 53.99 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.306 -171.342 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.856 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -116.87 134.72 59.52 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.269 -176.879 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.6 t -73.79 108.52 6.66 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 114.921 -1.036 . . . . 0.0 110.089 164.983 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.2 ttmm -61.84 -24.31 66.81 Favored 'General case' 0 N--CA 1.454 -0.257 0 CA-C-N 114.62 -1.173 . . . . 0.0 110.408 -179.976 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.87 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.6 mp -74.41 -67.29 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.232 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.598 -173.547 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -93.06 -38.73 11.47 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.75 -0.659 . . . . 0.0 110.447 -165.421 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.97 38.48 2.9 Favored Glycine 0 CA--C 1.528 0.844 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.527 -173.15 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.718 ' C ' HD13 ' A' ' 11' ' ' ILE . 84.2 t80 -103.3 155.78 18.21 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 115.324 -0.438 . . . . 0.0 110.09 167.069 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.856 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.42 137.3 58.13 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.002 -0.999 . . . . 0.0 110.056 -174.456 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.401 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -101.48 124.75 47.66 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.072 163.971 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 41.2 t0 -109.97 111.59 23.07 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.359 171.055 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.738 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 50.7 mt-10 -66.35 -29.11 69.23 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 115.274 -0.875 . . . . 0.0 110.448 -171.452 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 12.5 t70 -66.3 -29.35 69.55 Favored 'General case' 0 C--N 1.331 -0.232 0 CA-C-N 115.261 -0.881 . . . . 0.0 110.335 175.78 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.72 -28.07 14.96 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.308 -170.457 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.23 -170.21 32.68 Favored Glycine 0 CA--C 1.526 0.759 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.781 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.496 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -141.06 65.88 23.74 Favored Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.589 0.709 . . . . 0.0 109.842 173.598 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 13.9 Cg_exo -53.5 -29.78 51.01 Favored 'Trans proline' 0 N--CA 1.484 0.965 0 C-N-CA 122.541 2.161 . . . . 0.0 113.589 -172.058 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.64 -38.89 89.35 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 115.022 -0.99 . . . . 0.0 110.383 -177.906 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 3.4 m-80 -114.04 19.71 16.27 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.357 -171.424 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.722 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.88 52.75 6.77 Favored Glycine 0 CA--C 1.525 0.714 0 N-CA-C 110.406 -1.078 . . . . 0.0 110.406 170.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.722 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.4 mp -119.98 123.16 70.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 115.36 -0.42 . . . . 0.0 110.332 170.365 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.5 138.3 83.59 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.089 -0.96 . . . . 0.0 109.772 176.308 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -57.03 72.64 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.109 0 C-N-CA 122.31 2.007 . . . . 0.0 113.492 174.008 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.65 -34.63 0.09 OUTLIER Glycine 0 CA--C 1.525 0.711 0 N-CA-C 109.84 -1.304 . . . . 0.0 109.84 -162.528 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.488 ' HB ' HG23 ' A' ' 23' ' ' ILE . 20.3 m -60.64 162.49 6.48 Favored 'General case' 0 C--N 1.331 -0.223 0 CA-C-N 114.796 -0.702 . . . . 0.0 110.589 179.309 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.751 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 8.7 mttm -116.81 172.65 7.1 Favored 'General case' 0 C--N 1.33 -0.246 0 CA-C-N 115.077 -0.965 . . . . 0.0 110.496 179.028 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.9 t80 -61.84 -64.79 0.82 Allowed 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.013 -0.994 . . . . 0.0 110.211 -175.009 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 40.2 tt0 -86.05 13.68 7.34 Favored 'General case' 0 N--CA 1.454 -0.238 0 CA-C-N 114.323 -1.308 . . . . 0.0 111.338 178.045 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.461 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.5 OUTLIER -112.8 20.05 16.82 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 115.864 -0.607 . . . . 0.0 110.401 163.003 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.751 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.1 mt -80.44 172.27 10.25 Favored Pre-proline 0 CA--C 1.544 0.73 0 CA-C-N 115.364 -0.835 . . . . 0.0 109.631 170.733 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.52 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.7 156.88 2.78 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.592 2.194 . . . . 0.0 113.801 173.027 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -61.75 -50.34 72.76 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.328 -170.274 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.637 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.5 OUTLIER -106.1 33.67 3.7 Favored 'General case' 0 N--CA 1.453 -0.288 0 CA-C-N 115.003 -0.999 . . . . 0.0 110.426 -176.243 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.435 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 64.4 t90 -62.38 109.09 1.24 Allowed 'General case' 0 C--N 1.33 -0.253 0 CA-C-N 114.875 -1.057 . . . . 0.0 110.389 176.852 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.711 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.9 m -117.04 175.73 3.0 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.189 0 CA-C-N 114.86 -1.064 . . . . 0.0 110.435 179.874 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -65.87 122.55 81.46 Favored Pre-proline 0 C--O 1.249 1.077 0 CA-C-N 115.302 -0.863 . . . . 0.0 109.53 -175.68 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.416 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 21.9 Cg_exo -57.55 -21.26 45.42 Favored 'Trans proline' 0 N--CA 1.484 0.918 0 C-N-CA 122.498 2.132 . . . . 0.0 113.845 170.954 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.92 -80.7 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.174 0 CA-C-N 115.135 -0.938 . . . . 0.0 110.475 178.745 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.0 p -82.1 -23.9 35.47 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.81 -0.632 . . . . 0.0 110.627 -161.26 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 86.92 29.44 23.27 Favored Glycine 0 CA--C 1.526 0.769 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.517 -175.034 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.419 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.8 114.48 62.12 Favored Pre-proline 0 CA--C 1.544 0.726 0 CA-C-O 121.345 0.593 . . . . 0.0 109.566 168.312 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.711 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.2 Cg_exo -47.4 164.03 0.15 Allowed 'Trans proline' 0 N--CA 1.484 0.929 0 C-N-CA 122.856 2.371 . . . . 0.0 113.636 171.003 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -60.96 -11.95 9.74 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.605 -0.725 . . . . 0.0 110.531 -165.624 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 88.3 p -61.58 -25.4 67.3 Favored 'General case' 0 C--N 1.332 -0.189 0 CA-C-N 115.394 -0.821 . . . . 0.0 110.516 -172.944 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.87 ' HB3' HD11 ' A' ' 7' ' ' ILE . 22.0 mm-40 -113.29 19.08 17.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.462 -170.982 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.479 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 1.9 m-85 -92.42 97.43 10.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.447 -0.797 . . . . 0.0 110.088 164.24 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' H ' ' A' ' 50' ' ' LYS . 19.4 tt0 -63.58 -167.2 0.02 OUTLIER 'General case' 0 C--O 1.231 0.087 0 CA-C-N 114.52 -1.218 . . . . 0.0 110.336 176.712 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.498 ' H ' ' HG2' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -131.71 119.11 20.89 Favored 'General case' 0 C--N 1.332 -0.191 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.332 -176.655 . . . . . . . . 3 3 . 1 . 026 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.461 ' HG ' ' HG2' ' A' ' 2' ' ' LYS . 14.2 mt 60.01 57.72 2.95 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 115.313 -0.858 . . . . 0.0 110.616 168.128 . . . . . . . . 2 2 . 1 . 026 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.9 mp0 58.15 -84.49 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.347 0 CA-C-N 115.29 -0.868 . . . . 0.0 111.129 173.73 . . . . . . . . 1 1 . 1 . 026 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 m-20 . . . . . 0 C--O 1.24 0.576 0 CA-C-N 115.656 -0.702 . . . . 0.0 110.388 -170.043 . . . . . . . . 0 0 . 1 . 026 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 027 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.82 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.775 0 N-CA-C 109.745 -0.465 . . . . 0.0 109.745 . . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -123.54 136.68 54.68 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.334 171.812 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.529 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -120.19 154.12 35.28 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.397 169.699 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.508 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.7 p -122.97 155.01 28.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-N 115.08 -0.964 . . . . 0.0 110.141 177.428 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.2 t -84.95 116.77 23.55 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 115.621 -0.718 . . . . 0.0 110.012 162.016 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.423 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -89.43 17.53 6.15 Favored 'General case' 0 N--CA 1.452 -0.341 0 CA-C-N 114.453 -1.249 . . . . 0.0 110.836 176.595 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.764 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.0 mp -98.14 -79.72 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.23 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.492 158.347 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 26.6 p -79.88 -29.45 39.96 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.931 -0.577 . . . . 0.0 110.479 -162.849 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.51 26.68 9.75 Favored Glycine 0 CA--C 1.527 0.813 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.484 -175.992 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.508 ' O ' HG23 ' A' ' 4' ' ' VAL . 62.4 t80 -79.57 170.06 17.11 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.117 0.485 . . . . 0.0 110.24 166.32 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.505 ' HA ' ' HA ' ' A' ' 4' ' ' VAL . 4.3 mp -139.79 142.38 32.49 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.236 0 CA-C-N 115.156 -0.929 . . . . 0.0 110.514 179.514 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 17.1 t80 -103.97 117.36 34.11 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.21 165.137 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -104.48 115.12 29.8 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.353 169.939 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.82 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 24.0 mt-10 -66.69 -22.89 66.07 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.353 -0.84 . . . . 0.0 110.426 -169.348 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 25' ' ' PRO . 0.4 OUTLIER -63.37 -28.38 69.95 Favored 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.348 -0.842 . . . . 0.0 110.317 170.233 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.32 -42.77 11.38 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.32 -0.855 . . . . 0.0 110.259 -170.428 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 85.04 -156.98 31.61 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.494 -1.042 . . . . 0.0 110.494 -170.237 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.559 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.5 t0 -162.27 56.38 0.64 Allowed Pre-proline 0 CA--C 1.543 0.691 0 CA-C-O 121.432 0.634 . . . . 0.0 109.734 -171.945 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.4 Cg_endo -56.33 -13.31 9.71 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.566 2.177 . . . . 0.0 113.536 -173.714 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 42.2 t0 -73.66 -25.03 60.08 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.502 175.675 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.498 ' C ' HD12 ' A' ' 23' ' ' ILE . 5.4 m-80 -115.64 14.81 16.55 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.266 -0.879 . . . . 0.0 110.418 170.682 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 69.71 53.63 15.33 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 110.464 -1.054 . . . . 0.0 110.464 175.855 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.559 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.6 mp -114.33 143.72 23.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 115.3 -0.45 . . . . 0.0 110.468 171.161 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 53.4 m -96.73 143.26 25.81 Favored Pre-proline 0 CA--C 1.543 0.678 0 CA-C-N 115.223 -0.899 . . . . 0.0 109.787 179.892 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.443 ' HB3' ' O ' ' A' ' 15' ' ' ASP . 2.7 Cg_exo -54.08 91.06 0.04 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.521 2.147 . . . . 0.0 113.505 173.604 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 131.07 18.87 1.3 Allowed Glycine 0 CA--C 1.526 0.73 0 CA-C-N 114.893 -1.049 . . . . 0.0 110.519 -179.483 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.483 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -88.77 159.72 17.63 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.381 -0.41 . . . . 0.0 110.39 169.045 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.632 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -105.15 158.95 16.23 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.325 -0.852 . . . . 0.0 110.366 -169.475 . . . . . . . . 3 3 . 1 . 027 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.529 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.6 t80 -61.75 -66.0 0.6 Allowed 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 114.845 -1.071 . . . . 0.0 110.248 -176.115 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 6.8 pt-20 -79.04 6.52 9.22 Favored 'General case' 0 N--CA 1.452 -0.367 0 CA-C-N 114.511 -1.222 . . . . 0.0 111.772 176.242 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.516 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 11.6 tp10 -107.08 20.44 19.01 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.829 -0.623 . . . . 0.0 110.417 165.531 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.632 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 64.8 mt -84.64 171.35 11.23 Favored Pre-proline 0 CA--C 1.544 0.716 0 CA-C-N 115.317 -0.856 . . . . 0.0 109.653 168.984 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.524 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.4 Cg_exo -50.13 161.33 1.09 Allowed 'Trans proline' 0 N--CA 1.485 0.992 0 C-N-CA 122.602 2.202 . . . . 0.0 113.737 173.418 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -61.93 -53.27 57.97 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.396 -171.922 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.709 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.6 m-20 -104.94 40.86 1.42 Allowed 'General case' 0 N--CA 1.454 -0.233 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.392 -178.572 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.421 ' CH2' ' CE2' ' A' ' 48' ' ' PHE . 75.6 t90 -61.42 121.61 13.09 Favored 'General case' 0 C--N 1.332 -0.195 0 CA-C-N 114.895 -1.048 . . . . 0.0 110.306 179.106 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.709 HG13 ' O ' ' A' ' 35' ' ' ASP . 30.4 m -120.48 175.29 4.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 115.069 -0.969 . . . . 0.0 110.318 -172.556 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 13.9 t -71.64 122.55 87.49 Favored Pre-proline 0 C--O 1.25 1.128 0 CA-C-N 114.793 -1.094 . . . . 0.0 109.504 178.892 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.401 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 7.6 Cg_exo -49.65 -27.68 15.4 Favored 'Trans proline' 0 N--CA 1.485 0.973 0 C-N-CA 122.996 2.464 . . . . 0.0 113.635 168.049 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.682 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.37 -81.43 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.249 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.393 -176.257 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.4 p -79.59 -20.18 47.57 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.575 -0.739 . . . . 0.0 110.928 -163.884 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 76.99 34.33 42.57 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.417 -1.073 . . . . 0.0 110.417 -175.193 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -86.95 144.51 36.77 Favored Pre-proline 0 CA--C 1.544 0.746 0 CA-C-O 121.188 0.518 . . . . 0.0 109.721 170.132 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.416 ' HA ' HG12 ' A' ' 37' ' ' VAL . 3.0 Cg_exo -57.54 157.48 22.68 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.601 2.201 . . . . 0.0 113.488 174.334 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 1.2 pttp -61.37 -9.82 6.12 Favored 'General case' 0 N--CA 1.454 -0.244 0 CA-C-N 114.656 -1.156 . . . . 0.0 110.68 175.921 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 42.0 p -92.81 18.89 8.24 Favored 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.932 -1.031 . . . . 0.0 110.524 -178.589 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.764 ' HB3' HD11 ' A' ' 7' ' ' ILE . 2.8 mm-40 -134.9 18.41 3.5 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 115.557 -0.747 . . . . 0.0 110.264 165.12 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.421 ' CE2' ' CH2' ' A' ' 36' ' ' TRP . 3.0 m-85 -94.26 105.11 17.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.306 168.494 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.423 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 5.8 mt-10 -73.96 166.9 22.55 Favored 'General case' 0 C--O 1.23 0.051 0 CA-C-N 114.528 -1.214 . . . . 0.0 110.381 177.692 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -104.15 143.49 32.86 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.212 -0.904 . . . . 0.0 110.477 175.817 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 12.7 tp -94.6 19.1 10.3 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 115.297 -0.865 . . . . 0.0 110.425 -176.164 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -76.72 -48.24 19.41 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.341 -0.845 . . . . 0.0 110.36 169.404 . . . . . . . . 2 2 . 1 . 027 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.239 0.539 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.327 169.836 . . . . . . . . 1 1 . 1 . 027 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 N-CA-C 109.771 -0.455 . . . . 0.0 109.771 . . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmmt -114.12 138.9 49.81 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.323 170.132 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.526 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 22.1 m95 -119.71 152.52 37.03 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.311 168.983 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.788 HG23 ' CD1' ' A' ' 11' ' ' ILE . 3.8 p -120.15 157.47 22.65 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.233 0 CA-C-N 114.879 -1.055 . . . . 0.0 110.03 179.728 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 18.1 t -86.71 118.2 25.96 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-N 115.501 -0.772 . . . . 0.0 109.754 159.772 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 1.8 ttmt -88.04 16.53 5.93 Favored 'General case' 0 N--CA 1.453 -0.294 0 CA-C-N 114.444 -1.253 . . . . 0.0 110.957 175.881 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.645 HD13 ' CB ' ' A' ' 43' ' ' ALA . 4.0 mp -100.1 -77.95 0.38 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 115.758 -0.655 . . . . 0.0 110.561 159.526 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.1 p -83.78 -33.78 24.92 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 116.024 -0.534 . . . . 0.0 110.53 -163.242 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.3 31.58 6.11 Favored Glycine 0 CA--C 1.525 0.7 0 CA-C-N 114.629 -1.169 . . . . 0.0 110.557 -175.39 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.611 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.5 t80 -87.74 134.92 33.58 Favored 'General case' 0 C--O 1.237 0.403 0 CA-C-N 115.436 -0.382 . . . . 0.0 109.971 166.394 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.788 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.3 mm -104.33 140.0 23.68 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 CA-C-N 114.574 -1.194 . . . . 0.0 110.187 -179.597 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 13.5 t80 -99.9 131.93 45.57 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.142 163.956 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.3 t0 -116.32 113.36 22.85 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.323 -0.853 . . . . 0.0 110.393 171.388 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.697 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 29.1 mt-10 -65.43 -31.52 72.66 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.413 -0.812 . . . . 0.0 110.41 -172.039 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -63.11 -32.97 74.47 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.01 -0.996 . . . . 0.0 110.357 177.783 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -102.14 -17.81 15.83 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.34 -0.845 . . . . 0.0 110.274 -171.188 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 74.63 -172.74 52.43 Favored Glycine 0 CA--C 1.526 0.738 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 169.658 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.563 ' N ' ' HD3' ' A' ' 19' ' ' PRO . 16.5 t0 -138.26 48.08 1.81 Allowed Pre-proline 0 CA--C 1.542 0.659 0 CA-C-O 121.515 0.674 . . . . 0.0 109.822 -176.951 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.563 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_exo -50.16 -18.09 3.03 Favored 'Trans proline' 0 N--CA 1.484 0.943 0 C-N-CA 122.374 2.049 . . . . 0.0 113.571 -179.831 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.03 -25.49 66.95 Favored 'General case' 0 C--N 1.331 -0.236 0 CA-C-N 114.871 -1.059 . . . . 0.0 110.495 175.7 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 20.3 m-80 -135.71 21.0 3.32 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.199 -0.909 . . . . 0.0 110.397 -175.707 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.662 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.49 46.59 5.17 Favored Glycine 0 CA--C 1.527 0.791 0 N-CA-C 110.391 -1.084 . . . . 0.0 110.391 169.552 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.662 HD12 ' C ' ' A' ' 22' ' ' GLY . 3.3 mp -123.59 133.68 68.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.352 0 CA-C-N 115.249 -0.475 . . . . 0.0 110.364 171.05 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 1.9 t -92.41 142.98 26.61 Favored Pre-proline 0 CA--C 1.544 0.718 0 CA-C-N 115.073 -0.967 . . . . 0.0 109.749 178.933 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_endo -51.79 90.42 0.03 OUTLIER 'Trans proline' 0 N--CA 1.484 0.962 0 C-N-CA 122.569 2.179 . . . . 0.0 113.559 172.123 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.25 19.24 1.11 Allowed Glycine 0 CA--C 1.526 0.746 0 N-CA-C 110.522 -1.031 . . . . 0.0 110.522 -179.922 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.55 ' HB ' HG23 ' A' ' 23' ' ' ILE . 99.0 m -91.88 143.58 26.35 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-O 121.056 0.455 . . . . 0.0 110.384 168.169 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.483 ' H ' ' HG2' ' A' ' 31' ' ' GLU . 13.9 mtpt -97.7 164.72 12.29 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.214 -0.903 . . . . 0.0 110.466 -174.112 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.526 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 81.1 t80 -61.54 -63.94 1.11 Allowed 'General case' 0 C--O 1.232 0.132 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.47 -168.309 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.5 tt0 -79.03 7.09 7.91 Favored 'General case' 0 C--O 1.234 0.26 0 CA-C-N 114.865 -1.062 . . . . 0.0 111.74 -176.119 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.483 ' HG2' ' H ' ' A' ' 28' ' ' LYS . 6.0 pt-20 -109.49 20.74 17.85 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.842 -0.617 . . . . 0.0 110.35 166.417 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.503 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 24.0 mt -80.96 170.31 16.0 Favored Pre-proline 0 CA--C 1.543 0.696 0 CA-C-N 115.378 -0.828 . . . . 0.0 109.731 168.19 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.503 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -50.87 157.54 3.7 Favored 'Trans proline' 0 N--CA 1.483 0.911 0 C-N-CA 122.55 2.167 . . . . 0.0 113.665 176.608 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 4.3 m-20 -61.71 -48.57 80.16 Favored 'General case' 0 C--N 1.333 -0.133 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.397 -171.99 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.686 ' O ' HG13 ' A' ' 37' ' ' VAL . 2.3 m-20 -102.68 26.11 8.37 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.495 -172.687 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.425 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 67.0 t90 -61.79 106.93 0.75 Allowed 'General case' 0 C--N 1.331 -0.235 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.371 -175.099 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.707 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.6 m -111.23 176.38 1.62 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.176 0 CA-C-N 114.92 -1.036 . . . . 0.0 110.459 179.022 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.414 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 15.2 t -63.34 123.04 79.32 Favored Pre-proline 0 C--O 1.251 1.173 0 CA-C-N 115.277 -0.874 . . . . 0.0 109.479 -178.156 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.489 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.1 Cg_exo -50.3 -26.09 14.97 Favored 'Trans proline' 0 N--CA 1.485 0.974 0 C-N-CA 123.03 2.487 . . . . 0.0 113.731 168.379 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -96.99 -81.46 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.256 0 CA-C-N 115.058 -0.974 . . . . 0.0 110.382 -177.545 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -79.69 -20.66 46.03 Favored 'General case' 0 C--N 1.332 -0.173 0 CA-C-N 115.525 -0.761 . . . . 0.0 110.965 -162.856 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.411 ' O ' ' HD3' ' A' ' 44' ' ' PRO . . . 84.89 28.69 30.92 Favored Glycine 0 CA--C 1.526 0.737 0 N-CA-C 110.501 -1.039 . . . . 0.0 110.501 -177.425 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.645 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -91.29 110.47 42.86 Favored Pre-proline 0 C--O 1.243 0.719 0 CA-C-O 121.331 0.586 . . . . 0.0 109.684 173.158 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.707 ' HA ' HG12 ' A' ' 37' ' ' VAL . 10.9 Cg_exo -47.02 159.11 0.37 Allowed 'Trans proline' 0 N--CA 1.484 0.961 0 C-N-CA 122.82 2.347 . . . . 0.0 113.616 173.015 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.485 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.66 -13.02 12.07 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 115.598 -0.728 . . . . 0.0 110.588 -163.417 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 78.3 p -61.64 -22.31 65.16 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.47 -173.499 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.583 ' CB ' HD11 ' A' ' 7' ' ' ILE . 2.1 mt-10 -116.93 26.49 9.77 Favored 'General case' 0 C--N 1.33 -0.25 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.302 -175.721 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -98.24 109.08 21.9 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 115.354 -0.839 . . . . 0.0 110.314 167.08 . . . . . . . . 1 1 . 1 . 028 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.65 ' HB3' HG13 ' A' ' 4' ' ' VAL . 27.1 tp10 -73.78 154.04 39.73 Favored 'General case' 0 C--O 1.23 0.071 0 CA-C-N 114.599 -1.182 . . . . 0.0 110.248 178.49 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.452 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -107.72 146.41 32.15 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.375 -177.485 . . . . . . . . 3 3 . 1 . 028 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -120.47 28.93 7.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.308 -0.86 . . . . 0.0 110.379 -170.444 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -132.82 -161.13 1.11 Allowed 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.349 170.368 . . . . . . . . 2 2 . 1 . 028 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 9.4 m-20 . . . . . 0 C--O 1.24 0.6 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.36 170.145 . . . . . . . . 0 0 . 1 . 028 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 029 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.781 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.116 0.484 . . . . 0.0 109.723 . . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -124.45 125.76 44.79 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.573 -0.74 . . . . 0.0 110.35 170.003 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.515 ' CE2' ' HB3' ' A' ' 50' ' ' LYS . 11.4 m95 -99.91 148.08 24.85 Favored 'General case' 0 C--N 1.331 -0.201 0 CA-C-N 115.143 -0.935 . . . . 0.0 110.165 173.871 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.677 HG23 HG13 ' A' ' 11' ' ' ILE . 5.2 p -121.97 132.04 71.81 Favored 'Isoleucine or valine' 0 C--O 1.243 0.743 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.585 -177.36 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 13.0 t -71.58 109.6 5.62 Favored 'General case' 0 CA--C 1.529 0.17 0 CA-C-N 114.539 -1.21 . . . . 0.0 110.077 172.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -62.43 -24.81 67.62 Favored 'General case' 0 N--CA 1.454 -0.248 0 CA-C-N 114.505 -1.225 . . . . 0.0 110.513 179.59 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.603 HD11 ' CB ' ' A' ' 47' ' ' GLU . 4.4 mp -73.61 -70.89 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.171 0 CA-C-N 114.803 -1.09 . . . . 0.0 110.548 -175.424 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.1 p -89.46 -38.13 14.28 Favored 'General case' 0 C--N 1.332 -0.177 0 CA-C-N 115.814 -0.63 . . . . 0.0 110.51 -164.939 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.39 29.51 4.46 Favored Glycine 0 CA--C 1.526 0.778 0 CA-C-N 114.753 -1.112 . . . . 0.0 110.447 -176.081 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.555 ' CG ' HD13 ' A' ' 40' ' ' ILE . 71.1 t80 -91.82 169.98 10.25 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.054 0.454 . . . . 0.0 110.309 168.377 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.677 HG13 HG23 ' A' ' 4' ' ' VAL . 5.0 mp -145.12 127.7 10.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.469 -178.817 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.408 ' CE2' HD11 ' A' ' 32' ' ' LEU . 19.0 t80 -80.26 126.63 31.37 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 115.519 -0.764 . . . . 0.0 110.169 165.46 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 43.2 t0 -114.75 111.42 21.23 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.281 -0.872 . . . . 0.0 110.438 170.969 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.781 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 43.7 mt-10 -65.74 -18.17 65.14 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.291 -0.868 . . . . 0.0 110.354 -171.013 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t70 -71.75 -28.71 63.84 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.375 170.994 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.04 -57.2 2.98 Favored 'General case' 0 C--N 1.332 -0.192 0 CA-C-N 115.023 -0.99 . . . . 0.0 110.362 179.424 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 99.19 -145.44 17.64 Favored Glycine 0 CA--C 1.527 0.79 0 N-CA-C 110.421 -1.072 . . . . 0.0 110.421 -179.489 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.77 ' HB3' HD13 ' A' ' 23' ' ' ILE . 33.4 t0 -158.44 67.03 3.38 Favored Pre-proline 0 CA--C 1.544 0.717 0 CA-C-O 121.457 0.646 . . . . 0.0 109.779 -175.527 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 10.1 Cg_exo -55.69 -35.38 93.02 Favored 'Trans proline' 0 N--CA 1.485 0.996 0 C-N-CA 122.476 2.117 . . . . 0.0 113.574 -173.29 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 76.4 m-20 -63.38 -19.87 65.03 Favored 'General case' 0 C--N 1.33 -0.242 0 CA-C-N 114.903 -1.044 . . . . 0.0 110.429 179.915 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . 81.6 m-20 -124.03 19.49 9.18 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.247 -0.888 . . . . 0.0 110.372 -175.688 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 73.14 33.42 59.34 Favored Glycine 0 CA--C 1.526 0.76 0 N-CA-C 110.406 -1.077 . . . . 0.0 110.406 169.607 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.77 HD13 ' HB3' ' A' ' 18' ' ' ASP . 4.9 mp -107.12 141.16 23.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.425 -0.388 . . . . 0.0 110.393 169.629 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 14.5 m -101.24 151.26 37.68 Favored Pre-proline 0 CA--C 1.542 0.655 0 CA-C-N 115.045 -0.979 . . . . 0.0 109.856 178.154 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -58.93 72.86 0.05 OUTLIER 'Trans proline' 0 N--CA 1.485 0.972 0 C-N-CA 122.433 2.088 . . . . 0.0 113.58 171.85 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.02 -34.04 0.08 OUTLIER Glycine 0 N--CA 1.466 0.683 0 N-CA-C 109.936 -1.266 . . . . 0.0 109.936 -161.957 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.491 HG21 HD23 ' A' ' 32' ' ' LEU . 26.2 m -60.69 151.59 28.84 Favored 'General case' 0 C--N 1.333 -0.144 0 CA-C-N 114.919 -0.641 . . . . 0.0 110.691 -177.346 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.507 ' HB3' ' HB3' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -96.7 166.48 11.63 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.465 -0.788 . . . . 0.0 110.374 171.852 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.5 ' CG ' ' CE2' ' A' ' 3' ' ' TRP . 79.5 t80 -61.8 -64.69 0.86 Allowed 'General case' 0 C--N 1.334 -0.105 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.282 -176.861 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 27.1 mt-10 -78.87 8.02 6.19 Favored 'General case' 0 C--O 1.234 0.28 0 CA-C-N 114.444 -1.253 . . . . 0.0 111.607 178.546 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.507 ' HB3' ' HB3' ' A' ' 28' ' ' LYS . 20.7 tt0 -108.2 20.81 18.21 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.637 -0.711 . . . . 0.0 110.478 165.208 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.511 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 56.3 mt -83.99 169.19 17.84 Favored Pre-proline 0 CA--C 1.545 0.75 0 CA-C-N 115.315 -0.857 . . . . 0.0 109.767 169.64 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.511 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 12.8 Cg_exo -48.84 155.38 2.57 Favored 'Trans proline' 0 N--CA 1.485 0.978 0 C-N-CA 122.628 2.219 . . . . 0.0 113.614 170.525 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -62.01 -51.97 65.86 Favored 'General case' 0 C--N 1.332 -0.16 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.323 -172.503 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.489 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.3 OUTLIER -106.8 38.92 1.96 Allowed 'General case' 0 N--CA 1.455 -0.188 0 CA-C-N 114.888 -1.051 . . . . 0.0 110.359 -178.471 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 86.7 t90 -61.7 122.43 15.31 Favored 'General case' 0 N--CA 1.454 -0.246 0 CA-C-N 114.901 -1.045 . . . . 0.0 110.456 175.363 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.489 HG13 ' O ' ' A' ' 35' ' ' ASP . 11.1 m -116.8 165.87 11.69 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.356 -172.541 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.401 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.2 t -63.21 125.98 88.18 Favored Pre-proline 0 C--O 1.251 1.143 0 CA-C-N 114.839 -1.073 . . . . 0.0 109.438 176.323 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 1.8 Cg_endo -62.21 -17.46 56.96 Favored 'Trans proline' 0 N--CA 1.486 1.032 0 C-N-CA 122.57 2.18 . . . . 0.0 113.677 171.796 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.668 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.4 mp -96.12 -81.18 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.333 -0.132 0 CA-C-N 115.038 -0.983 . . . . 0.0 110.443 176.482 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 29.7 p -81.16 -23.13 38.46 Favored 'General case' 0 C--N 1.332 -0.183 0 CA-C-N 115.809 -0.632 . . . . 0.0 110.731 -162.711 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.401 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 82.46 32.42 28.0 Favored Glycine 0 CA--C 1.525 0.718 0 CA-C-N 114.913 -1.04 . . . . 0.0 110.518 -175.198 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.13 138.42 32.56 Favored Pre-proline 0 C--O 1.245 0.824 0 N-CA-C 109.602 -0.518 . . . . 0.0 109.602 170.105 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . . . . . . . . . 3.3 Cg_exo -52.74 158.31 6.35 Favored 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.438 2.092 . . . . 0.0 113.349 171.184 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.19 -10.41 6.54 Favored 'General case' 0 C--O 1.232 0.152 0 CA-C-N 114.714 -1.13 . . . . 0.0 110.622 -179.859 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 60.5 p -61.64 -35.12 77.01 Favored 'General case' 0 C--N 1.333 -0.11 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.555 -176.267 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.603 ' CB ' HD11 ' A' ' 7' ' ' ILE . 0.3 OUTLIER -106.19 19.13 20.99 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.448 -0.796 . . . . 0.0 110.462 -169.945 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -89.19 114.34 25.64 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.489 -0.778 . . . . 0.0 109.954 163.861 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.595 ' O ' HG12 ' A' ' 4' ' ' VAL . 0.8 OUTLIER -94.99 109.8 21.79 Favored 'General case' 0 N--CA 1.453 -0.277 0 CA-C-N 114.723 -1.126 . . . . 0.0 110.54 -168.705 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.515 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.1 OUTLIER -65.17 124.63 22.65 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.318 -0.855 . . . . 0.0 110.268 -173.889 . . . . . . . . 3 3 . 1 . 029 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -133.23 44.42 2.82 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.36 -169.166 . . . . . . . . 2 2 . 1 . 029 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.3 pt-20 57.78 172.86 0.05 Allowed 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.045 168.839 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.446 ' HB2' ' HA ' ' A' ' 1' ' ' ALA . 5.3 t70 . . . . . 0 C--O 1.24 0.593 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.389 -171.621 . . . . . . . . 1 1 . 1 . 029 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.613 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.736 0 CA-C-O 121.08 0.467 . . . . 0.0 109.796 . . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -134.48 129.41 35.15 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.588 -0.733 . . . . 0.0 110.412 171.856 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.513 ' CD1' ' HB2' ' A' ' 29' ' ' PHE . 59.9 m95 -113.89 122.46 47.06 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.386 -0.824 . . . . 0.0 110.447 -170.882 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.598 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.6 p -86.91 162.51 2.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.148 -0.933 . . . . 0.0 110.365 -174.703 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.437 ' N ' HG22 ' A' ' 4' ' ' VAL . 20.4 t -92.09 118.22 30.61 Favored 'General case' 0 C--N 1.328 -0.37 0 CA-C-N 115.747 -0.66 . . . . 0.0 109.642 160.527 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 10.4 tptt -87.81 16.4 5.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 CA-C-N 114.114 -1.403 . . . . 0.0 110.997 176.107 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.868 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.5 mp -99.93 -78.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.17 0 CA-C-N 115.831 -0.622 . . . . 0.0 110.48 157.805 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 28.5 p -82.86 -38.47 22.91 Favored 'General case' 0 C--N 1.332 -0.174 0 CA-C-N 116.055 -0.52 . . . . 0.0 110.551 -162.898 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 107.46 17.8 10.96 Favored Glycine 0 CA--C 1.526 0.771 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.609 178.946 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.788 ' O ' HD13 ' A' ' 11' ' ' ILE . 80.4 t80 -64.75 162.56 15.75 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 121.053 0.454 . . . . 0.0 109.914 161.624 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.788 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.27 154.89 38.06 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.209 0 CA-C-N 114.75 -1.114 . . . . 0.0 110.229 177.762 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 15.5 t80 -112.23 133.24 54.47 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.176 166.48 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.1 t0 -113.95 107.65 15.97 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.412 -0.813 . . . . 0.0 110.399 169.133 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.613 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 19.9 mt-10 -66.54 -27.46 67.77 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.389 -170.687 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.1 t70 -72.42 -31.38 65.44 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.217 -0.901 . . . . 0.0 110.324 175.946 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -89.2 -24.03 22.25 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.287 -171.929 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.61 -159.2 46.02 Favored Glycine 0 CA--C 1.525 0.712 0 N-CA-C 110.474 -1.05 . . . . 0.0 110.474 -177.883 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.494 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.9 t0 -155.21 57.21 1.57 Allowed Pre-proline 0 CA--C 1.543 0.674 0 CA-C-O 121.538 0.685 . . . . 0.0 109.772 -175.3 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -56.05 -16.83 17.67 Favored 'Trans proline' 0 N--CA 1.485 0.984 0 C-N-CA 122.453 2.102 . . . . 0.0 113.522 -173.098 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -75.16 -17.43 60.39 Favored 'General case' 0 C--N 1.331 -0.226 0 CA-C-N 114.916 -1.038 . . . . 0.0 110.478 178.826 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.471 HD21 ' HB3' ' A' ' 39' ' ' PRO . 0.2 OUTLIER -127.26 18.92 6.98 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.282 -0.872 . . . . 0.0 110.418 170.691 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.43 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 71.38 47.18 36.99 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.456 -1.058 . . . . 0.0 110.456 169.079 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.645 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.6 mp -104.89 139.0 27.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 115.415 -0.393 . . . . 0.0 110.302 168.612 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 29.0 m -89.79 140.42 27.88 Favored Pre-proline 0 CA--C 1.542 0.638 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.865 177.882 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.2 Cg_endo -57.17 72.62 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.13 0 C-N-CA 122.235 1.957 . . . . 0.0 113.431 171.341 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.48 -33.1 0.08 OUTLIER Glycine 0 CA--C 1.525 0.716 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -161.77 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.976 HG21 HD23 ' A' ' 32' ' ' LEU . 25.7 m -60.38 141.88 55.69 Favored 'General case' 0 N--CA 1.456 -0.134 0 CA-C-N 114.622 -0.789 . . . . 0.0 110.674 178.985 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.65 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 12.6 mmtp -96.66 163.17 13.13 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.378 168.973 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.54 ' CZ ' ' HG3' ' A' ' 45' ' ' LYS . 58.0 t80 -61.87 -65.81 0.63 Allowed 'General case' 0 C--N 1.333 -0.115 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.361 -171.257 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 12.3 pm0 -78.74 8.56 5.21 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 114.556 -1.202 . . . . 0.0 111.628 178.862 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.65 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 7.3 mm-40 -116.03 20.3 14.5 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.545 -0.752 . . . . 0.0 110.462 166.213 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.976 HD23 HG21 ' A' ' 27' ' ' THR . 19.3 mt -73.78 167.86 31.19 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.363 -0.835 . . . . 0.0 109.682 167.328 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.463 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 1.5 Cg_endo -53.16 151.86 20.61 Favored 'Trans proline' 0 N--CA 1.483 0.906 0 C-N-CA 122.67 2.247 . . . . 0.0 113.622 173.416 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -61.72 -48.22 81.75 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.098 -0.956 . . . . 0.0 110.447 -176.114 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 17.1 t0 -95.74 23.96 5.77 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.235 -0.893 . . . . 0.0 110.437 -172.302 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . . . . . . . . . 23.8 t90 -68.84 112.98 5.87 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.29 -0.868 . . . . 0.0 110.453 171.402 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.671 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.2 m -115.57 -175.94 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.274 0 CA-C-N 115.369 -0.832 . . . . 0.0 110.329 169.131 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.4 t -62.09 123.64 78.79 Favored Pre-proline 0 C--O 1.254 1.293 0 CA-C-N 115.164 -0.926 . . . . 0.0 109.39 175.761 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.471 ' HB3' HD21 ' A' ' 21' ' ' ASN . 22.3 Cg_exo -52.99 -24.46 24.84 Favored 'Trans proline' 0 N--CA 1.484 0.938 0 C-N-CA 122.74 2.294 . . . . 0.0 113.863 169.905 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.697 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.1 mp -97.64 -83.66 0.19 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.187 0 CA-C-N 115.056 -0.975 . . . . 0.0 110.331 179.207 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -76.01 -21.98 56.29 Favored 'General case' 0 C--N 1.331 -0.222 0 CA-C-N 115.452 -0.794 . . . . 0.0 110.953 -161.122 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 83.99 20.02 60.11 Favored Glycine 0 CA--C 1.526 0.722 0 N-CA-C 110.503 -1.039 . . . . 0.0 110.503 -178.248 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -79.27 115.11 50.49 Favored Pre-proline 0 C--O 1.242 0.685 0 CA-C-O 121.426 0.632 . . . . 0.0 109.509 166.372 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.671 ' HA ' HG12 ' A' ' 37' ' ' VAL . 13.2 Cg_exo -51.26 171.25 0.13 Allowed 'Trans proline' 0 N--CA 1.487 1.141 0 C-N-CA 122.395 2.063 . . . . 0.0 113.674 179.815 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.54 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 18.9 ttpp -61.21 -9.47 4.97 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.497 -176.557 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 63.3 p -61.4 -41.18 96.72 Favored 'General case' 0 C--N 1.332 -0.153 0 CA-C-N 114.962 -1.017 . . . . 0.0 110.523 -179.215 . . . . . . . . 1 1 . 1 . 030 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.868 ' HB3' HD11 ' A' ' 7' ' ' ILE . 5.6 mm-40 -103.26 29.45 5.56 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.335 -170.861 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.44 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.3 m-85 -103.66 119.43 38.88 Favored 'General case' 0 C--N 1.33 -0.24 0 CA-C-N 114.877 -1.056 . . . . 0.0 110.393 174.568 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.434 ' HB2' HG13 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -89.43 -167.87 1.99 Allowed 'General case' 0 N--CA 1.456 -0.163 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.425 -177.157 . . . . . . . . 3 3 . 1 . 030 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -122.48 144.27 49.17 Favored 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.98 -1.009 . . . . 0.0 110.408 179.977 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -129.2 69.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.415 170.23 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -81.33 -24.02 37.42 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.332 -0.849 . . . . 0.0 110.428 -170.014 . . . . . . . . 2 2 . 1 . 030 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.6 p30 . . . . . 0 C--O 1.24 0.577 0 CA-C-N 115.004 -0.998 . . . . 0.0 110.57 175.774 . . . . . . . . 0 0 . 1 . 030 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.697 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.109 0.48 . . . . 0.0 109.76 . . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.7 mmtt -113.38 135.99 53.26 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 115.333 -0.849 . . . . 0.0 110.39 177.065 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.602 ' O ' HG23 ' A' ' 11' ' ' ILE . 27.0 m95 -123.39 148.41 46.11 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.306 -0.861 . . . . 0.0 110.409 172.042 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.5 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 6.4 p -119.99 156.6 22.69 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.188 0 CA-C-N 114.941 -1.027 . . . . 0.0 110.241 178.392 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.4 t -84.86 115.26 22.66 Favored 'General case' 0 C--O 1.235 0.297 0 CA-C-N 115.712 -0.676 . . . . 0.0 110.088 163.046 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -61.5 -22.94 65.55 Favored 'General case' 0 N--CA 1.454 -0.243 0 CA-C-N 114.363 -1.289 . . . . 0.0 110.488 177.144 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.662 ' N ' HD12 ' A' ' 7' ' ' ILE . 2.2 mp -85.73 -70.84 0.47 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.251 0 CA-C-N 115.145 -0.934 . . . . 0.0 110.837 -171.695 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 30.1 p -88.21 -28.8 20.93 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.854 -0.612 . . . . 0.0 110.557 -167.086 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.11 18.1 25.43 Favored Glycine 0 CA--C 1.525 0.69 0 CA-C-N 114.795 -1.093 . . . . 0.0 110.596 -177.793 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.588 ' CG ' HD13 ' A' ' 40' ' ' ILE . 62.6 t80 -69.41 170.12 11.07 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-O 121.132 0.491 . . . . 0.0 110.173 166.113 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.602 HG23 ' O ' ' A' ' 3' ' ' TRP . 5.0 mp -143.13 138.4 26.83 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.253 0 CA-C-N 115.094 -0.957 . . . . 0.0 110.53 179.257 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.686 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -97.88 136.07 38.72 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.128 165.488 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 47.0 t0 -117.34 112.88 21.32 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.264 -0.88 . . . . 0.0 110.397 169.185 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.697 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 19.0 mt-10 -62.19 -18.38 60.84 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.48 -173.052 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.2 t70 -85.78 -19.44 30.72 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.259 -0.882 . . . . 0.0 110.397 -173.442 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.79 -20.61 14.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.376 -0.829 . . . . 0.0 110.265 -169.19 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.866 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 81.69 -146.02 25.42 Favored Glycine 0 CA--C 1.527 0.805 0 N-CA-C 110.329 -1.108 . . . . 0.0 110.329 -169.766 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.66 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.2 OUTLIER -169.69 90.11 0.55 Allowed Pre-proline 0 C--O 1.249 1.048 0 N-CA-C 109.601 -0.518 . . . . 0.0 109.601 166.29 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.6 Cg_exo -49.78 -30.4 22.89 Favored 'Trans proline' 0 N--CA 1.485 1.001 0 C-N-CA 122.647 2.231 . . . . 0.0 113.574 -174.942 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 17.4 t70 -62.0 -33.79 74.99 Favored 'General case' 0 C--N 1.332 -0.155 0 CA-C-N 115.165 -0.925 . . . . 0.0 110.409 -173.527 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.585 ' HB2' HD13 ' A' ' 23' ' ' ILE . 27.5 m-80 -110.74 -12.71 14.27 Favored 'General case' 0 N--CA 1.451 -0.384 0 CA-C-N 115.192 -0.913 . . . . 0.0 111.641 -177.872 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.544 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 86.22 51.33 3.56 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.53 -1.028 . . . . 0.0 110.53 -174.639 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.866 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.7 mp -104.43 124.81 59.18 Favored 'Isoleucine or valine' 0 C--O 1.235 0.318 0 N-CA-C 109.75 -0.463 . . . . 0.0 109.75 168.223 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.413 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 69.7 m -87.33 142.35 33.26 Favored Pre-proline 0 CA--C 1.544 0.74 0 CA-C-N 114.605 -1.18 . . . . 0.0 109.666 -176.489 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.567 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 4.6 Cg_exo -61.72 71.77 0.1 OUTLIER 'Trans proline' 0 N--CA 1.484 0.953 0 C-N-CA 122.565 2.177 . . . . 0.0 113.464 -172.89 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 177.14 -35.43 0.08 OUTLIER Glycine 0 N--CA 1.467 0.741 0 N-CA-C 109.935 -1.266 . . . . 0.0 109.935 -160.619 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.412 ' HB ' HG23 ' A' ' 23' ' ' ILE . 25.7 m -61.04 149.19 37.74 Favored 'General case' 0 C--N 1.331 -0.199 0 CA-C-N 115.197 -0.501 . . . . 0.0 110.549 -174.456 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -94.54 167.5 11.45 Favored 'General case' 0 C--O 1.235 0.341 0 CA-C-N 115.058 -0.973 . . . . 0.0 110.442 176.922 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.511 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 73.8 t80 -61.69 -65.82 0.63 Allowed 'General case' 0 C--O 1.232 0.168 0 CA-C-N 114.833 -1.076 . . . . 0.0 110.28 -175.889 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -79.02 8.87 4.96 Favored 'General case' 0 C--O 1.235 0.292 0 CA-C-N 114.486 -1.234 . . . . 0.0 111.682 178.699 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 -96.04 -13.67 23.54 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 115.533 -0.758 . . . . 0.0 110.448 168.986 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.686 HD11 ' CE2' ' A' ' 12' ' ' TYR . 16.1 mt -61.12 168.5 2.8 Favored Pre-proline 0 CA--C 1.545 0.786 0 CA-C-N 115.11 -0.95 . . . . 0.0 109.772 172.723 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.463 ' CB ' ' HB2' ' A' ' 36' ' ' TRP . 11.8 Cg_exo -52.6 152.26 16.91 Favored 'Trans proline' 0 N--CA 1.484 0.916 0 C-N-CA 122.625 2.217 . . . . 0.0 113.529 170.73 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -75.37 -28.27 59.46 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.039 166.666 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.557 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.7 OUTLIER -71.35 -18.01 62.4 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 115.032 -0.986 . . . . 0.0 110.508 170.353 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.463 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 63.7 t90 -61.2 114.98 3.45 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.397 -168.05 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -124.76 -172.1 0.76 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.195 -0.911 . . . . 0.0 110.381 179.064 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.453 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 14.5 t -69.41 123.64 88.82 Favored Pre-proline 0 C--O 1.253 1.242 0 CA-C-N 114.911 -1.04 . . . . 0.0 109.441 179.802 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.451 ' HB2' HD12 ' A' ' 40' ' ' ILE . 21.5 Cg_exo -52.13 -23.7 18.17 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.859 2.373 . . . . 0.0 113.683 169.028 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.655 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.93 -80.38 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-N 115.129 -0.941 . . . . 0.0 110.479 -177.357 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -80.55 -20.9 42.4 Favored 'General case' 0 C--N 1.331 -0.205 0 CA-C-N 115.637 -0.71 . . . . 0.0 111.029 -163.753 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.453 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 105.36 -16.59 44.95 Favored Glycine 0 CA--C 1.525 0.661 0 N-CA-C 110.667 -0.973 . . . . 0.0 110.667 -179.365 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.45 ' HB1' ' CD ' ' A' ' 47' ' ' GLU . . . -61.62 116.47 20.77 Favored Pre-proline 0 C--O 1.243 0.713 0 CA-C-O 121.388 0.613 . . . . 0.0 109.653 -170.662 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 6.6 Cg_exo -51.15 160.98 1.79 Allowed 'Trans proline' 0 N--CA 1.486 1.034 0 C-N-CA 122.603 2.202 . . . . 0.0 113.7 176.124 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.439 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.21 -11.11 8.06 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.524 -0.762 . . . . 0.0 110.461 -170.073 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 54.0 p -60.92 -19.05 60.06 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 114.996 -1.002 . . . . 0.0 110.445 175.222 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.582 ' HB3' ' CD1' ' A' ' 7' ' ' ILE . 5.3 mt-10 -114.22 22.63 13.61 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.452 -171.485 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.2 m-85 -110.6 113.11 25.47 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 114.938 -1.028 . . . . 0.0 110.429 178.478 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -73.67 152.85 40.34 Favored 'General case' 0 C--O 1.23 0.047 0 CA-C-N 114.782 -1.099 . . . . 0.0 110.261 176.375 . . . . . . . . 2 2 . 1 . 031 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.502 ' HB3' ' CZ3' ' A' ' 3' ' ' TRP . 0.5 OUTLIER -110.42 124.6 52.04 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 114.988 -1.005 . . . . 0.0 110.426 179.894 . . . . . . . . 3 3 . 1 . 031 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 2.6 tp -126.83 70.28 1.28 Allowed 'General case' 0 C--N 1.33 -0.258 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.448 -177.045 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 14.7 tt0 -103.61 -25.54 13.14 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.475 -172.303 . . . . . . . . 1 1 . 1 . 031 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 1.1 t0 . . . . . 0 C--O 1.24 0.603 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.403 177.128 . . . . . . . . 0 0 . 1 . 031 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 032 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.831 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.773 0 CA-C-O 121.216 0.532 . . . . 0.0 109.764 . . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.509 ' HD3' ' HB2' ' A' ' 53' ' ' ASP . 0.0 OUTLIER -123.75 153.87 40.31 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 115.489 -0.778 . . . . 0.0 110.379 172.582 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.495 ' CG ' ' CD1' ' A' ' 29' ' ' PHE . 46.6 m95 -135.66 122.59 21.28 Favored 'General case' 0 C--O 1.234 0.246 0 CA-C-N 115.215 -0.902 . . . . 0.0 110.308 -176.173 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.809 HG23 ' CD1' ' A' ' 11' ' ' ILE . 6.7 p -98.71 133.53 40.88 Favored 'Isoleucine or valine' 0 C--O 1.242 0.69 0 CA-C-N 115.328 -0.851 . . . . 0.0 110.279 -177.095 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 19.0 t -69.24 110.0 4.38 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 114.855 -1.066 . . . . 0.0 109.725 163.725 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.553 ' HB2' ' HG3' ' A' ' 49' ' ' GLU . 1.4 tppt? -85.13 13.67 5.97 Favored 'General case' 0 N--CA 1.452 -0.37 0 CA-C-N 114.738 -1.119 . . . . 0.0 111.29 179.698 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.776 HD11 ' HB3' ' A' ' 47' ' ' GLU . 3.8 mp -90.77 -75.36 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.209 0 CA-C-N 115.824 -0.625 . . . . 0.0 110.368 160.009 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 27.3 p -86.7 -41.48 14.14 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.818 -0.628 . . . . 0.0 110.517 -161.445 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 113.94 19.4 6.43 Favored Glycine 0 CA--C 1.526 0.761 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.575 -179.6 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.719 ' C ' HD13 ' A' ' 11' ' ' ILE . 86.7 t80 -80.06 160.28 25.87 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.345 -0.427 . . . . 0.0 110.142 168.082 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.809 ' CD1' HG23 ' A' ' 4' ' ' VAL . 7.4 mm -127.57 158.26 39.05 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.236 0 CA-C-N 114.703 -1.135 . . . . 0.0 110.109 -179.08 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.46 ' CE2' HD11 ' A' ' 32' ' ' LEU . 15.1 t80 -119.25 130.48 55.46 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 114.971 -1.013 . . . . 0.0 110.056 164.5 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -114.12 111.21 21.22 Favored 'General case' 0 C--O 1.236 0.363 0 CA-C-N 115.372 -0.831 . . . . 0.0 110.371 170.991 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.831 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 47.5 mt-10 -62.37 -17.62 59.48 Favored 'General case' 0 C--O 1.233 0.216 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.807 -174.096 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 2.9 t70 -60.73 -76.32 0.05 Allowed 'General case' 0 C--N 1.326 -0.417 0 CA-C-N 115.773 -0.649 . . . . 0.0 109.693 163.798 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.05 -19.42 52.81 Favored 'General case' 0 N--CA 1.455 -0.213 0 CA-C-N 113.876 -1.511 . . . . 0.0 110.537 -170.364 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 60.96 -158.71 29.19 Favored Glycine 0 CA--C 1.527 0.807 0 N-CA-C 110.455 -1.058 . . . . 0.0 110.455 -173.956 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.5 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 17.8 t70 -135.01 63.39 57.36 Favored Pre-proline 0 CA--C 1.542 0.65 0 CA-C-O 121.592 0.711 . . . . 0.0 109.839 -173.538 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -56.51 -22.24 41.91 Favored 'Trans proline' 0 N--CA 1.485 0.989 0 C-N-CA 122.424 2.082 . . . . 0.0 113.517 -175.868 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -61.63 -29.85 70.33 Favored 'General case' 0 C--N 1.332 -0.171 0 CA-C-N 114.858 -1.065 . . . . 0.0 110.435 -179.078 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 2.1 m-80 -130.51 21.07 5.15 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 115.3 -0.863 . . . . 0.0 110.392 -171.612 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.671 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 82.39 46.83 6.31 Favored Glycine 0 CA--C 1.525 0.703 0 N-CA-C 110.466 -1.053 . . . . 0.0 110.466 169.472 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.671 HD12 ' C ' ' A' ' 22' ' ' GLY . 2.5 mp -118.15 123.62 71.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 115.396 -0.402 . . . . 0.0 110.349 169.303 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 5.4 m -73.51 139.85 78.4 Favored Pre-proline 0 CA--C 1.543 0.674 0 CA-C-N 115.119 -0.946 . . . . 0.0 109.83 177.208 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 2.0 Cg_endo -57.19 72.56 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.091 0 C-N-CA 122.272 1.981 . . . . 0.0 113.532 173.393 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.3 0.08 OUTLIER Glycine 0 CA--C 1.526 0.757 0 N-CA-C 109.749 -1.34 . . . . 0.0 109.749 -162.841 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.484 ' HB ' HG23 ' A' ' 23' ' ' ILE . 18.3 m -60.27 149.74 32.46 Favored 'General case' 0 N--CA 1.455 -0.18 0 CA-C-N 114.672 -0.764 . . . . 0.0 110.701 176.461 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.543 ' HB2' ' HB2' ' A' ' 31' ' ' GLU . 30.9 mttt -106.08 171.17 7.49 Favored 'General case' 0 C--N 1.331 -0.227 0 CA-C-N 115.269 -0.878 . . . . 0.0 110.443 177.179 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.495 ' CD1' ' CG ' ' A' ' 3' ' ' TRP . 80.4 t80 -61.92 -65.09 0.74 Allowed 'General case' 0 CA--C 1.526 0.039 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.357 -172.81 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 2.1 tt0 -78.8 6.47 8.97 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.729 -1.123 . . . . 0.0 111.716 179.873 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.543 ' HB2' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -105.6 22.2 15.92 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.899 -0.591 . . . . 0.0 110.395 163.696 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.486 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 17.6 mt -88.31 169.95 12.49 Favored Pre-proline 0 CA--C 1.546 0.804 0 CA-C-N 115.247 -0.888 . . . . 0.0 109.622 168.157 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.453 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 8.5 Cg_exo -53.86 150.74 28.86 Favored 'Trans proline' 0 N--CA 1.484 0.945 0 C-N-CA 122.728 2.285 . . . . 0.0 113.36 168.251 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -76.97 -27.92 54.95 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.046 166.963 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.545 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.1 OUTLIER -68.8 -20.13 64.32 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.489 169.672 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.451 ' HB2' ' CB ' ' A' ' 33' ' ' PRO . 64.2 t90 -61.21 109.86 1.24 Allowed 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 115.418 -0.81 . . . . 0.0 110.259 -167.23 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.672 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.8 m -118.25 179.19 1.88 Allowed 'Isoleucine or valine' 0 C--N 1.332 -0.171 0 CA-C-N 114.956 -1.02 . . . . 0.0 110.343 178.171 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . . . . . . . . . 13.8 t -66.75 119.66 65.22 Favored Pre-proline 0 C--O 1.25 1.087 0 CA-C-N 115.198 -0.91 . . . . 0.0 109.475 179.834 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.427 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 17.9 Cg_exo -51.92 -26.29 24.32 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.781 2.32 . . . . 0.0 113.834 169.86 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.571 HD13 ' CG ' ' A' ' 10' ' ' TYR . 3.6 mp -92.18 -79.13 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.24 0 CA-C-N 114.842 -1.072 . . . . 0.0 110.557 -177.052 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.3 p -83.14 -25.43 31.9 Favored 'General case' 0 C--O 1.232 0.163 0 CA-C-N 115.855 -0.612 . . . . 0.0 110.514 -162.189 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 89.89 28.24 19.03 Favored Glycine 0 CA--C 1.528 0.852 0 CA-C-N 114.741 -1.118 . . . . 0.0 110.512 -175.482 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -91.56 116.73 67.02 Favored Pre-proline 0 C--O 1.243 0.739 0 CA-C-O 121.263 0.554 . . . . 0.0 109.591 169.236 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.672 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.0 Cg_exo -51.46 177.26 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.45 2.1 . . . . 0.0 113.758 177.293 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.457 ' HG3' ' CZ ' ' A' ' 29' ' ' PHE . 1.4 ttpm? -61.08 -13.52 17.6 Favored 'General case' 0 C--N 1.333 -0.123 0 CA-C-N 115.24 -0.891 . . . . 0.0 110.683 -173.142 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 29.4 t -61.96 -37.36 84.47 Favored 'General case' 0 C--N 1.332 -0.187 0 CA-C-N 115.374 -0.83 . . . . 0.0 110.345 -171.782 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.776 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.9 OUTLIER -106.25 20.61 18.71 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.512 -0.767 . . . . 0.0 110.334 -166.279 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.449 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 2.1 m-85 -92.64 104.78 17.04 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 115.316 -0.857 . . . . 0.0 110.223 167.17 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.553 ' HG3' ' HB2' ' A' ' 6' ' ' LYS . 1.9 mt-10 -84.86 127.87 34.35 Favored 'General case' 0 N--CA 1.455 -0.184 0 CA-C-N 114.315 -1.311 . . . . 0.0 110.41 -176.409 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.43 ' HB3' ' CE2' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -78.92 109.15 12.92 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.233 -0.894 . . . . 0.0 110.363 -170.659 . . . . . . . . 3 3 . 1 . 032 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.639 HD23 ' O ' ' A' ' 51' ' ' LEU . 2.7 tt -115.35 65.21 0.69 Allowed 'General case' 0 N--CA 1.454 -0.272 0 CA-C-N 114.945 -1.025 . . . . 0.0 110.426 -175.57 . . . . . . . . 2 2 . 1 . 032 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 -61.03 155.76 19.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.428 -169.303 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . 0.509 ' HB2' ' HD3' ' A' ' 2' ' ' LYS . 11.0 t0 . . . . . 0 C--O 1.24 0.579 0 CA-C-N 115.324 -0.853 . . . . 0.0 110.361 -169.707 . . . . . . . . 1 1 . 1 . 032 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 033 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.602 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.771 0 CA-C-O 121.15 0.5 . . . . 0.0 109.74 . . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 1.1 mttt -116.91 131.17 57.02 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.434 173.097 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 23.5 m95 -114.74 120.64 40.77 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.262 -0.881 . . . . 0.0 110.453 172.533 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.618 HG23 ' CD1' ' A' ' 11' ' ' ILE . 4.4 p -86.22 162.33 2.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.253 177.782 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.422 ' N ' HG22 ' A' ' 4' ' ' VAL . 27.6 t -87.43 118.55 26.96 Favored 'General case' 0 C--O 1.237 0.444 0 CA-C-N 115.784 -0.644 . . . . 0.0 109.42 160.999 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -85.11 13.2 6.48 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.166 -1.379 . . . . 0.0 111.197 176.086 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.515 HD13 ' CB ' ' A' ' 43' ' ' ALA . 3.9 mp -98.17 -78.57 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.228 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.51 158.464 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -85.37 -38.05 19.18 Favored 'General case' 0 C--O 1.233 0.197 0 CA-C-N 116.076 -0.511 . . . . 0.0 110.588 -160.637 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.92 20.25 9.51 Favored Glycine 0 CA--C 1.526 0.734 0 CA-C-N 114.69 -1.141 . . . . 0.0 110.612 -179.526 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.834 ' O ' HD13 ' A' ' 11' ' ' ILE . 72.5 t80 -68.53 161.79 27.11 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-O 121.032 0.444 . . . . 0.0 109.811 160.682 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.834 HD13 ' O ' ' A' ' 10' ' ' TYR . 7.1 mm -127.3 154.11 37.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 CA-C-N 115.092 -0.958 . . . . 0.0 110.325 -178.149 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.466 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 19.2 t80 -115.63 134.91 54.59 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.073 165.714 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.7 t0 -117.79 109.33 16.45 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.349 168.562 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.602 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 31.8 mt-10 -64.97 -22.78 67.05 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.462 -169.703 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -69.36 -32.2 71.1 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 115.403 -0.817 . . . . 0.0 110.367 171.717 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -95.83 -30.34 13.73 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 115.304 -0.862 . . . . 0.0 110.285 -170.725 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 78.36 -149.44 33.82 Favored Glycine 0 CA--C 1.527 0.814 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 177.88 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.563 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.2 t0 -152.65 56.09 1.66 Allowed Pre-proline 0 CA--C 1.543 0.686 0 CA-C-O 121.514 0.674 . . . . 0.0 109.723 -171.372 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 5.9 Cg_endo -50.72 -19.3 5.02 Favored 'Trans proline' 0 N--CA 1.484 0.95 0 C-N-CA 122.565 2.177 . . . . 0.0 113.552 -176.222 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -60.92 -37.92 83.97 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.931 -1.031 . . . . 0.0 110.452 174.529 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -120.7 19.32 11.87 Favored 'General case' 0 C--N 1.331 -0.204 0 CA-C-N 114.927 -1.033 . . . . 0.0 110.352 178.921 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.478 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 70.79 53.31 11.93 Favored Glycine 0 CA--C 1.526 0.772 0 N-CA-C 110.394 -1.082 . . . . 0.0 110.394 168.37 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.652 ' N ' HD12 ' A' ' 23' ' ' ILE . 2.5 mp -107.41 123.12 62.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.298 168.21 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -71.69 135.89 83.33 Favored Pre-proline 0 CA--C 1.541 0.631 0 CA-C-N 115.329 -0.851 . . . . 0.0 109.871 -174.0 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 3.4 Cg_endo -56.79 72.88 0.04 OUTLIER 'Trans proline' 0 N--CA 1.486 1.069 0 C-N-CA 122.2 1.934 . . . . 0.0 113.431 173.632 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.97 -34.4 0.08 OUTLIER Glycine 0 CA--C 1.526 0.753 0 N-CA-C 109.82 -1.312 . . . . 0.0 109.82 -162.255 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.471 HG21 HD23 ' A' ' 32' ' ' LEU . 19.8 m -60.49 152.91 24.57 Favored 'General case' 0 C--N 1.331 -0.212 0 CA-C-N 114.766 -0.717 . . . . 0.0 110.515 178.283 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.534 ' HA ' ' HG2' ' A' ' 14' ' ' GLU . 0.0 OUTLIER -118.92 174.64 6.18 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.444 -0.798 . . . . 0.0 110.588 168.215 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.6 t80 -60.79 -64.1 1.07 Allowed 'General case' 0 N--CA 1.464 0.241 0 CA-C-N 115.886 -0.597 . . . . 0.0 110.447 -161.24 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 1.7 tp10 -78.76 9.4 4.19 Favored 'General case' 0 C--O 1.234 0.274 0 CA-C-N 114.905 -1.043 . . . . 0.0 111.576 -177.367 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.464 ' CB ' ' HG2' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -101.12 -9.05 21.71 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.642 168.089 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.471 HD23 HG21 ' A' ' 27' ' ' THR . 22.8 mt -60.77 159.98 22.65 Favored Pre-proline 0 CA--C 1.545 0.778 0 CA-C-N 114.999 -1.001 . . . . 0.0 109.8 172.863 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.49 ' HG2' ' HB2' ' A' ' 36' ' ' TRP . 1.9 Cg_endo -48.57 144.75 13.5 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.685 2.257 . . . . 0.0 113.627 170.282 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -61.46 -42.96 99.57 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.275 -0.875 . . . . 0.0 110.306 173.396 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.59 ' O ' HG13 ' A' ' 37' ' ' VAL . 58.8 m-20 -69.48 -14.21 62.76 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 115.139 -0.937 . . . . 0.0 111.075 -178.311 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.49 ' HB2' ' HG2' ' A' ' 33' ' ' PRO . 71.8 t90 -60.47 132.41 53.81 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 115.917 -0.583 . . . . 0.0 110.493 -162.739 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG12 ' HA ' ' A' ' 44' ' ' PRO . 30.8 m -133.57 -177.32 2.03 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-N 115.104 -0.953 . . . . 0.0 110.338 -174.088 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.423 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.7 t -71.11 124.29 90.76 Favored Pre-proline 0 C--O 1.252 1.236 0 CA-C-N 114.847 -1.069 . . . . 0.0 109.399 177.273 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.423 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.2 Cg_endo -56.67 -22.5 44.4 Favored 'Trans proline' 0 N--CA 1.483 0.875 0 C-N-CA 122.838 2.359 . . . . 0.0 113.716 170.388 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.656 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -95.89 -81.95 0.22 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.187 0 CA-C-N 114.839 -1.073 . . . . 0.0 110.41 -179.569 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -78.85 -22.09 46.59 Favored 'General case' 0 C--N 1.332 -0.179 0 CA-C-N 115.613 -0.722 . . . . 0.0 110.817 -163.286 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 79.59 31.65 40.14 Favored Glycine 0 CA--C 1.527 0.832 0 N-CA-C 110.468 -1.053 . . . . 0.0 110.468 -175.379 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.515 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -83.53 142.53 43.12 Favored Pre-proline 0 CA--C 1.543 0.711 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 168.512 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.77 ' HA ' HG12 ' A' ' 37' ' ' VAL . 8.1 Cg_exo -58.42 159.88 18.38 Favored 'Trans proline' 0 N--CA 1.484 0.946 0 C-N-CA 122.362 2.042 . . . . 0.0 113.52 179.644 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.507 ' HG2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -60.04 -12.26 7.77 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.519 -1.219 . . . . 0.0 110.538 172.766 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 31.0 t -94.34 21.96 6.52 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-N 114.767 -1.106 . . . . 0.0 110.379 -177.965 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.515 ' CB ' HD11 ' A' ' 7' ' ' ILE . 14.5 mm-40 -139.9 23.97 2.4 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.352 167.45 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -99.74 111.33 23.67 Favored 'General case' 0 N--CA 1.454 -0.267 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.346 172.826 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' O ' HG12 ' A' ' 4' ' ' VAL . 3.5 tp10 -89.96 142.19 27.94 Favored 'General case' 0 N--CA 1.454 -0.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 110.548 -170.922 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -92.87 129.68 38.71 Favored 'General case' 0 C--N 1.332 -0.162 0 CA-C-N 115.034 -0.985 . . . . 0.0 110.409 -176.295 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.459 HD23 ' O ' ' A' ' 51' ' ' LEU . 5.3 tt 60.08 82.56 0.15 Allowed 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.586 170.425 . . . . . . . . 2 2 . 1 . 033 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.57 ' HB2' HG11 ' A' ' 4' ' ' VAL . 0.0 OUTLIER -99.99 87.34 3.47 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.318 -0.856 . . . . 0.0 110.364 170.472 . . . . . . . . 3 3 . 1 . 033 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--O 1.24 0.585 0 CA-C-N 115.378 -0.828 . . . . 0.0 110.338 -170.109 . . . . . . . . 1 1 . 1 . 033 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.743 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.755 0 CA-C-O 121.088 0.471 . . . . 0.0 109.753 . . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -113.54 119.34 37.18 Favored 'General case' 0 C--N 1.33 -0.259 0 CA-C-N 115.346 -0.843 . . . . 0.0 110.429 176.266 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.538 ' CZ3' ' HG2' ' A' ' 50' ' ' LYS . 18.5 m95 -104.42 154.45 19.85 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.287 -0.87 . . . . 0.0 110.413 175.226 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 10' ' ' TYR . 7.1 p -123.57 155.96 30.05 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.192 0 CA-C-N 114.977 -1.011 . . . . 0.0 110.148 177.182 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.582 ' SG ' HD12 ' A' ' 7' ' ' ILE . 22.1 t -81.36 114.38 20.09 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.818 -0.628 . . . . 0.0 109.637 160.649 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 7.4 ttpt -61.77 -24.17 66.67 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 114.45 -1.25 . . . . 0.0 110.41 177.114 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.96 HD11 ' HB3' ' A' ' 47' ' ' GLU . 2.1 mt -80.76 -69.13 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.255 0 CA-C-N 114.94 -1.027 . . . . 0.0 110.669 -171.29 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -90.84 -35.05 15.03 Favored 'General case' 0 C--N 1.333 -0.134 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.552 -167.736 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 101.64 34.63 4.34 Favored Glycine 0 CA--C 1.527 0.832 0 CA-C-N 114.619 -1.173 . . . . 0.0 110.522 -175.172 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.741 ' HB2' HD13 ' A' ' 40' ' ' ILE . 59.2 t80 -85.44 170.15 12.96 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-O 121.1 0.476 . . . . 0.0 110.094 162.95 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.531 HG23 ' O ' ' A' ' 3' ' ' TRP . 3.7 mp -142.31 140.7 28.94 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.215 0 CA-C-N 115.042 -0.981 . . . . 0.0 110.464 -178.501 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.472 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.3 t80 -104.38 137.6 42.02 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.351 -0.841 . . . . 0.0 110.137 164.409 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 40.8 t0 -122.33 110.77 16.08 Favored 'General case' 0 C--O 1.235 0.337 0 CA-C-N 115.268 -0.878 . . . . 0.0 110.392 169.868 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.743 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 23.5 mt-10 -62.12 -17.93 59.28 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.838 -1.074 . . . . 0.0 110.796 -174.45 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 8.5 t70 -60.7 -76.57 0.05 OUTLIER 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 115.778 -0.646 . . . . 0.0 109.688 163.897 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.11 -18.38 46.87 Favored 'General case' 0 N--CA 1.453 -0.292 0 CA-C-N 113.879 -1.509 . . . . 0.0 110.547 -170.058 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 63.2 -163.68 30.16 Favored Glycine 0 CA--C 1.527 0.836 0 N-CA-C 110.403 -1.079 . . . . 0.0 110.403 -172.26 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.5 ' H ' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -136.22 50.04 3.77 Favored Pre-proline 0 CA--C 1.542 0.663 0 CA-C-O 121.457 0.646 . . . . 0.0 109.792 -171.584 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.436 ' CD ' ' N ' ' A' ' 18' ' ' ASP . 6.2 Cg_endo -49.71 -16.81 1.62 Allowed 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.395 2.063 . . . . 0.0 113.551 179.23 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -61.02 -27.33 68.25 Favored 'General case' 0 N--CA 1.454 -0.242 0 CA-C-N 114.891 -1.05 . . . . 0.0 110.445 175.633 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.425 HD21 ' HB3' ' A' ' 39' ' ' PRO . 3.8 m-80 -137.38 28.61 2.75 Favored 'General case' 0 C--N 1.331 -0.214 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.378 -177.968 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 78.09 48.12 7.88 Favored Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.386 -1.086 . . . . 0.0 110.386 168.596 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.5 ' HB ' ' H ' ' A' ' 18' ' ' ASP . 4.2 mp -117.45 128.67 74.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.366 -0.417 . . . . 0.0 110.379 170.039 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 46.4 m -76.61 141.64 69.38 Favored Pre-proline 0 CA--C 1.543 0.685 0 CA-C-N 115.059 -0.973 . . . . 0.0 109.77 178.89 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -54.82 89.45 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.024 0 C-N-CA 122.507 2.138 . . . . 0.0 113.557 172.649 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 133.77 18.95 0.95 Allowed Glycine 0 CA--C 1.526 0.751 0 N-CA-C 110.516 -1.034 . . . . 0.0 110.516 178.549 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.471 ' HB ' ' CG2' ' A' ' 23' ' ' ILE . 90.5 m -84.08 148.48 26.8 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.497 -0.351 . . . . 0.0 110.323 166.691 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.674 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -91.5 164.72 13.69 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.271 -0.877 . . . . 0.0 110.412 -174.509 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.498 ' CE2' ' HD2' ' A' ' 45' ' ' LYS . 59.4 t80 -61.61 -66.53 0.52 Allowed 'General case' 0 C--O 1.232 0.17 0 CA-C-N 114.811 -1.086 . . . . 0.0 110.266 -175.81 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -78.95 6.18 9.88 Favored 'General case' 0 N--CA 1.452 -0.33 0 CA-C-N 114.411 -1.268 . . . . 0.0 111.72 177.329 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.674 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 8.8 mm-40 -99.75 21.55 12.3 Favored 'General case' 0 C--N 1.327 -0.389 0 CA-C-N 115.949 -0.569 . . . . 0.0 110.405 164.294 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.564 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 32.8 mt -89.62 173.92 5.39 Favored Pre-proline 0 CA--C 1.544 0.713 0 CA-C-N 115.312 -0.858 . . . . 0.0 109.679 166.961 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.588 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 22.6 Cg_exo -50.94 154.56 7.0 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.597 2.198 . . . . 0.0 113.656 175.022 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.5 m-20 -67.43 -33.13 74.53 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 115.158 -0.928 . . . . 0.0 110.029 167.425 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -106.64 20.14 19.45 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.71 -1.132 . . . . 0.0 110.716 177.741 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.588 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 39.4 t90 -60.59 104.78 0.37 Allowed 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.309 -0.86 . . . . 0.0 110.335 164.208 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.73 HG12 ' HA ' ' A' ' 44' ' ' PRO . 19.1 m -114.84 179.44 1.44 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.213 0 CA-C-N 115.274 -0.876 . . . . 0.0 110.334 174.206 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.483 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 14.8 t -63.14 123.49 80.52 Favored Pre-proline 0 C--O 1.252 1.206 0 CA-C-N 115.058 -0.974 . . . . 0.0 109.448 177.61 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.425 ' HB3' HD21 ' A' ' 21' ' ' ASN . 21.6 Cg_exo -53.08 -24.97 27.14 Favored 'Trans proline' 0 N--CA 1.484 0.933 0 C-N-CA 122.808 2.339 . . . . 0.0 113.847 169.175 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.741 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -95.87 -84.28 0.17 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.196 0 CA-C-N 114.96 -1.018 . . . . 0.0 110.244 -179.572 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 32.0 p -76.0 -17.88 59.51 Favored 'General case' 0 N--CA 1.455 -0.201 0 CA-C-N 115.299 -0.864 . . . . 0.0 111.133 -162.325 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 88.43 23.38 37.13 Favored Glycine 0 CA--C 1.525 0.7 0 N-CA-C 110.442 -1.063 . . . . 0.0 110.442 178.828 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.748 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -94.88 122.7 59.74 Favored Pre-proline 0 C--O 1.244 0.766 0 CA-C-N 115.008 -0.596 . . . . 0.0 109.531 -178.56 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.73 ' HA ' HG12 ' A' ' 37' ' ' VAL . 11.7 Cg_exo -53.5 173.14 0.19 Allowed 'Trans proline' 0 N--CA 1.488 1.172 0 C-N-CA 122.279 1.986 . . . . 0.0 113.593 -178.822 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.498 ' HD2' ' CE2' ' A' ' 29' ' ' PHE . 4.4 ttpt -61.34 -10.92 8.11 Favored 'General case' 0 C--O 1.232 0.147 0 CA-C-N 114.787 -1.097 . . . . 0.0 110.689 -177.452 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 6.3 t -92.04 21.51 4.97 Favored 'General case' 0 C--O 1.231 0.108 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.55 -171.528 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.96 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.0 OUTLIER -144.81 24.38 1.51 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.278 -0.873 . . . . 0.0 110.296 166.864 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.458 ' HB2' ' HZ ' ' A' ' 29' ' ' PHE . 3.0 m-85 -98.19 109.95 22.62 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.205 -0.907 . . . . 0.0 110.413 168.971 . . . . . . . . 2 2 . 1 . 034 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.6 tt0 -74.29 -177.47 3.03 Favored 'General case' 0 C--O 1.23 0.065 0 CA-C-N 114.845 -1.07 . . . . 0.0 110.274 176.092 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.538 ' HG2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -126.27 146.25 50.08 Favored 'General case' 0 N--CA 1.453 -0.289 0 CA-C-N 115.064 -0.971 . . . . 0.0 110.426 175.2 . . . . . . . . 3 3 . 1 . 034 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 3.2 tp 60.05 97.54 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.279 0 CA-C-N 114.949 -1.023 . . . . 0.0 110.522 171.318 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 5.8 mt-10 -61.1 -176.26 0.06 Allowed 'General case' 0 N--CA 1.455 -0.225 0 CA-C-N 114.798 -1.092 . . . . 0.0 110.464 177.77 . . . . . . . . 1 1 . 1 . 034 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 19.5 t0 . . . . . 0 C--O 1.239 0.541 0 CA-C-N 115.345 -0.843 . . . . 0.0 110.354 171.089 . . . . . . . . 0 0 . 1 . 034 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.54 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.473 0.72 0 CA-C-O 121.119 0.485 . . . . 0.0 109.762 . . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 6.1 pttt -119.68 132.79 55.76 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.538 -0.755 . . . . 0.0 110.484 170.791 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.519 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 25.9 m95 -116.33 121.55 42.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.379 -0.828 . . . . 0.0 110.278 171.672 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.575 HG23 ' O ' ' A' ' 10' ' ' TYR . 4.4 p -89.98 154.99 3.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-N 114.967 -1.015 . . . . 0.0 110.285 179.183 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.487 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 36.1 t -81.75 112.55 19.02 Favored 'General case' 0 N--CA 1.466 0.342 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 160.263 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 8.6 ttmt -61.75 -23.18 66.0 Favored 'General case' 0 N--CA 1.454 -0.251 0 CA-C-N 114.4 -1.273 . . . . 0.0 110.47 178.493 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.831 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.3 mp -79.65 -65.43 0.78 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.305 0 CA-C-N 115.181 -0.918 . . . . 0.0 110.903 -171.624 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.5 p -92.29 -40.43 10.95 Favored 'General case' 0 C--O 1.232 0.159 0 CA-C-N 115.63 -0.714 . . . . 0.0 110.611 -170.161 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 112.23 19.58 7.08 Favored Glycine 0 CA--C 1.527 0.79 0 CA-C-N 114.733 -1.122 . . . . 0.0 110.513 -179.506 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.575 ' O ' HG23 ' A' ' 4' ' ' VAL . 78.3 t80 -69.23 169.66 11.7 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-O 120.949 0.404 . . . . 0.0 110.12 165.009 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.494 ' N ' ' CG ' ' A' ' 10' ' ' TYR . 4.0 mp -145.8 131.0 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.153 0 CA-C-N 114.761 -1.108 . . . . 0.0 110.388 -179.771 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 16.4 t80 -83.92 143.28 29.96 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 115.299 -0.864 . . . . 0.0 110.087 162.489 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.3 t0 -124.95 104.4 8.56 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.397 168.904 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.54 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 31.1 mt-10 -61.97 -18.01 58.94 Favored 'General case' 0 C--O 1.234 0.244 0 CA-C-N 114.791 -1.095 . . . . 0.0 110.781 -174.753 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 7.7 t70 -60.93 -77.65 0.04 OUTLIER 'General case' 0 C--N 1.326 -0.45 0 CA-C-N 115.769 -0.65 . . . . 0.0 109.686 163.417 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.49 -23.35 64.44 Favored 'General case' 0 N--CA 1.454 -0.264 0 CA-C-N 113.843 -1.526 . . . . 0.0 110.434 -171.803 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 71.73 -155.44 52.05 Favored Glycine 0 CA--C 1.526 0.756 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -178.953 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.553 ' HB3' HD13 ' A' ' 23' ' ' ILE . 16.3 t0 -147.16 56.77 3.07 Favored Pre-proline 0 CA--C 1.542 0.658 0 CA-C-O 121.647 0.737 . . . . 0.0 109.817 -170.119 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_endo -54.31 -23.38 30.19 Favored 'Trans proline' 0 N--CA 1.484 0.932 0 C-N-CA 122.532 2.155 . . . . 0.0 113.564 -176.219 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -61.26 -35.7 77.98 Favored 'General case' 0 C--N 1.33 -0.252 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.449 177.382 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . . . . . . . . . 22.6 m-80 -119.68 19.59 12.51 Favored 'General case' 0 C--N 1.332 -0.178 0 CA-C-N 115.106 -0.952 . . . . 0.0 110.356 -176.521 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.433 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 78.7 51.82 5.33 Favored Glycine 0 CA--C 1.526 0.758 0 N-CA-C 110.398 -1.081 . . . . 0.0 110.398 168.835 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.556 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.0 mp -119.14 125.83 74.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 115.308 -0.446 . . . . 0.0 110.37 169.876 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -74.54 141.59 76.58 Favored Pre-proline 0 CA--C 1.542 0.643 0 CA-C-N 115.108 -0.951 . . . . 0.0 109.859 172.692 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -59.26 72.25 0.05 OUTLIER 'Trans proline' 0 N--CA 1.484 0.956 0 C-N-CA 122.498 2.132 . . . . 0.0 113.602 173.795 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.71 -34.39 0.08 OUTLIER Glycine 0 CA--C 1.525 0.685 0 N-CA-C 109.852 -1.299 . . . . 0.0 109.852 -162.201 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.556 ' HB ' HG23 ' A' ' 23' ' ' ILE . 23.5 m -60.76 158.02 13.69 Favored 'General case' 0 N--CA 1.455 -0.198 0 CA-C-N 114.888 -0.656 . . . . 0.0 110.598 -179.243 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.579 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 2.8 mmmt -110.58 173.13 6.47 Favored 'General case' 0 N--CA 1.453 -0.297 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.444 177.904 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 76.3 t80 -61.87 -64.66 0.87 Allowed 'General case' 0 C--N 1.334 -0.077 0 CA-C-N 114.876 -1.056 . . . . 0.0 110.293 -175.88 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 41.7 tt0 -78.82 6.47 8.99 Favored 'General case' 0 N--CA 1.452 -0.332 0 CA-C-N 114.684 -1.144 . . . . 0.0 111.707 178.784 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.43 ' HB3' ' H ' ' A' ' 28' ' ' LYS . 3.0 tt0 -105.33 21.88 16.38 Favored 'General case' 0 C--N 1.326 -0.422 0 CA-C-N 115.915 -0.584 . . . . 0.0 110.452 163.339 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.579 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 20.7 mt -91.63 173.36 5.4 Favored Pre-proline 0 CA--C 1.546 0.796 0 CA-C-N 115.279 -0.873 . . . . 0.0 109.551 167.922 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.568 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 15.4 Cg_exo -50.31 151.97 8.95 Favored 'Trans proline' 0 N--CA 1.483 0.898 0 C-N-CA 122.709 2.273 . . . . 0.0 113.532 171.592 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.1 OUTLIER -71.82 -30.6 65.66 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.066 -0.97 . . . . 0.0 110.042 169.202 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.74 ' O ' HG13 ' A' ' 37' ' ' VAL . 4.7 m-20 -105.42 21.74 16.65 Favored 'General case' 0 N--CA 1.452 -0.331 0 CA-C-N 114.684 -1.144 . . . . 0.0 110.704 174.928 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.567 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 63.7 t90 -60.38 122.46 14.62 Favored 'General case' 0 N--CA 1.454 -0.247 0 CA-C-N 114.964 -1.017 . . . . 0.0 110.457 166.53 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.74 HG13 ' O ' ' A' ' 35' ' ' ASP . 26.7 m -132.57 167.4 26.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.361 -172.607 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 17.9 t -62.15 119.0 45.14 Favored Pre-proline 0 C--O 1.253 1.244 0 CA-C-N 115.327 -0.851 . . . . 0.0 109.2 169.552 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -53.16 -25.08 28.22 Favored 'Trans proline' 0 N--CA 1.485 0.976 0 C-N-CA 122.868 2.378 . . . . 0.0 113.591 170.101 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.505 HD11 ' CD1' ' A' ' 10' ' ' TYR . 4.1 mp -93.09 -79.32 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 CA-C-N 114.93 -1.032 . . . . 0.0 110.515 -175.287 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.2 p -81.23 -24.16 37.58 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.647 -0.706 . . . . 0.0 110.685 -163.814 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 87.99 30.08 18.53 Favored Glycine 0 CA--C 1.527 0.808 0 CA-C-N 114.8 -1.091 . . . . 0.0 110.471 -175.944 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.46 ' HA ' ' HD2' ' A' ' 44' ' ' PRO . . . -91.65 107.48 22.52 Favored Pre-proline 0 CA--C 1.544 0.734 0 CA-C-O 121.29 0.567 . . . . 0.0 109.691 170.926 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.601 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 2.3 Cg_endo -46.16 169.28 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.003 0 C-N-CA 122.859 2.372 . . . . 0.0 113.626 169.855 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -61.19 -14.76 27.73 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 115.431 -0.804 . . . . 0.0 110.67 -169.588 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.32 -20.58 63.11 Favored 'General case' 0 C--N 1.331 -0.229 0 CA-C-N 115.574 -0.739 . . . . 0.0 110.423 -170.308 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.831 ' HB3' HD11 ' A' ' 7' ' ' ILE . 3.9 mt-10 -127.56 29.56 5.48 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.414 -0.812 . . . . 0.0 110.224 -169.679 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.487 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 5.5 m-85 -96.33 125.08 40.58 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 115.292 -0.867 . . . . 0.0 110.296 166.263 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.459 ' HB3' HG13 ' A' ' 4' ' ' VAL . 4.1 tp10 -83.66 156.76 22.5 Favored 'General case' 0 C--O 1.231 0.096 0 CA-C-N 114.894 -1.048 . . . . 0.0 110.271 175.706 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HB2' ' NZ ' ' A' ' 50' ' ' LYS . 0.0 OUTLIER -117.96 126.28 52.04 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 115.329 -0.85 . . . . 0.0 110.443 -170.316 . . . . . . . . 3 3 . 1 . 035 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 27.3 mt 60.09 56.94 3.16 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 115.124 -0.944 . . . . 0.0 110.694 -177.775 . . . . . . . . 1 1 . 1 . 035 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -136.63 167.4 21.47 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 115.363 -0.835 . . . . 0.0 110.366 169.108 . . . . . . . . 2 2 . 1 . 035 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 2.0 p30 . . . . . 0 C--O 1.239 0.504 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.397 179.544 . . . . . . . . 0 0 . 1 . 035 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 036 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.607 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.808 0 CA-C-O 121.137 0.494 . . . . 0.0 109.702 . . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.445 ' HE3' ' HB3' ' A' ' 2' ' ' LYS . 0.4 OUTLIER -112.7 136.69 51.99 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.531 -0.758 . . . . 0.0 110.332 170.681 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.547 ' O ' HG23 ' A' ' 11' ' ' ILE . 33.5 m95 -114.72 171.66 7.51 Favored 'General case' 0 N--CA 1.454 -0.26 0 CA-C-N 115.02 -0.991 . . . . 0.0 110.491 177.245 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.577 HG13 ' HB3' ' A' ' 49' ' ' GLU . 4.6 p -144.09 154.02 15.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 115.123 -0.944 . . . . 0.0 110.323 -179.581 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.0 t -85.52 117.34 24.37 Favored 'General case' 0 C--O 1.236 0.37 0 CA-C-N 115.75 -0.659 . . . . 0.0 109.924 164.97 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.468 ' HD2' ' N ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -88.03 16.08 6.5 Favored 'General case' 0 N--CA 1.453 -0.325 0 CA-C-N 114.432 -1.258 . . . . 0.0 110.987 176.506 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.704 HD13 ' HB3' ' A' ' 47' ' ' GLU . 2.0 mp -100.51 -79.0 0.34 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-N 115.911 -0.586 . . . . 0.0 110.465 159.328 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.1 p -80.91 -31.3 35.19 Favored 'General case' 0 C--N 1.333 -0.137 0 CA-C-N 115.977 -0.556 . . . . 0.0 110.489 -162.676 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 99.34 24.22 10.47 Favored Glycine 0 CA--C 1.526 0.77 0 CA-C-N 114.713 -1.13 . . . . 0.0 110.572 -177.027 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.625 ' CG ' HD13 ' A' ' 40' ' ' ILE . 65.2 t80 -76.6 170.21 16.83 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-O 121.027 0.441 . . . . 0.0 110.191 164.828 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.547 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.0 mp -143.24 146.42 21.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.257 0 CA-C-N 115.194 -0.912 . . . . 0.0 110.389 -175.274 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . . . . . . . . . 12.4 t80 -111.24 139.09 46.91 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.388 -0.824 . . . . 0.0 110.143 164.394 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 44.4 t0 -124.91 107.15 10.57 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.171 -0.922 . . . . 0.0 110.451 173.811 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.607 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 28.6 mt-10 -61.42 -19.53 62.05 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.377 -0.828 . . . . 0.0 110.407 -172.203 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -84.72 -21.47 30.09 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 115.3 -0.864 . . . . 0.0 110.393 -172.335 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -101.04 -26.5 13.69 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 114.973 -1.012 . . . . 0.0 110.278 177.608 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 87.64 -176.96 46.62 Favored Glycine 0 CA--C 1.526 0.777 0 CA-C-N 114.88 -1.054 . . . . 0.0 110.478 -176.647 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.5 t0 -135.87 58.78 25.26 Favored Pre-proline 0 CA--C 1.543 0.675 0 CA-C-O 121.503 0.668 . . . . 0.0 109.68 -178.588 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -55.57 -24.71 46.11 Favored 'Trans proline' 0 N--CA 1.486 1.062 0 C-N-CA 122.472 2.115 . . . . 0.0 113.475 -171.8 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -61.39 -28.89 69.57 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.457 179.225 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.434 ' C ' HD12 ' A' ' 23' ' ' ILE . 4.1 m-80 -122.82 18.28 10.22 Favored 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.161 -0.927 . . . . 0.0 110.382 -176.209 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.412 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 79.25 48.11 7.07 Favored Glycine 0 CA--C 1.525 0.674 0 N-CA-C 110.447 -1.061 . . . . 0.0 110.447 170.439 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.697 HG23 ' HB ' ' A' ' 27' ' ' THR . 4.1 mp -119.38 136.72 55.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 115.348 -0.426 . . . . 0.0 110.316 172.034 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER -93.3 147.9 34.61 Favored Pre-proline 0 CA--C 1.544 0.715 0 CA-C-N 115.02 -0.991 . . . . 0.0 109.827 176.994 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 4.7 Cg_exo -55.52 91.34 0.04 OUTLIER 'Trans proline' 0 N--CA 1.485 1.012 0 C-N-CA 122.549 2.166 . . . . 0.0 113.466 173.272 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.52 19.03 1.37 Allowed Glycine 0 CA--C 1.526 0.765 0 N-CA-C 110.514 -1.034 . . . . 0.0 110.514 179.585 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.697 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.6 m -90.82 152.51 20.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 115.377 -0.411 . . . . 0.0 110.35 168.415 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.571 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.1 OUTLIER -97.75 158.7 15.37 Favored 'General case' 0 C--O 1.235 0.305 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.316 -170.464 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.52 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 78.6 t80 -61.59 -65.28 0.72 Allowed 'General case' 0 C--O 1.231 0.124 0 CA-C-N 114.806 -1.088 . . . . 0.0 110.276 -177.41 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -78.98 6.12 10.07 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.459 -1.246 . . . . 0.0 111.693 177.29 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.473 ' CB ' ' HB2' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -104.32 20.83 17.69 Favored 'General case' 0 C--N 1.328 -0.362 0 CA-C-N 116.005 -0.543 . . . . 0.0 110.532 163.884 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.571 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 19.3 mt -89.43 174.02 5.33 Favored Pre-proline 0 CA--C 1.546 0.815 0 CA-C-N 115.341 -0.845 . . . . 0.0 109.559 167.097 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.555 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.3 Cg_exo -51.48 153.13 10.94 Favored 'Trans proline' 0 N--CA 1.483 0.909 0 C-N-CA 122.622 2.215 . . . . 0.0 113.58 172.526 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -74.14 -29.31 61.74 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 115.001 -0.999 . . . . 0.0 109.966 167.421 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 1.3 t0 -98.25 16.15 22.31 Favored 'General case' 0 N--CA 1.451 -0.386 0 CA-C-N 114.66 -1.154 . . . . 0.0 111.15 173.96 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.536 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 31.5 t90 -69.86 101.97 1.85 Allowed 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 115.422 -0.808 . . . . 0.0 110.477 164.028 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.684 HG12 ' HA ' ' A' ' 44' ' ' PRO . 17.5 m -113.25 -176.59 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 115.373 -0.83 . . . . 0.0 110.344 172.168 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.455 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 13.6 t -62.76 123.15 78.41 Favored Pre-proline 0 C--O 1.251 1.162 0 CA-C-N 115.25 -0.886 . . . . 0.0 109.478 179.475 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.436 ' HB2' HD12 ' A' ' 40' ' ' ILE . 22.4 Cg_exo -51.56 -24.07 16.23 Favored 'Trans proline' 0 N--CA 1.484 0.94 0 C-N-CA 122.898 2.399 . . . . 0.0 113.849 168.577 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.659 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -98.15 -81.25 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.163 -0.926 . . . . 0.0 110.411 -178.892 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.9 p -80.48 -20.42 43.75 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.611 -0.722 . . . . 0.0 111.079 -162.181 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.455 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 103.54 -14.94 53.79 Favored Glycine 0 CA--C 1.524 0.644 0 N-CA-C 110.732 -0.947 . . . . 0.0 110.732 -179.835 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.497 ' HB1' ' CG ' ' A' ' 47' ' ' GLU . . . -61.56 117.12 24.67 Favored Pre-proline 0 C--O 1.242 0.695 0 CA-C-O 121.38 0.609 . . . . 0.0 109.744 -174.199 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.684 ' HA ' HG12 ' A' ' 37' ' ' VAL . 16.1 Cg_exo -49.82 164.25 0.42 Allowed 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.465 2.11 . . . . 0.0 113.782 178.152 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.407 ' H ' ' HG3' ' A' ' 45' ' ' LYS . 0.0 OUTLIER -61.28 -8.92 4.24 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.507 -0.77 . . . . 0.0 110.423 -172.028 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 95.2 p -91.67 18.78 7.07 Favored 'General case' 0 N--CA 1.453 -0.283 0 CA-C-N 114.749 -1.114 . . . . 0.0 110.792 176.772 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.704 ' HB3' HD13 ' A' ' 7' ' ' ILE . 0.5 OUTLIER -120.11 16.1 12.4 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.431 164.604 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.1 m-85 -109.86 117.97 35.25 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.335 -0.848 . . . . 0.0 110.504 -173.429 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.577 ' HB3' HG13 ' A' ' 4' ' ' VAL . 7.4 tp10 -81.12 173.35 12.65 Favored 'General case' 0 C--O 1.23 0.072 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.246 174.877 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.415 ' HG2' ' N ' ' A' ' 51' ' ' LEU . 6.7 tttt -121.7 162.37 20.88 Favored 'General case' 0 N--CA 1.453 -0.284 0 CA-C-N 115.093 -0.958 . . . . 0.0 110.45 -176.23 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.415 ' N ' ' HG2' ' A' ' 50' ' ' LYS . 0.1 OUTLIER 60.0 80.64 0.2 Allowed 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 115.211 -0.904 . . . . 0.0 110.589 169.597 . . . . . . . . 3 3 . 1 . 036 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -171.39 144.14 1.93 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.352 -0.84 . . . . 0.0 110.416 168.935 . . . . . . . . 2 2 . 1 . 036 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--O 1.241 0.623 0 CA-C-N 115.405 -0.816 . . . . 0.0 110.362 -170.132 . . . . . . . . 1 1 . 1 . 036 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 037 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.684 ' HB3' ' CD ' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.475 0.793 0 N-CA-C 109.687 -0.486 . . . . 0.0 109.687 . . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 11.2 tttp -131.61 113.93 14.21 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.454 -170.799 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.513 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 28.6 m95 -108.04 156.62 19.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 115.136 -0.938 . . . . 0.0 110.428 -177.954 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.926 HG23 HG13 ' A' ' 11' ' ' ILE . 9.0 p -132.69 137.43 54.08 Favored 'Isoleucine or valine' 0 C--O 1.236 0.376 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.283 173.121 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 17.8 t -74.26 109.82 8.06 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 115.01 -0.996 . . . . 0.0 109.925 164.329 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -64.94 -23.27 67.17 Favored 'General case' 0 N--CA 1.453 -0.313 0 CA-C-N 114.988 -1.006 . . . . 0.0 110.793 178.874 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.567 HD11 ' HG3' ' A' ' 47' ' ' GLU . 18.0 mm -71.07 -66.85 0.51 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.154 0 CA-C-N 114.645 -1.161 . . . . 0.0 110.38 -173.358 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.0 p -92.21 -39.73 11.39 Favored 'General case' 0 C--N 1.333 -0.124 0 CA-C-N 115.407 -0.815 . . . . 0.0 110.37 -169.064 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 102.5 49.76 1.17 Allowed Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.395 -1.082 . . . . 0.0 110.395 -166.682 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.583 ' CG ' HD13 ' A' ' 40' ' ' ILE . 77.3 t80 -117.92 134.46 54.92 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 115.333 -0.433 . . . . 0.0 110.204 169.202 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.926 HG13 HG23 ' A' ' 4' ' ' VAL . 2.5 mp -109.13 136.51 44.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 CA-C-N 114.862 -1.063 . . . . 0.0 110.459 -176.944 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.696 ' CE2' HD11 ' A' ' 32' ' ' LEU . 29.2 t80 -104.0 107.42 18.29 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.389 -0.823 . . . . 0.0 110.249 168.975 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -93.14 108.3 19.93 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 115.381 -0.827 . . . . 0.0 110.281 167.271 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.684 ' CD ' ' HB3' ' A' ' 1' ' ' ALA . 21.8 mt-10 -61.11 -22.44 64.65 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.375 -0.83 . . . . 0.0 110.401 -169.23 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 4.7 t0 -77.83 -27.87 50.06 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.102 -0.954 . . . . 0.0 110.399 -178.299 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -88.77 -26.73 21.58 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.364 -0.835 . . . . 0.0 110.395 170.05 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.427 ' C ' ' HD3' ' A' ' 19' ' ' PRO . . . 61.99 -172.23 8.97 Favored Glycine 0 CA--C 1.526 0.756 0 CA-C-N 114.77 -1.104 . . . . 0.0 110.384 175.425 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.52 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 15.8 t0 -131.94 55.59 18.99 Favored Pre-proline 0 CA--C 1.542 0.647 0 CA-C-O 121.658 0.742 . . . . 0.0 109.772 -165.424 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.459 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 9.8 Cg_exo -51.75 -18.51 6.45 Favored 'Trans proline' 0 N--CA 1.484 0.919 0 C-N-CA 122.548 2.165 . . . . 0.0 113.568 -177.496 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.76 -49.38 76.63 Favored 'General case' 0 N--CA 1.454 -0.256 0 CA-C-N 114.918 -1.037 . . . . 0.0 110.46 177.282 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.519 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.9 OUTLIER -104.18 19.56 19.93 Favored 'General case' 0 N--CA 1.454 -0.235 0 CA-C-N 115.024 -0.989 . . . . 0.0 110.389 -179.571 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.569 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 83.78 56.38 2.63 Favored Glycine 0 CA--C 1.525 0.699 0 N-CA-C 110.448 -1.061 . . . . 0.0 110.448 169.923 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.569 HD12 ' C ' ' A' ' 22' ' ' GLY . 4.5 mp -132.15 118.48 36.82 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.237 0 CA-C-N 115.044 -0.578 . . . . 0.0 110.466 178.581 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 15.9 m -79.89 150.19 71.72 Favored Pre-proline 0 CA--C 1.543 0.701 0 CA-C-N 115.294 -0.866 . . . . 0.0 109.819 -176.019 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 6.1 Cg_exo -55.05 89.49 0.04 OUTLIER 'Trans proline' 0 N--CA 1.487 1.09 0 C-N-CA 122.475 2.117 . . . . 0.0 113.527 173.575 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 132.59 18.95 1.09 Allowed Glycine 0 CA--C 1.526 0.719 0 N-CA-C 110.426 -1.07 . . . . 0.0 110.426 178.126 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.522 ' HB ' HG23 ' A' ' 23' ' ' ILE . 90.8 m -80.69 140.19 35.75 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.419 -0.391 . . . . 0.0 110.308 168.567 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.503 ' CB ' ' HB2' ' A' ' 31' ' ' GLU . 0.0 OUTLIER -87.27 161.57 17.91 Favored 'General case' 0 C--O 1.234 0.264 0 CA-C-N 114.931 -1.032 . . . . 0.0 110.505 -178.848 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.579 ' O ' HD12 ' A' ' 32' ' ' LEU . 73.3 t80 -61.86 -65.64 0.66 Allowed 'General case' 0 C--O 1.233 0.223 0 CA-C-N 115.035 -0.984 . . . . 0.0 110.284 -173.346 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 51.8 tt0 -78.88 8.91 4.77 Favored 'General case' 0 C--O 1.234 0.276 0 CA-C-N 114.492 -1.231 . . . . 0.0 111.707 179.55 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.503 ' HB2' ' CB ' ' A' ' 28' ' ' LYS . 0.0 OUTLIER -93.41 -15.11 25.99 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 115.478 -0.783 . . . . 0.0 110.441 167.922 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.696 HD11 ' CE2' ' A' ' 12' ' ' TYR . 6.5 mt -61.23 171.73 1.13 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.235 -0.893 . . . . 0.0 109.759 170.778 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.589 ' HB2' ' N ' ' A' ' 36' ' ' TRP . 16.0 Cg_exo -51.81 152.87 12.59 Favored 'Trans proline' 0 N--CA 1.483 0.862 0 C-N-CA 122.685 2.256 . . . . 0.0 113.493 171.147 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -72.96 -30.2 63.65 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.986 166.714 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.73 18.12 20.18 Favored 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 114.757 -1.11 . . . . 0.0 110.963 174.678 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.589 ' N ' ' HB2' ' A' ' 33' ' ' PRO . 33.8 t90 -65.19 107.86 1.7 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.383 -0.826 . . . . 0.0 110.393 164.525 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.705 HG12 ' HA ' ' A' ' 44' ' ' PRO . 18.7 m -119.73 172.06 7.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-N 115.108 -0.951 . . . . 0.0 110.393 177.415 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.44 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 14.8 t -62.64 122.52 74.48 Favored Pre-proline 0 C--O 1.25 1.1 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.421 -175.679 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.44 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 5.2 Cg_exo -53.64 -25.49 33.72 Favored 'Trans proline' 0 N--CA 1.484 0.952 0 C-N-CA 122.918 2.412 . . . . 0.0 113.672 169.854 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.65 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.2 mp -93.01 -80.0 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.214 0 CA-C-N 114.778 -1.101 . . . . 0.0 110.432 -178.614 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 30.2 p -82.47 -23.85 34.51 Favored 'General case' 0 C--N 1.332 -0.157 0 CA-C-N 115.754 -0.657 . . . . 0.0 110.673 -162.419 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.41 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 90.11 19.26 47.25 Favored Glycine 0 CA--C 1.525 0.679 0 N-CA-C 110.527 -1.029 . . . . 0.0 110.527 -177.867 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.48 ' HB1' ' HG2' ' A' ' 47' ' ' GLU . . . -81.16 119.4 75.79 Favored Pre-proline 0 C--O 1.242 0.701 0 CA-C-O 121.356 0.598 . . . . 0.0 109.461 168.289 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.705 ' HA ' HG12 ' A' ' 37' ' ' VAL . 21.7 Cg_exo -47.86 171.0 0.05 OUTLIER 'Trans proline' 0 N--CA 1.486 1.061 0 C-N-CA 122.802 2.334 . . . . 0.0 113.643 170.604 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -61.45 -10.07 6.89 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.454 -0.794 . . . . 0.0 110.608 -169.649 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 7.0 t -93.07 20.71 6.49 Favored 'General case' 0 C--N 1.334 -0.083 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.456 -173.765 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.567 ' HG3' HD11 ' A' ' 7' ' ' ILE . 0.6 OUTLIER -126.48 17.54 7.58 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 115.41 -0.814 . . . . 0.0 110.434 165.859 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 1.4 m-85 -105.8 101.79 11.27 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 115.26 -0.882 . . . . 0.0 110.426 174.615 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 5.6 tt0 -74.1 -170.65 0.98 Allowed 'General case' 0 C--N 1.333 -0.113 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.333 176.028 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -105.93 149.86 26.19 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.351 169.972 . . . . . . . . 2 2 . 1 . 037 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.73 HD23 HG11 ' A' ' 4' ' ' VAL . 0.2 OUTLIER -119.25 68.38 0.8 Allowed 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.336 -0.847 . . . . 0.0 110.389 169.704 . . . . . . . . 3 3 . 1 . 037 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 4.5 mt-10 -93.2 -158.56 0.62 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.363 170.716 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 C--O 1.239 0.534 0 CA-C-N 115.284 -0.871 . . . . 0.0 110.381 170.411 . . . . . . . . 1 1 . 1 . 037 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.798 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.75 0 CA-C-O 121.194 0.521 . . . . 0.0 109.742 . . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -116.2 134.85 54.46 Favored 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 115.527 -0.76 . . . . 0.0 110.377 171.702 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.524 ' NE1' ' HB2' ' A' ' 29' ' ' PHE . 21.3 m95 -116.11 174.8 5.85 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 115.326 -0.852 . . . . 0.0 110.356 170.818 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.493 HG23 ' O ' ' A' ' 10' ' ' TYR . 6.7 p -140.96 148.68 21.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 115.146 -0.934 . . . . 0.0 110.326 179.927 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.488 ' HB2' ' CZ ' ' A' ' 48' ' ' PHE . 35.7 t -82.88 114.92 21.51 Favored 'General case' 0 N--CA 1.468 0.458 0 N-CA-C 109.27 -0.641 . . . . 0.0 109.27 161.014 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 24.9 tptt -90.48 18.59 6.06 Favored 'General case' 0 N--CA 1.454 -0.241 0 CA-C-N 114.735 -1.121 . . . . 0.0 110.77 176.469 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.532 HD11 ' HB3' ' A' ' 47' ' ' GLU . 9.5 mm -93.64 -71.73 0.54 Allowed 'Isoleucine or valine' 0 C--N 1.33 -0.24 0 CA-C-N 115.523 -0.762 . . . . 0.0 110.376 162.992 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.9 p -88.1 -37.4 16.26 Favored 'General case' 0 C--N 1.332 -0.184 0 CA-C-N 115.684 -0.689 . . . . 0.0 110.412 -167.342 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 109.02 27.97 4.63 Favored Glycine 0 CA--C 1.526 0.773 0 CA-C-N 114.797 -1.092 . . . . 0.0 110.506 -175.948 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.493 ' O ' HG23 ' A' ' 4' ' ' VAL . 71.6 t80 -84.44 169.87 14.1 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.076 0.465 . . . . 0.0 110.28 168.683 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.554 ' N ' HD12 ' A' ' 11' ' ' ILE . 3.2 mp -138.15 138.89 42.99 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.175 0 CA-C-N 114.911 -1.041 . . . . 0.0 110.479 179.492 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.545 ' CZ ' HD21 ' A' ' 32' ' ' LEU . 20.5 t80 -97.18 124.89 41.38 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 115.314 -0.857 . . . . 0.0 110.117 166.96 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 49.2 t0 -106.8 109.93 21.97 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 115.23 -0.895 . . . . 0.0 110.392 168.861 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.798 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 20.6 mt-10 -65.54 -28.91 69.51 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 115.33 -0.85 . . . . 0.0 110.413 -171.141 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 3.4 t0 -66.45 -26.33 67.15 Favored 'General case' 0 C--N 1.33 -0.247 0 CA-C-N 114.959 -1.019 . . . . 0.0 110.415 -178.582 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -97.16 -19.08 18.89 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.368 -168.516 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . 0.954 ' HA2' HG22 ' A' ' 23' ' ' ILE . . . 78.54 -139.83 22.8 Favored Glycine 0 CA--C 1.526 0.78 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -168.054 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.649 ' CG ' HD13 ' A' ' 23' ' ' ILE . 0.3 OUTLIER -170.18 89.69 0.52 Allowed Pre-proline 0 C--O 1.25 1.108 0 N-CA-C 109.515 -0.55 . . . . 0.0 109.515 166.683 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.9 Cg_exo -49.6 -30.47 21.92 Favored 'Trans proline' 0 N--CA 1.486 1.083 0 C-N-CA 122.65 2.233 . . . . 0.0 113.572 -172.162 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -75.44 -17.55 60.13 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 115.437 -0.801 . . . . 0.0 110.367 -170.886 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.427 ' O ' HD12 ' A' ' 23' ' ' ILE . 24.5 m-80 -130.22 18.54 5.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 115.312 -0.858 . . . . 0.0 110.455 172.939 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.518 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 61.94 49.41 75.88 Favored Glycine 0 CA--C 1.525 0.706 0 N-CA-C 110.48 -1.048 . . . . 0.0 110.48 171.286 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.954 HG22 ' HA2' ' A' ' 17' ' ' GLY . 1.6 mp -101.6 125.76 55.61 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 N-CA-C 109.667 -0.494 . . . . 0.0 109.667 168.301 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . 0.401 ' HA ' ' HD3' ' A' ' 25' ' ' PRO . 1.0 OUTLIER -84.89 140.29 37.45 Favored Pre-proline 0 CA--C 1.544 0.735 0 CA-C-N 114.676 -1.147 . . . . 0.0 109.699 -173.374 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . 0.575 ' HA ' ' N ' ' A' ' 17' ' ' GLY . 3.0 Cg_exo -61.91 71.07 0.1 Allowed 'Trans proline' 0 N--CA 1.485 1.004 0 C-N-CA 122.563 2.175 . . . . 0.0 113.495 -173.583 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 176.64 -35.56 0.09 OUTLIER Glycine 0 N--CA 1.466 0.653 0 N-CA-C 109.906 -1.278 . . . . 0.0 109.906 -161.229 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 23.2 m -60.92 162.02 7.48 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 115.039 -0.581 . . . . 0.0 110.535 -176.626 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.538 ' HB3' ' HB2' ' A' ' 31' ' ' GLU . 0.1 OUTLIER -112.23 171.37 7.55 Favored 'General case' 0 C--O 1.236 0.364 0 CA-C-N 115.097 -0.956 . . . . 0.0 110.39 177.601 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.524 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 79.9 t80 -61.56 -65.18 0.73 Allowed 'General case' 0 C--O 1.232 0.161 0 CA-C-N 114.815 -1.084 . . . . 0.0 110.325 -177.007 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -79.19 7.18 8.05 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-N 114.493 -1.23 . . . . 0.0 111.683 178.4 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.538 ' HB2' ' HB3' ' A' ' 28' ' ' LYS . 1.5 mm-40 -112.17 20.65 16.63 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.807 -0.633 . . . . 0.0 110.389 165.86 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.545 HD21 ' CZ ' ' A' ' 12' ' ' TYR . 76.0 mt -76.19 171.4 12.23 Favored Pre-proline 0 CA--C 1.544 0.732 0 CA-C-N 115.36 -0.836 . . . . 0.0 109.635 169.217 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.528 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 16.8 Cg_exo -47.91 158.9 0.71 Allowed 'Trans proline' 0 N--CA 1.484 0.947 0 C-N-CA 122.627 2.218 . . . . 0.0 113.744 172.27 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -61.6 -49.2 77.58 Favored 'General case' 0 C--N 1.332 -0.169 0 CA-C-N 115.5 -0.773 . . . . 0.0 110.463 -168.634 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.765 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -117.3 40.51 3.02 Favored 'General case' 0 N--CA 1.455 -0.218 0 CA-C-N 115.08 -0.963 . . . . 0.0 110.377 179.189 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.449 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 91.7 t90 -61.32 134.49 57.0 Favored 'General case' 0 N--CA 1.455 -0.217 0 CA-C-N 114.844 -1.071 . . . . 0.0 110.442 178.757 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.765 HG13 ' O ' ' A' ' 35' ' ' ASP . 22.4 m -132.19 170.47 19.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 115.302 -0.863 . . . . 0.0 110.402 -170.979 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.428 ' HA ' ' HD2' ' A' ' 39' ' ' PRO . 15.5 t -64.84 123.63 84.12 Favored Pre-proline 0 C--O 1.252 1.222 0 CA-C-N 115.216 -0.902 . . . . 0.0 109.333 -179.192 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.428 ' HD2' ' HA ' ' A' ' 38' ' ' CYS . 2.8 Cg_endo -55.42 -23.49 38.82 Favored 'Trans proline' 0 N--CA 1.484 0.942 0 C-N-CA 122.835 2.357 . . . . 0.0 113.679 169.976 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.663 HD12 ' N ' ' A' ' 40' ' ' ILE . 2.7 mp -95.53 -80.66 0.25 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.224 0 CA-C-N 114.836 -1.074 . . . . 0.0 110.571 -178.338 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.1 p -80.35 -22.85 40.99 Favored 'General case' 0 C--N 1.331 -0.209 0 CA-C-N 115.702 -0.681 . . . . 0.0 110.833 -163.72 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 84.9 26.94 35.88 Favored Glycine 0 CA--C 1.527 0.796 0 N-CA-C 110.452 -1.059 . . . . 0.0 110.452 -176.575 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -87.63 114.36 58.55 Favored Pre-proline 0 C--O 1.242 0.7 0 CA-C-O 121.429 0.633 . . . . 0.0 109.54 168.911 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.615 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 20.7 Cg_exo -47.09 167.96 0.07 OUTLIER 'Trans proline' 0 N--CA 1.486 1.049 0 C-N-CA 122.714 2.276 . . . . 0.0 113.641 169.961 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -61.02 -10.83 6.52 Favored 'General case' 0 C--N 1.331 -0.23 0 CA-C-N 115.555 -0.748 . . . . 0.0 110.535 -167.348 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 13.8 p -61.49 -39.97 92.88 Favored 'General case' 0 C--N 1.333 -0.14 0 CA-C-N 115.109 -0.95 . . . . 0.0 110.408 -177.335 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.532 ' HB3' HD11 ' A' ' 7' ' ' ILE . 1.6 mp0 -96.25 19.9 11.19 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 115.36 -0.837 . . . . 0.0 110.449 -169.257 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . 0.488 ' CZ ' ' HB2' ' A' ' 5' ' ' CYS . 2.2 m-85 -98.5 130.67 45.09 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.456 168.25 . . . . . . . . 2 2 . 1 . 038 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.4 tm-20 -89.42 178.59 6.28 Favored 'General case' 0 C--N 1.332 -0.185 0 CA-C-N 115.506 -0.77 . . . . 0.0 110.258 168.398 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.413 ' HD2' ' CZ3' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -119.04 143.21 47.23 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 115.256 -0.884 . . . . 0.0 110.44 178.913 . . . . . . . . 3 3 . 1 . 038 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . . . . . . . . . 1.7 mp 60.05 39.82 19.35 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 115.293 -0.867 . . . . 0.0 110.534 169.876 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.9 tt0 58.31 -86.75 0.02 OUTLIER 'General case' 0 N--CA 1.452 -0.334 0 CA-C-N 115.256 -0.884 . . . . 0.0 111.208 169.665 . . . . . . . . 1 1 . 1 . 038 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 74.2 m-20 . . . . . 0 C--O 1.24 0.555 0 CA-C-N 115.967 -0.56 . . . . 0.0 110.386 170.104 . . . . . . . . 0 0 . 1 . 038 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 039 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.52 ' O ' ' HB2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.748 0 N-CA-C 109.677 -0.49 . . . . 0.0 109.677 . . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -114.66 127.59 55.85 Favored 'General case' 0 C--N 1.331 -0.237 0 CA-C-N 115.404 -0.816 . . . . 0.0 110.41 -175.155 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.557 ' O ' HG23 ' A' ' 11' ' ' ILE . 34.5 m95 -115.32 162.02 17.69 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 115.047 -0.979 . . . . 0.0 110.494 178.632 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.516 ' HA ' ' HA ' ' A' ' 11' ' ' ILE . 4.5 p -130.32 160.35 41.52 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 115.279 -0.873 . . . . 0.0 110.385 178.988 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . . . . . . . . . 14.7 t -87.23 117.08 25.74 Favored 'General case' 0 C--O 1.238 0.467 0 CA-C-N 115.667 -0.697 . . . . 0.0 110.038 163.199 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . 0.52 ' HG2' ' HG3' ' A' ' 49' ' ' GLU . 9.7 mtmt -62.46 -24.97 67.74 Favored 'General case' 0 N--CA 1.453 -0.31 0 CA-C-N 114.323 -1.308 . . . . 0.0 110.636 176.222 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.8 HD11 ' HB3' ' A' ' 47' ' ' GLU . 4.1 mp -81.67 -76.13 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.182 0 CA-C-N 114.716 -1.129 . . . . 0.0 110.736 -175.967 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 29.8 p -85.74 -30.4 23.13 Favored 'General case' 0 C--N 1.331 -0.213 0 CA-C-N 115.875 -0.602 . . . . 0.0 110.545 -164.23 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 97.62 26.87 9.5 Favored Glycine 0 CA--C 1.527 0.831 0 CA-C-N 114.668 -1.151 . . . . 0.0 110.487 -177.691 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.691 ' HB2' HD13 ' A' ' 40' ' ' ILE . 71.4 t80 -75.94 170.26 16.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 121.025 0.441 . . . . 0.0 110.21 163.439 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.557 HG23 ' O ' ' A' ' 3' ' ' TRP . 4.2 mp -142.43 136.48 28.28 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.277 0 CA-C-N 115.118 -0.946 . . . . 0.0 110.456 -179.626 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.55 ' CE2' HD11 ' A' ' 32' ' ' LEU . 12.2 t80 -94.08 141.27 28.73 Favored 'General case' 0 C--N 1.328 -0.355 0 CA-C-N 115.366 -0.834 . . . . 0.0 110.196 164.448 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 45.9 t0 -121.58 104.85 9.94 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 115.207 -0.906 . . . . 0.0 110.42 170.984 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.52 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 37.6 mt-10 -62.76 -17.02 60.31 Favored 'General case' 0 C--O 1.234 0.286 0 CA-C-N 114.796 -1.093 . . . . 0.0 110.812 -175.101 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 10.3 t0 -60.76 -76.37 0.05 Allowed 'General case' 0 C--N 1.326 -0.454 0 CA-C-N 115.837 -0.62 . . . . 0.0 109.67 163.348 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -59.95 -40.57 89.43 Favored 'General case' 0 N--CA 1.453 -0.281 0 CA-C-N 113.889 -1.505 . . . . 0.0 110.515 -169.964 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 92.22 -162.97 27.49 Favored Glycine 0 CA--C 1.527 0.804 0 N-CA-C 110.445 -1.062 . . . . 0.0 110.445 -177.362 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.526 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.2 t0 -147.18 58.52 4.25 Favored Pre-proline 0 CA--C 1.543 0.683 0 CA-C-O 121.501 0.667 . . . . 0.0 109.763 -170.788 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . . . . . . . . . 4.8 Cg_endo -58.27 -24.66 68.72 Favored 'Trans proline' 0 N--CA 1.485 1.016 0 C-N-CA 122.49 2.127 . . . . 0.0 113.574 -171.064 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 24.8 t0 -68.21 -22.4 64.8 Favored 'General case' 0 C--N 1.331 -0.203 0 CA-C-N 115.026 -0.988 . . . . 0.0 110.377 -178.039 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.477 ' HB2' ' CD1' ' A' ' 23' ' ' ILE . 51.7 m-80 -103.59 -12.69 16.91 Favored 'General case' 0 N--CA 1.452 -0.356 0 CA-C-N 115.09 -0.959 . . . . 0.0 111.574 175.126 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 96.61 46.49 2.5 Favored Glycine 0 CA--C 1.525 0.717 0 N-CA-C 110.483 -1.047 . . . . 0.0 110.483 -175.606 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.528 ' N ' HD12 ' A' ' 23' ' ' ILE . 4.0 mp -114.87 132.02 65.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 115.326 -0.437 . . . . 0.0 110.468 173.095 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -87.8 154.04 52.73 Favored Pre-proline 0 CA--C 1.543 0.711 0 CA-C-N 115.026 -0.988 . . . . 0.0 109.746 177.928 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 5.4 Cg_endo -48.62 135.43 27.32 Favored 'Trans proline' 0 N--CA 1.485 0.993 0 C-N-CA 122.565 2.177 . . . . 0.0 113.418 169.81 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 77.86 1.34 78.19 Favored Glycine 0 C--N 1.344 1.008 0 CA-C-N 114.14 -1.391 . . . . 0.0 111.857 173.366 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 90.1 m -65.31 140.91 58.73 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-O 120.78 0.324 . . . . 0.0 110.31 168.28 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.521 ' HB2' ' HB3' ' A' ' 31' ' ' GLU . 3.7 mttm -90.31 166.49 13.29 Favored 'General case' 0 C--N 1.328 -0.352 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.372 -169.788 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.519 ' HB2' ' NE1' ' A' ' 3' ' ' TRP . 77.1 t80 -61.63 -65.33 0.71 Allowed 'General case' 0 CA--C 1.529 0.138 0 CA-C-N 114.821 -1.081 . . . . 0.0 110.271 -176.41 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 14.3 mt-10 -79.08 8.84 5.09 Favored 'General case' 0 C--O 1.236 0.344 0 CA-C-N 114.462 -1.244 . . . . 0.0 111.617 179.293 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.521 ' HB3' ' HB2' ' A' ' 28' ' ' LYS . 1.1 tp10 -97.38 -12.65 22.53 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 115.616 -0.72 . . . . 0.0 110.513 169.279 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.561 ' HB3' ' HD2' ' A' ' 33' ' ' PRO . 39.8 mt -61.12 173.85 0.65 Allowed Pre-proline 0 CA--C 1.545 0.767 0 CA-C-N 115.173 -0.921 . . . . 0.0 109.666 169.39 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.577 ' HD2' ' CD1' ' A' ' 36' ' ' TRP . 19.0 Cg_exo -50.66 153.55 7.84 Favored 'Trans proline' 0 N--CA 1.483 0.887 0 C-N-CA 122.595 2.197 . . . . 0.0 113.729 172.954 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 0.4 OUTLIER -67.96 -33.13 74.07 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 115.117 -0.947 . . . . 0.0 110.032 167.971 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.427 ' O ' HG13 ' A' ' 37' ' ' VAL . 1.3 t0 -107.7 22.78 15.46 Favored 'General case' 0 N--CA 1.454 -0.265 0 CA-C-N 114.705 -1.134 . . . . 0.0 110.562 177.876 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.577 ' CD1' ' HD2' ' A' ' 33' ' ' PRO . 60.6 t90 -60.34 108.08 0.75 Allowed 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 114.878 -1.055 . . . . 0.0 110.422 167.451 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.496 HG12 ' HA ' ' A' ' 44' ' ' PRO . 29.8 m -112.92 176.74 1.77 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 CA-C-N 114.883 -1.053 . . . . 0.0 110.338 -178.952 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.416 ' HB3' ' H ' ' A' ' 42' ' ' GLY . 16.1 t -65.01 125.08 88.45 Favored Pre-proline 0 C--O 1.252 1.187 0 CA-C-N 114.826 -1.079 . . . . 0.0 109.404 176.613 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . . . . . . . . . 21.8 Cg_exo -53.56 -24.9 30.65 Favored 'Trans proline' 0 N--CA 1.485 0.979 0 C-N-CA 122.686 2.258 . . . . 0.0 113.758 170.04 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.691 HD13 ' HB2' ' A' ' 10' ' ' TYR . 5.2 mp -97.13 -84.31 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.456 -0.147 0 CA-C-N 115.019 -0.991 . . . . 0.0 110.286 178.422 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 31.7 p -75.16 -20.36 59.39 Favored 'General case' 0 N--CA 1.456 -0.174 0 CA-C-N 115.503 -0.771 . . . . 0.0 111.042 -161.123 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.416 ' H ' ' HB3' ' A' ' 38' ' ' CYS . . . 78.41 38.15 25.8 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 110.482 -1.047 . . . . 0.0 110.482 -177.082 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . . . . . . . . . . . -95.27 135.99 22.93 Favored Pre-proline 0 C--O 1.242 0.687 0 CA-C-O 121.18 0.514 . . . . 0.0 109.654 170.609 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.496 ' HA ' HG12 ' A' ' 37' ' ' VAL . 5.8 Cg_exo -55.23 157.46 14.05 Favored 'Trans proline' 0 N--CA 1.484 0.964 0 C-N-CA 122.481 2.121 . . . . 0.0 113.411 175.505 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.434 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.25 -16.91 50.22 Favored 'General case' 0 N--CA 1.456 -0.13 0 CA-C-N 114.61 -1.177 . . . . 0.0 110.537 178.938 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 17.2 t -60.95 -17.68 52.85 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 115.114 -0.948 . . . . 0.0 110.495 177.278 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.8 ' HB3' HD11 ' A' ' 7' ' ' ILE . 0.4 OUTLIER -118.91 19.73 12.97 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 115.285 -0.87 . . . . 0.0 110.35 -172.352 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -100.72 118.06 36.08 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 115.169 -0.923 . . . . 0.0 110.405 170.717 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' HG3' ' HG2' ' A' ' 6' ' ' LYS . 0.0 OUTLIER -72.85 -170.85 0.77 Allowed 'General case' 0 C--N 1.334 -0.096 0 CA-C-N 115.115 -0.948 . . . . 0.0 110.418 174.234 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.432 ' HA ' ' HA ' ' A' ' 3' ' ' TRP . 0.0 OUTLIER -145.06 142.41 29.7 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 115.433 -0.803 . . . . 0.0 110.346 -172.636 . . . . . . . . 3 3 . 1 . 039 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.414 HD12 ' HA ' ' A' ' 51' ' ' LEU . 6.4 tp 59.9 86.52 0.09 Allowed 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.242 -0.89 . . . . 0.0 110.523 168.739 . . . . . . . . 2 2 . 1 . 039 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . . . . . . . . . 1.6 pp20? -107.92 114.95 29.25 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 115.334 -0.848 . . . . 0.0 110.402 169.454 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.62 0 CA-C-N 115.364 -0.834 . . . . 0.0 110.345 -170.214 . . . . . . . . 1 1 . 1 . 039 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 040 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.768 ' HB3' ' OE2' ' A' ' 14' ' ' GLU . . . . . . . . 0 N--CA 1.474 0.756 0 CA-C-O 121.094 0.473 . . . . 0.0 109.751 . . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 2' ' ' LYS . . . . . 0.509 ' HG3' ' HG2' ' A' ' 52' ' ' GLU . 0.0 OUTLIER -125.91 135.61 52.09 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 115.514 -0.766 . . . . 0.0 110.325 171.441 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 3' ' ' TRP . . . . . 0.496 ' CZ3' ' CE2' ' A' ' 29' ' ' PHE . 24.6 m95 -116.96 128.38 55.14 Favored 'General case' 0 C--N 1.331 -0.218 0 CA-C-N 114.936 -1.029 . . . . 0.0 110.333 -179.735 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 4' ' ' VAL . . . . . 0.953 HG23 HG13 ' A' ' 11' ' ' ILE . 9.3 p -103.78 133.02 48.88 Favored 'Isoleucine or valine' 0 C--O 1.24 0.567 0 CA-C-N 115.342 -0.845 . . . . 0.0 110.442 -177.8 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 5' ' ' CYS . . . . . 0.571 ' SG ' HD12 ' A' ' 7' ' ' ILE . 19.2 t -71.07 111.77 6.7 Favored 'General case' 0 C--O 1.235 0.317 0 CA-C-N 114.844 -1.071 . . . . 0.0 109.804 167.836 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 6' ' ' LYS . . . . . . . . . . . . . 13.1 ttpt -87.77 16.51 5.68 Favored 'General case' 0 N--CA 1.452 -0.366 0 CA-C-N 114.778 -1.101 . . . . 0.0 111.103 178.501 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.837 HD11 ' CB ' ' A' ' 47' ' ' GLU . 2.7 mt -93.39 -74.52 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 115.511 -0.768 . . . . 0.0 110.484 162.724 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 8' ' ' CYS . . . . . . . . . . . . . 25.8 p -84.86 -37.86 20.16 Favored 'General case' 0 C--N 1.332 -0.182 0 CA-C-N 115.725 -0.67 . . . . 0.0 110.421 -165.078 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 9' ' ' GLY . . . . . . . . . . . . . . . 105.45 34.91 3.22 Favored Glycine 0 CA--C 1.526 0.752 0 CA-C-N 114.672 -1.149 . . . . 0.0 110.527 -174.098 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 10' ' ' TYR . . . . . 0.529 ' CG ' HD13 ' A' ' 40' ' ' ILE . 78.6 t80 -94.84 169.71 9.95 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.382 -0.409 . . . . 0.0 110.283 167.257 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 11' ' ' ILE . . . . . 0.953 HG13 HG23 ' A' ' 4' ' ' VAL . 4.8 mp -146.66 122.25 2.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.198 0 CA-C-N 114.948 -1.024 . . . . 0.0 110.47 -179.265 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 12' ' ' TYR . . . . . 0.469 ' CZ ' ' HA ' ' A' ' 14' ' ' GLU . 21.7 t80 -74.76 136.09 41.72 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 115.445 -0.798 . . . . 0.0 110.123 164.259 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 13' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -121.37 108.96 14.3 Favored 'General case' 0 C--O 1.236 0.385 0 CA-C-N 115.267 -0.878 . . . . 0.0 110.349 168.894 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . 0.768 ' OE2' ' HB3' ' A' ' 1' ' ' ALA . 27.4 mt-10 -62.27 -17.72 59.28 Favored 'General case' 0 C--O 1.233 0.224 0 CA-C-N 114.924 -1.035 . . . . 0.0 110.808 -173.75 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 6.2 t0 -60.93 -77.63 0.04 OUTLIER 'General case' 0 C--N 1.325 -0.46 0 CA-C-N 115.775 -0.648 . . . . 0.0 109.653 163.355 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -60.44 -30.82 69.89 Favored 'General case' 0 N--CA 1.453 -0.276 0 CA-C-N 113.796 -1.547 . . . . 0.0 110.505 -171.816 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 81.39 -136.46 16.11 Favored Glycine 0 CA--C 1.526 0.729 0 N-CA-C 110.498 -1.041 . . . . 0.0 110.498 178.334 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.506 ' HB3' ' HB ' ' A' ' 23' ' ' ILE . 16.5 t0 -170.09 58.22 0.3 Allowed Pre-proline 0 CA--C 1.542 0.639 0 CA-C-O 121.668 0.747 . . . . 0.0 109.824 -170.416 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 19' ' ' PRO . . . . . 0.488 ' HD3' ' N ' ' A' ' 18' ' ' ASP . 10.7 Cg_exo -57.53 -16.83 25.35 Favored 'Trans proline' 0 N--CA 1.485 0.994 0 C-N-CA 122.465 2.11 . . . . 0.0 113.57 -174.521 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 20' ' ' ASP . . . . . . . . . . . . . 14.2 t70 -77.28 -24.25 51.02 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.105 -0.952 . . . . 0.0 110.381 -177.472 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 21' ' ' ASN . . . . . 0.442 ' C ' HD12 ' A' ' 23' ' ' ILE . 0.5 OUTLIER -116.02 19.08 15.24 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 115.265 -0.88 . . . . 0.0 110.43 171.104 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . 0.441 ' C ' HD12 ' A' ' 23' ' ' ILE . . . 74.28 45.05 26.28 Favored Glycine 0 CA--C 1.526 0.754 0 N-CA-C 110.418 -1.073 . . . . 0.0 110.418 169.328 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . 0.624 ' N ' HD12 ' A' ' 23' ' ' ILE . 3.0 mp -108.51 129.72 62.45 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 115.408 -0.396 . . . . 0.0 110.402 169.686 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 24' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -80.28 143.88 57.02 Favored Pre-proline 0 CA--C 1.544 0.736 0 CA-C-N 115.06 -0.973 . . . . 0.0 109.851 176.204 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_endo -56.13 90.74 0.04 OUTLIER 'Trans proline' 0 N--CA 1.483 0.897 0 C-N-CA 122.549 2.166 . . . . 0.0 113.652 174.243 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 130.68 18.91 1.36 Allowed Glycine 0 CA--C 1.526 0.774 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 178.573 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . 0.571 ' HB ' HG23 ' A' ' 23' ' ' ILE . 93.4 m -80.33 153.83 28.15 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-O 120.975 0.417 . . . . 0.0 110.351 169.359 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 28' ' ' LYS . . . . . 0.731 ' O ' ' HG ' ' A' ' 32' ' ' LEU . 0.0 OUTLIER -101.34 157.63 16.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 115.255 -0.884 . . . . 0.0 110.501 -173.497 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 29' ' ' PHE . . . . . 0.521 ' CZ ' ' HB2' ' A' ' 45' ' ' LYS . 78.7 t80 -61.73 -65.85 0.63 Allowed 'General case' 0 CA--C 1.529 0.142 0 CA-C-N 115.084 -0.962 . . . . 0.0 110.279 -174.27 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 -79.04 7.07 7.96 Favored 'General case' 0 N--CA 1.453 -0.318 0 CA-C-N 114.478 -1.237 . . . . 0.0 111.676 177.262 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 31' ' ' GLU . . . . . 0.418 ' CB ' ' HB3' ' A' ' 28' ' ' LYS . 0.6 OUTLIER -113.07 20.5 16.25 Favored 'General case' 0 C--N 1.327 -0.405 0 CA-C-N 115.764 -0.653 . . . . 0.0 110.395 165.66 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.731 ' HG ' ' O ' ' A' ' 28' ' ' LYS . 44.6 mt -79.78 171.15 13.18 Favored Pre-proline 0 CA--C 1.545 0.768 0 CA-C-N 115.398 -0.819 . . . . 0.0 109.629 168.622 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 33' ' ' PRO . . . . . 0.522 ' HD2' ' HB3' ' A' ' 32' ' ' LEU . 17.0 Cg_exo -49.08 158.1 1.5 Allowed 'Trans proline' 0 N--CA 1.485 0.99 0 C-N-CA 122.529 2.153 . . . . 0.0 113.776 172.691 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 34' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -61.81 -51.18 69.31 Favored 'General case' 0 C--N 1.333 -0.149 0 CA-C-N 115.339 -0.846 . . . . 0.0 110.343 -170.718 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 35' ' ' ASP . . . . . 0.77 ' O ' HG13 ' A' ' 37' ' ' VAL . 0.2 OUTLIER -105.83 33.87 3.57 Favored 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 114.946 -1.024 . . . . 0.0 110.387 -174.645 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 36' ' ' TRP . . . . . 0.434 ' HD1' ' HG2' ' A' ' 33' ' ' PRO . 74.5 t90 -61.65 116.53 4.84 Favored 'General case' 0 C--N 1.331 -0.216 0 CA-C-N 114.995 -1.002 . . . . 0.0 110.384 -178.14 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 37' ' ' VAL . . . . . 0.77 HG13 ' O ' ' A' ' 35' ' ' ASP . 32.0 m -118.24 173.56 4.78 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.266 0 CA-C-N 114.982 -1.008 . . . . 0.0 110.355 -175.726 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 38' ' ' CYS . . . . . 0.5 ' HB3' ' H ' ' A' ' 43' ' ' ALA . 13.4 t -68.76 122.39 84.72 Favored Pre-proline 0 C--O 1.249 1.05 0 CA-C-N 115.035 -0.984 . . . . 0.0 109.52 179.582 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 39' ' ' PRO . . . . . 0.4 ' HD3' ' O ' ' A' ' 37' ' ' VAL . 22.9 Cg_exo -55.28 -22.84 34.69 Favored 'Trans proline' 0 N--CA 1.485 1.013 0 C-N-CA 122.568 2.179 . . . . 0.0 113.86 170.458 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 40' ' ' ILE . . . . . 0.599 HD12 ' N ' ' A' ' 40' ' ' ILE . 3.4 mp -93.93 -80.2 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.203 0 CA-C-N 115.051 -0.977 . . . . 0.0 110.516 -179.092 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 41' ' ' CYS . . . . . . . . . . . . . 28.8 p -82.16 -23.0 35.8 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 115.763 -0.653 . . . . 0.0 110.769 -162.455 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 92.09 28.4 13.63 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 110.446 -1.062 . . . . 0.0 110.446 -178.473 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 43' ' ' ALA . . . . . 0.738 ' CB ' HD13 ' A' ' 7' ' ' ILE . . . -97.32 121.93 57.27 Favored Pre-proline 0 C--O 1.244 0.789 0 CA-C-N 114.892 -0.654 . . . . 0.0 109.527 178.108 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 44' ' ' PRO . . . . . 0.509 ' HA ' ' HA ' ' A' ' 37' ' ' VAL . 21.3 Cg_exo -47.96 165.24 0.14 Allowed 'Trans proline' 0 N--CA 1.486 1.044 0 C-N-CA 122.674 2.249 . . . . 0.0 113.795 170.806 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.521 ' HB2' ' CZ ' ' A' ' 29' ' ' PHE . 0.0 OUTLIER -61.41 -11.69 11.39 Favored 'General case' 0 C--N 1.332 -0.193 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.653 -168.88 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 46' ' ' SER . . . . . . . . . . . . . 30.0 t -61.55 -28.41 69.31 Favored 'General case' 0 C--N 1.332 -0.168 0 CA-C-N 115.479 -0.782 . . . . 0.0 110.607 -171.222 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 47' ' ' GLU . . . . . 0.837 ' CB ' HD11 ' A' ' 7' ' ' ILE . 1.7 mt-10 -109.15 19.66 19.23 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.505 -0.77 . . . . 0.0 110.41 -171.674 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 48' ' ' PHE . . . . . . . . . . . . . 2.0 m-85 -94.58 107.62 19.61 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 115.362 -0.836 . . . . 0.0 110.185 166.004 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.442 ' O ' HG12 ' A' ' 4' ' ' VAL . 1.9 tp10 -86.02 124.58 32.62 Favored 'General case' 0 N--CA 1.455 -0.221 0 CA-C-N 114.527 -1.215 . . . . 0.0 110.483 -177.914 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 50' ' ' LYS . . . . . 0.571 ' HG3' HD23 ' A' ' 51' ' ' LEU . 2.1 ptpt -70.91 165.95 22.21 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 115.311 -0.859 . . . . 0.0 110.456 -169.182 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 51' ' ' LEU . . . . . 0.571 HD23 ' HG3' ' A' ' 50' ' ' LYS . 0.3 OUTLIER 60.18 60.21 2.14 Favored 'General case' 0 C--O 1.235 0.32 0 CA-C-N 115.565 -0.743 . . . . 0.0 110.702 170.574 . . . . . . . . 3 3 . 1 . 040 nuclear nobuild full ' A' A ' 52' ' ' GLU . . . . . 0.509 ' HG2' ' HG3' ' A' ' 2' ' ' LYS . 5.1 mm-40 57.7 -168.77 0.12 Allowed 'General case' 0 N--CA 1.452 -0.351 0 CA-C-N 115.033 -0.985 . . . . 0.0 110.999 167.197 . . . . . . . . 2 2 . 1 . 040 nuclear nobuild full ' A' A ' 53' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--O 1.241 0.614 0 CA-C-N 115.012 -0.995 . . . . 0.0 110.391 179.781 . . . . . . . . 1 1 . 1 . 040 nuclear nobuild full ' A' A ' 54' ' ' ' ZN' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_